13:01:41,898 graphrag.config.read_dotenv INFO Loading pipeline .env file
13:01:41,910 graphrag.index.cli INFO using default configuration: {
    "llm": {
        "api_key": "REDACTED, length 56",
        "type": "openai_chat",
        "model": "llama3-8b-8192",
        "max_tokens": 3000,
        "request_timeout": 300.0,
        "api_base": "https://api.groq.com/openai/v1",
        "api_version": null,
        "proxy": null,
        "cognitive_services_endpoint": null,
        "deployment_name": null,
        "model_supports_json": true,
        "tokens_per_minute": 0,
        "requests_per_minute": 0,
        "max_retries": 5,
        "max_retry_wait": 20.0,
        "sleep_on_rate_limit_recommendation": true,
        "concurrent_requests": 5
    },
    "parallelization": {
        "stagger": 0.5,
        "num_threads": 50
    },
    "async_mode": "threaded",
    "root_dir": ".",
    "reporting": {
        "type": "file",
        "base_dir": "output/${timestamp}/reports",
        "storage_account_blob_url": null
    },
    "storage": {
        "type": "file",
        "base_dir": "output/${timestamp}/artifacts",
        "storage_account_blob_url": null
    },
    "cache": {
        "type": "file",
        "base_dir": "cache",
        "storage_account_blob_url": null
    },
    "input": {
        "type": "file",
        "file_type": "text",
        "base_dir": "input",
        "storage_account_blob_url": null,
        "encoding": "utf-8",
        "file_pattern": ".*\\.txt$",
        "file_filter": null,
        "source_column": null,
        "timestamp_column": null,
        "timestamp_format": null,
        "text_column": "text",
        "title_column": null,
        "document_attribute_columns": []
    },
    "embed_graph": {
        "enabled": false,
        "num_walks": 10,
        "walk_length": 40,
        "window_size": 2,
        "iterations": 3,
        "random_seed": 597832,
        "strategy": null
    },
    "embeddings": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_embedding",
            "model": "nomic-ai/nomic-embed-text-v1.5-GGUF/nomic-embed-text-v1.5.Q2_K.gguf",
            "max_tokens": 4000,
            "request_timeout": 180.0,
            "api_base": "http://localhost:1234/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": null,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 10,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 25
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "batch_size": 16,
        "batch_max_tokens": 8191,
        "target": "required",
        "skip": [],
        "vector_store": null,
        "strategy": null
    },
    "chunks": {
        "size": 300,
        "overlap": 100,
        "group_by_columns": [
            "id"
        ],
        "strategy": null
    },
    "snapshots": {
        "graphml": false,
        "raw_entities": false,
        "top_level_nodes": false
    },
    "entity_extraction": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_chat",
            "model": "llama3-8b-8192",
            "max_tokens": 3000,
            "request_timeout": 300.0,
            "api_base": "https://api.groq.com/openai/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": true,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 5,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "prompt": "prompts/entity_extraction.txt",
        "entity_types": [
            "organization",
            "person",
            "geo",
            "event"
        ],
        "max_gleanings": 0,
        "strategy": null
    },
    "summarize_descriptions": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_chat",
            "model": "llama3-8b-8192",
            "max_tokens": 3000,
            "request_timeout": 300.0,
            "api_base": "https://api.groq.com/openai/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": true,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 5,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "prompt": "prompts/summarize_descriptions.txt",
        "max_length": 500,
        "strategy": null
    },
    "community_reports": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_chat",
            "model": "llama3-8b-8192",
            "max_tokens": 3000,
            "request_timeout": 300.0,
            "api_base": "https://api.groq.com/openai/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": true,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 5,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "prompt": null,
        "max_length": 2000,
        "max_input_length": 8000,
        "strategy": null
    },
    "claim_extraction": {
        "llm": {
            "api_key": "REDACTED, length 56",
            "type": "openai_chat",
            "model": "llama3-8b-8192",
            "max_tokens": 3000,
            "request_timeout": 300.0,
            "api_base": "https://api.groq.com/openai/v1",
            "api_version": null,
            "proxy": null,
            "cognitive_services_endpoint": null,
            "deployment_name": null,
            "model_supports_json": true,
            "tokens_per_minute": 0,
            "requests_per_minute": 0,
            "max_retries": 5,
            "max_retry_wait": 20.0,
            "sleep_on_rate_limit_recommendation": true,
            "concurrent_requests": 5
        },
        "parallelization": {
            "stagger": 0.5,
            "num_threads": 50
        },
        "async_mode": "threaded",
        "enabled": false,
        "prompt": "prompts/claim_extraction.txt",
        "description": "Any claims or facts that could be relevant to information discovery.",
        "max_gleanings": 0,
        "strategy": null
    },
    "cluster_graph": {
        "max_cluster_size": 10,
        "strategy": null
    },
    "umap": {
        "enabled": false
    },
    "local_search": {
        "text_unit_prop": 0.5,
        "community_prop": 0.1,
        "conversation_history_max_turns": 5,
        "top_k_entities": 10,
        "top_k_relationships": 10,
        "max_tokens": 12000,
        "llm_max_tokens": 2000
    },
    "global_search": {
        "max_tokens": 3000,
        "data_max_tokens": 12000,
        "map_max_tokens": 1000,
        "reduce_max_tokens": 2000,
        "concurrency": 32
    },
    "encoding_model": "cl100k_base",
    "skip_workflows": []
}
13:01:41,915 graphrag.index.create_pipeline_config INFO skipping workflows 
13:01:41,918 graphrag.index.run INFO Running pipeline
13:01:41,918 graphrag.index.storage.file_pipeline_storage INFO Creating file storage at output\20240715-130141\artifacts
13:01:41,920 graphrag.index.input.load_input INFO loading input from root_dir=input
13:01:41,920 graphrag.index.input.load_input INFO using file storage for input
13:01:41,922 graphrag.index.storage.file_pipeline_storage INFO search input for files matching .*\.txt$
13:01:41,923 graphrag.index.input.text INFO found text files from input, found [('breast_cancer.txt', {})]
13:01:41,934 graphrag.index.workflows.load INFO Workflow Run Order: ['create_base_text_units', 'create_base_extracted_entities', 'create_summarized_entities', 'create_base_entity_graph', 'create_final_entities', 'create_final_nodes', 'create_final_communities', 'join_text_units_to_entity_ids', 'create_final_relationships', 'join_text_units_to_relationship_ids', 'create_final_community_reports', 'create_final_text_units', 'create_base_documents', 'create_final_documents']
13:01:41,935 graphrag.index.run INFO Final # of rows loaded: 1
13:01:42,213 graphrag.index.run INFO Running workflow: create_base_text_units...
13:01:42,213 graphrag.index.run INFO dependencies for create_base_text_units: []
13:01:42,247 datashaper.workflow.workflow INFO executing verb orderby
13:01:42,274 datashaper.workflow.workflow INFO executing verb zip
13:01:42,291 datashaper.workflow.workflow INFO executing verb aggregate_override
13:01:42,314 datashaper.workflow.workflow INFO executing verb chunk
13:01:42,635 datashaper.workflow.workflow INFO executing verb select
13:01:42,645 datashaper.workflow.workflow INFO executing verb unroll
13:01:42,664 datashaper.workflow.workflow INFO executing verb rename
13:01:42,672 datashaper.workflow.workflow INFO executing verb genid
13:01:42,680 datashaper.workflow.workflow INFO executing verb unzip
13:01:42,690 datashaper.workflow.workflow INFO executing verb copy
13:01:42,696 datashaper.workflow.workflow INFO executing verb filter
13:01:42,721 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_base_text_units.parquet
13:01:43,166 graphrag.index.run INFO Running workflow: create_base_extracted_entities...
13:01:43,168 graphrag.index.run INFO dependencies for create_base_extracted_entities: ['create_base_text_units']
13:01:43,170 graphrag.index.run INFO read table from storage: create_base_text_units.parquet
13:01:43,284 datashaper.workflow.workflow INFO executing verb entity_extract
13:01:43,311 graphrag.llm.openai.create_openai_client INFO Creating OpenAI client base_url=https://api.groq.com/openai/v1
13:01:43,331 graphrag.index.llm.load_llm INFO create TPM/RPM limiter for llama3-8b-8192: TPM=0, RPM=0
13:01:43,332 graphrag.index.llm.load_llm INFO create concurrency limiter for llama3-8b-8192: 5
13:01:43,775 datashaper.workflow.workflow INFO executing verb merge_graphs
13:01:43,910 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_base_extracted_entities.parquet
13:01:44,248 graphrag.index.run INFO Running workflow: create_summarized_entities...
13:01:44,248 graphrag.index.run INFO dependencies for create_summarized_entities: ['create_base_extracted_entities']
13:01:44,249 graphrag.index.run INFO read table from storage: create_base_extracted_entities.parquet
13:01:44,337 datashaper.workflow.workflow INFO executing verb summarize_descriptions
13:01:45,745 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_summarized_entities.parquet
13:01:46,50 graphrag.index.run INFO Running workflow: create_base_entity_graph...
13:01:46,51 graphrag.index.run INFO dependencies for create_base_entity_graph: ['create_summarized_entities']
13:01:46,51 graphrag.index.run INFO read table from storage: create_summarized_entities.parquet
13:01:46,99 datashaper.workflow.workflow INFO executing verb cluster_graph
13:01:46,584 datashaper.workflow.workflow INFO executing verb select
13:01:46,592 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_base_entity_graph.parquet
13:01:46,962 graphrag.index.run INFO Running workflow: create_final_entities...
13:01:46,962 graphrag.index.run INFO dependencies for create_final_entities: ['create_base_entity_graph']
13:01:46,963 graphrag.index.run INFO read table from storage: create_base_entity_graph.parquet
13:01:47,58 datashaper.workflow.workflow INFO executing verb unpack_graph
13:01:47,291 datashaper.workflow.workflow INFO executing verb rename
13:01:47,305 datashaper.workflow.workflow INFO executing verb select
13:01:47,342 datashaper.workflow.workflow INFO executing verb dedupe
13:01:47,409 datashaper.workflow.workflow INFO executing verb rename
13:01:47,432 datashaper.workflow.workflow INFO executing verb filter
13:01:47,508 datashaper.workflow.workflow INFO executing verb text_split
13:01:47,556 datashaper.workflow.workflow INFO executing verb drop
13:01:47,575 datashaper.workflow.workflow INFO executing verb merge
13:01:47,894 datashaper.workflow.workflow INFO executing verb text_embed
13:01:47,898 graphrag.llm.openai.create_openai_client INFO Creating OpenAI client base_url=http://localhost:1234/v1
13:01:47,914 graphrag.index.llm.load_llm INFO create TPM/RPM limiter for nomic-ai/nomic-embed-text-v1.5-GGUF/nomic-embed-text-v1.5.Q2_K.gguf: TPM=0, RPM=0
13:01:47,914 graphrag.index.llm.load_llm INFO create concurrency limiter for nomic-ai/nomic-embed-text-v1.5-GGUF/nomic-embed-text-v1.5.Q2_K.gguf: 25
13:01:48,41 graphrag.index.verbs.text.embed.strategies.openai INFO embedding 969 inputs via 969 snippets using 61 batches. max_batch_size=16, max_tokens=8191
13:01:48,935 datashaper.workflow.workflow INFO executing verb drop
13:01:48,953 datashaper.workflow.workflow INFO executing verb filter
13:01:48,991 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_final_entities.parquet
13:01:49,694 graphrag.index.run INFO Running workflow: create_final_nodes...
13:01:49,695 graphrag.index.run INFO dependencies for create_final_nodes: ['create_base_entity_graph']
13:01:49,696 graphrag.index.run INFO read table from storage: create_base_entity_graph.parquet
13:01:49,755 datashaper.workflow.workflow INFO executing verb layout_graph
13:01:51,52 datashaper.workflow.workflow INFO executing verb unpack_graph
13:01:51,282 datashaper.workflow.workflow INFO executing verb unpack_graph
13:01:51,894 datashaper.workflow.workflow INFO executing verb filter
13:01:52,161 datashaper.workflow.workflow INFO executing verb drop
13:01:52,181 datashaper.workflow.workflow INFO executing verb select
13:01:52,206 datashaper.workflow.workflow INFO executing verb rename
13:01:52,234 datashaper.workflow.workflow INFO executing verb join
13:01:52,285 datashaper.workflow.workflow INFO executing verb convert
13:01:52,382 datashaper.workflow.workflow INFO executing verb rename
13:01:52,389 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_final_nodes.parquet
13:01:52,889 graphrag.index.run INFO Running workflow: create_final_communities...
13:01:52,890 graphrag.index.run INFO dependencies for create_final_communities: ['create_base_entity_graph']
13:01:52,892 graphrag.index.run INFO read table from storage: create_base_entity_graph.parquet
13:01:53,51 datashaper.workflow.workflow INFO executing verb unpack_graph
13:01:53,408 datashaper.workflow.workflow INFO executing verb unpack_graph
13:01:53,621 datashaper.workflow.workflow INFO executing verb aggregate_override
13:01:53,704 datashaper.workflow.workflow INFO executing verb join
13:01:53,758 datashaper.workflow.workflow INFO executing verb join
13:01:53,809 datashaper.workflow.workflow INFO executing verb concat
13:01:53,835 datashaper.workflow.workflow INFO executing verb filter
13:01:54,374 datashaper.workflow.workflow INFO executing verb aggregate_override
13:01:54,438 datashaper.workflow.workflow INFO executing verb join
13:01:54,483 datashaper.workflow.workflow INFO executing verb filter
13:01:54,569 datashaper.workflow.workflow INFO executing verb fill
13:01:54,625 datashaper.workflow.workflow INFO executing verb merge
13:01:54,684 datashaper.workflow.workflow INFO executing verb copy
13:01:54,705 datashaper.workflow.workflow INFO executing verb select
13:01:54,709 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_final_communities.parquet
13:01:55,116 graphrag.index.run INFO Running workflow: join_text_units_to_entity_ids...
13:01:55,129 graphrag.index.run INFO dependencies for join_text_units_to_entity_ids: ['create_final_entities']
13:01:55,130 graphrag.index.run INFO read table from storage: create_final_entities.parquet
13:01:55,261 datashaper.workflow.workflow INFO executing verb select
13:01:55,299 datashaper.workflow.workflow INFO executing verb unroll
13:01:55,336 datashaper.workflow.workflow INFO executing verb aggregate_override
13:01:55,349 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table join_text_units_to_entity_ids.parquet
13:01:55,679 graphrag.index.run INFO Running workflow: create_final_relationships...
13:01:55,679 graphrag.index.run INFO dependencies for create_final_relationships: ['create_base_entity_graph', 'create_final_nodes']
13:01:55,680 graphrag.index.run INFO read table from storage: create_base_entity_graph.parquet
13:01:55,693 graphrag.index.run INFO read table from storage: create_final_nodes.parquet
13:01:55,782 datashaper.workflow.workflow INFO executing verb unpack_graph
13:01:55,998 datashaper.workflow.workflow INFO executing verb filter
13:01:56,140 datashaper.workflow.workflow INFO executing verb rename
13:01:56,180 datashaper.workflow.workflow INFO executing verb filter
13:01:56,338 datashaper.workflow.workflow INFO executing verb drop
13:01:56,364 datashaper.workflow.workflow INFO executing verb compute_edge_combined_degree
13:01:56,431 datashaper.workflow.workflow INFO executing verb convert
13:01:56,551 datashaper.workflow.workflow INFO executing verb convert
13:01:56,558 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_final_relationships.parquet
13:01:56,994 graphrag.index.run INFO Running workflow: join_text_units_to_relationship_ids...
13:01:56,994 graphrag.index.run INFO dependencies for join_text_units_to_relationship_ids: ['create_final_relationships']
13:01:56,995 graphrag.index.run INFO read table from storage: create_final_relationships.parquet
13:01:57,89 datashaper.workflow.workflow INFO executing verb select
13:01:57,133 datashaper.workflow.workflow INFO executing verb unroll
13:01:57,162 datashaper.workflow.workflow INFO executing verb aggregate_override
13:01:57,204 datashaper.workflow.workflow INFO executing verb select
13:01:57,208 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table join_text_units_to_relationship_ids.parquet
13:01:57,631 graphrag.index.run INFO Running workflow: create_final_community_reports...
13:01:57,631 graphrag.index.run INFO dependencies for create_final_community_reports: ['create_final_relationships', 'create_final_nodes']
13:01:57,632 graphrag.index.run INFO read table from storage: create_final_relationships.parquet
13:01:57,640 graphrag.index.run INFO read table from storage: create_final_nodes.parquet
13:01:57,706 datashaper.workflow.workflow INFO executing verb prepare_community_reports_nodes
13:01:57,791 datashaper.workflow.workflow INFO executing verb prepare_community_reports_edges
13:01:57,841 datashaper.workflow.workflow INFO executing verb restore_community_hierarchy
13:01:57,884 datashaper.workflow.workflow INFO executing verb prepare_community_reports
13:01:57,890 graphrag.index.verbs.graph.report.prepare_community_reports INFO Number of nodes at level=2 => 969
13:01:57,998 graphrag.index.verbs.graph.report.prepare_community_reports INFO Number of nodes at level=1 => 969
13:01:58,399 graphrag.index.verbs.graph.report.prepare_community_reports INFO Number of nodes at level=0 => 969
13:01:58,592 datashaper.workflow.workflow INFO executing verb create_community_reports
13:02:00,121 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:02:00,131 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 0 retries took 1.422000000020489. input_tokens=2268, output_tokens=380
13:02:01,534 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:02:01,538 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 0 retries took 2.8130000000237487. input_tokens=2998, output_tokens=881
13:02:02,586 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:02:02,589 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 0 retries took 3.89000000001397. input_tokens=5323, output_tokens=644
13:02:04,88 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:02:04,93 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 0 retries took 1.5. input_tokens=2975, output_tokens=549
13:02:04,384 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:02:04,386 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 0 retries took 5.703000000037719. input_tokens=2895, output_tokens=524
13:02:07,759 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:02:07,760 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 0 retries took 9.062000000034459. input_tokens=2857, output_tokens=476
13:02:11,139 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:02:11,146 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 0 retries took 11.01500000001397. input_tokens=3567, output_tokens=553
13:02:13,579 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:02:13,584 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 0 retries took 12.03200000000652. input_tokens=2754, output_tokens=423
13:02:14,443 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:14,477 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n145,"""TRASTUZUMAB""","Here is a comprehensive summary of the data provided:\n\nTrastuzumab is a humanized anti-HER2 monoclonal antibody that is part of the anti-HER2 backbone for HER2+ IBC. It is a medication used in the treatment of HER2+ IBC, HER2-positive breast cancer, and breast cancer in general. Trastuzumab is a targeted therapy that targets HER2 receptors, blocking the HER2 protein to treat HER2-positive breast cancer. It is often used in combination with other medications, such as pertuzumab, docetaxel, and epirubicin, to treat breast cancer. Trastuzumab is also used in clinical trials and has been approved for HER2+ disease, including IBC. It is a type of monoclonal antibody that targets HER2 and is a treatment option for IBC, used in combination with lapatinib and paclitaxel. Additionally, trastuzumab is a chemotherapy drug used in the NeoSphere clinical trial and is a type of cancer treatment. Overall, trastuzumab is a medication used to treat HER2+ breast cancer by blocking the HER2 protein and is a targeted therapy approved for HER2+ disease, including IBC.",15\r\n200,"""NERATINIB""","Here is a comprehensive summary of the data:\n\nNeratinib is a medication used in various treatment settings for breast cancer. Specifically, it is used in adjuvant therapy for high-risk recurrent disease, including inflammatory breast cancer (IBC). Additionally, neratinib is used to treat HER2-positive breast cancer, particularly in high-risk situations. It is also offered as a treatment option for patients with HER2-positive breast cancer. Neratinib is a chemotherapy drug and a tyrosine kinase inhibitor, which is used in clinical trials. Overall, neratinib is a medication used in cancer treatment, with a focus on breast cancer, particularly HER2-positive disease.\n\nNote: I resolved the contradictions by combining the information from the different descriptions to provide a comprehensive summary. I also rephrased some of the sentences to ensure clarity and coherence.",8\r\n171,"""OVERMOYER ET AL.""","Here is a comprehensive summary of the data:\n\nOvermoyer et al. are researchers who have reported on the efficacy of a specific treatment regimen. According to their findings, neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab has shown promising results.",5\r\n62,"""HER2+ IBC""","Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.",4\r\n165,"""NEOSPHERE TRIAL""","Here is a comprehensive summary of the data:\n\nThe ""NEOSPHERE TRIAL"" is a clinical trial that investigated the use of pertuzumab plus trastuzumab in combination with an anthracycline-containing regimen in patients with HER2-positive breast cancer. Specifically, it is a phase 2 randomized neoadjuvant trial that tested the combination of pertuzumab with trastuzumab in breast cancer patients.",4\r\n114,"""NAC""","Here is a comprehensive summary of the data:\n\nNAC refers to neoadjuvant chemotherapy, a type of chemotherapy regimen used in the treatment of breast cancer. Specifically, NAC is a treatment protocol that is evaluated in clinical trials for the treatment of HER2-positive locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). It is a treatment option for IBC, used in combination with lapatinib, and has shown survival benefits for patients with LABC, including IBC, when combined with trastuzumab. NAC is a type of neoadjuvant chemotherapy that is associated with PD-L1 expression and is used in the TRYPHAENA study.",11\r\n340,"""PATIENT""","""Patient is the individual receiving treatment.""",10\r\n153,"""PERTUZUMAB""","Here is a comprehensive summary of the data provided:\n\nPertuzumab is a humanized anti-HER2 monoclonal antibody that binds the HER2 receptor at a different epitope from trastuzumab. It is a medication used in cancer treatment, specifically in the treatment of HER2-positive breast cancer, including inflammatory breast cancer (IBC). Pertuzumab is also used to treat HER2+ breast cancer, especially in combination with trastuzumab, by blocking the HER2 protein. As a targeted therapy, it targets HER2 receptors and induces antibody-dependent cell-mediated cytotoxicity. Pertuzumab is a type of monoclonal antibody that binds to the HER2 receptor and is used in breast cancer treatment. It is often used in combination with other treatments, such as T-DM1, as part of a treatment regimen for HER2+ breast cancer. Additionally, pertuzumab has been used in clinical trials, including the NeoSphere clinical trial, and is a chemotherapy drug.",10\r\n665,"""LANCET ONCOL""","Here is a comprehensive summary of the data:\n\n""Lancet Oncol"" is a medical research journal that has published numerous studies on various topics related to breast cancer. Specifically, the journal has published studies on adjuvant bevacizumab-containing therapy in triple-negative breast cancer, as well as neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer. Additionally, the journal has published research on Nab-paclitaxel and bevacizumab treatment in new models of inflammatory breast cancer, and has identified pathological response and circulating tumor cell count as indicators of excellent prognosis in treated HER2+ inflammatory breast cancer patients. Furthermore, the journal has published the results of the GeparQuinto study, which focused on inflammatory breast cancer. The journal has also published a study on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy. Overall, ""Lancet Oncol"" is a reputable and influential publication in the field of oncology, providing valuable insights and research findings to healthcare professionals and researchers.",3\r\n70,"""HER2""","Here is a comprehensive summary of the data:\n\nHER2 is a human epidermal growth factor receptor 2, a biomarker for breast cancer. It is a protein receptor that is often overexpressed in breast cancer, with an estimated prevalence of 25-35% in inflammatory breast cancer (IBC). HER2 is a target for breast cancer treatment, and its overexpression is associated with poor prognosis. The protein receptor is targeted by various therapies, including trastuzumab, lapatinib, pertuzumab, and T-DM1, among others. HER2 is also a predictive marker for the efficacy of trastuzumab addition in breast cancer treatment. Additionally, HER2 is a receptor that can dimerize with other ligands HER receptors and is associated with PD-L1 expression in breast cancer. HER2 status refers to the human epidermal growth factor receptor 2 status, which is an important factor in determining the effectiveness of breast cancer treatment. Overall, HER2 is a critical protein receptor in breast cancer, and its expression and targeting are crucial in the development of effective treatment strategies.",6\r\n189,"""T-DM1""","Here is a comprehensive summary of the data:\n\n""T-DM1"" is a medication used in the treatment of breast cancer. Specifically, it is a treatment for HER2+ Inflammatory Breast Cancer (IBC) cases without a pathologic complete response (pCR). Additionally, T-DM1 is a type of antibody-drug conjugate used to treat HER2+ breast cancer.",3\r\n151,"""ANTHRACYCLINE-CONTAINING REGIMEN""","Here is a comprehensive summary of the data:\n\nThe ""ANTHRACYCLINE-CONTAINING REGIMEN"" is a treatment protocol for breast cancer, specifically a type of chemotherapy regimen used to treat breast cancer. Furthermore, it is also used to treat HER2+ Inflammatory Breast Cancer (IBC). This regimen is a type of chemotherapy that is effective in treating HER2+ IBC.",1\r\n174,"""ATINIB""",No Description,1\r\n146,"""NOAH STUDY""","Here is a comprehensive summary of the data:\n\nThe NOAH study is a randomized phase 3 clinical trial that investigated the efficacy of trastuzumab addition in breast cancer treatment.",1\r\n107,"""BREAST MRI""","Here is a comprehensive summary of the data:\n\nBreast MRI is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n289,"""CAPECITABINE""","Here is a comprehensive summary of the data:\n\nCapecitabine is a chemotherapy drug used in the treatment of breast cancer. It is also a medication used in cancer treatment.",2\r\n97,"""CYCLOPHOSPHAMIDE""","Here is a comprehensive summary of the data:\n\nCyclophosphamide is a chemotherapy medication used in the treatment of breast cancer. It is a key component of a treatment regimen and is often used in combination with other medications, such as docetaxel, epirubicin, and trastuzumab, to effectively treat breast cancer. As a chemotherapy drug, cyclophosphamide is designed to target and destroy cancer cells, helping to slow or stop the growth of tumors.",1\r\n98,"""DOXORUBICIN""","Here is a comprehensive summary of the data:\n\nDoxorubicin is a chemotherapy medication used in the treatment of breast cancer and as part of a treatment regimen. It is a chemotherapy drug used to treat various types of cancer, including breast cancer.\n\nNote: I resolved the contradictions by combining the descriptions to provide a clear and concise summary. I also removed the quotation marks from the output to make it easier to read.",1\r\n337,"""ER""","Here is a comprehensive summary of the data:\n\nThe entity ""ER"" refers to estrogen receptor, which is a receptor associated with PD-L1 expression in breast cancer.",2\r\n148,"""FLUOROURACIL""","""Fluorouracil is a chemotherapy medication.""",1\r\n108,"""MAMMOGRAPHY""","Here is a comprehensive summary of the data:\n\nMammography is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n147,"""METHOTREXATE""","""Methotrexate is a chemotherapy medication.""",1\r\n680,"""N ENGL J MED""","Here is a comprehensive summary of the data:\n\n""N ENGL J MED"" is a medical journal that publishes research on various medical topics, including breast cancer. Specifically, it has published several studies on breast cancer, providing valuable insights and findings in the field. As a medical journal, it is dedicated to sharing knowledge and advancing the understanding of various medical conditions, including breast cancer. Additionally, it has published a study on pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, providing important information for healthcare professionals and researchers.",2\r\n109,"""SONOGRAPHY""","Here is a comprehensive summary of the data:\n\nSonography is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n685,"""VIALE G""","Here is a comprehensive summary of the data:\n\nVIALE G is a researcher who has been involved in a study on pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer. As an author, VIALE G has contributed to a medical study and a research paper, showcasing their expertise and involvement in the field of breast cancer research.",2\r\n773,"""TRASTUZUMAB EMTANSINE""","Here is a comprehensive summary of the data:\n\nTrastuzumab Emtansine is a medication that is used as a treatment for residual invasive HER2-positive breast cancer.",2\r\n256,"""ADJUVANT THERAPY""","Here is a comprehensive summary of the data:\n\nAdjuvant therapy refers to a treatment given after primary treatment to reduce the risk of recurrence. Specifically, in the context of Inflammatory Breast Cancer (IBC), adjuvant therapy is a type of treatment administered after surgery. This treatment is designed to target any remaining cancer cells that may have been left behind after initial surgery, with the goal of preventing the recurrence of the disease.",1\r\n341,"""AROMATASE INHIBITOR""","""Aromatase inhibitor is a medication used in cancer treatment.""",1\r\n303,"""BISPHOSPHONATE""","Here is a comprehensive summary of the data:\n\nBisphosphonate is a medication that has multiple uses in various medical contexts. In cancer treatment, it is used to help manage the disease. Specifically, it is used to increase bone density and improve survival rates in breast cancer patients. Additionally, bisphosphonate is used to treat osteoporosis by increasing bone density, which can help prevent fractures and other bone-related complications. Overall, bisphosphonate is a medication with a range of applications in both cancer treatment and osteoporosis management.",1\r\n775,"""KRISTINE""","""KRISTINE is a clinical trial.""",1\r\n292,"""TAMOXIFEN""","Here is a comprehensive summary of the data:\n\nTamoxifen is a medication that has been extensively studied in various papers and is used in the treatment of breast cancer. Specifically, it is a type of hormone therapy used in the treatment of breast cancer, and has been associated with improved survival outcomes when used for extended adjuvant endocrine therapy. Additionally, Tamoxifen is also used in cancer treatment more broadly.",1\r\n202,"""EXTENET""","Here is a comprehensive summary of the data:\n\nExteNET is a clinical trial that focused on HER2-positive breast cancer patients. Specifically, the trial studied the use of neratinib in breast cancer patients, providing valuable insights into its effectiveness in this patient population.",2\r\n198,"""KATERINE TRIAL""","Here is a comprehensive summary of the data:\n\nThe ""KATERINE TRIAL"" is a clinical trial that evaluates the effectiveness of adjuvant therapy in patients with HER2+ breast cancer, specifically in cases of inflammatory breast cancer (IBC) without a pathologic complete response (pCR). The trial investigates the use of adjuvant T-DM1, a type of targeted therapy, in these patients. The trial\'s findings recommend the use of adjuvant T-DM1 in HER2+ IBC cases without a pCR.\n\nNote: I resolved the contradictions by combining the information from the three descriptions, ensuring that the summary is coherent and accurate.",2\r\n288,"""CREATE-X""","""CREATE-X is a randomized phase 3 study on adjuvant capecitabine for breast cancer patients.""",2\r\n781,"""HARVEY VJ""","""Harvey VJ is an author of a medical study.""",1\r\n201,"""HER4""","""HER4 is a protein that is targeted by neratinib.""",1\r\n69,"""HR""","Here is a comprehensive summary of the data:\n\nHR, which stands for hormone receptor, is a protein receptor that plays a crucial role in breast cancer treatment. It is often overexpressed in breast cancer, making it a target for treatment. HR refers to the hormone receptor status, which is an important factor in determining the effectiveness of breast cancer treatment. In summary, HR is a protein receptor that is a target for breast cancer treatment due to its overexpression in the disease, and its status is an important consideration in treatment planning.",1\r\n778,"""CHAN A""","""Chan A is an author of a medical study.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n72,"""IBC""","""TRASTUZUMAB""","""Trastuzumab is used in the treatment of IBC, a type of breast cancer.""",69\r\n75,"""IBC""","""NERATINIB""","""Neratinib is used in adjuvant therapy for high-risk recurrent disease like IBC.""",62\r\n74,"""IBC""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of a neoadjuvant treatment for IBC patients, which is a high-risk disease.""",59\r\n78,"""IBC""","""HER2+ IBC""","""HER2+ IBC is a subtype of IBC.""",58\r\n73,"""IBC""","""NEOSPHERE TRIAL""","""The NeoSphere trial included 29 IBC patients.""",58\r\n196,"""TRASTUZUMAB""","""LAPATINIB""","""Trastuzumab and lapatinib are combined in a dual antibody treatment for breast cancer.""",27\r\n160,"""NAC""","""TRASTUZUMAB""","Based on the provided data, here is a comprehensive summary:\n\nNAC (Neoadjuvant Anthracycline-based Chemotherapy) is a treatment regimen that is combined with trastuzumab to treat certain types of breast cancer. Specifically, NAC is used in combination with trastuzumab to treat both Inflammatory Breast Cancer (IBC) and Locally Advanced Breast Cancer (LABC), which includes IBC. This treatment combination has been shown to provide survival benefits for patients with LABC, including those with IBC.\n\nNote: I resolved the potential contradiction by combining the two descriptions, ensuring that the summary accurately reflects the information provided.",26\r\n199,"""TRASTUZUMAB""","""PATIENT""","""Trastuzumab is used as a treatment option for patients.""",25\r\n192,"""TRASTUZUMAB""","""PERTUZUMAB""","Here is a comprehensive summary of the data:\n\nTrastuzumab and Pertuzumab are two medications that are used together to treat breast cancer, specifically HER2+ breast cancer. They are often used in combination therapy to combat this type of cancer. Both medications have similar mechanisms of binding to HER2 epitopes, making them suitable for combination therapy. Specifically, they are used together to treat breast cancer, with the combination of the two medications providing a more effective treatment option than either medication alone.\n\nNote: I resolved the contradictions by combining the information from all three descriptions to provide a clear and concise summary.",25\r\n246,"""GEPARQUINTO""","""LANCET ONCOL""","""GeparQuinto is published in Lancet Oncol.""",24\r\n163,"""NAC""","""LAPATINIB""","""NAC with lapatinib has a low pCR rate in HER2+ patients.""",23\r\n198,"""TRASTUZUMAB""","""BEVACIZUMAB""","""Bevacizumab is used in combination with Trastuzumab in the studies.""",23\r\n143,"""PACLITAXEL""","""TRASTUZUMAB""","""Trastuzumab is combined with paclitaxel in a treatment for breast cancer.""",23\r\n131,"""HER2""","""TRASTUZUMAB""","""Trastuzumab is targeted towards HER2+ disease, including IBC.""",21\r\n194,"""TRASTUZUMAB""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",20\r\n204,"""PERTUZUMAB""","""PATIENT""","""Pertuzumab is used as a treatment option for patients.""",20\r\n115,"""HER2+ IBC""","""TRASTUZUMAB""","""Trastuzumab is used as a standard neoadjuvant treatment for HER2+ IBC patients.""",19\r\n140,"""PACLITAXEL""","""NAC""","""Paclitaxel is part of the NAC regimen.""",19\r\n193,"""TRASTUZUMAB""","""NEOSPHERE TRIAL""","""Trastuzumab was used in the NeoSphere trial as part of combination therapy with pertuzumab and docetaxel.""",19\r\n132,"""HER2""","""LAPATINIB""","""Lapatinib blocks intracellular HER2, which is a target for cancer treatment.""",18\r\n164,"""NAC""","""PD-L1""","""NAC is associated with PD-L1 expression in breast cancer.""",18\r\n256,"""NERATINIB""","""PATIENT""","""Neratinib is offered as a treatment option for patients.""",18\r\n197,"""TRASTUZUMAB""","""T-DM1""","""T-DM1 is compared to trastuzumab in terms of response and toxicity in the neoadjuvant setting.""",18\r\n191,"""TRASTUZUMAB""","""ANTHRACYCLINE-CONTAINING REGIMEN""","""Trastuzumab is used in combination with an anthracycline-containing regimen for breast cancer treatment.""",16\r\n195,"""TRASTUZUMAB""","""ATINIB""","""atinib and trastuzumab are both medications used in cancer treatment, with different effects on pCR rate.""",16\r\n135,"""HER2""","""PATIENT""","""Patient\'s HER2 status is used to determine treatment options.""",16\r\n527,"""PIERGA JY""","""LANCET ONCOL""","""Pierga JY published a study in Lancet Oncol on inflammatory breast cancer.""",16\r\n190,"""TRASTUZUMAB""","""NOAH STUDY""","Here is a comprehensive summary of the data:\n\nThe NOAH study evaluated the efficacy of trastuzumab, specifically in the context of neoadjuvant treatment, in combination with chemotherapy, compared to chemotherapy alone. Additionally, the study investigated the effectiveness of adding trastuzumab to breast cancer treatment.\n\nNote: I resolved the potential contradiction by combining the two descriptions, focusing on the specific context of neoadjuvant treatment and the addition of trastuzumab to breast cancer treatment.",16\r\n202,"""PERTUZUMAB""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",15\r\n212,"""TRYPHAENA""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the results of the TRYPHAENA study, which investigated the efficacy of a neoadjuvant treatment for IBC patients.""",15\r\n133,"""HER2""","""NERATINIB""","""Neratinib targets HER2, a protein involved in breast cancer.""",14\r\n114,"""HER2+ IBC""","""PERTUZUMAB""","""Pertuzumab is used as a standard neoadjuvant treatment for HER2+ IBC patients.""",14\r\n201,"""PERTUZUMAB""","""NEOSPHERE TRIAL""","""Pertuzumab was used in the NeoSphere trial as part of combination therapy with trastuzumab and docetaxel.""",14\r\n134,"""HER2""","""PD-L1""","""HER2 is associated with PD-L1 expression in breast cancer.""",13\r\n28,"""BREAST CANCER""","""NEOSPHERE TRIAL""","""The NeoSphere trial tested the combination of pertuzumab with trastuzumab in breast cancer patients.""",13\r\n141,"""PACLITAXEL""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",13\r\n203,"""PERTUZUMAB""","""T-DM1""","Here is a comprehensive summary of the data:\n\nPertuzumab and T-DM1 are two entities related to the treatment of breast cancer. According to the descriptions, T-DM1 is an alternative to pertuzumab in the treatment of breast cancer, suggesting that it can be used as a substitute or complementary therapy. Additionally, T-DM1 is often combined with pertuzumab in a treatment for breast cancer, indicating that the two entities are frequently used together. Furthermore, T-DM1 is used in combination with pertuzumab in the neoadjuvant setting, which is a treatment approach that involves administering medications before surgery to shrink tumors and make them more manageable. Notably, this combination therapy is associated with a favorable toxicity profile, meaning that it is well-tolerated by patients.\n\nOverall, the descriptions suggest that pertuzumab and T-DM1 are both used in the treatment of breast cancer, often in combination with each other, and that this combination therapy has a favorable safety profile.",13\r\n152,"""BREAST MRI""","""NAC""","""Breast MRI is used to assess the effectiveness of NAC in IBC.""",12\r\n291,"""CAPECITABINE""","""PATIENT""","""Capecitabine is used as a treatment option for patients.""",12\r\n149,"""CYCLOPHOSPHAMIDE""","""NAC""","""Cyclophosphamide is part of the NAC regimen.""",12\r\n150,"""DOXORUBICIN""","""NAC""","""Doxorubicin is part of the NAC regimen.""",12\r\n300,"""ER""","""PATIENT""","""Patient\'s ER status is used to determine treatment options.""",12\r\n162,"""NAC""","""FLUOROURACIL""","""Fluorouracil is part of the NAC regimen.""",12\r\n153,"""MAMMOGRAPHY""","""NAC""","""Mammography is used to assess the effectiveness of NAC in IBC.""",12\r\n161,"""NAC""","""METHOTREXATE""","""Methotrexate is part of the NAC regimen.""",12\r\n208,"""PERTUZUMAB""","""N ENGL J MED""","""N Engl J Med published a paper on Pertuzumab.""",12\r\n154,"""SONOGRAPHY""","""NAC""","""Sonography is used to assess the effectiveness of NAC in IBC.""",12\r\n157,"""EGFR""","""NERATINIB""","""Neratinib targets EGFR, a protein involved in breast cancer.""",12\r\n205,"""PERTUZUMAB""","""VIALE G""","""Viale G is involved in the development of Pertuzumab.""",12\r\n206,"""PERTUZUMAB""","""TRASTUZUMAB EMTANSINE""","""Trastuzumab Emtansine is related to Pertuzumab.""",12\r\n285,"""ADJUVANT THERAPY""","""PATIENT""","""Adjuvant therapy is given to patients after primary treatment.""",11\r\n301,"""PATIENT""","""AROMATASE INHIBITOR""","""Aromatase inhibitor is used as a treatment option for patients.""",11\r\n293,"""BISPHOSPHONATE""","""PATIENT""","""Bisphosphonate is used as a treatment option for patients.""",11\r\n108,"""INSTITUTE""","""HER2+ IBC""","""The institute has reported on the results of HER2+ IBC, including its longest median OS after brain metastasis and relation to the anti-HER2 therapy era.""",11\r\n207,"""PERTUZUMAB""","""KRISTINE""","""KRISTINE is a clinical trial involving Pertuzumab.""",11\r\n292,"""TAMOXIFEN""","""PATIENT""","""Tamoxifen is used as a treatment option for patients.""",11\r\n254,"""NERATINIB""","""EXTENET""","""Neratinib was studied in the ExteNET clinical trial.""",10\r\n253,"""KATERINE TRIAL""","""NERATINIB""","""The KATERINE trial recommended adjuvant T-DM1, which includes Neratinib, in HER2+ IBC cases without a pCR.""",10\r\n128,"""OS""","""CREATE-X""","""CREATE-X shows that adjuvant capecitabine can improve overall survival in breast cancer patients.""",9\r\n295,"""PD-L1""","""ER""","""ER is associated with PD-L1 expression in breast cancer.""",9\r\n257,"""NERATINIB""","""HARVEY VJ""","""Harvey VJ is involved in the development of Neratinib.""",9\r\n255,"""NERATINIB""","""HER4""","""Neratinib targets HER4, a protein involved in breast cancer.""",9\r\n130,"""HR""","""HER2""","""HER2 and HR are protein receptors that are targets for breast cancer treatment.""",7\r\n258,"""EXTENET""","""LANCET ONCOL""","""ExteNET is published in Lancet Oncol.""",5\r\n252,"""T-DM1""","""KATERINE TRIAL""","""The KATERINE trial evaluated the use of T-DM1 as adjuvant therapy in patients with HER2+ breast cancer.""",5\r\n290,"""CREATE-X""","""CAPECITABINE""","""CREATE-X is a study on the effectiveness of adjuvant capecitabine in breast cancer patients.""",4\r\n583,"""N ENGL J MED""","""TRASTUZUMAB EMTANSINE""","""Trastuzumab Emtansine is published in N Engl J Med.""",4\r\n584,"""VIALE G""","""CHAN A""","""Viale G and Chan A are co-authors of a medical study.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:14,479 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 1/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:16,70 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:16,90 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n145,"""TRASTUZUMAB""","Here is a comprehensive summary of the data provided:\n\nTrastuzumab is a humanized anti-HER2 monoclonal antibody that is part of the anti-HER2 backbone for HER2+ IBC. It is a medication used in the treatment of HER2+ IBC, HER2-positive breast cancer, and breast cancer in general. Trastuzumab is a targeted therapy that targets HER2 receptors, blocking the HER2 protein to treat HER2-positive breast cancer. It is often used in combination with other medications, such as pertuzumab, docetaxel, and epirubicin, to treat breast cancer. Trastuzumab is also used in clinical trials and has been approved for HER2+ disease, including IBC. It is a type of monoclonal antibody that targets HER2 and is a treatment option for IBC, used in combination with lapatinib and paclitaxel. Additionally, trastuzumab is a chemotherapy drug used in the NeoSphere clinical trial and is a type of cancer treatment. Overall, trastuzumab is a medication used to treat HER2+ breast cancer by blocking the HER2 protein and is a targeted therapy approved for HER2+ disease, including IBC.",15\r\n200,"""NERATINIB""","Here is a comprehensive summary of the data:\n\nNeratinib is a medication used in various treatment settings for breast cancer. Specifically, it is used in adjuvant therapy for high-risk recurrent disease, including inflammatory breast cancer (IBC). Additionally, neratinib is used to treat HER2-positive breast cancer, particularly in high-risk situations. It is also offered as a treatment option for patients with HER2-positive breast cancer. Neratinib is a chemotherapy drug and a tyrosine kinase inhibitor, which is used in clinical trials. Overall, neratinib is a medication used in cancer treatment, with a focus on breast cancer, particularly HER2-positive disease.\n\nNote: I resolved the contradictions by combining the information from the different descriptions to provide a comprehensive summary. I also rephrased some of the sentences to ensure clarity and coherence.",8\r\n171,"""OVERMOYER ET AL.""","Here is a comprehensive summary of the data:\n\nOvermoyer et al. are researchers who have reported on the efficacy of a specific treatment regimen. According to their findings, neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab has shown promising results.",5\r\n62,"""HER2+ IBC""","Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.",4\r\n165,"""NEOSPHERE TRIAL""","Here is a comprehensive summary of the data:\n\nThe ""NEOSPHERE TRIAL"" is a clinical trial that investigated the use of pertuzumab plus trastuzumab in combination with an anthracycline-containing regimen in patients with HER2-positive breast cancer. Specifically, it is a phase 2 randomized neoadjuvant trial that tested the combination of pertuzumab with trastuzumab in breast cancer patients.",4\r\n114,"""NAC""","Here is a comprehensive summary of the data:\n\nNAC refers to neoadjuvant chemotherapy, a type of chemotherapy regimen used in the treatment of breast cancer. Specifically, NAC is a treatment protocol that is evaluated in clinical trials for the treatment of HER2-positive locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). It is a treatment option for IBC, used in combination with lapatinib, and has shown survival benefits for patients with LABC, including IBC, when combined with trastuzumab. NAC is a type of neoadjuvant chemotherapy that is associated with PD-L1 expression and is used in the TRYPHAENA study.",11\r\n340,"""PATIENT""","""Patient is the individual receiving treatment.""",10\r\n153,"""PERTUZUMAB""","Here is a comprehensive summary of the data provided:\n\nPertuzumab is a humanized anti-HER2 monoclonal antibody that binds the HER2 receptor at a different epitope from trastuzumab. It is a medication used in cancer treatment, specifically in the treatment of HER2-positive breast cancer, including inflammatory breast cancer (IBC). Pertuzumab is also used to treat HER2+ breast cancer, especially in combination with trastuzumab, by blocking the HER2 protein. As a targeted therapy, it targets HER2 receptors and induces antibody-dependent cell-mediated cytotoxicity. Pertuzumab is a type of monoclonal antibody that binds to the HER2 receptor and is used in breast cancer treatment. It is often used in combination with other treatments, such as T-DM1, as part of a treatment regimen for HER2+ breast cancer. Additionally, pertuzumab has been used in clinical trials, including the NeoSphere clinical trial, and is a chemotherapy drug.",10\r\n665,"""LANCET ONCOL""","Here is a comprehensive summary of the data:\n\n""Lancet Oncol"" is a medical research journal that has published numerous studies on various topics related to breast cancer. Specifically, the journal has published studies on adjuvant bevacizumab-containing therapy in triple-negative breast cancer, as well as neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer. Additionally, the journal has published research on Nab-paclitaxel and bevacizumab treatment in new models of inflammatory breast cancer, and has identified pathological response and circulating tumor cell count as indicators of excellent prognosis in treated HER2+ inflammatory breast cancer patients. Furthermore, the journal has published the results of the GeparQuinto study, which focused on inflammatory breast cancer. The journal has also published a study on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy. Overall, ""Lancet Oncol"" is a reputable and influential publication in the field of oncology, providing valuable insights and research findings to healthcare professionals and researchers.",3\r\n70,"""HER2""","Here is a comprehensive summary of the data:\n\nHER2 is a human epidermal growth factor receptor 2, a biomarker for breast cancer. It is a protein receptor that is often overexpressed in breast cancer, with an estimated prevalence of 25-35% in inflammatory breast cancer (IBC). HER2 is a target for breast cancer treatment, and its overexpression is associated with poor prognosis. The protein receptor is targeted by various therapies, including trastuzumab, lapatinib, pertuzumab, and T-DM1, among others. HER2 is also a predictive marker for the efficacy of trastuzumab addition in breast cancer treatment. Additionally, HER2 is a receptor that can dimerize with other ligands HER receptors and is associated with PD-L1 expression in breast cancer. HER2 status refers to the human epidermal growth factor receptor 2 status, which is an important factor in determining the effectiveness of breast cancer treatment. Overall, HER2 is a critical protein receptor in breast cancer, and its expression and targeting are crucial in the development of effective treatment strategies.",6\r\n189,"""T-DM1""","Here is a comprehensive summary of the data:\n\n""T-DM1"" is a medication used in the treatment of breast cancer. Specifically, it is a treatment for HER2+ Inflammatory Breast Cancer (IBC) cases without a pathologic complete response (pCR). Additionally, T-DM1 is a type of antibody-drug conjugate used to treat HER2+ breast cancer.",3\r\n151,"""ANTHRACYCLINE-CONTAINING REGIMEN""","Here is a comprehensive summary of the data:\n\nThe ""ANTHRACYCLINE-CONTAINING REGIMEN"" is a treatment protocol for breast cancer, specifically a type of chemotherapy regimen used to treat breast cancer. Furthermore, it is also used to treat HER2+ Inflammatory Breast Cancer (IBC). This regimen is a type of chemotherapy that is effective in treating HER2+ IBC.",1\r\n174,"""ATINIB""",No Description,1\r\n146,"""NOAH STUDY""","Here is a comprehensive summary of the data:\n\nThe NOAH study is a randomized phase 3 clinical trial that investigated the efficacy of trastuzumab addition in breast cancer treatment.",1\r\n107,"""BREAST MRI""","Here is a comprehensive summary of the data:\n\nBreast MRI is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n289,"""CAPECITABINE""","Here is a comprehensive summary of the data:\n\nCapecitabine is a chemotherapy drug used in the treatment of breast cancer. It is also a medication used in cancer treatment.",2\r\n97,"""CYCLOPHOSPHAMIDE""","Here is a comprehensive summary of the data:\n\nCyclophosphamide is a chemotherapy medication used in the treatment of breast cancer. It is a key component of a treatment regimen and is often used in combination with other medications, such as docetaxel, epirubicin, and trastuzumab, to effectively treat breast cancer. As a chemotherapy drug, cyclophosphamide is designed to target and destroy cancer cells, helping to slow or stop the growth of tumors.",1\r\n98,"""DOXORUBICIN""","Here is a comprehensive summary of the data:\n\nDoxorubicin is a chemotherapy medication used in the treatment of breast cancer and as part of a treatment regimen. It is a chemotherapy drug used to treat various types of cancer, including breast cancer.\n\nNote: I resolved the contradictions by combining the descriptions to provide a clear and concise summary. I also removed the quotation marks from the output to make it easier to read.",1\r\n337,"""ER""","Here is a comprehensive summary of the data:\n\nThe entity ""ER"" refers to estrogen receptor, which is a receptor associated with PD-L1 expression in breast cancer.",2\r\n148,"""FLUOROURACIL""","""Fluorouracil is a chemotherapy medication.""",1\r\n108,"""MAMMOGRAPHY""","Here is a comprehensive summary of the data:\n\nMammography is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n147,"""METHOTREXATE""","""Methotrexate is a chemotherapy medication.""",1\r\n680,"""N ENGL J MED""","Here is a comprehensive summary of the data:\n\n""N ENGL J MED"" is a medical journal that publishes research on various medical topics, including breast cancer. Specifically, it has published several studies on breast cancer, providing valuable insights and findings in the field. As a medical journal, it is dedicated to sharing knowledge and advancing the understanding of various medical conditions, including breast cancer. Additionally, it has published a study on pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, providing important information for healthcare professionals and researchers.",2\r\n109,"""SONOGRAPHY""","Here is a comprehensive summary of the data:\n\nSonography is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n685,"""VIALE G""","Here is a comprehensive summary of the data:\n\nVIALE G is a researcher who has been involved in a study on pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer. As an author, VIALE G has contributed to a medical study and a research paper, showcasing their expertise and involvement in the field of breast cancer research.",2\r\n773,"""TRASTUZUMAB EMTANSINE""","Here is a comprehensive summary of the data:\n\nTrastuzumab Emtansine is a medication that is used as a treatment for residual invasive HER2-positive breast cancer.",2\r\n256,"""ADJUVANT THERAPY""","Here is a comprehensive summary of the data:\n\nAdjuvant therapy refers to a treatment given after primary treatment to reduce the risk of recurrence. Specifically, in the context of Inflammatory Breast Cancer (IBC), adjuvant therapy is a type of treatment administered after surgery. This treatment is designed to target any remaining cancer cells that may have been left behind after initial surgery, with the goal of preventing the recurrence of the disease.",1\r\n341,"""AROMATASE INHIBITOR""","""Aromatase inhibitor is a medication used in cancer treatment.""",1\r\n303,"""BISPHOSPHONATE""","Here is a comprehensive summary of the data:\n\nBisphosphonate is a medication that has multiple uses in various medical contexts. In cancer treatment, it is used to help manage the disease. Specifically, it is used to increase bone density and improve survival rates in breast cancer patients. Additionally, bisphosphonate is used to treat osteoporosis by increasing bone density, which can help prevent fractures and other bone-related complications. Overall, bisphosphonate is a medication with a range of applications in both cancer treatment and osteoporosis management.",1\r\n775,"""KRISTINE""","""KRISTINE is a clinical trial.""",1\r\n292,"""TAMOXIFEN""","Here is a comprehensive summary of the data:\n\nTamoxifen is a medication that has been extensively studied in various papers and is used in the treatment of breast cancer. Specifically, it is a type of hormone therapy used in the treatment of breast cancer, and has been associated with improved survival outcomes when used for extended adjuvant endocrine therapy. Additionally, Tamoxifen is also used in cancer treatment more broadly.",1\r\n202,"""EXTENET""","Here is a comprehensive summary of the data:\n\nExteNET is a clinical trial that focused on HER2-positive breast cancer patients. Specifically, the trial studied the use of neratinib in breast cancer patients, providing valuable insights into its effectiveness in this patient population.",2\r\n198,"""KATERINE TRIAL""","Here is a comprehensive summary of the data:\n\nThe ""KATERINE TRIAL"" is a clinical trial that evaluates the effectiveness of adjuvant therapy in patients with HER2+ breast cancer, specifically in cases of inflammatory breast cancer (IBC) without a pathologic complete response (pCR). The trial investigates the use of adjuvant T-DM1, a type of targeted therapy, in these patients. The trial\'s findings recommend the use of adjuvant T-DM1 in HER2+ IBC cases without a pCR.\n\nNote: I resolved the contradictions by combining the information from the three descriptions, ensuring that the summary is coherent and accurate.",2\r\n288,"""CREATE-X""","""CREATE-X is a randomized phase 3 study on adjuvant capecitabine for breast cancer patients.""",2\r\n781,"""HARVEY VJ""","""Harvey VJ is an author of a medical study.""",1\r\n201,"""HER4""","""HER4 is a protein that is targeted by neratinib.""",1\r\n69,"""HR""","Here is a comprehensive summary of the data:\n\nHR, which stands for hormone receptor, is a protein receptor that plays a crucial role in breast cancer treatment. It is often overexpressed in breast cancer, making it a target for treatment. HR refers to the hormone receptor status, which is an important factor in determining the effectiveness of breast cancer treatment. In summary, HR is a protein receptor that is a target for breast cancer treatment due to its overexpression in the disease, and its status is an important consideration in treatment planning.",1\r\n778,"""CHAN A""","""Chan A is an author of a medical study.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n72,"""IBC""","""TRASTUZUMAB""","""Trastuzumab is used in the treatment of IBC, a type of breast cancer.""",69\r\n75,"""IBC""","""NERATINIB""","""Neratinib is used in adjuvant therapy for high-risk recurrent disease like IBC.""",62\r\n74,"""IBC""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of a neoadjuvant treatment for IBC patients, which is a high-risk disease.""",59\r\n78,"""IBC""","""HER2+ IBC""","""HER2+ IBC is a subtype of IBC.""",58\r\n73,"""IBC""","""NEOSPHERE TRIAL""","""The NeoSphere trial included 29 IBC patients.""",58\r\n196,"""TRASTUZUMAB""","""LAPATINIB""","""Trastuzumab and lapatinib are combined in a dual antibody treatment for breast cancer.""",27\r\n160,"""NAC""","""TRASTUZUMAB""","Based on the provided data, here is a comprehensive summary:\n\nNAC (Neoadjuvant Anthracycline-based Chemotherapy) is a treatment regimen that is combined with trastuzumab to treat certain types of breast cancer. Specifically, NAC is used in combination with trastuzumab to treat both Inflammatory Breast Cancer (IBC) and Locally Advanced Breast Cancer (LABC), which includes IBC. This treatment combination has been shown to provide survival benefits for patients with LABC, including those with IBC.\n\nNote: I resolved the potential contradiction by combining the two descriptions, ensuring that the summary accurately reflects the information provided.",26\r\n199,"""TRASTUZUMAB""","""PATIENT""","""Trastuzumab is used as a treatment option for patients.""",25\r\n192,"""TRASTUZUMAB""","""PERTUZUMAB""","Here is a comprehensive summary of the data:\n\nTrastuzumab and Pertuzumab are two medications that are used together to treat breast cancer, specifically HER2+ breast cancer. They are often used in combination therapy to combat this type of cancer. Both medications have similar mechanisms of binding to HER2 epitopes, making them suitable for combination therapy. Specifically, they are used together to treat breast cancer, with the combination of the two medications providing a more effective treatment option than either medication alone.\n\nNote: I resolved the contradictions by combining the information from all three descriptions to provide a clear and concise summary.",25\r\n246,"""GEPARQUINTO""","""LANCET ONCOL""","""GeparQuinto is published in Lancet Oncol.""",24\r\n163,"""NAC""","""LAPATINIB""","""NAC with lapatinib has a low pCR rate in HER2+ patients.""",23\r\n198,"""TRASTUZUMAB""","""BEVACIZUMAB""","""Bevacizumab is used in combination with Trastuzumab in the studies.""",23\r\n143,"""PACLITAXEL""","""TRASTUZUMAB""","""Trastuzumab is combined with paclitaxel in a treatment for breast cancer.""",23\r\n131,"""HER2""","""TRASTUZUMAB""","""Trastuzumab is targeted towards HER2+ disease, including IBC.""",21\r\n194,"""TRASTUZUMAB""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",20\r\n204,"""PERTUZUMAB""","""PATIENT""","""Pertuzumab is used as a treatment option for patients.""",20\r\n115,"""HER2+ IBC""","""TRASTUZUMAB""","""Trastuzumab is used as a standard neoadjuvant treatment for HER2+ IBC patients.""",19\r\n140,"""PACLITAXEL""","""NAC""","""Paclitaxel is part of the NAC regimen.""",19\r\n193,"""TRASTUZUMAB""","""NEOSPHERE TRIAL""","""Trastuzumab was used in the NeoSphere trial as part of combination therapy with pertuzumab and docetaxel.""",19\r\n132,"""HER2""","""LAPATINIB""","""Lapatinib blocks intracellular HER2, which is a target for cancer treatment.""",18\r\n164,"""NAC""","""PD-L1""","""NAC is associated with PD-L1 expression in breast cancer.""",18\r\n256,"""NERATINIB""","""PATIENT""","""Neratinib is offered as a treatment option for patients.""",18\r\n197,"""TRASTUZUMAB""","""T-DM1""","""T-DM1 is compared to trastuzumab in terms of response and toxicity in the neoadjuvant setting.""",18\r\n191,"""TRASTUZUMAB""","""ANTHRACYCLINE-CONTAINING REGIMEN""","""Trastuzumab is used in combination with an anthracycline-containing regimen for breast cancer treatment.""",16\r\n195,"""TRASTUZUMAB""","""ATINIB""","""atinib and trastuzumab are both medications used in cancer treatment, with different effects on pCR rate.""",16\r\n135,"""HER2""","""PATIENT""","""Patient\'s HER2 status is used to determine treatment options.""",16\r\n527,"""PIERGA JY""","""LANCET ONCOL""","""Pierga JY published a study in Lancet Oncol on inflammatory breast cancer.""",16\r\n190,"""TRASTUZUMAB""","""NOAH STUDY""","Here is a comprehensive summary of the data:\n\nThe NOAH study evaluated the efficacy of trastuzumab, specifically in the context of neoadjuvant treatment, in combination with chemotherapy, compared to chemotherapy alone. Additionally, the study investigated the effectiveness of adding trastuzumab to breast cancer treatment.\n\nNote: I resolved the potential contradiction by combining the two descriptions, focusing on the specific context of neoadjuvant treatment and the addition of trastuzumab to breast cancer treatment.",16\r\n202,"""PERTUZUMAB""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",15\r\n212,"""TRYPHAENA""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the results of the TRYPHAENA study, which investigated the efficacy of a neoadjuvant treatment for IBC patients.""",15\r\n133,"""HER2""","""NERATINIB""","""Neratinib targets HER2, a protein involved in breast cancer.""",14\r\n114,"""HER2+ IBC""","""PERTUZUMAB""","""Pertuzumab is used as a standard neoadjuvant treatment for HER2+ IBC patients.""",14\r\n201,"""PERTUZUMAB""","""NEOSPHERE TRIAL""","""Pertuzumab was used in the NeoSphere trial as part of combination therapy with trastuzumab and docetaxel.""",14\r\n134,"""HER2""","""PD-L1""","""HER2 is associated with PD-L1 expression in breast cancer.""",13\r\n28,"""BREAST CANCER""","""NEOSPHERE TRIAL""","""The NeoSphere trial tested the combination of pertuzumab with trastuzumab in breast cancer patients.""",13\r\n141,"""PACLITAXEL""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",13\r\n203,"""PERTUZUMAB""","""T-DM1""","Here is a comprehensive summary of the data:\n\nPertuzumab and T-DM1 are two entities related to the treatment of breast cancer. According to the descriptions, T-DM1 is an alternative to pertuzumab in the treatment of breast cancer, suggesting that it can be used as a substitute or complementary therapy. Additionally, T-DM1 is often combined with pertuzumab in a treatment for breast cancer, indicating that the two entities are frequently used together. Furthermore, T-DM1 is used in combination with pertuzumab in the neoadjuvant setting, which is a treatment approach that involves administering medications before surgery to shrink tumors and make them more manageable. Notably, this combination therapy is associated with a favorable toxicity profile, meaning that it is well-tolerated by patients.\n\nOverall, the descriptions suggest that pertuzumab and T-DM1 are both used in the treatment of breast cancer, often in combination with each other, and that this combination therapy has a favorable safety profile.",13\r\n152,"""BREAST MRI""","""NAC""","""Breast MRI is used to assess the effectiveness of NAC in IBC.""",12\r\n291,"""CAPECITABINE""","""PATIENT""","""Capecitabine is used as a treatment option for patients.""",12\r\n149,"""CYCLOPHOSPHAMIDE""","""NAC""","""Cyclophosphamide is part of the NAC regimen.""",12\r\n150,"""DOXORUBICIN""","""NAC""","""Doxorubicin is part of the NAC regimen.""",12\r\n300,"""ER""","""PATIENT""","""Patient\'s ER status is used to determine treatment options.""",12\r\n162,"""NAC""","""FLUOROURACIL""","""Fluorouracil is part of the NAC regimen.""",12\r\n153,"""MAMMOGRAPHY""","""NAC""","""Mammography is used to assess the effectiveness of NAC in IBC.""",12\r\n161,"""NAC""","""METHOTREXATE""","""Methotrexate is part of the NAC regimen.""",12\r\n208,"""PERTUZUMAB""","""N ENGL J MED""","""N Engl J Med published a paper on Pertuzumab.""",12\r\n154,"""SONOGRAPHY""","""NAC""","""Sonography is used to assess the effectiveness of NAC in IBC.""",12\r\n157,"""EGFR""","""NERATINIB""","""Neratinib targets EGFR, a protein involved in breast cancer.""",12\r\n205,"""PERTUZUMAB""","""VIALE G""","""Viale G is involved in the development of Pertuzumab.""",12\r\n206,"""PERTUZUMAB""","""TRASTUZUMAB EMTANSINE""","""Trastuzumab Emtansine is related to Pertuzumab.""",12\r\n285,"""ADJUVANT THERAPY""","""PATIENT""","""Adjuvant therapy is given to patients after primary treatment.""",11\r\n301,"""PATIENT""","""AROMATASE INHIBITOR""","""Aromatase inhibitor is used as a treatment option for patients.""",11\r\n293,"""BISPHOSPHONATE""","""PATIENT""","""Bisphosphonate is used as a treatment option for patients.""",11\r\n108,"""INSTITUTE""","""HER2+ IBC""","""The institute has reported on the results of HER2+ IBC, including its longest median OS after brain metastasis and relation to the anti-HER2 therapy era.""",11\r\n207,"""PERTUZUMAB""","""KRISTINE""","""KRISTINE is a clinical trial involving Pertuzumab.""",11\r\n292,"""TAMOXIFEN""","""PATIENT""","""Tamoxifen is used as a treatment option for patients.""",11\r\n254,"""NERATINIB""","""EXTENET""","""Neratinib was studied in the ExteNET clinical trial.""",10\r\n253,"""KATERINE TRIAL""","""NERATINIB""","""The KATERINE trial recommended adjuvant T-DM1, which includes Neratinib, in HER2+ IBC cases without a pCR.""",10\r\n128,"""OS""","""CREATE-X""","""CREATE-X shows that adjuvant capecitabine can improve overall survival in breast cancer patients.""",9\r\n295,"""PD-L1""","""ER""","""ER is associated with PD-L1 expression in breast cancer.""",9\r\n257,"""NERATINIB""","""HARVEY VJ""","""Harvey VJ is involved in the development of Neratinib.""",9\r\n255,"""NERATINIB""","""HER4""","""Neratinib targets HER4, a protein involved in breast cancer.""",9\r\n130,"""HR""","""HER2""","""HER2 and HR are protein receptors that are targets for breast cancer treatment.""",7\r\n258,"""EXTENET""","""LANCET ONCOL""","""ExteNET is published in Lancet Oncol.""",5\r\n252,"""T-DM1""","""KATERINE TRIAL""","""The KATERINE trial evaluated the use of T-DM1 as adjuvant therapy in patients with HER2+ breast cancer.""",5\r\n290,"""CREATE-X""","""CAPECITABINE""","""CREATE-X is a study on the effectiveness of adjuvant capecitabine in breast cancer patients.""",4\r\n583,"""N ENGL J MED""","""TRASTUZUMAB EMTANSINE""","""Trastuzumab Emtansine is published in N Engl J Med.""",4\r\n584,"""VIALE G""","""CHAN A""","""Viale G and Chan A are co-authors of a medical study.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:16,91 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 2/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:18,37 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:02:18,41 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 0 retries took 4.311999999976251. input_tokens=4693, output_tokens=584
13:02:18,503 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:18,516 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n437,"""CRISTOFANILLI M""","Here is a comprehensive summary of the data:\n\nCristofanilli M is a researcher who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on inflammatory breast cancer management in the National Comprehensive Cancer Network. Additionally, they were involved in the GeparQuinto study, which further highlights their expertise in this area.\n\nCristofanilli M is also an author of several research papers and studies on inflammatory breast cancer. These publications include a study on breast cancer treatment, as well as studies on inflammatory breast cancer management, neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer, paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer, and the prognostic significance of HER-2 status in women with inflammatory breast cancer.\n\nOverall, Cristofanilli M is a prominent researcher in the field of inflammatory breast cancer, with a focus on management, treatment, and prognosis.",18\r\n172,"""LAPATINIB""","Here is a comprehensive summary of the data:\n\nLapatinib is a small-molecule tyrosine kinase inhibitor that blocks intracellular HER2 and EGFR signaling pathways. It is a targeted therapy used to treat cancer, and is also used in combination with other therapies, such as Pazopanib, trastuzumab, and NAC, to treat various types of cancer, including breast cancer. Specifically, it is a treatment option for inflammatory breast cancer (IBC) when used in combination with NAC and trastuzumab. Additionally, lapatinib is an antibody-drug conjugate used in breast cancer treatment. Overall, lapatinib is a medication used in cancer treatment, specifically targeting HER2 and EGFR signaling pathways to inhibit the growth and spread of cancer cells.",12\r\n228,"""PAZOPANIB""","Here is a comprehensive summary of the data:\n\nPazopanib is a small-molecule multi-tyrosine kinase inhibitor used to treat cancer. Specifically, it is a targeted therapy used in combination with other treatments for breast cancer, and also used in combination therapy to treat a disease.\n\nNote: I resolved the contradictions by combining the information from all the descriptions to provide a single, coherent summary.",7\r\n435,"""MATRO JM""","Here is a comprehensive summary of the data:\n\nMatro JM is a person who has conducted a study on inflammatory breast cancer management in the National Comprehensive Cancer Network.",5\r\n844,"""JOHNSTON SR""","Here is a comprehensive summary of the data:\n\nJohnston SR is a researcher who has made significant contributions to the field of breast cancer research. Specifically, he has been involved in studies focused on HER2-positive advanced breast cancer, demonstrating his expertise in this area. Additionally, he has also authored a research paper on inflammatory breast cancer, showcasing his breadth of knowledge and expertise in the field.",3\r\n528,"""GONZALEZ-ANGULO AM""","""Gonzalez-Angulo AM is an author of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",1\r\n529,"""KAU SW""","Here is a comprehensive summary of the data:\n\nKau SW is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Kau SW is an author of two studies that have shed light on the prognosis and treatment of inflammatory breast cancer. In one study, Kau SW investigated the impact of paclitaxel on the prognosis of estrogen receptor negative inflammatory breast cancer, demonstrating its potential to improve patient outcomes. In another study, Kau SW examined the prognostic significance of HER-2 status in women with inflammatory breast cancer, providing valuable insights into the role of this biomarker in predicting patient outcomes.",1\r\n530,"""FRYE DK""","""Frye DK is an author of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",1\r\n536,"""SMITH T""","""Smith T is an author of a study on breast cancer treatment.""",1\r\n537,"""WASAFF B""","""Wasaff B is an author of a study on breast cancer treatment.""",1\r\n538,"""IBRAHIM N""","""Ibrahim N is an author of a study on breast cancer treatment.""",1\r\n850,"""MANIKHAS A""","Here is a comprehensive summary of the data:\n\nManikhas A is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Manikhas A has been involved in studies focused on HER2-positive advanced breast cancer, demonstrating expertise in this area. Additionally, Manikhas A has also authored a research paper on inflammatory breast cancer, further expanding their scope of research and expertise.",1\r\n856,"""GOMEZ HL""","""Gomez HL is a researcher involved in studies on HER2-positive advanced breast cancer.""",1\r\n851,"""GLADKOV O""","Here is a comprehensive summary of the data:\n\nGladkov O is a researcher who has been involved in studies on HER2-positive advanced breast cancer and inflammatory breast cancer. Specifically, Gladkov O is an author of a research paper on inflammatory breast cancer, and has also contributed to studies on HER2-positive advanced breast cancer.\n\nNote: I did not find any contradictions in the provided descriptions, so the summary is a straightforward concatenation of the information.",1\r\n852,"""SHAO Z""","Here is a comprehensive summary of the data:\n\nShao Z is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Shao Z has been involved in studies on HER2-positive advanced breast cancer, demonstrating their expertise in this area. Additionally, Shao Z has also authored a research paper on inflammatory breast cancer, further highlighting their breadth of knowledge and research experience in the field of breast cancer.",1\r\n244,"""AFATINIB""","Here is a comprehensive summary of the data:\n\nAfatinib is a drug used in the treatment of HER2-positive inflammatory breast cancer. Specifically, it is an irreversible ErbB family blocker with preclinical activity in trastuzumab-resistant cell lines.",3\r\n247,"""SURVIVAL""","Here is a comprehensive summary of the data:\n\nThe entity ""SURVIVAL"" refers to the length of time a patient lives after being diagnosed with breast cancer. Specifically, it refers to the length of time a patient with breast cancer lives after diagnosis.\n\nNote: The two descriptions provided are identical, with only minor wording variations. I have combined them into a single summary to provide a clear and concise overview of the entity ""SURVIVAL"".",3\r\n229,"""VEG20007""","""VEG20007 is a randomized phase 2 study evaluating first-line lapatinib plus pazopanib therapy or lapatinib monotherapy.""",1\r\n236,"""LAPATINIB MONOTHERAPY""","""Lapatinib monotherapy is a treatment approach that uses a single medication to treat a disease.""",2\r\n438,"""HUGHES ME""","Here is a comprehensive summary of the data:\n\nHughes ME is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the National Comprehensive Cancer Network (NCCN) and authored a study on the same subject.",1\r\n436,"""LI T""","Here is a comprehensive summary of the data:\n\nLi T is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, Li T conducted a study on the topic within the National Comprehensive Cancer Network (NCCN), demonstrating expertise in the area. Additionally, Li T is an author of a study on inflammatory breast cancer management, further solidifying their reputation as a knowledgeable and experienced researcher in this field.",1\r\n439,"""OTTESEN RA""","Here is a comprehensive summary of the data:\n\nOttesen RA is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the national comprehensive cancer network, demonstrating their expertise and involvement in the field. Additionally, Ottesen RA is also an author of a study on inflammatory breast cancer management, further solidifying their reputation as a knowledgeable and authoritative figure in this area of research.",1\r\n440,"""WEEKS JC""","Here is a comprehensive summary of the data:\n\nWeeks JC is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the National Comprehensive Cancer Network (NCCN) and authored a study on the same subject.",1\r\n243,"""DISEASE""",No Description,1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n239,"""GEPARQUINTO""","""CRISTOFANILLI M""","""Cristofanilli M is a researcher involved in the GeparQuinto study.""",39\r\n227,"""LAPATINIB""","""CRISTOFANILLI M""","""Cristofanilli M is an author of a research paper on a randomized phase II study of lapatinib plus pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.""",30\r\n196,"""TRASTUZUMAB""","""LAPATINIB""","""Trastuzumab and lapatinib are combined in a dual antibody treatment for breast cancer.""",27\r\n277,"""PAZOPANIB""","""CRISTOFANILLI M""","""Cristofanilli M is an author of a research paper on a randomized phase II study of lapatinib plus pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.""",25\r\n353,"""MATRO JM""","""CRISTOFANILLI M""","""Matro JM and Cristofanilli M are co-authors of a study on inflammatory breast cancer management.""",23\r\n163,"""NAC""","""LAPATINIB""","""NAC with lapatinib has a low pCR rate in HER2+ patients.""",23\r\n326,"""HORTOBAGYI GN""","""CRISTOFANILLI M""","""Cristofanilli M and Hortobagyi GN are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",22\r\n358,"""CRISTOFANILLI M""","""BUZDAR AU""","""Cristofanilli M and Buzdar AU are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",21\r\n365,"""CRISTOFANILLI M""","""JOHNSTON SR""","""Cristofanilli M and Johnston SR are co-authors of a study on HER2-positive advanced breast cancer.""",21\r\n361,"""CRISTOFANILLI M""","""SNEIGE N""","""Cristofanilli M and Sneige N are co-authors of a study on breast cancer treatment.""",20\r\n120,"""PCR""","""LAPATINIB""","""lapatinib has a lower pCR rate than expected in HER2+ patients.""",20\r\n142,"""PACLITAXEL""","""LAPATINIB""","Here is a comprehensive summary of the data:\n\nPACLITAXEL and LAPATINIB are two medications used in cancer treatment. Specifically, they are combined in a treatment for breast cancer, where LAPATINIB is paired with PACLITAXEL to provide a comprehensive treatment approach. Additionally, both medications have different effects on the pCR (pathological complete response) rate, indicating that they have distinct mechanisms of action in cancer treatment.",20\r\n357,"""CRISTOFANILLI M""","""GONZALEZ-ANGULO AM""","""Cristofanilli M and Gonzalez-Angulo AM are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n359,"""CRISTOFANILLI M""","""KAU SW""","""Cristofanilli M and Kau SW are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n360,"""CRISTOFANILLI M""","""FRYE DK""","""Cristofanilli M and Frye DK are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n362,"""CRISTOFANILLI M""","""SMITH T""","""Cristofanilli M and Smith T are co-authors of a study on breast cancer treatment.""",19\r\n363,"""CRISTOFANILLI M""","""WASAFF B""","""Cristofanilli M and Wasaff B are co-authors of a study on breast cancer treatment.""",19\r\n364,"""CRISTOFANILLI M""","""IBRAHIM N""","""Cristofanilli M and Ibrahim N are co-authors of a study on breast cancer treatment.""",19\r\n366,"""CRISTOFANILLI M""","""MANIKHAS A""","""Cristofanilli M and Manikhas A are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n367,"""CRISTOFANILLI M""","""GOMEZ HL""","""Cristofanilli M and Gomez HL are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n368,"""CRISTOFANILLI M""","""GLADKOV O""","""Cristofanilli M and Gladkov O are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n369,"""CRISTOFANILLI M""","""SHAO Z""","""Cristofanilli M and Shao Z are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n222,"""LAPATINIB""","""PAZOPANIB""","""pazopanib is used in combination with lapatinib in a clinical trial (VEG20007) for the treatment of cancer.""",19\r\n125,"""OS""","""LAPATINIB""","""lapatinib does not differ in 3-year OS rate compared to trastuzumab.""",19\r\n132,"""HER2""","""LAPATINIB""","""Lapatinib blocks intracellular HER2, which is a target for cancer treatment.""",18\r\n224,"""LAPATINIB""","""AFATINIB""","""Lapatinib and Afatinib are both targeted therapies used to treat breast cancer, with Afatinib showing preclinical activity in trastuzumab-resistant cell lines.""",15\r\n226,"""LAPATINIB""","""JOHNSTON SR""","""Johnston SR is an author of a research paper on the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.""",15\r\n225,"""LAPATINIB""","""SURVIVAL""","""Lapatinib is associated with a higher rate of serious adverse events, which can impact patient survival.""",15\r\n223,"""LAPATINIB""","""VEG20007""","""VEG20007 is a study evaluating the effectiveness of lapatinib monotherapy or lapatinib plus pazopanib therapy for the treatment of cancer.""",13\r\n272,"""PAZOPANIB""","""COMBINATION THERAPY""","""Pazopanib is used in combination therapy to treat the disease.""",13\r\n274,"""PAZOPANIB""","""AFATINIB""","""Pazopanib and Afatinib are both targeted therapies used to treat breast cancer, with Pazopanib showing a higher rate of serious adverse events than Afatinib.""",10\r\n276,"""PAZOPANIB""","""JOHNSTON SR""","""Johnston SR is an author of a research paper on the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.""",10\r\n275,"""PAZOPANIB""","""SURVIVAL""","""Pazopanib is associated with a higher rate of serious adverse events, which can impact patient survival.""",10\r\n273,"""PAZOPANIB""","""LAPATINIB MONOTHERAPY""","""Pazopanib is used in lapatinib monotherapy to treat the disease.""",9\r\n283,"""AFATINIB""","""SURVIVAL""","""Afatinib is associated with a shorter survival time, which can impact patient outcomes.""",6\r\n354,"""MATRO JM""","""HUGHES ME""","""Matro JM and Hughes ME are co-authors of a study on inflammatory breast cancer management.""",6\r\n352,"""MATRO JM""","""LI T""","""Matro JM and Li T are co-authors of a study on inflammatory breast cancer management.""",6\r\n355,"""MATRO JM""","""OTTESEN RA""","""Matro JM and Ottesen RA are co-authors of a study on inflammatory breast cancer management.""",6\r\n356,"""MATRO JM""","""WEEKS JC""","""Matro JM and Weeks JC are co-authors of a study on inflammatory breast cancer management.""",6\r\n281,"""LAPATINIB MONOTHERAPY""","""DISEASE""","""Lapatinib monotherapy is used to treat the disease.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:18,516 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 1/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:18,882 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:02:18,886 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 0 retries took 5.1560000000172295. input_tokens=3157, output_tokens=540
13:02:19,30 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:02:19,34 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 0 retries took 5.313000000023749. input_tokens=4660, output_tokens=752
13:02:19,302 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:02:19,304 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 0 retries took 5.577999999979511. input_tokens=4263, output_tokens=590
13:02:19,404 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:19,408 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n459,"""CLIN BREAST CANCER""","Based on the provided data, here is a comprehensive summary of the entity ""CLIN BREAST CANCER"":\n\nCLIN BREAST CANCER is a medical journal that publishes research on breast cancer, specifically focusing on the management of inflammatory breast cancer. The journal has published studies on various aspects of breast cancer, including a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. This treatment regimen involves pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, along with trastuzumab as preoperative treatment.",7\r\n669,"""CANCELLO G""","Here is a comprehensive summary of the data:\n\nCancello G is a researcher who has been involved in studies on inflammatory breast cancer. Specifically, Cancello G is an author of a study on a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. The treatment regimen consisted of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, plus trastuzumab, as preoperative treatment.",2\r\n670,"""DELLAPASQUA S""","Here is a comprehensive summary of the data:\n\nDellapasqua S is a researcher who has been involved in studies on inflammatory breast cancer. Specifically, Dellapasqua S is an author of a study on a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. The treatment regimen consisted of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, plus trastuzumab, as preoperative treatment.",2\r\n815,"""BAGNARDI V""","""Bagnardi V is a researcher involved in studies on inflammatory breast cancer.""",1\r\n813,"""PALAZZO A""","""Palazzo A is a researcher involved in studies on inflammatory breast cancer.""",1\r\n814,"""MUNZONE E""","""Munzone E is a researcher involved in studies on inflammatory breast cancer.""",1\r\n816,"""MAZZA M""","""Mazza M is a researcher involved in studies on inflammatory breast cancer.""",1\r\n667,"""TORRISI R""","""Torrisi R is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",5\r\n671,"""BALDUZZI A""","""Balduzzi A is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n668,"""CARDILLO A""","""Cardillo A is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n672,"""GHISINI R""","""Ghisini R is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n398,"""CLIN BREAST CANCER""","""PIERGA JY""","""Pierga JY published a study in Clin Breast Cancer on inflammatory breast cancer.""",20\r\n397,"""CLIN BREAST CANCER""","""CANCELLO G""","""Cancello G published a study in Clin Breast Cancer on inflammatory breast cancer.""",9\r\n393,"""CLIN BREAST CANCER""","""DELLAPASQUA S""","""Dellapasqua S published a study in Clin Breast Cancer on inflammatory breast cancer.""",9\r\n395,"""CLIN BREAST CANCER""","""BAGNARDI V""","""Bagnardi V published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n392,"""CLIN BREAST CANCER""","""PALAZZO A""","""Palazzo A published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n394,"""CLIN BREAST CANCER""","""MUNZONE E""","""Munzone E published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n396,"""CLIN BREAST CANCER""","""MAZZA M""","""Mazza M published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n573,"""TORRISI R""","""CANCELLO G""","""Torrisi R and Cancello G are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",7\r\n574,"""TORRISI R""","""DELLAPASQUA S""","""Torrisi R and Dellapasqua S are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",7\r\n575,"""TORRISI R""","""BALDUZZI A""","""Torrisi R and Balduzzi A are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n572,"""TORRISI R""","""CARDILLO A""","""Torrisi R and Cardillo A are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n576,"""TORRISI R""","""GHISINI R""","""Torrisi R and Ghisini R are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:19,409 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 1/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:19,414 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:19,417 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n48,"""IBC""","Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.",54\r\n85,"""PACLITAXEL""","Here is a comprehensive summary of the data provided:\n\n""PACLITAXEL"" is a chemotherapy agent used to treat breast cancer, specifically in the treatment of HER2-negative locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). It is a chemotherapy drug studied in various clinical trials and has been evaluated for its effectiveness in treating breast cancer. PACLITAXEL is used in combination with other medications, such as pembrolizumab, bevacizumab, trastuzumab, and lapatinib, to treat breast cancer. It is also used as a single agent in the treatment regimen for breast cancer. PACLITAXEL is a type of chemotherapy medication used in the treatment of breast cancer, and it is a treatment option for IBC patients.",8\r\n322,"""PD-L1""","Here is a comprehensive summary of the data:\n\nPD-L1 is a protein that plays a crucial role in immunotherapy, particularly in the context of inflammatory breast cancer (IBC). It is expressed on the surface of some cancer cells and is targeted by atezolizumab, a therapeutic agent. Additionally, PD-L1 is an immune checkpoint molecule found in tumor cells and TILs (tumor-infiltrating lymphocytes) of IBC. Furthermore, PD-L1 refers to a protein expressed on the surface of tumor cells that can inhibit the immune system\'s ability to recognize and attack cancer cells. Overall, PD-L1 is a key protein involved in the immune response to cancer, and its expression and function have significant implications for the development of effective cancer therapies.",7\r\n117,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","Here is a comprehensive summary of the data:\n\nHIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION is a treatment regimen for Inflammatory Breast Cancer (IBC).\n\nThis summary includes information from the provided description, which states that HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION is a treatment regimen for IBC.",4\r\n335,"""ARIAS-PULIDO ET AL.""","Here is a comprehensive summary of the data:\n\nArias-Pulido et al. is a research group that has made significant contributions to the field of cancer research. Specifically, they reported on the presence of PD-L1 positivity in tumor-infiltrating lymphocytes (TILs) and its association with better disease-free survival (DFS).",3\r\n336,"""BERCKELAER ET AL.""","Here is a comprehensive summary of the data:\n\nBerckelaer et al. is a research group that has reported on PD-L1 expression in TILs (Tumor-Infiltrating Lymphocytes).",3\r\n338,"""TILS""","Here is a comprehensive summary of the data:\n\nTILs (Tumor-Infiltrating Lymphocytes) are a type of immune cell that plays a crucial role in immunotherapy, particularly in the context of inflammatory breast cancer (IBC). They are more frequently found in IBC than in non-IBC, indicating a specific association with this type of cancer. TILs are associated with PD-L1 expression, which is linked to better disease-free survival (DFS). As immune cells found in the tumor microenvironment, TILs are an important component of the immune response against cancer.",3\r\n17,"""IMMUNOTHERAPY""","Here is a comprehensive summary of the data:\n\nImmunotherapy is a type of cancer treatment that uses the body\'s immune system to fight cancer. It is a type of systemic treatment that targets cancer cells and helps the body\'s immune system recognize and attack them. Specifically, immunotherapy is a treatment option for breast cancer, including inflammatory breast cancer (IBC). This type of treatment harnesses the body\'s natural defenses to combat cancer, making it a promising approach for cancer patients.",3\r\n86,"""FAC""","Here is a comprehensive summary of the data:\n\nFAC is a chemotherapy regimen used to treat breast cancer, as well as a technology used in clinical trials.",2\r\n343,"""I-SPY2""","Here is a comprehensive summary of the data:\n\n""I-SPY2"" is a clinical trial that combines chemotherapy and an immune checkpoint inhibitor for the treatment of Inflammatory Breast Cancer (IBC).",2\r\n75,"""RADIATION ONCOLOGIST""","Here is a comprehensive summary of the data:\n\nA radiation oncologist is a medical professional who specializes in the treatment of cancer using radiation therapy. They are a type of doctor who focuses on the use of radiation therapy to combat cancer.\n\nNote: I combined the two descriptions to create a single, coherent summary that includes all the relevant information.",2\r\n116,"""INTERNATIONAL EXPERT CONSENSUS""","Here is a comprehensive summary of the data:\n\nThe ""INTERNATIONAL EXPERT CONSENSUS"" refers to a collective agreement on the treatment of Inflammatory Breast Cancer (IBC).",2\r\n143,"""STANDARD OF CARE""","""Standard of Care refers to the accepted and widely used treatment approach for IBC.""",2\r\n342,"""KEYNOTE-522""","Here is a comprehensive summary of the data:\n\nKEYNOTE-522 is a clinical trial that combines chemotherapy and an immune checkpoint inhibitor for the treatment of Inflammatory Breast Cancer (IBC).",2\r\n87,"""ANTHRACYCLINE""","Here is a comprehensive summary of the data:\n\nAnthracycline is a chemotherapy agent used to treat breast cancer. It is a type of chemotherapy specifically designed to combat breast cancer.\n\nNote: I resolved the contradictions by combining the two descriptions into a single, coherent summary.",1\r\n252,"""ANTHRACYCLINE-BASED CHEMOTHERAPY""","""Anthracycline-based Chemotherapy is a type of chemotherapy used in the treatment of IBC.""",1\r\n347,"""ANTI-EGFR AGENT""","""Anti-EGFR agents are a type of targeted therapy that targets the EGFR protein, which is overexpressed in IBC.""",1\r\n348,"""ANTIPD-L1 ANTIBODY""","""Anti-PD-L1 antibodies are a type of immune checkpoint inhibitor that helps the immune system fight cancer, including IBC.""",1\r\n353,"""BC""",No Description,1\r\n334,"""BERTUCCI ET AL.""","""Bertucci et al. is a research group that reported PD-L1 overexpression in breast cancer tumors.""",1\r\n215,"""CARBOPLATIN""","Here is a comprehensive summary of the data:\n\nCarboplatin is a chemotherapy agent used in the treatment of various types of cancer, including breast cancer and inflammatory breast cancer (IBC). It is a chemotherapy drug that is often used in combination with other medications to treat cancer. Specifically, Carboplatin is used in the treatment of breast cancer, and it is also used to treat IBC. Additionally, it is classified as a type of cancer treatment and a type of chemotherapy used in the treatment of IBC. Overall, Carboplatin is a medication used in cancer treatment, specifically in the treatment of breast cancer and IBC.",1\r\n80,"""CHEMOTHERAPY""","Here is a comprehensive summary of the data:\n\nChemotherapy is a type of systemic treatment that uses chemicals to kill cancer cells, including those associated with breast cancer, including inflammatory breast cancer (IBC). It is a treatment option for breast cancer, including IBC, and is evaluated in clinical trials for its effectiveness in treating the disease. Specifically, chemotherapy is combined with T-DM1 in the TCHP regimen, a treatment approach that has shown promise in the fight against breast cancer. Overall, chemotherapy is a widely used and effective treatment for breast cancer, including IBC, that has been shown to be effective in clinical trials and is often used in combination with other treatments.",1\r\n74,"""DIAGNOSTIC RADIOLOGIST""","""Diagnostic radiologist is a type of doctor who specializes in the interpretation of imaging tests.""",1\r\n89,"""DITSCH ET AL.""","""Ditsch et al. are researchers who conducted a study on chemotherapy dose intensity in IBC patients.""",1\r\n88,"""FAC REGIMEN""","""FAC regimen is a chemotherapy treatment protocol.""",1\r\n71,"""MEDICAL ONCOLOGIST""","""Medical oncologist is a type of doctor who specializes in cancer treatment.""",1\r\n72,"""SURGEON""","""Surgeon is a type of doctor who specializes in surgical procedures.""",1\r\n73,"""PATHOLOGIST""","""Pathologist is a type of doctor who specializes in the diagnosis of diseases through the examination of tissues and cells.""",1\r\n84,"""MD ANDERSON""",No Description,1\r\n106,"""NON-IBC""","Here is a comprehensive summary of the data:\n\nNon-IBC (Non-Inflammatory Breast Cancer) refers to a type of breast cancer that is not Inflammatory Breast Cancer (IBC). Notably, Non-IBC has a similar pathological complete response (pCR) rate to ER-negative IBC, indicating that it shares some similarities with IBC in terms of treatment outcomes.",1\r\n285,"""TALIMOGENE LAHERPAREPVEC""","Here is a comprehensive summary of the data:\n\nTalimogene laherparepvec is a treatment regimen. Specifically, it is a treatment regimen for local recurrence IBC (inflammatory breast cancer) or inoperable non-IBC (non-inflammatory breast cancer).",1\r\n319,"""MULTIDISCIPLINARY TEAM""","Here is a comprehensive summary of the data:\n\nThe MULTIDISCIPLINARY TEAM is a group of healthcare professionals who work together to provide comprehensive care for patients with breast cancer. This team of experts evaluates and treats patients with breast cancer, offering a collaborative approach to patient care.",1\r\n346,"""IMMUNE CHECKPOINT INHIBITOR""","""Immune checkpoint inhibitors are a type of treatment that helps the immune system fight cancer, including IBC.""",1\r\n351,"""LAABC""","""LAABC is a type of breast cancer that is different from IBC.""",1\r\n352,"""LA BC""","""LA BC is an abbreviation for Localized Adenocarcinoma Breast Cancer, a type of breast cancer.""",1\r\n38,"""TUMOR EMBOLI""","Here is a comprehensive summary of the data:\n\nTumor emboli refer to the presence of tumor cells in the lymphatic vessels, which may be present or absent in biopsy specimens.",1\r\n41,"""LYMPHEDEMA""","""Lymphedema is a condition characterized by swelling caused by tumor emboli within dermal lymphatics.""",1\r\n90,"""ESTROGEN RECEPTOR""",No Description,1\r\n121,"""CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH""","""Center for International Blood and Marrow Transplant Research is an organization that conducts research on blood and marrow transplants.""",1\r\n120,"""INTERNATIONAL BLOOD AND MARROW TRANSPLANT REGISTRY""","""International Blood and Marrow Transplant Registry is an organization that tracks and reports on blood and marrow transplant data.""",1\r\n18,"""ONGOING IBC CLINICAL TRIALS""","""Ongoing IBC Clinical Trials refer to current research studies investigating new treatments for IBC.""",1\r\n96,"""G-CSF""","Here is a comprehensive summary of the data:\n\nG-CSF is a medication used to support the treatment regimen, specifically in clinical trials for the treatment of HER2-negative (HER2-) Locally Advanced Breast Cancer (LABC) or Inflammatory Breast Cancer (IBC). It is a growth factor used to support the dose-dense chemotherapy regimen, as well as to support the growth of white blood cells during chemotherapy. Additionally, G-CSF is a technology used in clinical trials, highlighting its role in the development and evaluation of new treatments. Overall, G-CSF plays a crucial role in supporting patients undergoing chemotherapy, particularly those with HER2- LABC or IBC, and is an important component of clinical trials aimed at improving treatment outcomes.",1\r\n78,"""TEAM""","""Team is a group of medical professionals working together to improve the survival of IBC.""",1\r\n144,"""RANDOMIZED TRIALS""","""Randomized Trials are studies that compare the effectiveness of different treatment approaches for IBC.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n72,"""IBC""","""TRASTUZUMAB""","""Trastuzumab is used in the treatment of IBC, a type of breast cancer.""",69\r\n30,"""BREAST CANCER""","""IBC""","""IBC is a subtype of Breast Cancer that requires specific treatment.""",63\r\n52,"""IBC""","""PCR""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) patients who achieve pCR (Pathological Complete Response) have better survival outcomes than those who do not. pCR is a measure of the effectiveness of treatment for IBC, indicating that the treatment has successfully eliminated all cancer cells from the breast tissue.",62\r\n62,"""IBC""","""PACLITAXEL""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) is a type of breast cancer that can be treated with Paclitaxel, a chemotherapy medication. According to the descriptions, Paclitaxel is used as part of a neoadjuvant regimen to treat IBC patients, and it is also used to treat IBC patients directly. Additionally, Paclitaxel is used to treat IBC, a type of breast cancer. Overall, Paclitaxel is a treatment option for IBC patients, and its use is likely part of a comprehensive treatment plan that may include other medications and therapies.",62\r\n75,"""IBC""","""NERATINIB""","""Neratinib is used in adjuvant therapy for high-risk recurrent disease like IBC.""",62\r\n40,"""SYSTEMIC TREATMENT""","""IBC""","""IBC is treated with systemic treatment, including chemotherapy and targeted therapy.""",62\r\n53,"""IBC""","""OS""","""IBC patients have poor overall survival rates, with a 5-year OS rate of less than 5%.""",61\r\n89,"""IBC""","""PD-L1""","""IBC is associated with PD-L1, an immune checkpoint molecule found in tumor cells and TILs.""",61\r\n91,"""IBC""","""INSTITUTE""","""Institute demonstrates IBC preclinical data supporting a combination of targeted therapy and an immune checkpoint inhibitor.""",61\r\n85,"""IBC""","""PEMBROLIZUMAB""","""Pembrolizumab is used in the treatment of IBC, a type of breast cancer characterized by rapid onset and aggressive growth.""",60\r\n74,"""IBC""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of a neoadjuvant treatment for IBC patients, which is a high-risk disease.""",59\r\n67,"""IBC""","""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""High-dose chemotherapy with autologous hematopoietic stem cell transplantation is a treatment option for IBC.""",58\r\n73,"""IBC""","""NEOSPHERE TRIAL""","""The NeoSphere trial included 29 IBC patients.""",58\r\n76,"""IBC""","""PANITUMUMAB""","""Panitumumab is used in certain circumstances for IBC cases, targeting EGFR expression.""",58\r\n77,"""IBC""","""EGFR""","""EGFR expression is associated with worse prognosis in IBC cases.""",58\r\n78,"""IBC""","""HER2+ IBC""","""HER2+ IBC is a subtype of IBC.""",58\r\n88,"""IBC""","""ARIAS-PULIDO ET AL.""","""Arias-Pulido et al. studied PD-L1 positivity in IBC samples.""",57\r\n87,"""IBC""","""BERCKELAER ET AL.""","""Berckelaer et al. studied PD-L1 expression in TILs in the context of IBC.""",57\r\n71,"""IBC""","""LABC""","""LABC includes IBC, a type of breast cancer with high-risk characteristics.""",57\r\n90,"""IBC""","""TILS""","Here is a comprehensive summary of the data:\n\nThe entities ""IBC"" and ""TILs"" are related to each other. TILs (Tumor-Infiltrating Lymphocytes) are found in the tumor microenvironment of IBC (Invasive Breast Cancer). Additionally, TILs are more frequently found in IBC compared to non-IBC.",57\r\n3,"""VICENTE VALERO""","""IBC""","""Vicente Valero is a member of the IBC working group.""",57\r\n43,"""IMMUNOTHERAPY""","""IBC""","Here is a comprehensive summary of the data:\n\nIMMUNOTHERAPY is a potential treatment option for Inflammatory Breast Cancer (IBC).",57\r\n63,"""IBC""","""FAC""","""FAC is used to treat IBC patients.""",56\r\n93,"""IBC""","""I-SPY2""","""IBC is the disease being treated in the I-SPY2 clinical trial.""",56\r\n58,"""IBC""","""RADIATION ONCOLOGIST""","""Radiation oncologists are part of a multidisciplinary team that treats IBC patients.""",56\r\n61,"""IBC""","""CRISTOFANILLI ET AL.""","""Cristofanilli et al. conducted a study on IBC patients.""",56\r\n68,"""IBC""","""INTERNATIONAL EXPERT CONSENSUS""","""International Expert Consensus provides guidance on the treatment of IBC.""",56\r\n70,"""IBC""","""STANDARD OF CARE""","""IBC is treated according to the Standard of Care, which involves the use of various therapies, including chemotherapy and transplantation.""",56\r\n79,"""IBC""","""TARGETED THERAPY""","""Targeted Therapy is a treatment option for IBC.""",56\r\n81,"""IBC""","""TAXANE-BASED CHEMOTHERAPY""","""Taxane-based Chemotherapy is used in the treatment of IBC.""",56\r\n92,"""IBC""","""KEYNOTE-522""","""IBC is the disease being treated in the KEYNOTE-522 clinical trial.""",56\r\n64,"""IBC""","""ANTHRACYCLINE""","""Anthracycline is used to treat IBC patients.""",55\r\n80,"""IBC""","""ANTHRACYCLINE-BASED CHEMOTHERAPY""","""Anthracycline-based Chemotherapy is used in the treatment of IBC.""",55\r\n95,"""IBC""","""ANTI-EGFR AGENT""","""Anti-EGFR agents are a potential treatment for IBC.""",55\r\n96,"""IBC""","""ANTIPD-L1 ANTIBODY""","""Anti-PD-L1 antibodies are a potential treatment for IBC.""",55\r\n98,"""IBC""","""BC""","""BC is related to IBC as a medical organization or institution may be involved in the study and treatment of IBC.""",55\r\n86,"""IBC""","""BERTUCCI ET AL.""","""Bertucci et al. reported PD-L1 overexpression in IBC tumors.""",55\r\n82,"""IBC""","""CARBOPLATIN""","""Carboplatin is used in the treatment of IBC.""",55\r\n60,"""IBC""","""CHEMOTHERAPY""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) is a type of breast cancer that can be treated with chemotherapy. According to the descriptions, chemotherapy is a potential treatment option for IBC, and it has been reported to be effective in treating the disease. Specifically, chemotherapy has been used to treat IBC with a reported objective response rate of 74% and a median overall survival (OS) of 37 months.",55\r\n57,"""IBC""","""DIAGNOSTIC RADIOLOGIST""","""Diagnostic radiologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n66,"""IBC""","""DITSCH ET AL.""","""Ditsch et al. conducted a study on chemotherapy dose intensity in IBC patients.""",55\r\n65,"""IBC""","""FAC REGIMEN""","""FAC regimen is used to treat IBC, a type of breast cancer.""",55\r\n54,"""IBC""","""MEDICAL ONCOLOGIST""","""Medical oncologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n55,"""IBC""","""SURGEON""","""Surgeons are part of a multidisciplinary team that treats IBC patients.""",55\r\n56,"""IBC""","""PATHOLOGIST""","""Pathologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n59,"""IBC""","""MD ANDERSON""","""MD Anderson conducted a retrospective study on IBC patients, providing insights into the treatment of IBC.""",55\r\n69,"""IBC""","""NON-IBC""","""IBC and non-IBC are compared in terms of OS rate and outcomes.""",55\r\n83,"""IBC""","""TALIMOGENE LAHERPAREPVEC""","""Talimogene laherparepvec is a treatment for IBC patients, specifically for TNBC patients.""",55\r\n84,"""IBC""","""MULTIDISCIPLINARY TEAM""","""The Multidisciplinary team evaluates and treats patients with IBC, a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body.""",55\r\n94,"""IBC""","""IMMUNE CHECKPOINT INHIBITOR""","""Immune checkpoint inhibitors are a potential treatment for IBC.""",55\r\n97,"""IBC""","""LAABC""","""LAABC is different from IBC.""",55\r\n99,"""IBC""","""LA BC""","""IBC is distinct from LA BC as a unique entity with different characteristics and treatment approaches.""",55\r\n46,"""TUMOR EMBOLI""","""IBC""","""IBC is characterized by the presence of tumor emboli in dermal lymphatics, which may be present or absent in biopsy specimens.""",55\r\n47,"""LYMPHEDEMA""","""IBC""","""IBC is characterized by lymphedema caused by tumor emboli within dermal lymphatics.""",55\r\n143,"""PACLITAXEL""","""TRASTUZUMAB""","""Trastuzumab is combined with paclitaxel in a treatment for breast cancer.""",23\r\n142,"""PACLITAXEL""","""LAPATINIB""","Here is a comprehensive summary of the data:\n\nPACLITAXEL and LAPATINIB are two medications used in cancer treatment. Specifically, they are combined in a treatment for breast cancer, where LAPATINIB is paired with PACLITAXEL to provide a comprehensive treatment approach. Additionally, both medications have different effects on the pCR (pathological complete response) rate, indicating that they have distinct mechanisms of action in cancer treatment.",20\r\n140,"""PACLITAXEL""","""NAC""","""Paclitaxel is part of the NAC regimen.""",19\r\n164,"""NAC""","""PD-L1""","""NAC is associated with PD-L1 expression in breast cancer.""",18\r\n144,"""PACLITAXEL""","""BEVACIZUMAB""","""Paclitaxel is used in certain circumstances with bevacizumab for metastatic breast cancer.""",16\r\n129,"""OS""","""PD-L1""","""PD-L1 expression in tumor cells is associated with worse overall survival in breast cancer patients.""",14\r\n141,"""PACLITAXEL""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",13\r\n134,"""HER2""","""PD-L1""","""HER2 is associated with PD-L1 expression in breast cancer.""",13\r\n27,"""BREAST CANCER""","""IMMUNOTHERAPY""","""Immunotherapy is a potential future direction for systemic therapy in Breast Cancer treatment, leveraging the body\'s immune system to fight cancer.""",12\r\n297,"""PD-L1""","""ARIAS-PULIDO ET AL.""","""Arias-Pulido et al. reported on PD-L1 positivity in IBC samples.""",10\r\n296,"""PD-L1""","""BERCKELAER ET AL.""","""Berckelaer et al. reported on PD-L1 expression in TILs.""",10\r\n145,"""PACLITAXEL""","""AC REGIME""","""AC regime and paclitaxel are used together in a chemotherapy regimen for breast cancer treatment.""",10\r\n139,"""PACLITAXEL""","""ESTROGEN RECEPTOR""","""Estrogen receptor is relevant to paclitaxel\'s effectiveness in treating breast cancer.""",9\r\n295,"""PD-L1""","""ER""","""ER is associated with PD-L1 expression in breast cancer.""",9\r\n298,"""ARIAS-PULIDO ET AL.""","""TILS""","""Arias-Pulido et al. reported PD-L1 positivity in TILs and its association with better DFS.""",6\r\n299,"""BERCKELAER ET AL.""","""TILS""","""Berckelaer et al. reported PD-L1 expression in TILs.""",6\r\n165,"""INTERNATIONAL EXPERT CONSENSUS""","""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""International Expert Consensus recommends High-dose chemotherapy with autologous hematopoietic stem cell transplantation as a treatment option for IBC.""",6\r\n167,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH""","""Center for International Blood and Marrow Transplant Research conducts research on High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IBC treatment.""",5\r\n166,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""INTERNATIONAL BLOOD AND MARROW TRANSPLANT REGISTRY""","""International Blood and Marrow Transplant Registry tracks data on High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IBC treatment.""",5\r\n302,"""KEYNOTE-522""","""I-SPY2""","""KEYNOTE-522 and I-SPY2 are clinical trials that combine chemotherapy and an immune checkpoint inhibitor.""",4\r\n42,"""IMMUNOTHERAPY""","""ONGOING IBC CLINICAL TRIALS""","""Immunotherapy is being investigated in Ongoing IBC Clinical Trials as a potential new treatment for IBC.""",4\r\n146,"""FAC""","""G-CSF""","""FAC and G-CSF are technologies used together in clinical trials.""",3\r\n136,"""RADIATION ONCOLOGIST""","""TEAM""","""Radiation oncologist is a member of the team working to improve the survival of IBC.""",3\r\n189,"""STANDARD OF CARE""","""RANDOMIZED TRIALS""","""Randomized Trials are used to determine the Standard of Care for IBC treatment.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:19,418 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 1/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:19,467 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:19,472 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n145,"""TRASTUZUMAB""","Here is a comprehensive summary of the data provided:\n\nTrastuzumab is a humanized anti-HER2 monoclonal antibody that is part of the anti-HER2 backbone for HER2+ IBC. It is a medication used in the treatment of HER2+ IBC, HER2-positive breast cancer, and breast cancer in general. Trastuzumab is a targeted therapy that targets HER2 receptors, blocking the HER2 protein to treat HER2-positive breast cancer. It is often used in combination with other medications, such as pertuzumab, docetaxel, and epirubicin, to treat breast cancer. Trastuzumab is also used in clinical trials and has been approved for HER2+ disease, including IBC. It is a type of monoclonal antibody that targets HER2 and is a treatment option for IBC, used in combination with lapatinib and paclitaxel. Additionally, trastuzumab is a chemotherapy drug used in the NeoSphere clinical trial and is a type of cancer treatment. Overall, trastuzumab is a medication used to treat HER2+ breast cancer by blocking the HER2 protein and is a targeted therapy approved for HER2+ disease, including IBC.",15\r\n200,"""NERATINIB""","Here is a comprehensive summary of the data:\n\nNeratinib is a medication used in various treatment settings for breast cancer. Specifically, it is used in adjuvant therapy for high-risk recurrent disease, including inflammatory breast cancer (IBC). Additionally, neratinib is used to treat HER2-positive breast cancer, particularly in high-risk situations. It is also offered as a treatment option for patients with HER2-positive breast cancer. Neratinib is a chemotherapy drug and a tyrosine kinase inhibitor, which is used in clinical trials. Overall, neratinib is a medication used in cancer treatment, with a focus on breast cancer, particularly HER2-positive disease.\n\nNote: I resolved the contradictions by combining the information from the different descriptions to provide a comprehensive summary. I also rephrased some of the sentences to ensure clarity and coherence.",8\r\n171,"""OVERMOYER ET AL.""","Here is a comprehensive summary of the data:\n\nOvermoyer et al. are researchers who have reported on the efficacy of a specific treatment regimen. According to their findings, neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab has shown promising results.",5\r\n62,"""HER2+ IBC""","Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.",4\r\n165,"""NEOSPHERE TRIAL""","Here is a comprehensive summary of the data:\n\nThe ""NEOSPHERE TRIAL"" is a clinical trial that investigated the use of pertuzumab plus trastuzumab in combination with an anthracycline-containing regimen in patients with HER2-positive breast cancer. Specifically, it is a phase 2 randomized neoadjuvant trial that tested the combination of pertuzumab with trastuzumab in breast cancer patients.",4\r\n114,"""NAC""","Here is a comprehensive summary of the data:\n\nNAC refers to neoadjuvant chemotherapy, a type of chemotherapy regimen used in the treatment of breast cancer. Specifically, NAC is a treatment protocol that is evaluated in clinical trials for the treatment of HER2-positive locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). It is a treatment option for IBC, used in combination with lapatinib, and has shown survival benefits for patients with LABC, including IBC, when combined with trastuzumab. NAC is a type of neoadjuvant chemotherapy that is associated with PD-L1 expression and is used in the TRYPHAENA study.",11\r\n340,"""PATIENT""","""Patient is the individual receiving treatment.""",10\r\n153,"""PERTUZUMAB""","Here is a comprehensive summary of the data provided:\n\nPertuzumab is a humanized anti-HER2 monoclonal antibody that binds the HER2 receptor at a different epitope from trastuzumab. It is a medication used in cancer treatment, specifically in the treatment of HER2-positive breast cancer, including inflammatory breast cancer (IBC). Pertuzumab is also used to treat HER2+ breast cancer, especially in combination with trastuzumab, by blocking the HER2 protein. As a targeted therapy, it targets HER2 receptors and induces antibody-dependent cell-mediated cytotoxicity. Pertuzumab is a type of monoclonal antibody that binds to the HER2 receptor and is used in breast cancer treatment. It is often used in combination with other treatments, such as T-DM1, as part of a treatment regimen for HER2+ breast cancer. Additionally, pertuzumab has been used in clinical trials, including the NeoSphere clinical trial, and is a chemotherapy drug.",10\r\n665,"""LANCET ONCOL""","Here is a comprehensive summary of the data:\n\n""Lancet Oncol"" is a medical research journal that has published numerous studies on various topics related to breast cancer. Specifically, the journal has published studies on adjuvant bevacizumab-containing therapy in triple-negative breast cancer, as well as neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer. Additionally, the journal has published research on Nab-paclitaxel and bevacizumab treatment in new models of inflammatory breast cancer, and has identified pathological response and circulating tumor cell count as indicators of excellent prognosis in treated HER2+ inflammatory breast cancer patients. Furthermore, the journal has published the results of the GeparQuinto study, which focused on inflammatory breast cancer. The journal has also published a study on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy. Overall, ""Lancet Oncol"" is a reputable and influential publication in the field of oncology, providing valuable insights and research findings to healthcare professionals and researchers.",3\r\n70,"""HER2""","Here is a comprehensive summary of the data:\n\nHER2 is a human epidermal growth factor receptor 2, a biomarker for breast cancer. It is a protein receptor that is often overexpressed in breast cancer, with an estimated prevalence of 25-35% in inflammatory breast cancer (IBC). HER2 is a target for breast cancer treatment, and its overexpression is associated with poor prognosis. The protein receptor is targeted by various therapies, including trastuzumab, lapatinib, pertuzumab, and T-DM1, among others. HER2 is also a predictive marker for the efficacy of trastuzumab addition in breast cancer treatment. Additionally, HER2 is a receptor that can dimerize with other ligands HER receptors and is associated with PD-L1 expression in breast cancer. HER2 status refers to the human epidermal growth factor receptor 2 status, which is an important factor in determining the effectiveness of breast cancer treatment. Overall, HER2 is a critical protein receptor in breast cancer, and its expression and targeting are crucial in the development of effective treatment strategies.",6\r\n189,"""T-DM1""","Here is a comprehensive summary of the data:\n\n""T-DM1"" is a medication used in the treatment of breast cancer. Specifically, it is a treatment for HER2+ Inflammatory Breast Cancer (IBC) cases without a pathologic complete response (pCR). Additionally, T-DM1 is a type of antibody-drug conjugate used to treat HER2+ breast cancer.",3\r\n151,"""ANTHRACYCLINE-CONTAINING REGIMEN""","Here is a comprehensive summary of the data:\n\nThe ""ANTHRACYCLINE-CONTAINING REGIMEN"" is a treatment protocol for breast cancer, specifically a type of chemotherapy regimen used to treat breast cancer. Furthermore, it is also used to treat HER2+ Inflammatory Breast Cancer (IBC). This regimen is a type of chemotherapy that is effective in treating HER2+ IBC.",1\r\n174,"""ATINIB""",No Description,1\r\n146,"""NOAH STUDY""","Here is a comprehensive summary of the data:\n\nThe NOAH study is a randomized phase 3 clinical trial that investigated the efficacy of trastuzumab addition in breast cancer treatment.",1\r\n107,"""BREAST MRI""","Here is a comprehensive summary of the data:\n\nBreast MRI is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n289,"""CAPECITABINE""","Here is a comprehensive summary of the data:\n\nCapecitabine is a chemotherapy drug used in the treatment of breast cancer. It is also a medication used in cancer treatment.",2\r\n97,"""CYCLOPHOSPHAMIDE""","Here is a comprehensive summary of the data:\n\nCyclophosphamide is a chemotherapy medication used in the treatment of breast cancer. It is a key component of a treatment regimen and is often used in combination with other medications, such as docetaxel, epirubicin, and trastuzumab, to effectively treat breast cancer. As a chemotherapy drug, cyclophosphamide is designed to target and destroy cancer cells, helping to slow or stop the growth of tumors.",1\r\n98,"""DOXORUBICIN""","Here is a comprehensive summary of the data:\n\nDoxorubicin is a chemotherapy medication used in the treatment of breast cancer and as part of a treatment regimen. It is a chemotherapy drug used to treat various types of cancer, including breast cancer.\n\nNote: I resolved the contradictions by combining the descriptions to provide a clear and concise summary. I also removed the quotation marks from the output to make it easier to read.",1\r\n337,"""ER""","Here is a comprehensive summary of the data:\n\nThe entity ""ER"" refers to estrogen receptor, which is a receptor associated with PD-L1 expression in breast cancer.",2\r\n148,"""FLUOROURACIL""","""Fluorouracil is a chemotherapy medication.""",1\r\n108,"""MAMMOGRAPHY""","Here is a comprehensive summary of the data:\n\nMammography is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n147,"""METHOTREXATE""","""Methotrexate is a chemotherapy medication.""",1\r\n680,"""N ENGL J MED""","Here is a comprehensive summary of the data:\n\n""N ENGL J MED"" is a medical journal that publishes research on various medical topics, including breast cancer. Specifically, it has published several studies on breast cancer, providing valuable insights and findings in the field. As a medical journal, it is dedicated to sharing knowledge and advancing the understanding of various medical conditions, including breast cancer. Additionally, it has published a study on pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, providing important information for healthcare professionals and researchers.",2\r\n109,"""SONOGRAPHY""","Here is a comprehensive summary of the data:\n\nSonography is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n685,"""VIALE G""","Here is a comprehensive summary of the data:\n\nVIALE G is a researcher who has been involved in a study on pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer. As an author, VIALE G has contributed to a medical study and a research paper, showcasing their expertise and involvement in the field of breast cancer research.",2\r\n773,"""TRASTUZUMAB EMTANSINE""","Here is a comprehensive summary of the data:\n\nTrastuzumab Emtansine is a medication that is used as a treatment for residual invasive HER2-positive breast cancer.",2\r\n256,"""ADJUVANT THERAPY""","Here is a comprehensive summary of the data:\n\nAdjuvant therapy refers to a treatment given after primary treatment to reduce the risk of recurrence. Specifically, in the context of Inflammatory Breast Cancer (IBC), adjuvant therapy is a type of treatment administered after surgery. This treatment is designed to target any remaining cancer cells that may have been left behind after initial surgery, with the goal of preventing the recurrence of the disease.",1\r\n341,"""AROMATASE INHIBITOR""","""Aromatase inhibitor is a medication used in cancer treatment.""",1\r\n303,"""BISPHOSPHONATE""","Here is a comprehensive summary of the data:\n\nBisphosphonate is a medication that has multiple uses in various medical contexts. In cancer treatment, it is used to help manage the disease. Specifically, it is used to increase bone density and improve survival rates in breast cancer patients. Additionally, bisphosphonate is used to treat osteoporosis by increasing bone density, which can help prevent fractures and other bone-related complications. Overall, bisphosphonate is a medication with a range of applications in both cancer treatment and osteoporosis management.",1\r\n775,"""KRISTINE""","""KRISTINE is a clinical trial.""",1\r\n292,"""TAMOXIFEN""","Here is a comprehensive summary of the data:\n\nTamoxifen is a medication that has been extensively studied in various papers and is used in the treatment of breast cancer. Specifically, it is a type of hormone therapy used in the treatment of breast cancer, and has been associated with improved survival outcomes when used for extended adjuvant endocrine therapy. Additionally, Tamoxifen is also used in cancer treatment more broadly.",1\r\n202,"""EXTENET""","Here is a comprehensive summary of the data:\n\nExteNET is a clinical trial that focused on HER2-positive breast cancer patients. Specifically, the trial studied the use of neratinib in breast cancer patients, providing valuable insights into its effectiveness in this patient population.",2\r\n198,"""KATERINE TRIAL""","Here is a comprehensive summary of the data:\n\nThe ""KATERINE TRIAL"" is a clinical trial that evaluates the effectiveness of adjuvant therapy in patients with HER2+ breast cancer, specifically in cases of inflammatory breast cancer (IBC) without a pathologic complete response (pCR). The trial investigates the use of adjuvant T-DM1, a type of targeted therapy, in these patients. The trial\'s findings recommend the use of adjuvant T-DM1 in HER2+ IBC cases without a pCR.\n\nNote: I resolved the contradictions by combining the information from the three descriptions, ensuring that the summary is coherent and accurate.",2\r\n288,"""CREATE-X""","""CREATE-X is a randomized phase 3 study on adjuvant capecitabine for breast cancer patients.""",2\r\n781,"""HARVEY VJ""","""Harvey VJ is an author of a medical study.""",1\r\n201,"""HER4""","""HER4 is a protein that is targeted by neratinib.""",1\r\n69,"""HR""","Here is a comprehensive summary of the data:\n\nHR, which stands for hormone receptor, is a protein receptor that plays a crucial role in breast cancer treatment. It is often overexpressed in breast cancer, making it a target for treatment. HR refers to the hormone receptor status, which is an important factor in determining the effectiveness of breast cancer treatment. In summary, HR is a protein receptor that is a target for breast cancer treatment due to its overexpression in the disease, and its status is an important consideration in treatment planning.",1\r\n778,"""CHAN A""","""Chan A is an author of a medical study.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n72,"""IBC""","""TRASTUZUMAB""","""Trastuzumab is used in the treatment of IBC, a type of breast cancer.""",69\r\n75,"""IBC""","""NERATINIB""","""Neratinib is used in adjuvant therapy for high-risk recurrent disease like IBC.""",62\r\n74,"""IBC""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of a neoadjuvant treatment for IBC patients, which is a high-risk disease.""",59\r\n78,"""IBC""","""HER2+ IBC""","""HER2+ IBC is a subtype of IBC.""",58\r\n73,"""IBC""","""NEOSPHERE TRIAL""","""The NeoSphere trial included 29 IBC patients.""",58\r\n196,"""TRASTUZUMAB""","""LAPATINIB""","""Trastuzumab and lapatinib are combined in a dual antibody treatment for breast cancer.""",27\r\n160,"""NAC""","""TRASTUZUMAB""","Based on the provided data, here is a comprehensive summary:\n\nNAC (Neoadjuvant Anthracycline-based Chemotherapy) is a treatment regimen that is combined with trastuzumab to treat certain types of breast cancer. Specifically, NAC is used in combination with trastuzumab to treat both Inflammatory Breast Cancer (IBC) and Locally Advanced Breast Cancer (LABC), which includes IBC. This treatment combination has been shown to provide survival benefits for patients with LABC, including those with IBC.\n\nNote: I resolved the potential contradiction by combining the two descriptions, ensuring that the summary accurately reflects the information provided.",26\r\n199,"""TRASTUZUMAB""","""PATIENT""","""Trastuzumab is used as a treatment option for patients.""",25\r\n192,"""TRASTUZUMAB""","""PERTUZUMAB""","Here is a comprehensive summary of the data:\n\nTrastuzumab and Pertuzumab are two medications that are used together to treat breast cancer, specifically HER2+ breast cancer. They are often used in combination therapy to combat this type of cancer. Both medications have similar mechanisms of binding to HER2 epitopes, making them suitable for combination therapy. Specifically, they are used together to treat breast cancer, with the combination of the two medications providing a more effective treatment option than either medication alone.\n\nNote: I resolved the contradictions by combining the information from all three descriptions to provide a clear and concise summary.",25\r\n246,"""GEPARQUINTO""","""LANCET ONCOL""","""GeparQuinto is published in Lancet Oncol.""",24\r\n163,"""NAC""","""LAPATINIB""","""NAC with lapatinib has a low pCR rate in HER2+ patients.""",23\r\n198,"""TRASTUZUMAB""","""BEVACIZUMAB""","""Bevacizumab is used in combination with Trastuzumab in the studies.""",23\r\n143,"""PACLITAXEL""","""TRASTUZUMAB""","""Trastuzumab is combined with paclitaxel in a treatment for breast cancer.""",23\r\n131,"""HER2""","""TRASTUZUMAB""","""Trastuzumab is targeted towards HER2+ disease, including IBC.""",21\r\n194,"""TRASTUZUMAB""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",20\r\n204,"""PERTUZUMAB""","""PATIENT""","""Pertuzumab is used as a treatment option for patients.""",20\r\n115,"""HER2+ IBC""","""TRASTUZUMAB""","""Trastuzumab is used as a standard neoadjuvant treatment for HER2+ IBC patients.""",19\r\n140,"""PACLITAXEL""","""NAC""","""Paclitaxel is part of the NAC regimen.""",19\r\n193,"""TRASTUZUMAB""","""NEOSPHERE TRIAL""","""Trastuzumab was used in the NeoSphere trial as part of combination therapy with pertuzumab and docetaxel.""",19\r\n132,"""HER2""","""LAPATINIB""","""Lapatinib blocks intracellular HER2, which is a target for cancer treatment.""",18\r\n164,"""NAC""","""PD-L1""","""NAC is associated with PD-L1 expression in breast cancer.""",18\r\n256,"""NERATINIB""","""PATIENT""","""Neratinib is offered as a treatment option for patients.""",18\r\n197,"""TRASTUZUMAB""","""T-DM1""","""T-DM1 is compared to trastuzumab in terms of response and toxicity in the neoadjuvant setting.""",18\r\n191,"""TRASTUZUMAB""","""ANTHRACYCLINE-CONTAINING REGIMEN""","""Trastuzumab is used in combination with an anthracycline-containing regimen for breast cancer treatment.""",16\r\n195,"""TRASTUZUMAB""","""ATINIB""","""atinib and trastuzumab are both medications used in cancer treatment, with different effects on pCR rate.""",16\r\n135,"""HER2""","""PATIENT""","""Patient\'s HER2 status is used to determine treatment options.""",16\r\n527,"""PIERGA JY""","""LANCET ONCOL""","""Pierga JY published a study in Lancet Oncol on inflammatory breast cancer.""",16\r\n190,"""TRASTUZUMAB""","""NOAH STUDY""","Here is a comprehensive summary of the data:\n\nThe NOAH study evaluated the efficacy of trastuzumab, specifically in the context of neoadjuvant treatment, in combination with chemotherapy, compared to chemotherapy alone. Additionally, the study investigated the effectiveness of adding trastuzumab to breast cancer treatment.\n\nNote: I resolved the potential contradiction by combining the two descriptions, focusing on the specific context of neoadjuvant treatment and the addition of trastuzumab to breast cancer treatment.",16\r\n202,"""PERTUZUMAB""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",15\r\n212,"""TRYPHAENA""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the results of the TRYPHAENA study, which investigated the efficacy of a neoadjuvant treatment for IBC patients.""",15\r\n133,"""HER2""","""NERATINIB""","""Neratinib targets HER2, a protein involved in breast cancer.""",14\r\n114,"""HER2+ IBC""","""PERTUZUMAB""","""Pertuzumab is used as a standard neoadjuvant treatment for HER2+ IBC patients.""",14\r\n201,"""PERTUZUMAB""","""NEOSPHERE TRIAL""","""Pertuzumab was used in the NeoSphere trial as part of combination therapy with trastuzumab and docetaxel.""",14\r\n134,"""HER2""","""PD-L1""","""HER2 is associated with PD-L1 expression in breast cancer.""",13\r\n28,"""BREAST CANCER""","""NEOSPHERE TRIAL""","""The NeoSphere trial tested the combination of pertuzumab with trastuzumab in breast cancer patients.""",13\r\n141,"""PACLITAXEL""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",13\r\n203,"""PERTUZUMAB""","""T-DM1""","Here is a comprehensive summary of the data:\n\nPertuzumab and T-DM1 are two entities related to the treatment of breast cancer. According to the descriptions, T-DM1 is an alternative to pertuzumab in the treatment of breast cancer, suggesting that it can be used as a substitute or complementary therapy. Additionally, T-DM1 is often combined with pertuzumab in a treatment for breast cancer, indicating that the two entities are frequently used together. Furthermore, T-DM1 is used in combination with pertuzumab in the neoadjuvant setting, which is a treatment approach that involves administering medications before surgery to shrink tumors and make them more manageable. Notably, this combination therapy is associated with a favorable toxicity profile, meaning that it is well-tolerated by patients.\n\nOverall, the descriptions suggest that pertuzumab and T-DM1 are both used in the treatment of breast cancer, often in combination with each other, and that this combination therapy has a favorable safety profile.",13\r\n152,"""BREAST MRI""","""NAC""","""Breast MRI is used to assess the effectiveness of NAC in IBC.""",12\r\n291,"""CAPECITABINE""","""PATIENT""","""Capecitabine is used as a treatment option for patients.""",12\r\n149,"""CYCLOPHOSPHAMIDE""","""NAC""","""Cyclophosphamide is part of the NAC regimen.""",12\r\n150,"""DOXORUBICIN""","""NAC""","""Doxorubicin is part of the NAC regimen.""",12\r\n300,"""ER""","""PATIENT""","""Patient\'s ER status is used to determine treatment options.""",12\r\n162,"""NAC""","""FLUOROURACIL""","""Fluorouracil is part of the NAC regimen.""",12\r\n153,"""MAMMOGRAPHY""","""NAC""","""Mammography is used to assess the effectiveness of NAC in IBC.""",12\r\n161,"""NAC""","""METHOTREXATE""","""Methotrexate is part of the NAC regimen.""",12\r\n208,"""PERTUZUMAB""","""N ENGL J MED""","""N Engl J Med published a paper on Pertuzumab.""",12\r\n154,"""SONOGRAPHY""","""NAC""","""Sonography is used to assess the effectiveness of NAC in IBC.""",12\r\n157,"""EGFR""","""NERATINIB""","""Neratinib targets EGFR, a protein involved in breast cancer.""",12\r\n205,"""PERTUZUMAB""","""VIALE G""","""Viale G is involved in the development of Pertuzumab.""",12\r\n206,"""PERTUZUMAB""","""TRASTUZUMAB EMTANSINE""","""Trastuzumab Emtansine is related to Pertuzumab.""",12\r\n285,"""ADJUVANT THERAPY""","""PATIENT""","""Adjuvant therapy is given to patients after primary treatment.""",11\r\n301,"""PATIENT""","""AROMATASE INHIBITOR""","""Aromatase inhibitor is used as a treatment option for patients.""",11\r\n293,"""BISPHOSPHONATE""","""PATIENT""","""Bisphosphonate is used as a treatment option for patients.""",11\r\n108,"""INSTITUTE""","""HER2+ IBC""","""The institute has reported on the results of HER2+ IBC, including its longest median OS after brain metastasis and relation to the anti-HER2 therapy era.""",11\r\n207,"""PERTUZUMAB""","""KRISTINE""","""KRISTINE is a clinical trial involving Pertuzumab.""",11\r\n292,"""TAMOXIFEN""","""PATIENT""","""Tamoxifen is used as a treatment option for patients.""",11\r\n254,"""NERATINIB""","""EXTENET""","""Neratinib was studied in the ExteNET clinical trial.""",10\r\n253,"""KATERINE TRIAL""","""NERATINIB""","""The KATERINE trial recommended adjuvant T-DM1, which includes Neratinib, in HER2+ IBC cases without a pCR.""",10\r\n128,"""OS""","""CREATE-X""","""CREATE-X shows that adjuvant capecitabine can improve overall survival in breast cancer patients.""",9\r\n295,"""PD-L1""","""ER""","""ER is associated with PD-L1 expression in breast cancer.""",9\r\n257,"""NERATINIB""","""HARVEY VJ""","""Harvey VJ is involved in the development of Neratinib.""",9\r\n255,"""NERATINIB""","""HER4""","""Neratinib targets HER4, a protein involved in breast cancer.""",9\r\n130,"""HR""","""HER2""","""HER2 and HR are protein receptors that are targets for breast cancer treatment.""",7\r\n258,"""EXTENET""","""LANCET ONCOL""","""ExteNET is published in Lancet Oncol.""",5\r\n252,"""T-DM1""","""KATERINE TRIAL""","""The KATERINE trial evaluated the use of T-DM1 as adjuvant therapy in patients with HER2+ breast cancer.""",5\r\n290,"""CREATE-X""","""CAPECITABINE""","""CREATE-X is a study on the effectiveness of adjuvant capecitabine in breast cancer patients.""",4\r\n583,"""N ENGL J MED""","""TRASTUZUMAB EMTANSINE""","""Trastuzumab Emtansine is published in N Engl J Med.""",4\r\n584,"""VIALE G""","""CHAN A""","""Viale G and Chan A are co-authors of a medical study.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:19,473 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 3/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:19,714 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:19,718 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n475,"""BUZDAR AU""","Here is a comprehensive summary of the data:\n\nBuzdar AU is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Buzdar AU has authored research papers and studies on combined-modality treatment of inflammatory breast carcinoma, inflammatory breast cancer, breast cancer, and paclitaxel\'s impact on improving the prognosis in estrogen receptor negative inflammatory breast cancer. These publications demonstrate Buzdar AU\'s expertise and dedication to advancing our understanding of breast cancer, particularly in the context of inflammatory breast carcinoma and the role of paclitaxel in treatment outcomes.",3\r\n474,"""UENO NT""","Here is a comprehensive summary of the data:\n\nUeno NT is a researcher who has authored several studies and research papers on breast cancer. Specifically, they have published papers on combined-modality treatment of inflammatory breast carcinoma, gene expression profiles of inflammatory breast cancer, and inflammatory breast cancer itself. Additionally, they have conducted a study on early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.",10\r\n559,"""BERTUCCI F""","Here is a comprehensive summary of the data:\n\nBertucci F is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Bertucci F has authored research papers and studies on inflammatory breast cancer, a type of breast cancer characterized by rapid growth and spread of cancer cells. The studies conducted by Bertucci F have focused on various aspects of inflammatory breast cancer, including the expression of PDL1, a protein that plays a crucial role in the immune response to cancer. Additionally, Bertucci F has explored the effectiveness of high-dose chemotherapy and haematopoietic stem cell transplantation as a treatment option for inflammatory breast cancer, examining the relationship between pathologic response and outcome. Furthermore, Bertucci F has authored multiple studies on breast cancer treatment, demonstrating a broad range of expertise in the field. Overall, Bertucci F\'s work has shed light on the complexities of inflammatory breast cancer and has contributed to the development of more effective treatment strategies for this aggressive form of breast cancer.",7\r\n565,"""FINETTI P""","Here is a comprehensive summary of the data:\n\nFinetti P is a researcher who has made significant contributions to the field of inflammatory breast cancer. Specifically, Finetti P is an author of two research papers: one on the gene expression profiles of inflammatory breast cancer and another on the expression of PDL1 in inflammatory breast cancer. These studies demonstrate Finetti P\'s expertise in the area of inflammatory breast cancer and highlight their role as a leading researcher in the field.",5\r\n567,"""LUCCI A""","Here is a comprehensive summary of the data:\n\nLUCCI A is a researcher who has made significant contributions to the field of breast cancer research. Specifically, LUCCI A is an author of two research papers. The first paper focuses on the gene expression profiles of inflammatory breast cancer, providing valuable insights into the molecular mechanisms underlying this aggressive form of breast cancer. The second paper investigates the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients. This research highlights the importance of exploring alternative treatment options for this patient population.",5\r\n568,"""ROBERTSON FM""","""Robertson FM is an author of a research paper on gene expression profiles of inflammatory breast cancer.""",5\r\n566,"""VERMEULEN P""","""Vermeulen P is an author of a research paper on gene expression profiles of inflammatory breast cancer.""",5\r\n476,"""SINGLETARY SE""","Here is a comprehensive summary of the data:\n\nSingletary SE is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Singletary SE has authored research papers on combined-modality treatment of inflammatory breast carcinoma, as well as studies on inflammatory breast cancer and breast cancer in general.",2\r\n477,"""AMES""","""Ames is an author of a study on breast cancer.""",1\r\n494,"""CANCER CHEMOTHER PHARMACOL""","Here is a comprehensive summary of the data:\n\nCancer Chemother Pharmacol is a journal that publishes research papers on breast cancer. The publication features research on breast cancer, providing a platform for scholars and experts to share their findings and contribute to the advancement of knowledge in this field.",6\r\n560,"""ESPINOSA FERNANDEZ""","""Espinosa Fernandez is an author of a research paper on inflammatory breast cancer.""",1\r\n482,"""AMES FC""","Here is a comprehensive summary of the data:\n\nAmes FC is an author of research papers on inflammatory breast cancer. Specifically, Ames FC has written papers on combined-modality treatment of inflammatory breast carcinoma and inflammatory breast cancer.",1\r\n495,"""FRYE D""","""Frye D is an author of a research paper on inflammatory breast cancer.""",1\r\n483,"""MCNEESE MD""","Here is a comprehensive summary of the data:\n\nMcNeese MD is a researcher who has authored research papers on inflammatory breast carcinoma. Specifically, McNeese MD has written papers on the combined-modality treatment of inflammatory breast carcinoma, as well as inflammatory breast cancer in general.",1\r\n491,"""KOH EH""","Here is a comprehensive summary of the data:\n\nKoh EH is an author of research papers related to inflammatory breast cancer. Specifically, Koh EH has written papers on combined-modality treatment of inflammatory breast carcinoma and inflammatory breast cancer.",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n358,"""CRISTOFANILLI M""","""BUZDAR AU""","""Cristofanilli M and Buzdar AU are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",21\r\n419,"""UENO NT""","""J CLIN ONCOL""","""Ueno NT is an author of a research paper published in J Clin Oncol.""",20\r\n420,"""UENO NT""","""BERTUCCI F""","""Bertucci F and Ueno NT are co-authors of a research paper on inflammatory breast cancer.""",17\r\n421,"""UENO NT""","""FINETTI P""","""Ueno NT and Finetti P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n423,"""UENO NT""","""LUCCI A""","""Ueno NT and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n424,"""UENO NT""","""ROBERTSON FM""","""Ueno NT and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n422,"""UENO NT""","""VERMEULEN P""","""Ueno NT and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n425,"""UENO NT""","""MATSUDA N""","""Matsuda N and Ueno NT are co-authors of a study on early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.""",15\r\n487,"""BERTUCCI F""","""GONCALVES A""","Here is a comprehensive summary of the data:\n\nGoncalves A and Bertucci F are co-authors of multiple studies related to breast cancer. Specifically, they have collaborated on research focused on inflammatory breast cancer and breast cancer treatment.",14\r\n416,"""UENO NT""","""BUZDAR AU""","""Ueno NT and Buzdar AU are co-authors of a study on breast cancer.""",13\r\n483,"""BERTUCCI F""","""FINETTI P""","""Bertucci F and Finetti P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n484,"""BERTUCCI F""","""VERMEULEN P""","""Bertucci F and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n485,"""BERTUCCI F""","""LUCCI A""","""Bertucci F and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n486,"""BERTUCCI F""","""ROBERTSON FM""","""Bertucci F and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n417,"""UENO NT""","""SINGLETARY SE""","""Ueno NT and Singletary SE are co-authors of a study on breast cancer.""",12\r\n418,"""UENO NT""","""AMES""","""Ueno NT and Ames are co-authors of a study on breast cancer.""",11\r\n493,"""FINETTI P""","""VERMEULEN P""","""Finetti P and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n494,"""FINETTI P""","""LUCCI A""","""Finetti P and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n495,"""FINETTI P""","""ROBERTSON FM""","""Finetti P and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n498,"""LUCCI A""","""ROBERTSON FM""","""Lucci A and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n496,"""VERMEULEN P""","""LUCCI A""","""Vermeulen P and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n497,"""VERMEULEN P""","""ROBERTSON FM""","""Vermeulen P and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n426,"""BUZDAR AU""","""CANCER CHEMOTHER PHARMACOL""","""Buzdar AU is an author of a research paper published in Cancer Chemother Pharmacol.""",9\r\n482,"""BERTUCCI F""","""ESPINOSA FERNANDEZ""","""Bertucci F and Espinosa Fernandez are co-authors of a research paper on inflammatory breast cancer.""",8\r\n427,"""SINGLETARY SE""","""CANCER CHEMOTHER PHARMACOL""","""Singletary SE is an author of a research paper published in Cancer Chemother Pharmacol.""",8\r\n434,"""AMES FC""","""CANCER CHEMOTHER PHARMACOL""","""Ames FC is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n438,"""CANCER CHEMOTHER PHARMACOL""","""FRYE D""","""Frye D is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n435,"""MCNEESE MD""","""CANCER CHEMOTHER PHARMACOL""","""McNeese MD is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n437,"""KOH EH""","""CANCER CHEMOTHER PHARMACOL""","""Koh EH is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:19,720 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 1/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:20,838 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:20,843 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n437,"""CRISTOFANILLI M""","Here is a comprehensive summary of the data:\n\nCristofanilli M is a researcher who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on inflammatory breast cancer management in the National Comprehensive Cancer Network. Additionally, they were involved in the GeparQuinto study, which further highlights their expertise in this area.\n\nCristofanilli M is also an author of several research papers and studies on inflammatory breast cancer. These publications include a study on breast cancer treatment, as well as studies on inflammatory breast cancer management, neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer, paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer, and the prognostic significance of HER-2 status in women with inflammatory breast cancer.\n\nOverall, Cristofanilli M is a prominent researcher in the field of inflammatory breast cancer, with a focus on management, treatment, and prognosis.",18\r\n172,"""LAPATINIB""","Here is a comprehensive summary of the data:\n\nLapatinib is a small-molecule tyrosine kinase inhibitor that blocks intracellular HER2 and EGFR signaling pathways. It is a targeted therapy used to treat cancer, and is also used in combination with other therapies, such as Pazopanib, trastuzumab, and NAC, to treat various types of cancer, including breast cancer. Specifically, it is a treatment option for inflammatory breast cancer (IBC) when used in combination with NAC and trastuzumab. Additionally, lapatinib is an antibody-drug conjugate used in breast cancer treatment. Overall, lapatinib is a medication used in cancer treatment, specifically targeting HER2 and EGFR signaling pathways to inhibit the growth and spread of cancer cells.",12\r\n228,"""PAZOPANIB""","Here is a comprehensive summary of the data:\n\nPazopanib is a small-molecule multi-tyrosine kinase inhibitor used to treat cancer. Specifically, it is a targeted therapy used in combination with other treatments for breast cancer, and also used in combination therapy to treat a disease.\n\nNote: I resolved the contradictions by combining the information from all the descriptions to provide a single, coherent summary.",7\r\n435,"""MATRO JM""","Here is a comprehensive summary of the data:\n\nMatro JM is a person who has conducted a study on inflammatory breast cancer management in the National Comprehensive Cancer Network.",5\r\n844,"""JOHNSTON SR""","Here is a comprehensive summary of the data:\n\nJohnston SR is a researcher who has made significant contributions to the field of breast cancer research. Specifically, he has been involved in studies focused on HER2-positive advanced breast cancer, demonstrating his expertise in this area. Additionally, he has also authored a research paper on inflammatory breast cancer, showcasing his breadth of knowledge and expertise in the field.",3\r\n528,"""GONZALEZ-ANGULO AM""","""Gonzalez-Angulo AM is an author of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",1\r\n529,"""KAU SW""","Here is a comprehensive summary of the data:\n\nKau SW is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Kau SW is an author of two studies that have shed light on the prognosis and treatment of inflammatory breast cancer. In one study, Kau SW investigated the impact of paclitaxel on the prognosis of estrogen receptor negative inflammatory breast cancer, demonstrating its potential to improve patient outcomes. In another study, Kau SW examined the prognostic significance of HER-2 status in women with inflammatory breast cancer, providing valuable insights into the role of this biomarker in predicting patient outcomes.",1\r\n530,"""FRYE DK""","""Frye DK is an author of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",1\r\n536,"""SMITH T""","""Smith T is an author of a study on breast cancer treatment.""",1\r\n537,"""WASAFF B""","""Wasaff B is an author of a study on breast cancer treatment.""",1\r\n538,"""IBRAHIM N""","""Ibrahim N is an author of a study on breast cancer treatment.""",1\r\n850,"""MANIKHAS A""","Here is a comprehensive summary of the data:\n\nManikhas A is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Manikhas A has been involved in studies focused on HER2-positive advanced breast cancer, demonstrating expertise in this area. Additionally, Manikhas A has also authored a research paper on inflammatory breast cancer, further expanding their scope of research and expertise.",1\r\n856,"""GOMEZ HL""","""Gomez HL is a researcher involved in studies on HER2-positive advanced breast cancer.""",1\r\n851,"""GLADKOV O""","Here is a comprehensive summary of the data:\n\nGladkov O is a researcher who has been involved in studies on HER2-positive advanced breast cancer and inflammatory breast cancer. Specifically, Gladkov O is an author of a research paper on inflammatory breast cancer, and has also contributed to studies on HER2-positive advanced breast cancer.\n\nNote: I did not find any contradictions in the provided descriptions, so the summary is a straightforward concatenation of the information.",1\r\n852,"""SHAO Z""","Here is a comprehensive summary of the data:\n\nShao Z is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Shao Z has been involved in studies on HER2-positive advanced breast cancer, demonstrating their expertise in this area. Additionally, Shao Z has also authored a research paper on inflammatory breast cancer, further highlighting their breadth of knowledge and research experience in the field of breast cancer.",1\r\n244,"""AFATINIB""","Here is a comprehensive summary of the data:\n\nAfatinib is a drug used in the treatment of HER2-positive inflammatory breast cancer. Specifically, it is an irreversible ErbB family blocker with preclinical activity in trastuzumab-resistant cell lines.",3\r\n247,"""SURVIVAL""","Here is a comprehensive summary of the data:\n\nThe entity ""SURVIVAL"" refers to the length of time a patient lives after being diagnosed with breast cancer. Specifically, it refers to the length of time a patient with breast cancer lives after diagnosis.\n\nNote: The two descriptions provided are identical, with only minor wording variations. I have combined them into a single summary to provide a clear and concise overview of the entity ""SURVIVAL"".",3\r\n229,"""VEG20007""","""VEG20007 is a randomized phase 2 study evaluating first-line lapatinib plus pazopanib therapy or lapatinib monotherapy.""",1\r\n236,"""LAPATINIB MONOTHERAPY""","""Lapatinib monotherapy is a treatment approach that uses a single medication to treat a disease.""",2\r\n438,"""HUGHES ME""","Here is a comprehensive summary of the data:\n\nHughes ME is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the National Comprehensive Cancer Network (NCCN) and authored a study on the same subject.",1\r\n436,"""LI T""","Here is a comprehensive summary of the data:\n\nLi T is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, Li T conducted a study on the topic within the National Comprehensive Cancer Network (NCCN), demonstrating expertise in the area. Additionally, Li T is an author of a study on inflammatory breast cancer management, further solidifying their reputation as a knowledgeable and experienced researcher in this field.",1\r\n439,"""OTTESEN RA""","Here is a comprehensive summary of the data:\n\nOttesen RA is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the national comprehensive cancer network, demonstrating their expertise and involvement in the field. Additionally, Ottesen RA is also an author of a study on inflammatory breast cancer management, further solidifying their reputation as a knowledgeable and authoritative figure in this area of research.",1\r\n440,"""WEEKS JC""","Here is a comprehensive summary of the data:\n\nWeeks JC is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the National Comprehensive Cancer Network (NCCN) and authored a study on the same subject.",1\r\n243,"""DISEASE""",No Description,1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n239,"""GEPARQUINTO""","""CRISTOFANILLI M""","""Cristofanilli M is a researcher involved in the GeparQuinto study.""",39\r\n227,"""LAPATINIB""","""CRISTOFANILLI M""","""Cristofanilli M is an author of a research paper on a randomized phase II study of lapatinib plus pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.""",30\r\n196,"""TRASTUZUMAB""","""LAPATINIB""","""Trastuzumab and lapatinib are combined in a dual antibody treatment for breast cancer.""",27\r\n277,"""PAZOPANIB""","""CRISTOFANILLI M""","""Cristofanilli M is an author of a research paper on a randomized phase II study of lapatinib plus pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.""",25\r\n353,"""MATRO JM""","""CRISTOFANILLI M""","""Matro JM and Cristofanilli M are co-authors of a study on inflammatory breast cancer management.""",23\r\n163,"""NAC""","""LAPATINIB""","""NAC with lapatinib has a low pCR rate in HER2+ patients.""",23\r\n326,"""HORTOBAGYI GN""","""CRISTOFANILLI M""","""Cristofanilli M and Hortobagyi GN are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",22\r\n358,"""CRISTOFANILLI M""","""BUZDAR AU""","""Cristofanilli M and Buzdar AU are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",21\r\n365,"""CRISTOFANILLI M""","""JOHNSTON SR""","""Cristofanilli M and Johnston SR are co-authors of a study on HER2-positive advanced breast cancer.""",21\r\n361,"""CRISTOFANILLI M""","""SNEIGE N""","""Cristofanilli M and Sneige N are co-authors of a study on breast cancer treatment.""",20\r\n120,"""PCR""","""LAPATINIB""","""lapatinib has a lower pCR rate than expected in HER2+ patients.""",20\r\n142,"""PACLITAXEL""","""LAPATINIB""","Here is a comprehensive summary of the data:\n\nPACLITAXEL and LAPATINIB are two medications used in cancer treatment. Specifically, they are combined in a treatment for breast cancer, where LAPATINIB is paired with PACLITAXEL to provide a comprehensive treatment approach. Additionally, both medications have different effects on the pCR (pathological complete response) rate, indicating that they have distinct mechanisms of action in cancer treatment.",20\r\n357,"""CRISTOFANILLI M""","""GONZALEZ-ANGULO AM""","""Cristofanilli M and Gonzalez-Angulo AM are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n359,"""CRISTOFANILLI M""","""KAU SW""","""Cristofanilli M and Kau SW are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n360,"""CRISTOFANILLI M""","""FRYE DK""","""Cristofanilli M and Frye DK are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n362,"""CRISTOFANILLI M""","""SMITH T""","""Cristofanilli M and Smith T are co-authors of a study on breast cancer treatment.""",19\r\n363,"""CRISTOFANILLI M""","""WASAFF B""","""Cristofanilli M and Wasaff B are co-authors of a study on breast cancer treatment.""",19\r\n364,"""CRISTOFANILLI M""","""IBRAHIM N""","""Cristofanilli M and Ibrahim N are co-authors of a study on breast cancer treatment.""",19\r\n366,"""CRISTOFANILLI M""","""MANIKHAS A""","""Cristofanilli M and Manikhas A are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n367,"""CRISTOFANILLI M""","""GOMEZ HL""","""Cristofanilli M and Gomez HL are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n368,"""CRISTOFANILLI M""","""GLADKOV O""","""Cristofanilli M and Gladkov O are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n369,"""CRISTOFANILLI M""","""SHAO Z""","""Cristofanilli M and Shao Z are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n222,"""LAPATINIB""","""PAZOPANIB""","""pazopanib is used in combination with lapatinib in a clinical trial (VEG20007) for the treatment of cancer.""",19\r\n125,"""OS""","""LAPATINIB""","""lapatinib does not differ in 3-year OS rate compared to trastuzumab.""",19\r\n132,"""HER2""","""LAPATINIB""","""Lapatinib blocks intracellular HER2, which is a target for cancer treatment.""",18\r\n224,"""LAPATINIB""","""AFATINIB""","""Lapatinib and Afatinib are both targeted therapies used to treat breast cancer, with Afatinib showing preclinical activity in trastuzumab-resistant cell lines.""",15\r\n226,"""LAPATINIB""","""JOHNSTON SR""","""Johnston SR is an author of a research paper on the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.""",15\r\n225,"""LAPATINIB""","""SURVIVAL""","""Lapatinib is associated with a higher rate of serious adverse events, which can impact patient survival.""",15\r\n223,"""LAPATINIB""","""VEG20007""","""VEG20007 is a study evaluating the effectiveness of lapatinib monotherapy or lapatinib plus pazopanib therapy for the treatment of cancer.""",13\r\n272,"""PAZOPANIB""","""COMBINATION THERAPY""","""Pazopanib is used in combination therapy to treat the disease.""",13\r\n274,"""PAZOPANIB""","""AFATINIB""","""Pazopanib and Afatinib are both targeted therapies used to treat breast cancer, with Pazopanib showing a higher rate of serious adverse events than Afatinib.""",10\r\n276,"""PAZOPANIB""","""JOHNSTON SR""","""Johnston SR is an author of a research paper on the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.""",10\r\n275,"""PAZOPANIB""","""SURVIVAL""","""Pazopanib is associated with a higher rate of serious adverse events, which can impact patient survival.""",10\r\n273,"""PAZOPANIB""","""LAPATINIB MONOTHERAPY""","""Pazopanib is used in lapatinib monotherapy to treat the disease.""",9\r\n283,"""AFATINIB""","""SURVIVAL""","""Afatinib is associated with a shorter survival time, which can impact patient outcomes.""",6\r\n354,"""MATRO JM""","""HUGHES ME""","""Matro JM and Hughes ME are co-authors of a study on inflammatory breast cancer management.""",6\r\n352,"""MATRO JM""","""LI T""","""Matro JM and Li T are co-authors of a study on inflammatory breast cancer management.""",6\r\n355,"""MATRO JM""","""OTTESEN RA""","""Matro JM and Ottesen RA are co-authors of a study on inflammatory breast cancer management.""",6\r\n356,"""MATRO JM""","""WEEKS JC""","""Matro JM and Weeks JC are co-authors of a study on inflammatory breast cancer management.""",6\r\n281,"""LAPATINIB MONOTHERAPY""","""DISEASE""","""Lapatinib monotherapy is used to treat the disease.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:20,844 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 2/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:21,320 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:21,323 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n475,"""BUZDAR AU""","Here is a comprehensive summary of the data:\n\nBuzdar AU is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Buzdar AU has authored research papers and studies on combined-modality treatment of inflammatory breast carcinoma, inflammatory breast cancer, breast cancer, and paclitaxel\'s impact on improving the prognosis in estrogen receptor negative inflammatory breast cancer. These publications demonstrate Buzdar AU\'s expertise and dedication to advancing our understanding of breast cancer, particularly in the context of inflammatory breast carcinoma and the role of paclitaxel in treatment outcomes.",3\r\n474,"""UENO NT""","Here is a comprehensive summary of the data:\n\nUeno NT is a researcher who has authored several studies and research papers on breast cancer. Specifically, they have published papers on combined-modality treatment of inflammatory breast carcinoma, gene expression profiles of inflammatory breast cancer, and inflammatory breast cancer itself. Additionally, they have conducted a study on early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.",10\r\n559,"""BERTUCCI F""","Here is a comprehensive summary of the data:\n\nBertucci F is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Bertucci F has authored research papers and studies on inflammatory breast cancer, a type of breast cancer characterized by rapid growth and spread of cancer cells. The studies conducted by Bertucci F have focused on various aspects of inflammatory breast cancer, including the expression of PDL1, a protein that plays a crucial role in the immune response to cancer. Additionally, Bertucci F has explored the effectiveness of high-dose chemotherapy and haematopoietic stem cell transplantation as a treatment option for inflammatory breast cancer, examining the relationship between pathologic response and outcome. Furthermore, Bertucci F has authored multiple studies on breast cancer treatment, demonstrating a broad range of expertise in the field. Overall, Bertucci F\'s work has shed light on the complexities of inflammatory breast cancer and has contributed to the development of more effective treatment strategies for this aggressive form of breast cancer.",7\r\n565,"""FINETTI P""","Here is a comprehensive summary of the data:\n\nFinetti P is a researcher who has made significant contributions to the field of inflammatory breast cancer. Specifically, Finetti P is an author of two research papers: one on the gene expression profiles of inflammatory breast cancer and another on the expression of PDL1 in inflammatory breast cancer. These studies demonstrate Finetti P\'s expertise in the area of inflammatory breast cancer and highlight their role as a leading researcher in the field.",5\r\n567,"""LUCCI A""","Here is a comprehensive summary of the data:\n\nLUCCI A is a researcher who has made significant contributions to the field of breast cancer research. Specifically, LUCCI A is an author of two research papers. The first paper focuses on the gene expression profiles of inflammatory breast cancer, providing valuable insights into the molecular mechanisms underlying this aggressive form of breast cancer. The second paper investigates the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients. This research highlights the importance of exploring alternative treatment options for this patient population.",5\r\n568,"""ROBERTSON FM""","""Robertson FM is an author of a research paper on gene expression profiles of inflammatory breast cancer.""",5\r\n566,"""VERMEULEN P""","""Vermeulen P is an author of a research paper on gene expression profiles of inflammatory breast cancer.""",5\r\n476,"""SINGLETARY SE""","Here is a comprehensive summary of the data:\n\nSingletary SE is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Singletary SE has authored research papers on combined-modality treatment of inflammatory breast carcinoma, as well as studies on inflammatory breast cancer and breast cancer in general.",2\r\n477,"""AMES""","""Ames is an author of a study on breast cancer.""",1\r\n494,"""CANCER CHEMOTHER PHARMACOL""","Here is a comprehensive summary of the data:\n\nCancer Chemother Pharmacol is a journal that publishes research papers on breast cancer. The publication features research on breast cancer, providing a platform for scholars and experts to share their findings and contribute to the advancement of knowledge in this field.",6\r\n560,"""ESPINOSA FERNANDEZ""","""Espinosa Fernandez is an author of a research paper on inflammatory breast cancer.""",1\r\n482,"""AMES FC""","Here is a comprehensive summary of the data:\n\nAmes FC is an author of research papers on inflammatory breast cancer. Specifically, Ames FC has written papers on combined-modality treatment of inflammatory breast carcinoma and inflammatory breast cancer.",1\r\n495,"""FRYE D""","""Frye D is an author of a research paper on inflammatory breast cancer.""",1\r\n483,"""MCNEESE MD""","Here is a comprehensive summary of the data:\n\nMcNeese MD is a researcher who has authored research papers on inflammatory breast carcinoma. Specifically, McNeese MD has written papers on the combined-modality treatment of inflammatory breast carcinoma, as well as inflammatory breast cancer in general.",1\r\n491,"""KOH EH""","Here is a comprehensive summary of the data:\n\nKoh EH is an author of research papers related to inflammatory breast cancer. Specifically, Koh EH has written papers on combined-modality treatment of inflammatory breast carcinoma and inflammatory breast cancer.",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n358,"""CRISTOFANILLI M""","""BUZDAR AU""","""Cristofanilli M and Buzdar AU are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",21\r\n419,"""UENO NT""","""J CLIN ONCOL""","""Ueno NT is an author of a research paper published in J Clin Oncol.""",20\r\n420,"""UENO NT""","""BERTUCCI F""","""Bertucci F and Ueno NT are co-authors of a research paper on inflammatory breast cancer.""",17\r\n421,"""UENO NT""","""FINETTI P""","""Ueno NT and Finetti P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n423,"""UENO NT""","""LUCCI A""","""Ueno NT and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n424,"""UENO NT""","""ROBERTSON FM""","""Ueno NT and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n422,"""UENO NT""","""VERMEULEN P""","""Ueno NT and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n425,"""UENO NT""","""MATSUDA N""","""Matsuda N and Ueno NT are co-authors of a study on early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.""",15\r\n487,"""BERTUCCI F""","""GONCALVES A""","Here is a comprehensive summary of the data:\n\nGoncalves A and Bertucci F are co-authors of multiple studies related to breast cancer. Specifically, they have collaborated on research focused on inflammatory breast cancer and breast cancer treatment.",14\r\n416,"""UENO NT""","""BUZDAR AU""","""Ueno NT and Buzdar AU are co-authors of a study on breast cancer.""",13\r\n483,"""BERTUCCI F""","""FINETTI P""","""Bertucci F and Finetti P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n484,"""BERTUCCI F""","""VERMEULEN P""","""Bertucci F and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n485,"""BERTUCCI F""","""LUCCI A""","""Bertucci F and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n486,"""BERTUCCI F""","""ROBERTSON FM""","""Bertucci F and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n417,"""UENO NT""","""SINGLETARY SE""","""Ueno NT and Singletary SE are co-authors of a study on breast cancer.""",12\r\n418,"""UENO NT""","""AMES""","""Ueno NT and Ames are co-authors of a study on breast cancer.""",11\r\n493,"""FINETTI P""","""VERMEULEN P""","""Finetti P and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n494,"""FINETTI P""","""LUCCI A""","""Finetti P and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n495,"""FINETTI P""","""ROBERTSON FM""","""Finetti P and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n498,"""LUCCI A""","""ROBERTSON FM""","""Lucci A and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n496,"""VERMEULEN P""","""LUCCI A""","""Vermeulen P and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n497,"""VERMEULEN P""","""ROBERTSON FM""","""Vermeulen P and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n426,"""BUZDAR AU""","""CANCER CHEMOTHER PHARMACOL""","""Buzdar AU is an author of a research paper published in Cancer Chemother Pharmacol.""",9\r\n482,"""BERTUCCI F""","""ESPINOSA FERNANDEZ""","""Bertucci F and Espinosa Fernandez are co-authors of a research paper on inflammatory breast cancer.""",8\r\n427,"""SINGLETARY SE""","""CANCER CHEMOTHER PHARMACOL""","""Singletary SE is an author of a research paper published in Cancer Chemother Pharmacol.""",8\r\n434,"""AMES FC""","""CANCER CHEMOTHER PHARMACOL""","""Ames FC is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n438,"""CANCER CHEMOTHER PHARMACOL""","""FRYE D""","""Frye D is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n435,"""MCNEESE MD""","""CANCER CHEMOTHER PHARMACOL""","""McNeese MD is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n437,"""KOH EH""","""CANCER CHEMOTHER PHARMACOL""","""Koh EH is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:21,323 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 2/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:21,438 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:21,440 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n459,"""CLIN BREAST CANCER""","Based on the provided data, here is a comprehensive summary of the entity ""CLIN BREAST CANCER"":\n\nCLIN BREAST CANCER is a medical journal that publishes research on breast cancer, specifically focusing on the management of inflammatory breast cancer. The journal has published studies on various aspects of breast cancer, including a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. This treatment regimen involves pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, along with trastuzumab as preoperative treatment.",7\r\n669,"""CANCELLO G""","Here is a comprehensive summary of the data:\n\nCancello G is a researcher who has been involved in studies on inflammatory breast cancer. Specifically, Cancello G is an author of a study on a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. The treatment regimen consisted of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, plus trastuzumab, as preoperative treatment.",2\r\n670,"""DELLAPASQUA S""","Here is a comprehensive summary of the data:\n\nDellapasqua S is a researcher who has been involved in studies on inflammatory breast cancer. Specifically, Dellapasqua S is an author of a study on a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. The treatment regimen consisted of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, plus trastuzumab, as preoperative treatment.",2\r\n815,"""BAGNARDI V""","""Bagnardi V is a researcher involved in studies on inflammatory breast cancer.""",1\r\n813,"""PALAZZO A""","""Palazzo A is a researcher involved in studies on inflammatory breast cancer.""",1\r\n814,"""MUNZONE E""","""Munzone E is a researcher involved in studies on inflammatory breast cancer.""",1\r\n816,"""MAZZA M""","""Mazza M is a researcher involved in studies on inflammatory breast cancer.""",1\r\n667,"""TORRISI R""","""Torrisi R is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",5\r\n671,"""BALDUZZI A""","""Balduzzi A is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n668,"""CARDILLO A""","""Cardillo A is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n672,"""GHISINI R""","""Ghisini R is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n398,"""CLIN BREAST CANCER""","""PIERGA JY""","""Pierga JY published a study in Clin Breast Cancer on inflammatory breast cancer.""",20\r\n397,"""CLIN BREAST CANCER""","""CANCELLO G""","""Cancello G published a study in Clin Breast Cancer on inflammatory breast cancer.""",9\r\n393,"""CLIN BREAST CANCER""","""DELLAPASQUA S""","""Dellapasqua S published a study in Clin Breast Cancer on inflammatory breast cancer.""",9\r\n395,"""CLIN BREAST CANCER""","""BAGNARDI V""","""Bagnardi V published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n392,"""CLIN BREAST CANCER""","""PALAZZO A""","""Palazzo A published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n394,"""CLIN BREAST CANCER""","""MUNZONE E""","""Munzone E published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n396,"""CLIN BREAST CANCER""","""MAZZA M""","""Mazza M published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n573,"""TORRISI R""","""CANCELLO G""","""Torrisi R and Cancello G are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",7\r\n574,"""TORRISI R""","""DELLAPASQUA S""","""Torrisi R and Dellapasqua S are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",7\r\n575,"""TORRISI R""","""BALDUZZI A""","""Torrisi R and Balduzzi A are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n572,"""TORRISI R""","""CARDILLO A""","""Torrisi R and Cardillo A are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n576,"""TORRISI R""","""GHISINI R""","""Torrisi R and Ghisini R are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:21,440 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 2/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:21,911 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:21,952 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n48,"""IBC""","Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.",54\r\n85,"""PACLITAXEL""","Here is a comprehensive summary of the data provided:\n\n""PACLITAXEL"" is a chemotherapy agent used to treat breast cancer, specifically in the treatment of HER2-negative locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). It is a chemotherapy drug studied in various clinical trials and has been evaluated for its effectiveness in treating breast cancer. PACLITAXEL is used in combination with other medications, such as pembrolizumab, bevacizumab, trastuzumab, and lapatinib, to treat breast cancer. It is also used as a single agent in the treatment regimen for breast cancer. PACLITAXEL is a type of chemotherapy medication used in the treatment of breast cancer, and it is a treatment option for IBC patients.",8\r\n322,"""PD-L1""","Here is a comprehensive summary of the data:\n\nPD-L1 is a protein that plays a crucial role in immunotherapy, particularly in the context of inflammatory breast cancer (IBC). It is expressed on the surface of some cancer cells and is targeted by atezolizumab, a therapeutic agent. Additionally, PD-L1 is an immune checkpoint molecule found in tumor cells and TILs (tumor-infiltrating lymphocytes) of IBC. Furthermore, PD-L1 refers to a protein expressed on the surface of tumor cells that can inhibit the immune system\'s ability to recognize and attack cancer cells. Overall, PD-L1 is a key protein involved in the immune response to cancer, and its expression and function have significant implications for the development of effective cancer therapies.",7\r\n117,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","Here is a comprehensive summary of the data:\n\nHIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION is a treatment regimen for Inflammatory Breast Cancer (IBC).\n\nThis summary includes information from the provided description, which states that HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION is a treatment regimen for IBC.",4\r\n335,"""ARIAS-PULIDO ET AL.""","Here is a comprehensive summary of the data:\n\nArias-Pulido et al. is a research group that has made significant contributions to the field of cancer research. Specifically, they reported on the presence of PD-L1 positivity in tumor-infiltrating lymphocytes (TILs) and its association with better disease-free survival (DFS).",3\r\n336,"""BERCKELAER ET AL.""","Here is a comprehensive summary of the data:\n\nBerckelaer et al. is a research group that has reported on PD-L1 expression in TILs (Tumor-Infiltrating Lymphocytes).",3\r\n338,"""TILS""","Here is a comprehensive summary of the data:\n\nTILs (Tumor-Infiltrating Lymphocytes) are a type of immune cell that plays a crucial role in immunotherapy, particularly in the context of inflammatory breast cancer (IBC). They are more frequently found in IBC than in non-IBC, indicating a specific association with this type of cancer. TILs are associated with PD-L1 expression, which is linked to better disease-free survival (DFS). As immune cells found in the tumor microenvironment, TILs are an important component of the immune response against cancer.",3\r\n17,"""IMMUNOTHERAPY""","Here is a comprehensive summary of the data:\n\nImmunotherapy is a type of cancer treatment that uses the body\'s immune system to fight cancer. It is a type of systemic treatment that targets cancer cells and helps the body\'s immune system recognize and attack them. Specifically, immunotherapy is a treatment option for breast cancer, including inflammatory breast cancer (IBC). This type of treatment harnesses the body\'s natural defenses to combat cancer, making it a promising approach for cancer patients.",3\r\n86,"""FAC""","Here is a comprehensive summary of the data:\n\nFAC is a chemotherapy regimen used to treat breast cancer, as well as a technology used in clinical trials.",2\r\n343,"""I-SPY2""","Here is a comprehensive summary of the data:\n\n""I-SPY2"" is a clinical trial that combines chemotherapy and an immune checkpoint inhibitor for the treatment of Inflammatory Breast Cancer (IBC).",2\r\n75,"""RADIATION ONCOLOGIST""","Here is a comprehensive summary of the data:\n\nA radiation oncologist is a medical professional who specializes in the treatment of cancer using radiation therapy. They are a type of doctor who focuses on the use of radiation therapy to combat cancer.\n\nNote: I combined the two descriptions to create a single, coherent summary that includes all the relevant information.",2\r\n116,"""INTERNATIONAL EXPERT CONSENSUS""","Here is a comprehensive summary of the data:\n\nThe ""INTERNATIONAL EXPERT CONSENSUS"" refers to a collective agreement on the treatment of Inflammatory Breast Cancer (IBC).",2\r\n143,"""STANDARD OF CARE""","""Standard of Care refers to the accepted and widely used treatment approach for IBC.""",2\r\n342,"""KEYNOTE-522""","Here is a comprehensive summary of the data:\n\nKEYNOTE-522 is a clinical trial that combines chemotherapy and an immune checkpoint inhibitor for the treatment of Inflammatory Breast Cancer (IBC).",2\r\n87,"""ANTHRACYCLINE""","Here is a comprehensive summary of the data:\n\nAnthracycline is a chemotherapy agent used to treat breast cancer. It is a type of chemotherapy specifically designed to combat breast cancer.\n\nNote: I resolved the contradictions by combining the two descriptions into a single, coherent summary.",1\r\n252,"""ANTHRACYCLINE-BASED CHEMOTHERAPY""","""Anthracycline-based Chemotherapy is a type of chemotherapy used in the treatment of IBC.""",1\r\n347,"""ANTI-EGFR AGENT""","""Anti-EGFR agents are a type of targeted therapy that targets the EGFR protein, which is overexpressed in IBC.""",1\r\n348,"""ANTIPD-L1 ANTIBODY""","""Anti-PD-L1 antibodies are a type of immune checkpoint inhibitor that helps the immune system fight cancer, including IBC.""",1\r\n353,"""BC""",No Description,1\r\n334,"""BERTUCCI ET AL.""","""Bertucci et al. is a research group that reported PD-L1 overexpression in breast cancer tumors.""",1\r\n215,"""CARBOPLATIN""","Here is a comprehensive summary of the data:\n\nCarboplatin is a chemotherapy agent used in the treatment of various types of cancer, including breast cancer and inflammatory breast cancer (IBC). It is a chemotherapy drug that is often used in combination with other medications to treat cancer. Specifically, Carboplatin is used in the treatment of breast cancer, and it is also used to treat IBC. Additionally, it is classified as a type of cancer treatment and a type of chemotherapy used in the treatment of IBC. Overall, Carboplatin is a medication used in cancer treatment, specifically in the treatment of breast cancer and IBC.",1\r\n80,"""CHEMOTHERAPY""","Here is a comprehensive summary of the data:\n\nChemotherapy is a type of systemic treatment that uses chemicals to kill cancer cells, including those associated with breast cancer, including inflammatory breast cancer (IBC). It is a treatment option for breast cancer, including IBC, and is evaluated in clinical trials for its effectiveness in treating the disease. Specifically, chemotherapy is combined with T-DM1 in the TCHP regimen, a treatment approach that has shown promise in the fight against breast cancer. Overall, chemotherapy is a widely used and effective treatment for breast cancer, including IBC, that has been shown to be effective in clinical trials and is often used in combination with other treatments.",1\r\n74,"""DIAGNOSTIC RADIOLOGIST""","""Diagnostic radiologist is a type of doctor who specializes in the interpretation of imaging tests.""",1\r\n89,"""DITSCH ET AL.""","""Ditsch et al. are researchers who conducted a study on chemotherapy dose intensity in IBC patients.""",1\r\n88,"""FAC REGIMEN""","""FAC regimen is a chemotherapy treatment protocol.""",1\r\n71,"""MEDICAL ONCOLOGIST""","""Medical oncologist is a type of doctor who specializes in cancer treatment.""",1\r\n72,"""SURGEON""","""Surgeon is a type of doctor who specializes in surgical procedures.""",1\r\n73,"""PATHOLOGIST""","""Pathologist is a type of doctor who specializes in the diagnosis of diseases through the examination of tissues and cells.""",1\r\n84,"""MD ANDERSON""",No Description,1\r\n106,"""NON-IBC""","Here is a comprehensive summary of the data:\n\nNon-IBC (Non-Inflammatory Breast Cancer) refers to a type of breast cancer that is not Inflammatory Breast Cancer (IBC). Notably, Non-IBC has a similar pathological complete response (pCR) rate to ER-negative IBC, indicating that it shares some similarities with IBC in terms of treatment outcomes.",1\r\n285,"""TALIMOGENE LAHERPAREPVEC""","Here is a comprehensive summary of the data:\n\nTalimogene laherparepvec is a treatment regimen. Specifically, it is a treatment regimen for local recurrence IBC (inflammatory breast cancer) or inoperable non-IBC (non-inflammatory breast cancer).",1\r\n319,"""MULTIDISCIPLINARY TEAM""","Here is a comprehensive summary of the data:\n\nThe MULTIDISCIPLINARY TEAM is a group of healthcare professionals who work together to provide comprehensive care for patients with breast cancer. This team of experts evaluates and treats patients with breast cancer, offering a collaborative approach to patient care.",1\r\n346,"""IMMUNE CHECKPOINT INHIBITOR""","""Immune checkpoint inhibitors are a type of treatment that helps the immune system fight cancer, including IBC.""",1\r\n351,"""LAABC""","""LAABC is a type of breast cancer that is different from IBC.""",1\r\n352,"""LA BC""","""LA BC is an abbreviation for Localized Adenocarcinoma Breast Cancer, a type of breast cancer.""",1\r\n38,"""TUMOR EMBOLI""","Here is a comprehensive summary of the data:\n\nTumor emboli refer to the presence of tumor cells in the lymphatic vessels, which may be present or absent in biopsy specimens.",1\r\n41,"""LYMPHEDEMA""","""Lymphedema is a condition characterized by swelling caused by tumor emboli within dermal lymphatics.""",1\r\n90,"""ESTROGEN RECEPTOR""",No Description,1\r\n121,"""CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH""","""Center for International Blood and Marrow Transplant Research is an organization that conducts research on blood and marrow transplants.""",1\r\n120,"""INTERNATIONAL BLOOD AND MARROW TRANSPLANT REGISTRY""","""International Blood and Marrow Transplant Registry is an organization that tracks and reports on blood and marrow transplant data.""",1\r\n18,"""ONGOING IBC CLINICAL TRIALS""","""Ongoing IBC Clinical Trials refer to current research studies investigating new treatments for IBC.""",1\r\n96,"""G-CSF""","Here is a comprehensive summary of the data:\n\nG-CSF is a medication used to support the treatment regimen, specifically in clinical trials for the treatment of HER2-negative (HER2-) Locally Advanced Breast Cancer (LABC) or Inflammatory Breast Cancer (IBC). It is a growth factor used to support the dose-dense chemotherapy regimen, as well as to support the growth of white blood cells during chemotherapy. Additionally, G-CSF is a technology used in clinical trials, highlighting its role in the development and evaluation of new treatments. Overall, G-CSF plays a crucial role in supporting patients undergoing chemotherapy, particularly those with HER2- LABC or IBC, and is an important component of clinical trials aimed at improving treatment outcomes.",1\r\n78,"""TEAM""","""Team is a group of medical professionals working together to improve the survival of IBC.""",1\r\n144,"""RANDOMIZED TRIALS""","""Randomized Trials are studies that compare the effectiveness of different treatment approaches for IBC.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n72,"""IBC""","""TRASTUZUMAB""","""Trastuzumab is used in the treatment of IBC, a type of breast cancer.""",69\r\n30,"""BREAST CANCER""","""IBC""","""IBC is a subtype of Breast Cancer that requires specific treatment.""",63\r\n52,"""IBC""","""PCR""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) patients who achieve pCR (Pathological Complete Response) have better survival outcomes than those who do not. pCR is a measure of the effectiveness of treatment for IBC, indicating that the treatment has successfully eliminated all cancer cells from the breast tissue.",62\r\n62,"""IBC""","""PACLITAXEL""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) is a type of breast cancer that can be treated with Paclitaxel, a chemotherapy medication. According to the descriptions, Paclitaxel is used as part of a neoadjuvant regimen to treat IBC patients, and it is also used to treat IBC patients directly. Additionally, Paclitaxel is used to treat IBC, a type of breast cancer. Overall, Paclitaxel is a treatment option for IBC patients, and its use is likely part of a comprehensive treatment plan that may include other medications and therapies.",62\r\n75,"""IBC""","""NERATINIB""","""Neratinib is used in adjuvant therapy for high-risk recurrent disease like IBC.""",62\r\n40,"""SYSTEMIC TREATMENT""","""IBC""","""IBC is treated with systemic treatment, including chemotherapy and targeted therapy.""",62\r\n53,"""IBC""","""OS""","""IBC patients have poor overall survival rates, with a 5-year OS rate of less than 5%.""",61\r\n89,"""IBC""","""PD-L1""","""IBC is associated with PD-L1, an immune checkpoint molecule found in tumor cells and TILs.""",61\r\n91,"""IBC""","""INSTITUTE""","""Institute demonstrates IBC preclinical data supporting a combination of targeted therapy and an immune checkpoint inhibitor.""",61\r\n85,"""IBC""","""PEMBROLIZUMAB""","""Pembrolizumab is used in the treatment of IBC, a type of breast cancer characterized by rapid onset and aggressive growth.""",60\r\n74,"""IBC""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of a neoadjuvant treatment for IBC patients, which is a high-risk disease.""",59\r\n67,"""IBC""","""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""High-dose chemotherapy with autologous hematopoietic stem cell transplantation is a treatment option for IBC.""",58\r\n73,"""IBC""","""NEOSPHERE TRIAL""","""The NeoSphere trial included 29 IBC patients.""",58\r\n76,"""IBC""","""PANITUMUMAB""","""Panitumumab is used in certain circumstances for IBC cases, targeting EGFR expression.""",58\r\n77,"""IBC""","""EGFR""","""EGFR expression is associated with worse prognosis in IBC cases.""",58\r\n78,"""IBC""","""HER2+ IBC""","""HER2+ IBC is a subtype of IBC.""",58\r\n88,"""IBC""","""ARIAS-PULIDO ET AL.""","""Arias-Pulido et al. studied PD-L1 positivity in IBC samples.""",57\r\n87,"""IBC""","""BERCKELAER ET AL.""","""Berckelaer et al. studied PD-L1 expression in TILs in the context of IBC.""",57\r\n71,"""IBC""","""LABC""","""LABC includes IBC, a type of breast cancer with high-risk characteristics.""",57\r\n90,"""IBC""","""TILS""","Here is a comprehensive summary of the data:\n\nThe entities ""IBC"" and ""TILs"" are related to each other. TILs (Tumor-Infiltrating Lymphocytes) are found in the tumor microenvironment of IBC (Invasive Breast Cancer). Additionally, TILs are more frequently found in IBC compared to non-IBC.",57\r\n3,"""VICENTE VALERO""","""IBC""","""Vicente Valero is a member of the IBC working group.""",57\r\n43,"""IMMUNOTHERAPY""","""IBC""","Here is a comprehensive summary of the data:\n\nIMMUNOTHERAPY is a potential treatment option for Inflammatory Breast Cancer (IBC).",57\r\n63,"""IBC""","""FAC""","""FAC is used to treat IBC patients.""",56\r\n93,"""IBC""","""I-SPY2""","""IBC is the disease being treated in the I-SPY2 clinical trial.""",56\r\n58,"""IBC""","""RADIATION ONCOLOGIST""","""Radiation oncologists are part of a multidisciplinary team that treats IBC patients.""",56\r\n61,"""IBC""","""CRISTOFANILLI ET AL.""","""Cristofanilli et al. conducted a study on IBC patients.""",56\r\n68,"""IBC""","""INTERNATIONAL EXPERT CONSENSUS""","""International Expert Consensus provides guidance on the treatment of IBC.""",56\r\n70,"""IBC""","""STANDARD OF CARE""","""IBC is treated according to the Standard of Care, which involves the use of various therapies, including chemotherapy and transplantation.""",56\r\n79,"""IBC""","""TARGETED THERAPY""","""Targeted Therapy is a treatment option for IBC.""",56\r\n81,"""IBC""","""TAXANE-BASED CHEMOTHERAPY""","""Taxane-based Chemotherapy is used in the treatment of IBC.""",56\r\n92,"""IBC""","""KEYNOTE-522""","""IBC is the disease being treated in the KEYNOTE-522 clinical trial.""",56\r\n64,"""IBC""","""ANTHRACYCLINE""","""Anthracycline is used to treat IBC patients.""",55\r\n80,"""IBC""","""ANTHRACYCLINE-BASED CHEMOTHERAPY""","""Anthracycline-based Chemotherapy is used in the treatment of IBC.""",55\r\n95,"""IBC""","""ANTI-EGFR AGENT""","""Anti-EGFR agents are a potential treatment for IBC.""",55\r\n96,"""IBC""","""ANTIPD-L1 ANTIBODY""","""Anti-PD-L1 antibodies are a potential treatment for IBC.""",55\r\n98,"""IBC""","""BC""","""BC is related to IBC as a medical organization or institution may be involved in the study and treatment of IBC.""",55\r\n86,"""IBC""","""BERTUCCI ET AL.""","""Bertucci et al. reported PD-L1 overexpression in IBC tumors.""",55\r\n82,"""IBC""","""CARBOPLATIN""","""Carboplatin is used in the treatment of IBC.""",55\r\n60,"""IBC""","""CHEMOTHERAPY""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) is a type of breast cancer that can be treated with chemotherapy. According to the descriptions, chemotherapy is a potential treatment option for IBC, and it has been reported to be effective in treating the disease. Specifically, chemotherapy has been used to treat IBC with a reported objective response rate of 74% and a median overall survival (OS) of 37 months.",55\r\n57,"""IBC""","""DIAGNOSTIC RADIOLOGIST""","""Diagnostic radiologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n66,"""IBC""","""DITSCH ET AL.""","""Ditsch et al. conducted a study on chemotherapy dose intensity in IBC patients.""",55\r\n65,"""IBC""","""FAC REGIMEN""","""FAC regimen is used to treat IBC, a type of breast cancer.""",55\r\n54,"""IBC""","""MEDICAL ONCOLOGIST""","""Medical oncologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n55,"""IBC""","""SURGEON""","""Surgeons are part of a multidisciplinary team that treats IBC patients.""",55\r\n56,"""IBC""","""PATHOLOGIST""","""Pathologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n59,"""IBC""","""MD ANDERSON""","""MD Anderson conducted a retrospective study on IBC patients, providing insights into the treatment of IBC.""",55\r\n69,"""IBC""","""NON-IBC""","""IBC and non-IBC are compared in terms of OS rate and outcomes.""",55\r\n83,"""IBC""","""TALIMOGENE LAHERPAREPVEC""","""Talimogene laherparepvec is a treatment for IBC patients, specifically for TNBC patients.""",55\r\n84,"""IBC""","""MULTIDISCIPLINARY TEAM""","""The Multidisciplinary team evaluates and treats patients with IBC, a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body.""",55\r\n94,"""IBC""","""IMMUNE CHECKPOINT INHIBITOR""","""Immune checkpoint inhibitors are a potential treatment for IBC.""",55\r\n97,"""IBC""","""LAABC""","""LAABC is different from IBC.""",55\r\n99,"""IBC""","""LA BC""","""IBC is distinct from LA BC as a unique entity with different characteristics and treatment approaches.""",55\r\n46,"""TUMOR EMBOLI""","""IBC""","""IBC is characterized by the presence of tumor emboli in dermal lymphatics, which may be present or absent in biopsy specimens.""",55\r\n47,"""LYMPHEDEMA""","""IBC""","""IBC is characterized by lymphedema caused by tumor emboli within dermal lymphatics.""",55\r\n143,"""PACLITAXEL""","""TRASTUZUMAB""","""Trastuzumab is combined with paclitaxel in a treatment for breast cancer.""",23\r\n142,"""PACLITAXEL""","""LAPATINIB""","Here is a comprehensive summary of the data:\n\nPACLITAXEL and LAPATINIB are two medications used in cancer treatment. Specifically, they are combined in a treatment for breast cancer, where LAPATINIB is paired with PACLITAXEL to provide a comprehensive treatment approach. Additionally, both medications have different effects on the pCR (pathological complete response) rate, indicating that they have distinct mechanisms of action in cancer treatment.",20\r\n140,"""PACLITAXEL""","""NAC""","""Paclitaxel is part of the NAC regimen.""",19\r\n164,"""NAC""","""PD-L1""","""NAC is associated with PD-L1 expression in breast cancer.""",18\r\n144,"""PACLITAXEL""","""BEVACIZUMAB""","""Paclitaxel is used in certain circumstances with bevacizumab for metastatic breast cancer.""",16\r\n129,"""OS""","""PD-L1""","""PD-L1 expression in tumor cells is associated with worse overall survival in breast cancer patients.""",14\r\n141,"""PACLITAXEL""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",13\r\n134,"""HER2""","""PD-L1""","""HER2 is associated with PD-L1 expression in breast cancer.""",13\r\n27,"""BREAST CANCER""","""IMMUNOTHERAPY""","""Immunotherapy is a potential future direction for systemic therapy in Breast Cancer treatment, leveraging the body\'s immune system to fight cancer.""",12\r\n297,"""PD-L1""","""ARIAS-PULIDO ET AL.""","""Arias-Pulido et al. reported on PD-L1 positivity in IBC samples.""",10\r\n296,"""PD-L1""","""BERCKELAER ET AL.""","""Berckelaer et al. reported on PD-L1 expression in TILs.""",10\r\n145,"""PACLITAXEL""","""AC REGIME""","""AC regime and paclitaxel are used together in a chemotherapy regimen for breast cancer treatment.""",10\r\n139,"""PACLITAXEL""","""ESTROGEN RECEPTOR""","""Estrogen receptor is relevant to paclitaxel\'s effectiveness in treating breast cancer.""",9\r\n295,"""PD-L1""","""ER""","""ER is associated with PD-L1 expression in breast cancer.""",9\r\n298,"""ARIAS-PULIDO ET AL.""","""TILS""","""Arias-Pulido et al. reported PD-L1 positivity in TILs and its association with better DFS.""",6\r\n299,"""BERCKELAER ET AL.""","""TILS""","""Berckelaer et al. reported PD-L1 expression in TILs.""",6\r\n165,"""INTERNATIONAL EXPERT CONSENSUS""","""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""International Expert Consensus recommends High-dose chemotherapy with autologous hematopoietic stem cell transplantation as a treatment option for IBC.""",6\r\n167,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH""","""Center for International Blood and Marrow Transplant Research conducts research on High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IBC treatment.""",5\r\n166,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""INTERNATIONAL BLOOD AND MARROW TRANSPLANT REGISTRY""","""International Blood and Marrow Transplant Registry tracks data on High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IBC treatment.""",5\r\n302,"""KEYNOTE-522""","""I-SPY2""","""KEYNOTE-522 and I-SPY2 are clinical trials that combine chemotherapy and an immune checkpoint inhibitor.""",4\r\n42,"""IMMUNOTHERAPY""","""ONGOING IBC CLINICAL TRIALS""","""Immunotherapy is being investigated in Ongoing IBC Clinical Trials as a potential new treatment for IBC.""",4\r\n146,"""FAC""","""G-CSF""","""FAC and G-CSF are technologies used together in clinical trials.""",3\r\n136,"""RADIATION ONCOLOGIST""","""TEAM""","""Radiation oncologist is a member of the team working to improve the survival of IBC.""",3\r\n189,"""STANDARD OF CARE""","""RANDOMIZED TRIALS""","""Randomized Trials are used to determine the Standard of Care for IBC treatment.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:21,953 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 2/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:23,556 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:23,559 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n437,"""CRISTOFANILLI M""","Here is a comprehensive summary of the data:\n\nCristofanilli M is a researcher who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on inflammatory breast cancer management in the National Comprehensive Cancer Network. Additionally, they were involved in the GeparQuinto study, which further highlights their expertise in this area.\n\nCristofanilli M is also an author of several research papers and studies on inflammatory breast cancer. These publications include a study on breast cancer treatment, as well as studies on inflammatory breast cancer management, neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer, paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer, and the prognostic significance of HER-2 status in women with inflammatory breast cancer.\n\nOverall, Cristofanilli M is a prominent researcher in the field of inflammatory breast cancer, with a focus on management, treatment, and prognosis.",18\r\n172,"""LAPATINIB""","Here is a comprehensive summary of the data:\n\nLapatinib is a small-molecule tyrosine kinase inhibitor that blocks intracellular HER2 and EGFR signaling pathways. It is a targeted therapy used to treat cancer, and is also used in combination with other therapies, such as Pazopanib, trastuzumab, and NAC, to treat various types of cancer, including breast cancer. Specifically, it is a treatment option for inflammatory breast cancer (IBC) when used in combination with NAC and trastuzumab. Additionally, lapatinib is an antibody-drug conjugate used in breast cancer treatment. Overall, lapatinib is a medication used in cancer treatment, specifically targeting HER2 and EGFR signaling pathways to inhibit the growth and spread of cancer cells.",12\r\n228,"""PAZOPANIB""","Here is a comprehensive summary of the data:\n\nPazopanib is a small-molecule multi-tyrosine kinase inhibitor used to treat cancer. Specifically, it is a targeted therapy used in combination with other treatments for breast cancer, and also used in combination therapy to treat a disease.\n\nNote: I resolved the contradictions by combining the information from all the descriptions to provide a single, coherent summary.",7\r\n435,"""MATRO JM""","Here is a comprehensive summary of the data:\n\nMatro JM is a person who has conducted a study on inflammatory breast cancer management in the National Comprehensive Cancer Network.",5\r\n844,"""JOHNSTON SR""","Here is a comprehensive summary of the data:\n\nJohnston SR is a researcher who has made significant contributions to the field of breast cancer research. Specifically, he has been involved in studies focused on HER2-positive advanced breast cancer, demonstrating his expertise in this area. Additionally, he has also authored a research paper on inflammatory breast cancer, showcasing his breadth of knowledge and expertise in the field.",3\r\n528,"""GONZALEZ-ANGULO AM""","""Gonzalez-Angulo AM is an author of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",1\r\n529,"""KAU SW""","Here is a comprehensive summary of the data:\n\nKau SW is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Kau SW is an author of two studies that have shed light on the prognosis and treatment of inflammatory breast cancer. In one study, Kau SW investigated the impact of paclitaxel on the prognosis of estrogen receptor negative inflammatory breast cancer, demonstrating its potential to improve patient outcomes. In another study, Kau SW examined the prognostic significance of HER-2 status in women with inflammatory breast cancer, providing valuable insights into the role of this biomarker in predicting patient outcomes.",1\r\n530,"""FRYE DK""","""Frye DK is an author of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",1\r\n536,"""SMITH T""","""Smith T is an author of a study on breast cancer treatment.""",1\r\n537,"""WASAFF B""","""Wasaff B is an author of a study on breast cancer treatment.""",1\r\n538,"""IBRAHIM N""","""Ibrahim N is an author of a study on breast cancer treatment.""",1\r\n850,"""MANIKHAS A""","Here is a comprehensive summary of the data:\n\nManikhas A is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Manikhas A has been involved in studies focused on HER2-positive advanced breast cancer, demonstrating expertise in this area. Additionally, Manikhas A has also authored a research paper on inflammatory breast cancer, further expanding their scope of research and expertise.",1\r\n856,"""GOMEZ HL""","""Gomez HL is a researcher involved in studies on HER2-positive advanced breast cancer.""",1\r\n851,"""GLADKOV O""","Here is a comprehensive summary of the data:\n\nGladkov O is a researcher who has been involved in studies on HER2-positive advanced breast cancer and inflammatory breast cancer. Specifically, Gladkov O is an author of a research paper on inflammatory breast cancer, and has also contributed to studies on HER2-positive advanced breast cancer.\n\nNote: I did not find any contradictions in the provided descriptions, so the summary is a straightforward concatenation of the information.",1\r\n852,"""SHAO Z""","Here is a comprehensive summary of the data:\n\nShao Z is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Shao Z has been involved in studies on HER2-positive advanced breast cancer, demonstrating their expertise in this area. Additionally, Shao Z has also authored a research paper on inflammatory breast cancer, further highlighting their breadth of knowledge and research experience in the field of breast cancer.",1\r\n244,"""AFATINIB""","Here is a comprehensive summary of the data:\n\nAfatinib is a drug used in the treatment of HER2-positive inflammatory breast cancer. Specifically, it is an irreversible ErbB family blocker with preclinical activity in trastuzumab-resistant cell lines.",3\r\n247,"""SURVIVAL""","Here is a comprehensive summary of the data:\n\nThe entity ""SURVIVAL"" refers to the length of time a patient lives after being diagnosed with breast cancer. Specifically, it refers to the length of time a patient with breast cancer lives after diagnosis.\n\nNote: The two descriptions provided are identical, with only minor wording variations. I have combined them into a single summary to provide a clear and concise overview of the entity ""SURVIVAL"".",3\r\n229,"""VEG20007""","""VEG20007 is a randomized phase 2 study evaluating first-line lapatinib plus pazopanib therapy or lapatinib monotherapy.""",1\r\n236,"""LAPATINIB MONOTHERAPY""","""Lapatinib monotherapy is a treatment approach that uses a single medication to treat a disease.""",2\r\n438,"""HUGHES ME""","Here is a comprehensive summary of the data:\n\nHughes ME is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the National Comprehensive Cancer Network (NCCN) and authored a study on the same subject.",1\r\n436,"""LI T""","Here is a comprehensive summary of the data:\n\nLi T is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, Li T conducted a study on the topic within the National Comprehensive Cancer Network (NCCN), demonstrating expertise in the area. Additionally, Li T is an author of a study on inflammatory breast cancer management, further solidifying their reputation as a knowledgeable and experienced researcher in this field.",1\r\n439,"""OTTESEN RA""","Here is a comprehensive summary of the data:\n\nOttesen RA is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the national comprehensive cancer network, demonstrating their expertise and involvement in the field. Additionally, Ottesen RA is also an author of a study on inflammatory breast cancer management, further solidifying their reputation as a knowledgeable and authoritative figure in this area of research.",1\r\n440,"""WEEKS JC""","Here is a comprehensive summary of the data:\n\nWeeks JC is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the National Comprehensive Cancer Network (NCCN) and authored a study on the same subject.",1\r\n243,"""DISEASE""",No Description,1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n239,"""GEPARQUINTO""","""CRISTOFANILLI M""","""Cristofanilli M is a researcher involved in the GeparQuinto study.""",39\r\n227,"""LAPATINIB""","""CRISTOFANILLI M""","""Cristofanilli M is an author of a research paper on a randomized phase II study of lapatinib plus pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.""",30\r\n196,"""TRASTUZUMAB""","""LAPATINIB""","""Trastuzumab and lapatinib are combined in a dual antibody treatment for breast cancer.""",27\r\n277,"""PAZOPANIB""","""CRISTOFANILLI M""","""Cristofanilli M is an author of a research paper on a randomized phase II study of lapatinib plus pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.""",25\r\n353,"""MATRO JM""","""CRISTOFANILLI M""","""Matro JM and Cristofanilli M are co-authors of a study on inflammatory breast cancer management.""",23\r\n163,"""NAC""","""LAPATINIB""","""NAC with lapatinib has a low pCR rate in HER2+ patients.""",23\r\n326,"""HORTOBAGYI GN""","""CRISTOFANILLI M""","""Cristofanilli M and Hortobagyi GN are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",22\r\n358,"""CRISTOFANILLI M""","""BUZDAR AU""","""Cristofanilli M and Buzdar AU are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",21\r\n365,"""CRISTOFANILLI M""","""JOHNSTON SR""","""Cristofanilli M and Johnston SR are co-authors of a study on HER2-positive advanced breast cancer.""",21\r\n361,"""CRISTOFANILLI M""","""SNEIGE N""","""Cristofanilli M and Sneige N are co-authors of a study on breast cancer treatment.""",20\r\n120,"""PCR""","""LAPATINIB""","""lapatinib has a lower pCR rate than expected in HER2+ patients.""",20\r\n142,"""PACLITAXEL""","""LAPATINIB""","Here is a comprehensive summary of the data:\n\nPACLITAXEL and LAPATINIB are two medications used in cancer treatment. Specifically, they are combined in a treatment for breast cancer, where LAPATINIB is paired with PACLITAXEL to provide a comprehensive treatment approach. Additionally, both medications have different effects on the pCR (pathological complete response) rate, indicating that they have distinct mechanisms of action in cancer treatment.",20\r\n357,"""CRISTOFANILLI M""","""GONZALEZ-ANGULO AM""","""Cristofanilli M and Gonzalez-Angulo AM are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n359,"""CRISTOFANILLI M""","""KAU SW""","""Cristofanilli M and Kau SW are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n360,"""CRISTOFANILLI M""","""FRYE DK""","""Cristofanilli M and Frye DK are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n362,"""CRISTOFANILLI M""","""SMITH T""","""Cristofanilli M and Smith T are co-authors of a study on breast cancer treatment.""",19\r\n363,"""CRISTOFANILLI M""","""WASAFF B""","""Cristofanilli M and Wasaff B are co-authors of a study on breast cancer treatment.""",19\r\n364,"""CRISTOFANILLI M""","""IBRAHIM N""","""Cristofanilli M and Ibrahim N are co-authors of a study on breast cancer treatment.""",19\r\n366,"""CRISTOFANILLI M""","""MANIKHAS A""","""Cristofanilli M and Manikhas A are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n367,"""CRISTOFANILLI M""","""GOMEZ HL""","""Cristofanilli M and Gomez HL are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n368,"""CRISTOFANILLI M""","""GLADKOV O""","""Cristofanilli M and Gladkov O are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n369,"""CRISTOFANILLI M""","""SHAO Z""","""Cristofanilli M and Shao Z are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n222,"""LAPATINIB""","""PAZOPANIB""","""pazopanib is used in combination with lapatinib in a clinical trial (VEG20007) for the treatment of cancer.""",19\r\n125,"""OS""","""LAPATINIB""","""lapatinib does not differ in 3-year OS rate compared to trastuzumab.""",19\r\n132,"""HER2""","""LAPATINIB""","""Lapatinib blocks intracellular HER2, which is a target for cancer treatment.""",18\r\n224,"""LAPATINIB""","""AFATINIB""","""Lapatinib and Afatinib are both targeted therapies used to treat breast cancer, with Afatinib showing preclinical activity in trastuzumab-resistant cell lines.""",15\r\n226,"""LAPATINIB""","""JOHNSTON SR""","""Johnston SR is an author of a research paper on the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.""",15\r\n225,"""LAPATINIB""","""SURVIVAL""","""Lapatinib is associated with a higher rate of serious adverse events, which can impact patient survival.""",15\r\n223,"""LAPATINIB""","""VEG20007""","""VEG20007 is a study evaluating the effectiveness of lapatinib monotherapy or lapatinib plus pazopanib therapy for the treatment of cancer.""",13\r\n272,"""PAZOPANIB""","""COMBINATION THERAPY""","""Pazopanib is used in combination therapy to treat the disease.""",13\r\n274,"""PAZOPANIB""","""AFATINIB""","""Pazopanib and Afatinib are both targeted therapies used to treat breast cancer, with Pazopanib showing a higher rate of serious adverse events than Afatinib.""",10\r\n276,"""PAZOPANIB""","""JOHNSTON SR""","""Johnston SR is an author of a research paper on the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.""",10\r\n275,"""PAZOPANIB""","""SURVIVAL""","""Pazopanib is associated with a higher rate of serious adverse events, which can impact patient survival.""",10\r\n273,"""PAZOPANIB""","""LAPATINIB MONOTHERAPY""","""Pazopanib is used in lapatinib monotherapy to treat the disease.""",9\r\n283,"""AFATINIB""","""SURVIVAL""","""Afatinib is associated with a shorter survival time, which can impact patient outcomes.""",6\r\n354,"""MATRO JM""","""HUGHES ME""","""Matro JM and Hughes ME are co-authors of a study on inflammatory breast cancer management.""",6\r\n352,"""MATRO JM""","""LI T""","""Matro JM and Li T are co-authors of a study on inflammatory breast cancer management.""",6\r\n355,"""MATRO JM""","""OTTESEN RA""","""Matro JM and Ottesen RA are co-authors of a study on inflammatory breast cancer management.""",6\r\n356,"""MATRO JM""","""WEEKS JC""","""Matro JM and Weeks JC are co-authors of a study on inflammatory breast cancer management.""",6\r\n281,"""LAPATINIB MONOTHERAPY""","""DISEASE""","""Lapatinib monotherapy is used to treat the disease.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:23,560 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 3/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:23,965 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:23,969 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n145,"""TRASTUZUMAB""","Here is a comprehensive summary of the data provided:\n\nTrastuzumab is a humanized anti-HER2 monoclonal antibody that is part of the anti-HER2 backbone for HER2+ IBC. It is a medication used in the treatment of HER2+ IBC, HER2-positive breast cancer, and breast cancer in general. Trastuzumab is a targeted therapy that targets HER2 receptors, blocking the HER2 protein to treat HER2-positive breast cancer. It is often used in combination with other medications, such as pertuzumab, docetaxel, and epirubicin, to treat breast cancer. Trastuzumab is also used in clinical trials and has been approved for HER2+ disease, including IBC. It is a type of monoclonal antibody that targets HER2 and is a treatment option for IBC, used in combination with lapatinib and paclitaxel. Additionally, trastuzumab is a chemotherapy drug used in the NeoSphere clinical trial and is a type of cancer treatment. Overall, trastuzumab is a medication used to treat HER2+ breast cancer by blocking the HER2 protein and is a targeted therapy approved for HER2+ disease, including IBC.",15\r\n200,"""NERATINIB""","Here is a comprehensive summary of the data:\n\nNeratinib is a medication used in various treatment settings for breast cancer. Specifically, it is used in adjuvant therapy for high-risk recurrent disease, including inflammatory breast cancer (IBC). Additionally, neratinib is used to treat HER2-positive breast cancer, particularly in high-risk situations. It is also offered as a treatment option for patients with HER2-positive breast cancer. Neratinib is a chemotherapy drug and a tyrosine kinase inhibitor, which is used in clinical trials. Overall, neratinib is a medication used in cancer treatment, with a focus on breast cancer, particularly HER2-positive disease.\n\nNote: I resolved the contradictions by combining the information from the different descriptions to provide a comprehensive summary. I also rephrased some of the sentences to ensure clarity and coherence.",8\r\n171,"""OVERMOYER ET AL.""","Here is a comprehensive summary of the data:\n\nOvermoyer et al. are researchers who have reported on the efficacy of a specific treatment regimen. According to their findings, neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab has shown promising results.",5\r\n62,"""HER2+ IBC""","Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.",4\r\n165,"""NEOSPHERE TRIAL""","Here is a comprehensive summary of the data:\n\nThe ""NEOSPHERE TRIAL"" is a clinical trial that investigated the use of pertuzumab plus trastuzumab in combination with an anthracycline-containing regimen in patients with HER2-positive breast cancer. Specifically, it is a phase 2 randomized neoadjuvant trial that tested the combination of pertuzumab with trastuzumab in breast cancer patients.",4\r\n114,"""NAC""","Here is a comprehensive summary of the data:\n\nNAC refers to neoadjuvant chemotherapy, a type of chemotherapy regimen used in the treatment of breast cancer. Specifically, NAC is a treatment protocol that is evaluated in clinical trials for the treatment of HER2-positive locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). It is a treatment option for IBC, used in combination with lapatinib, and has shown survival benefits for patients with LABC, including IBC, when combined with trastuzumab. NAC is a type of neoadjuvant chemotherapy that is associated with PD-L1 expression and is used in the TRYPHAENA study.",11\r\n340,"""PATIENT""","""Patient is the individual receiving treatment.""",10\r\n153,"""PERTUZUMAB""","Here is a comprehensive summary of the data provided:\n\nPertuzumab is a humanized anti-HER2 monoclonal antibody that binds the HER2 receptor at a different epitope from trastuzumab. It is a medication used in cancer treatment, specifically in the treatment of HER2-positive breast cancer, including inflammatory breast cancer (IBC). Pertuzumab is also used to treat HER2+ breast cancer, especially in combination with trastuzumab, by blocking the HER2 protein. As a targeted therapy, it targets HER2 receptors and induces antibody-dependent cell-mediated cytotoxicity. Pertuzumab is a type of monoclonal antibody that binds to the HER2 receptor and is used in breast cancer treatment. It is often used in combination with other treatments, such as T-DM1, as part of a treatment regimen for HER2+ breast cancer. Additionally, pertuzumab has been used in clinical trials, including the NeoSphere clinical trial, and is a chemotherapy drug.",10\r\n665,"""LANCET ONCOL""","Here is a comprehensive summary of the data:\n\n""Lancet Oncol"" is a medical research journal that has published numerous studies on various topics related to breast cancer. Specifically, the journal has published studies on adjuvant bevacizumab-containing therapy in triple-negative breast cancer, as well as neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer. Additionally, the journal has published research on Nab-paclitaxel and bevacizumab treatment in new models of inflammatory breast cancer, and has identified pathological response and circulating tumor cell count as indicators of excellent prognosis in treated HER2+ inflammatory breast cancer patients. Furthermore, the journal has published the results of the GeparQuinto study, which focused on inflammatory breast cancer. The journal has also published a study on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy. Overall, ""Lancet Oncol"" is a reputable and influential publication in the field of oncology, providing valuable insights and research findings to healthcare professionals and researchers.",3\r\n70,"""HER2""","Here is a comprehensive summary of the data:\n\nHER2 is a human epidermal growth factor receptor 2, a biomarker for breast cancer. It is a protein receptor that is often overexpressed in breast cancer, with an estimated prevalence of 25-35% in inflammatory breast cancer (IBC). HER2 is a target for breast cancer treatment, and its overexpression is associated with poor prognosis. The protein receptor is targeted by various therapies, including trastuzumab, lapatinib, pertuzumab, and T-DM1, among others. HER2 is also a predictive marker for the efficacy of trastuzumab addition in breast cancer treatment. Additionally, HER2 is a receptor that can dimerize with other ligands HER receptors and is associated with PD-L1 expression in breast cancer. HER2 status refers to the human epidermal growth factor receptor 2 status, which is an important factor in determining the effectiveness of breast cancer treatment. Overall, HER2 is a critical protein receptor in breast cancer, and its expression and targeting are crucial in the development of effective treatment strategies.",6\r\n189,"""T-DM1""","Here is a comprehensive summary of the data:\n\n""T-DM1"" is a medication used in the treatment of breast cancer. Specifically, it is a treatment for HER2+ Inflammatory Breast Cancer (IBC) cases without a pathologic complete response (pCR). Additionally, T-DM1 is a type of antibody-drug conjugate used to treat HER2+ breast cancer.",3\r\n151,"""ANTHRACYCLINE-CONTAINING REGIMEN""","Here is a comprehensive summary of the data:\n\nThe ""ANTHRACYCLINE-CONTAINING REGIMEN"" is a treatment protocol for breast cancer, specifically a type of chemotherapy regimen used to treat breast cancer. Furthermore, it is also used to treat HER2+ Inflammatory Breast Cancer (IBC). This regimen is a type of chemotherapy that is effective in treating HER2+ IBC.",1\r\n174,"""ATINIB""",No Description,1\r\n146,"""NOAH STUDY""","Here is a comprehensive summary of the data:\n\nThe NOAH study is a randomized phase 3 clinical trial that investigated the efficacy of trastuzumab addition in breast cancer treatment.",1\r\n107,"""BREAST MRI""","Here is a comprehensive summary of the data:\n\nBreast MRI is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n289,"""CAPECITABINE""","Here is a comprehensive summary of the data:\n\nCapecitabine is a chemotherapy drug used in the treatment of breast cancer. It is also a medication used in cancer treatment.",2\r\n97,"""CYCLOPHOSPHAMIDE""","Here is a comprehensive summary of the data:\n\nCyclophosphamide is a chemotherapy medication used in the treatment of breast cancer. It is a key component of a treatment regimen and is often used in combination with other medications, such as docetaxel, epirubicin, and trastuzumab, to effectively treat breast cancer. As a chemotherapy drug, cyclophosphamide is designed to target and destroy cancer cells, helping to slow or stop the growth of tumors.",1\r\n98,"""DOXORUBICIN""","Here is a comprehensive summary of the data:\n\nDoxorubicin is a chemotherapy medication used in the treatment of breast cancer and as part of a treatment regimen. It is a chemotherapy drug used to treat various types of cancer, including breast cancer.\n\nNote: I resolved the contradictions by combining the descriptions to provide a clear and concise summary. I also removed the quotation marks from the output to make it easier to read.",1\r\n337,"""ER""","Here is a comprehensive summary of the data:\n\nThe entity ""ER"" refers to estrogen receptor, which is a receptor associated with PD-L1 expression in breast cancer.",2\r\n148,"""FLUOROURACIL""","""Fluorouracil is a chemotherapy medication.""",1\r\n108,"""MAMMOGRAPHY""","Here is a comprehensive summary of the data:\n\nMammography is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n147,"""METHOTREXATE""","""Methotrexate is a chemotherapy medication.""",1\r\n680,"""N ENGL J MED""","Here is a comprehensive summary of the data:\n\n""N ENGL J MED"" is a medical journal that publishes research on various medical topics, including breast cancer. Specifically, it has published several studies on breast cancer, providing valuable insights and findings in the field. As a medical journal, it is dedicated to sharing knowledge and advancing the understanding of various medical conditions, including breast cancer. Additionally, it has published a study on pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, providing important information for healthcare professionals and researchers.",2\r\n109,"""SONOGRAPHY""","Here is a comprehensive summary of the data:\n\nSonography is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n685,"""VIALE G""","Here is a comprehensive summary of the data:\n\nVIALE G is a researcher who has been involved in a study on pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer. As an author, VIALE G has contributed to a medical study and a research paper, showcasing their expertise and involvement in the field of breast cancer research.",2\r\n773,"""TRASTUZUMAB EMTANSINE""","Here is a comprehensive summary of the data:\n\nTrastuzumab Emtansine is a medication that is used as a treatment for residual invasive HER2-positive breast cancer.",2\r\n256,"""ADJUVANT THERAPY""","Here is a comprehensive summary of the data:\n\nAdjuvant therapy refers to a treatment given after primary treatment to reduce the risk of recurrence. Specifically, in the context of Inflammatory Breast Cancer (IBC), adjuvant therapy is a type of treatment administered after surgery. This treatment is designed to target any remaining cancer cells that may have been left behind after initial surgery, with the goal of preventing the recurrence of the disease.",1\r\n341,"""AROMATASE INHIBITOR""","""Aromatase inhibitor is a medication used in cancer treatment.""",1\r\n303,"""BISPHOSPHONATE""","Here is a comprehensive summary of the data:\n\nBisphosphonate is a medication that has multiple uses in various medical contexts. In cancer treatment, it is used to help manage the disease. Specifically, it is used to increase bone density and improve survival rates in breast cancer patients. Additionally, bisphosphonate is used to treat osteoporosis by increasing bone density, which can help prevent fractures and other bone-related complications. Overall, bisphosphonate is a medication with a range of applications in both cancer treatment and osteoporosis management.",1\r\n775,"""KRISTINE""","""KRISTINE is a clinical trial.""",1\r\n292,"""TAMOXIFEN""","Here is a comprehensive summary of the data:\n\nTamoxifen is a medication that has been extensively studied in various papers and is used in the treatment of breast cancer. Specifically, it is a type of hormone therapy used in the treatment of breast cancer, and has been associated with improved survival outcomes when used for extended adjuvant endocrine therapy. Additionally, Tamoxifen is also used in cancer treatment more broadly.",1\r\n202,"""EXTENET""","Here is a comprehensive summary of the data:\n\nExteNET is a clinical trial that focused on HER2-positive breast cancer patients. Specifically, the trial studied the use of neratinib in breast cancer patients, providing valuable insights into its effectiveness in this patient population.",2\r\n198,"""KATERINE TRIAL""","Here is a comprehensive summary of the data:\n\nThe ""KATERINE TRIAL"" is a clinical trial that evaluates the effectiveness of adjuvant therapy in patients with HER2+ breast cancer, specifically in cases of inflammatory breast cancer (IBC) without a pathologic complete response (pCR). The trial investigates the use of adjuvant T-DM1, a type of targeted therapy, in these patients. The trial\'s findings recommend the use of adjuvant T-DM1 in HER2+ IBC cases without a pCR.\n\nNote: I resolved the contradictions by combining the information from the three descriptions, ensuring that the summary is coherent and accurate.",2\r\n288,"""CREATE-X""","""CREATE-X is a randomized phase 3 study on adjuvant capecitabine for breast cancer patients.""",2\r\n781,"""HARVEY VJ""","""Harvey VJ is an author of a medical study.""",1\r\n201,"""HER4""","""HER4 is a protein that is targeted by neratinib.""",1\r\n69,"""HR""","Here is a comprehensive summary of the data:\n\nHR, which stands for hormone receptor, is a protein receptor that plays a crucial role in breast cancer treatment. It is often overexpressed in breast cancer, making it a target for treatment. HR refers to the hormone receptor status, which is an important factor in determining the effectiveness of breast cancer treatment. In summary, HR is a protein receptor that is a target for breast cancer treatment due to its overexpression in the disease, and its status is an important consideration in treatment planning.",1\r\n778,"""CHAN A""","""Chan A is an author of a medical study.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n72,"""IBC""","""TRASTUZUMAB""","""Trastuzumab is used in the treatment of IBC, a type of breast cancer.""",69\r\n75,"""IBC""","""NERATINIB""","""Neratinib is used in adjuvant therapy for high-risk recurrent disease like IBC.""",62\r\n74,"""IBC""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of a neoadjuvant treatment for IBC patients, which is a high-risk disease.""",59\r\n78,"""IBC""","""HER2+ IBC""","""HER2+ IBC is a subtype of IBC.""",58\r\n73,"""IBC""","""NEOSPHERE TRIAL""","""The NeoSphere trial included 29 IBC patients.""",58\r\n196,"""TRASTUZUMAB""","""LAPATINIB""","""Trastuzumab and lapatinib are combined in a dual antibody treatment for breast cancer.""",27\r\n160,"""NAC""","""TRASTUZUMAB""","Based on the provided data, here is a comprehensive summary:\n\nNAC (Neoadjuvant Anthracycline-based Chemotherapy) is a treatment regimen that is combined with trastuzumab to treat certain types of breast cancer. Specifically, NAC is used in combination with trastuzumab to treat both Inflammatory Breast Cancer (IBC) and Locally Advanced Breast Cancer (LABC), which includes IBC. This treatment combination has been shown to provide survival benefits for patients with LABC, including those with IBC.\n\nNote: I resolved the potential contradiction by combining the two descriptions, ensuring that the summary accurately reflects the information provided.",26\r\n199,"""TRASTUZUMAB""","""PATIENT""","""Trastuzumab is used as a treatment option for patients.""",25\r\n192,"""TRASTUZUMAB""","""PERTUZUMAB""","Here is a comprehensive summary of the data:\n\nTrastuzumab and Pertuzumab are two medications that are used together to treat breast cancer, specifically HER2+ breast cancer. They are often used in combination therapy to combat this type of cancer. Both medications have similar mechanisms of binding to HER2 epitopes, making them suitable for combination therapy. Specifically, they are used together to treat breast cancer, with the combination of the two medications providing a more effective treatment option than either medication alone.\n\nNote: I resolved the contradictions by combining the information from all three descriptions to provide a clear and concise summary.",25\r\n246,"""GEPARQUINTO""","""LANCET ONCOL""","""GeparQuinto is published in Lancet Oncol.""",24\r\n163,"""NAC""","""LAPATINIB""","""NAC with lapatinib has a low pCR rate in HER2+ patients.""",23\r\n198,"""TRASTUZUMAB""","""BEVACIZUMAB""","""Bevacizumab is used in combination with Trastuzumab in the studies.""",23\r\n143,"""PACLITAXEL""","""TRASTUZUMAB""","""Trastuzumab is combined with paclitaxel in a treatment for breast cancer.""",23\r\n131,"""HER2""","""TRASTUZUMAB""","""Trastuzumab is targeted towards HER2+ disease, including IBC.""",21\r\n194,"""TRASTUZUMAB""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",20\r\n204,"""PERTUZUMAB""","""PATIENT""","""Pertuzumab is used as a treatment option for patients.""",20\r\n115,"""HER2+ IBC""","""TRASTUZUMAB""","""Trastuzumab is used as a standard neoadjuvant treatment for HER2+ IBC patients.""",19\r\n140,"""PACLITAXEL""","""NAC""","""Paclitaxel is part of the NAC regimen.""",19\r\n193,"""TRASTUZUMAB""","""NEOSPHERE TRIAL""","""Trastuzumab was used in the NeoSphere trial as part of combination therapy with pertuzumab and docetaxel.""",19\r\n132,"""HER2""","""LAPATINIB""","""Lapatinib blocks intracellular HER2, which is a target for cancer treatment.""",18\r\n164,"""NAC""","""PD-L1""","""NAC is associated with PD-L1 expression in breast cancer.""",18\r\n256,"""NERATINIB""","""PATIENT""","""Neratinib is offered as a treatment option for patients.""",18\r\n197,"""TRASTUZUMAB""","""T-DM1""","""T-DM1 is compared to trastuzumab in terms of response and toxicity in the neoadjuvant setting.""",18\r\n191,"""TRASTUZUMAB""","""ANTHRACYCLINE-CONTAINING REGIMEN""","""Trastuzumab is used in combination with an anthracycline-containing regimen for breast cancer treatment.""",16\r\n195,"""TRASTUZUMAB""","""ATINIB""","""atinib and trastuzumab are both medications used in cancer treatment, with different effects on pCR rate.""",16\r\n135,"""HER2""","""PATIENT""","""Patient\'s HER2 status is used to determine treatment options.""",16\r\n527,"""PIERGA JY""","""LANCET ONCOL""","""Pierga JY published a study in Lancet Oncol on inflammatory breast cancer.""",16\r\n190,"""TRASTUZUMAB""","""NOAH STUDY""","Here is a comprehensive summary of the data:\n\nThe NOAH study evaluated the efficacy of trastuzumab, specifically in the context of neoadjuvant treatment, in combination with chemotherapy, compared to chemotherapy alone. Additionally, the study investigated the effectiveness of adding trastuzumab to breast cancer treatment.\n\nNote: I resolved the potential contradiction by combining the two descriptions, focusing on the specific context of neoadjuvant treatment and the addition of trastuzumab to breast cancer treatment.",16\r\n202,"""PERTUZUMAB""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",15\r\n212,"""TRYPHAENA""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the results of the TRYPHAENA study, which investigated the efficacy of a neoadjuvant treatment for IBC patients.""",15\r\n133,"""HER2""","""NERATINIB""","""Neratinib targets HER2, a protein involved in breast cancer.""",14\r\n114,"""HER2+ IBC""","""PERTUZUMAB""","""Pertuzumab is used as a standard neoadjuvant treatment for HER2+ IBC patients.""",14\r\n201,"""PERTUZUMAB""","""NEOSPHERE TRIAL""","""Pertuzumab was used in the NeoSphere trial as part of combination therapy with trastuzumab and docetaxel.""",14\r\n134,"""HER2""","""PD-L1""","""HER2 is associated with PD-L1 expression in breast cancer.""",13\r\n28,"""BREAST CANCER""","""NEOSPHERE TRIAL""","""The NeoSphere trial tested the combination of pertuzumab with trastuzumab in breast cancer patients.""",13\r\n141,"""PACLITAXEL""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",13\r\n203,"""PERTUZUMAB""","""T-DM1""","Here is a comprehensive summary of the data:\n\nPertuzumab and T-DM1 are two entities related to the treatment of breast cancer. According to the descriptions, T-DM1 is an alternative to pertuzumab in the treatment of breast cancer, suggesting that it can be used as a substitute or complementary therapy. Additionally, T-DM1 is often combined with pertuzumab in a treatment for breast cancer, indicating that the two entities are frequently used together. Furthermore, T-DM1 is used in combination with pertuzumab in the neoadjuvant setting, which is a treatment approach that involves administering medications before surgery to shrink tumors and make them more manageable. Notably, this combination therapy is associated with a favorable toxicity profile, meaning that it is well-tolerated by patients.\n\nOverall, the descriptions suggest that pertuzumab and T-DM1 are both used in the treatment of breast cancer, often in combination with each other, and that this combination therapy has a favorable safety profile.",13\r\n152,"""BREAST MRI""","""NAC""","""Breast MRI is used to assess the effectiveness of NAC in IBC.""",12\r\n291,"""CAPECITABINE""","""PATIENT""","""Capecitabine is used as a treatment option for patients.""",12\r\n149,"""CYCLOPHOSPHAMIDE""","""NAC""","""Cyclophosphamide is part of the NAC regimen.""",12\r\n150,"""DOXORUBICIN""","""NAC""","""Doxorubicin is part of the NAC regimen.""",12\r\n300,"""ER""","""PATIENT""","""Patient\'s ER status is used to determine treatment options.""",12\r\n162,"""NAC""","""FLUOROURACIL""","""Fluorouracil is part of the NAC regimen.""",12\r\n153,"""MAMMOGRAPHY""","""NAC""","""Mammography is used to assess the effectiveness of NAC in IBC.""",12\r\n161,"""NAC""","""METHOTREXATE""","""Methotrexate is part of the NAC regimen.""",12\r\n208,"""PERTUZUMAB""","""N ENGL J MED""","""N Engl J Med published a paper on Pertuzumab.""",12\r\n154,"""SONOGRAPHY""","""NAC""","""Sonography is used to assess the effectiveness of NAC in IBC.""",12\r\n157,"""EGFR""","""NERATINIB""","""Neratinib targets EGFR, a protein involved in breast cancer.""",12\r\n205,"""PERTUZUMAB""","""VIALE G""","""Viale G is involved in the development of Pertuzumab.""",12\r\n206,"""PERTUZUMAB""","""TRASTUZUMAB EMTANSINE""","""Trastuzumab Emtansine is related to Pertuzumab.""",12\r\n285,"""ADJUVANT THERAPY""","""PATIENT""","""Adjuvant therapy is given to patients after primary treatment.""",11\r\n301,"""PATIENT""","""AROMATASE INHIBITOR""","""Aromatase inhibitor is used as a treatment option for patients.""",11\r\n293,"""BISPHOSPHONATE""","""PATIENT""","""Bisphosphonate is used as a treatment option for patients.""",11\r\n108,"""INSTITUTE""","""HER2+ IBC""","""The institute has reported on the results of HER2+ IBC, including its longest median OS after brain metastasis and relation to the anti-HER2 therapy era.""",11\r\n207,"""PERTUZUMAB""","""KRISTINE""","""KRISTINE is a clinical trial involving Pertuzumab.""",11\r\n292,"""TAMOXIFEN""","""PATIENT""","""Tamoxifen is used as a treatment option for patients.""",11\r\n254,"""NERATINIB""","""EXTENET""","""Neratinib was studied in the ExteNET clinical trial.""",10\r\n253,"""KATERINE TRIAL""","""NERATINIB""","""The KATERINE trial recommended adjuvant T-DM1, which includes Neratinib, in HER2+ IBC cases without a pCR.""",10\r\n128,"""OS""","""CREATE-X""","""CREATE-X shows that adjuvant capecitabine can improve overall survival in breast cancer patients.""",9\r\n295,"""PD-L1""","""ER""","""ER is associated with PD-L1 expression in breast cancer.""",9\r\n257,"""NERATINIB""","""HARVEY VJ""","""Harvey VJ is involved in the development of Neratinib.""",9\r\n255,"""NERATINIB""","""HER4""","""Neratinib targets HER4, a protein involved in breast cancer.""",9\r\n130,"""HR""","""HER2""","""HER2 and HR are protein receptors that are targets for breast cancer treatment.""",7\r\n258,"""EXTENET""","""LANCET ONCOL""","""ExteNET is published in Lancet Oncol.""",5\r\n252,"""T-DM1""","""KATERINE TRIAL""","""The KATERINE trial evaluated the use of T-DM1 as adjuvant therapy in patients with HER2+ breast cancer.""",5\r\n290,"""CREATE-X""","""CAPECITABINE""","""CREATE-X is a study on the effectiveness of adjuvant capecitabine in breast cancer patients.""",4\r\n583,"""N ENGL J MED""","""TRASTUZUMAB EMTANSINE""","""Trastuzumab Emtansine is published in N Engl J Med.""",4\r\n584,"""VIALE G""","""CHAN A""","""Viale G and Chan A are co-authors of a medical study.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:23,970 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 4/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:24,460 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:24,466 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n475,"""BUZDAR AU""","Here is a comprehensive summary of the data:\n\nBuzdar AU is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Buzdar AU has authored research papers and studies on combined-modality treatment of inflammatory breast carcinoma, inflammatory breast cancer, breast cancer, and paclitaxel\'s impact on improving the prognosis in estrogen receptor negative inflammatory breast cancer. These publications demonstrate Buzdar AU\'s expertise and dedication to advancing our understanding of breast cancer, particularly in the context of inflammatory breast carcinoma and the role of paclitaxel in treatment outcomes.",3\r\n474,"""UENO NT""","Here is a comprehensive summary of the data:\n\nUeno NT is a researcher who has authored several studies and research papers on breast cancer. Specifically, they have published papers on combined-modality treatment of inflammatory breast carcinoma, gene expression profiles of inflammatory breast cancer, and inflammatory breast cancer itself. Additionally, they have conducted a study on early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.",10\r\n559,"""BERTUCCI F""","Here is a comprehensive summary of the data:\n\nBertucci F is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Bertucci F has authored research papers and studies on inflammatory breast cancer, a type of breast cancer characterized by rapid growth and spread of cancer cells. The studies conducted by Bertucci F have focused on various aspects of inflammatory breast cancer, including the expression of PDL1, a protein that plays a crucial role in the immune response to cancer. Additionally, Bertucci F has explored the effectiveness of high-dose chemotherapy and haematopoietic stem cell transplantation as a treatment option for inflammatory breast cancer, examining the relationship between pathologic response and outcome. Furthermore, Bertucci F has authored multiple studies on breast cancer treatment, demonstrating a broad range of expertise in the field. Overall, Bertucci F\'s work has shed light on the complexities of inflammatory breast cancer and has contributed to the development of more effective treatment strategies for this aggressive form of breast cancer.",7\r\n565,"""FINETTI P""","Here is a comprehensive summary of the data:\n\nFinetti P is a researcher who has made significant contributions to the field of inflammatory breast cancer. Specifically, Finetti P is an author of two research papers: one on the gene expression profiles of inflammatory breast cancer and another on the expression of PDL1 in inflammatory breast cancer. These studies demonstrate Finetti P\'s expertise in the area of inflammatory breast cancer and highlight their role as a leading researcher in the field.",5\r\n567,"""LUCCI A""","Here is a comprehensive summary of the data:\n\nLUCCI A is a researcher who has made significant contributions to the field of breast cancer research. Specifically, LUCCI A is an author of two research papers. The first paper focuses on the gene expression profiles of inflammatory breast cancer, providing valuable insights into the molecular mechanisms underlying this aggressive form of breast cancer. The second paper investigates the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients. This research highlights the importance of exploring alternative treatment options for this patient population.",5\r\n568,"""ROBERTSON FM""","""Robertson FM is an author of a research paper on gene expression profiles of inflammatory breast cancer.""",5\r\n566,"""VERMEULEN P""","""Vermeulen P is an author of a research paper on gene expression profiles of inflammatory breast cancer.""",5\r\n476,"""SINGLETARY SE""","Here is a comprehensive summary of the data:\n\nSingletary SE is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Singletary SE has authored research papers on combined-modality treatment of inflammatory breast carcinoma, as well as studies on inflammatory breast cancer and breast cancer in general.",2\r\n477,"""AMES""","""Ames is an author of a study on breast cancer.""",1\r\n494,"""CANCER CHEMOTHER PHARMACOL""","Here is a comprehensive summary of the data:\n\nCancer Chemother Pharmacol is a journal that publishes research papers on breast cancer. The publication features research on breast cancer, providing a platform for scholars and experts to share their findings and contribute to the advancement of knowledge in this field.",6\r\n560,"""ESPINOSA FERNANDEZ""","""Espinosa Fernandez is an author of a research paper on inflammatory breast cancer.""",1\r\n482,"""AMES FC""","Here is a comprehensive summary of the data:\n\nAmes FC is an author of research papers on inflammatory breast cancer. Specifically, Ames FC has written papers on combined-modality treatment of inflammatory breast carcinoma and inflammatory breast cancer.",1\r\n495,"""FRYE D""","""Frye D is an author of a research paper on inflammatory breast cancer.""",1\r\n483,"""MCNEESE MD""","Here is a comprehensive summary of the data:\n\nMcNeese MD is a researcher who has authored research papers on inflammatory breast carcinoma. Specifically, McNeese MD has written papers on the combined-modality treatment of inflammatory breast carcinoma, as well as inflammatory breast cancer in general.",1\r\n491,"""KOH EH""","Here is a comprehensive summary of the data:\n\nKoh EH is an author of research papers related to inflammatory breast cancer. Specifically, Koh EH has written papers on combined-modality treatment of inflammatory breast carcinoma and inflammatory breast cancer.",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n358,"""CRISTOFANILLI M""","""BUZDAR AU""","""Cristofanilli M and Buzdar AU are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",21\r\n419,"""UENO NT""","""J CLIN ONCOL""","""Ueno NT is an author of a research paper published in J Clin Oncol.""",20\r\n420,"""UENO NT""","""BERTUCCI F""","""Bertucci F and Ueno NT are co-authors of a research paper on inflammatory breast cancer.""",17\r\n421,"""UENO NT""","""FINETTI P""","""Ueno NT and Finetti P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n423,"""UENO NT""","""LUCCI A""","""Ueno NT and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n424,"""UENO NT""","""ROBERTSON FM""","""Ueno NT and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n422,"""UENO NT""","""VERMEULEN P""","""Ueno NT and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n425,"""UENO NT""","""MATSUDA N""","""Matsuda N and Ueno NT are co-authors of a study on early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.""",15\r\n487,"""BERTUCCI F""","""GONCALVES A""","Here is a comprehensive summary of the data:\n\nGoncalves A and Bertucci F are co-authors of multiple studies related to breast cancer. Specifically, they have collaborated on research focused on inflammatory breast cancer and breast cancer treatment.",14\r\n416,"""UENO NT""","""BUZDAR AU""","""Ueno NT and Buzdar AU are co-authors of a study on breast cancer.""",13\r\n483,"""BERTUCCI F""","""FINETTI P""","""Bertucci F and Finetti P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n484,"""BERTUCCI F""","""VERMEULEN P""","""Bertucci F and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n485,"""BERTUCCI F""","""LUCCI A""","""Bertucci F and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n486,"""BERTUCCI F""","""ROBERTSON FM""","""Bertucci F and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n417,"""UENO NT""","""SINGLETARY SE""","""Ueno NT and Singletary SE are co-authors of a study on breast cancer.""",12\r\n418,"""UENO NT""","""AMES""","""Ueno NT and Ames are co-authors of a study on breast cancer.""",11\r\n493,"""FINETTI P""","""VERMEULEN P""","""Finetti P and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n494,"""FINETTI P""","""LUCCI A""","""Finetti P and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n495,"""FINETTI P""","""ROBERTSON FM""","""Finetti P and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n498,"""LUCCI A""","""ROBERTSON FM""","""Lucci A and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n496,"""VERMEULEN P""","""LUCCI A""","""Vermeulen P and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n497,"""VERMEULEN P""","""ROBERTSON FM""","""Vermeulen P and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n426,"""BUZDAR AU""","""CANCER CHEMOTHER PHARMACOL""","""Buzdar AU is an author of a research paper published in Cancer Chemother Pharmacol.""",9\r\n482,"""BERTUCCI F""","""ESPINOSA FERNANDEZ""","""Bertucci F and Espinosa Fernandez are co-authors of a research paper on inflammatory breast cancer.""",8\r\n427,"""SINGLETARY SE""","""CANCER CHEMOTHER PHARMACOL""","""Singletary SE is an author of a research paper published in Cancer Chemother Pharmacol.""",8\r\n434,"""AMES FC""","""CANCER CHEMOTHER PHARMACOL""","""Ames FC is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n438,"""CANCER CHEMOTHER PHARMACOL""","""FRYE D""","""Frye D is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n435,"""MCNEESE MD""","""CANCER CHEMOTHER PHARMACOL""","""McNeese MD is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n437,"""KOH EH""","""CANCER CHEMOTHER PHARMACOL""","""Koh EH is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:24,467 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 3/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:24,469 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:24,472 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n459,"""CLIN BREAST CANCER""","Based on the provided data, here is a comprehensive summary of the entity ""CLIN BREAST CANCER"":\n\nCLIN BREAST CANCER is a medical journal that publishes research on breast cancer, specifically focusing on the management of inflammatory breast cancer. The journal has published studies on various aspects of breast cancer, including a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. This treatment regimen involves pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, along with trastuzumab as preoperative treatment.",7\r\n669,"""CANCELLO G""","Here is a comprehensive summary of the data:\n\nCancello G is a researcher who has been involved in studies on inflammatory breast cancer. Specifically, Cancello G is an author of a study on a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. The treatment regimen consisted of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, plus trastuzumab, as preoperative treatment.",2\r\n670,"""DELLAPASQUA S""","Here is a comprehensive summary of the data:\n\nDellapasqua S is a researcher who has been involved in studies on inflammatory breast cancer. Specifically, Dellapasqua S is an author of a study on a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. The treatment regimen consisted of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, plus trastuzumab, as preoperative treatment.",2\r\n815,"""BAGNARDI V""","""Bagnardi V is a researcher involved in studies on inflammatory breast cancer.""",1\r\n813,"""PALAZZO A""","""Palazzo A is a researcher involved in studies on inflammatory breast cancer.""",1\r\n814,"""MUNZONE E""","""Munzone E is a researcher involved in studies on inflammatory breast cancer.""",1\r\n816,"""MAZZA M""","""Mazza M is a researcher involved in studies on inflammatory breast cancer.""",1\r\n667,"""TORRISI R""","""Torrisi R is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",5\r\n671,"""BALDUZZI A""","""Balduzzi A is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n668,"""CARDILLO A""","""Cardillo A is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n672,"""GHISINI R""","""Ghisini R is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n398,"""CLIN BREAST CANCER""","""PIERGA JY""","""Pierga JY published a study in Clin Breast Cancer on inflammatory breast cancer.""",20\r\n397,"""CLIN BREAST CANCER""","""CANCELLO G""","""Cancello G published a study in Clin Breast Cancer on inflammatory breast cancer.""",9\r\n393,"""CLIN BREAST CANCER""","""DELLAPASQUA S""","""Dellapasqua S published a study in Clin Breast Cancer on inflammatory breast cancer.""",9\r\n395,"""CLIN BREAST CANCER""","""BAGNARDI V""","""Bagnardi V published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n392,"""CLIN BREAST CANCER""","""PALAZZO A""","""Palazzo A published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n394,"""CLIN BREAST CANCER""","""MUNZONE E""","""Munzone E published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n396,"""CLIN BREAST CANCER""","""MAZZA M""","""Mazza M published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n573,"""TORRISI R""","""CANCELLO G""","""Torrisi R and Cancello G are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",7\r\n574,"""TORRISI R""","""DELLAPASQUA S""","""Torrisi R and Dellapasqua S are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",7\r\n575,"""TORRISI R""","""BALDUZZI A""","""Torrisi R and Balduzzi A are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n572,"""TORRISI R""","""CARDILLO A""","""Torrisi R and Cardillo A are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n576,"""TORRISI R""","""GHISINI R""","""Torrisi R and Ghisini R are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:24,472 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 3/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:25,29 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:25,32 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n48,"""IBC""","Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.",54\r\n85,"""PACLITAXEL""","Here is a comprehensive summary of the data provided:\n\n""PACLITAXEL"" is a chemotherapy agent used to treat breast cancer, specifically in the treatment of HER2-negative locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). It is a chemotherapy drug studied in various clinical trials and has been evaluated for its effectiveness in treating breast cancer. PACLITAXEL is used in combination with other medications, such as pembrolizumab, bevacizumab, trastuzumab, and lapatinib, to treat breast cancer. It is also used as a single agent in the treatment regimen for breast cancer. PACLITAXEL is a type of chemotherapy medication used in the treatment of breast cancer, and it is a treatment option for IBC patients.",8\r\n322,"""PD-L1""","Here is a comprehensive summary of the data:\n\nPD-L1 is a protein that plays a crucial role in immunotherapy, particularly in the context of inflammatory breast cancer (IBC). It is expressed on the surface of some cancer cells and is targeted by atezolizumab, a therapeutic agent. Additionally, PD-L1 is an immune checkpoint molecule found in tumor cells and TILs (tumor-infiltrating lymphocytes) of IBC. Furthermore, PD-L1 refers to a protein expressed on the surface of tumor cells that can inhibit the immune system\'s ability to recognize and attack cancer cells. Overall, PD-L1 is a key protein involved in the immune response to cancer, and its expression and function have significant implications for the development of effective cancer therapies.",7\r\n117,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","Here is a comprehensive summary of the data:\n\nHIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION is a treatment regimen for Inflammatory Breast Cancer (IBC).\n\nThis summary includes information from the provided description, which states that HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION is a treatment regimen for IBC.",4\r\n335,"""ARIAS-PULIDO ET AL.""","Here is a comprehensive summary of the data:\n\nArias-Pulido et al. is a research group that has made significant contributions to the field of cancer research. Specifically, they reported on the presence of PD-L1 positivity in tumor-infiltrating lymphocytes (TILs) and its association with better disease-free survival (DFS).",3\r\n336,"""BERCKELAER ET AL.""","Here is a comprehensive summary of the data:\n\nBerckelaer et al. is a research group that has reported on PD-L1 expression in TILs (Tumor-Infiltrating Lymphocytes).",3\r\n338,"""TILS""","Here is a comprehensive summary of the data:\n\nTILs (Tumor-Infiltrating Lymphocytes) are a type of immune cell that plays a crucial role in immunotherapy, particularly in the context of inflammatory breast cancer (IBC). They are more frequently found in IBC than in non-IBC, indicating a specific association with this type of cancer. TILs are associated with PD-L1 expression, which is linked to better disease-free survival (DFS). As immune cells found in the tumor microenvironment, TILs are an important component of the immune response against cancer.",3\r\n17,"""IMMUNOTHERAPY""","Here is a comprehensive summary of the data:\n\nImmunotherapy is a type of cancer treatment that uses the body\'s immune system to fight cancer. It is a type of systemic treatment that targets cancer cells and helps the body\'s immune system recognize and attack them. Specifically, immunotherapy is a treatment option for breast cancer, including inflammatory breast cancer (IBC). This type of treatment harnesses the body\'s natural defenses to combat cancer, making it a promising approach for cancer patients.",3\r\n86,"""FAC""","Here is a comprehensive summary of the data:\n\nFAC is a chemotherapy regimen used to treat breast cancer, as well as a technology used in clinical trials.",2\r\n343,"""I-SPY2""","Here is a comprehensive summary of the data:\n\n""I-SPY2"" is a clinical trial that combines chemotherapy and an immune checkpoint inhibitor for the treatment of Inflammatory Breast Cancer (IBC).",2\r\n75,"""RADIATION ONCOLOGIST""","Here is a comprehensive summary of the data:\n\nA radiation oncologist is a medical professional who specializes in the treatment of cancer using radiation therapy. They are a type of doctor who focuses on the use of radiation therapy to combat cancer.\n\nNote: I combined the two descriptions to create a single, coherent summary that includes all the relevant information.",2\r\n116,"""INTERNATIONAL EXPERT CONSENSUS""","Here is a comprehensive summary of the data:\n\nThe ""INTERNATIONAL EXPERT CONSENSUS"" refers to a collective agreement on the treatment of Inflammatory Breast Cancer (IBC).",2\r\n143,"""STANDARD OF CARE""","""Standard of Care refers to the accepted and widely used treatment approach for IBC.""",2\r\n342,"""KEYNOTE-522""","Here is a comprehensive summary of the data:\n\nKEYNOTE-522 is a clinical trial that combines chemotherapy and an immune checkpoint inhibitor for the treatment of Inflammatory Breast Cancer (IBC).",2\r\n87,"""ANTHRACYCLINE""","Here is a comprehensive summary of the data:\n\nAnthracycline is a chemotherapy agent used to treat breast cancer. It is a type of chemotherapy specifically designed to combat breast cancer.\n\nNote: I resolved the contradictions by combining the two descriptions into a single, coherent summary.",1\r\n252,"""ANTHRACYCLINE-BASED CHEMOTHERAPY""","""Anthracycline-based Chemotherapy is a type of chemotherapy used in the treatment of IBC.""",1\r\n347,"""ANTI-EGFR AGENT""","""Anti-EGFR agents are a type of targeted therapy that targets the EGFR protein, which is overexpressed in IBC.""",1\r\n348,"""ANTIPD-L1 ANTIBODY""","""Anti-PD-L1 antibodies are a type of immune checkpoint inhibitor that helps the immune system fight cancer, including IBC.""",1\r\n353,"""BC""",No Description,1\r\n334,"""BERTUCCI ET AL.""","""Bertucci et al. is a research group that reported PD-L1 overexpression in breast cancer tumors.""",1\r\n215,"""CARBOPLATIN""","Here is a comprehensive summary of the data:\n\nCarboplatin is a chemotherapy agent used in the treatment of various types of cancer, including breast cancer and inflammatory breast cancer (IBC). It is a chemotherapy drug that is often used in combination with other medications to treat cancer. Specifically, Carboplatin is used in the treatment of breast cancer, and it is also used to treat IBC. Additionally, it is classified as a type of cancer treatment and a type of chemotherapy used in the treatment of IBC. Overall, Carboplatin is a medication used in cancer treatment, specifically in the treatment of breast cancer and IBC.",1\r\n80,"""CHEMOTHERAPY""","Here is a comprehensive summary of the data:\n\nChemotherapy is a type of systemic treatment that uses chemicals to kill cancer cells, including those associated with breast cancer, including inflammatory breast cancer (IBC). It is a treatment option for breast cancer, including IBC, and is evaluated in clinical trials for its effectiveness in treating the disease. Specifically, chemotherapy is combined with T-DM1 in the TCHP regimen, a treatment approach that has shown promise in the fight against breast cancer. Overall, chemotherapy is a widely used and effective treatment for breast cancer, including IBC, that has been shown to be effective in clinical trials and is often used in combination with other treatments.",1\r\n74,"""DIAGNOSTIC RADIOLOGIST""","""Diagnostic radiologist is a type of doctor who specializes in the interpretation of imaging tests.""",1\r\n89,"""DITSCH ET AL.""","""Ditsch et al. are researchers who conducted a study on chemotherapy dose intensity in IBC patients.""",1\r\n88,"""FAC REGIMEN""","""FAC regimen is a chemotherapy treatment protocol.""",1\r\n71,"""MEDICAL ONCOLOGIST""","""Medical oncologist is a type of doctor who specializes in cancer treatment.""",1\r\n72,"""SURGEON""","""Surgeon is a type of doctor who specializes in surgical procedures.""",1\r\n73,"""PATHOLOGIST""","""Pathologist is a type of doctor who specializes in the diagnosis of diseases through the examination of tissues and cells.""",1\r\n84,"""MD ANDERSON""",No Description,1\r\n106,"""NON-IBC""","Here is a comprehensive summary of the data:\n\nNon-IBC (Non-Inflammatory Breast Cancer) refers to a type of breast cancer that is not Inflammatory Breast Cancer (IBC). Notably, Non-IBC has a similar pathological complete response (pCR) rate to ER-negative IBC, indicating that it shares some similarities with IBC in terms of treatment outcomes.",1\r\n285,"""TALIMOGENE LAHERPAREPVEC""","Here is a comprehensive summary of the data:\n\nTalimogene laherparepvec is a treatment regimen. Specifically, it is a treatment regimen for local recurrence IBC (inflammatory breast cancer) or inoperable non-IBC (non-inflammatory breast cancer).",1\r\n319,"""MULTIDISCIPLINARY TEAM""","Here is a comprehensive summary of the data:\n\nThe MULTIDISCIPLINARY TEAM is a group of healthcare professionals who work together to provide comprehensive care for patients with breast cancer. This team of experts evaluates and treats patients with breast cancer, offering a collaborative approach to patient care.",1\r\n346,"""IMMUNE CHECKPOINT INHIBITOR""","""Immune checkpoint inhibitors are a type of treatment that helps the immune system fight cancer, including IBC.""",1\r\n351,"""LAABC""","""LAABC is a type of breast cancer that is different from IBC.""",1\r\n352,"""LA BC""","""LA BC is an abbreviation for Localized Adenocarcinoma Breast Cancer, a type of breast cancer.""",1\r\n38,"""TUMOR EMBOLI""","Here is a comprehensive summary of the data:\n\nTumor emboli refer to the presence of tumor cells in the lymphatic vessels, which may be present or absent in biopsy specimens.",1\r\n41,"""LYMPHEDEMA""","""Lymphedema is a condition characterized by swelling caused by tumor emboli within dermal lymphatics.""",1\r\n90,"""ESTROGEN RECEPTOR""",No Description,1\r\n121,"""CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH""","""Center for International Blood and Marrow Transplant Research is an organization that conducts research on blood and marrow transplants.""",1\r\n120,"""INTERNATIONAL BLOOD AND MARROW TRANSPLANT REGISTRY""","""International Blood and Marrow Transplant Registry is an organization that tracks and reports on blood and marrow transplant data.""",1\r\n18,"""ONGOING IBC CLINICAL TRIALS""","""Ongoing IBC Clinical Trials refer to current research studies investigating new treatments for IBC.""",1\r\n96,"""G-CSF""","Here is a comprehensive summary of the data:\n\nG-CSF is a medication used to support the treatment regimen, specifically in clinical trials for the treatment of HER2-negative (HER2-) Locally Advanced Breast Cancer (LABC) or Inflammatory Breast Cancer (IBC). It is a growth factor used to support the dose-dense chemotherapy regimen, as well as to support the growth of white blood cells during chemotherapy. Additionally, G-CSF is a technology used in clinical trials, highlighting its role in the development and evaluation of new treatments. Overall, G-CSF plays a crucial role in supporting patients undergoing chemotherapy, particularly those with HER2- LABC or IBC, and is an important component of clinical trials aimed at improving treatment outcomes.",1\r\n78,"""TEAM""","""Team is a group of medical professionals working together to improve the survival of IBC.""",1\r\n144,"""RANDOMIZED TRIALS""","""Randomized Trials are studies that compare the effectiveness of different treatment approaches for IBC.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n72,"""IBC""","""TRASTUZUMAB""","""Trastuzumab is used in the treatment of IBC, a type of breast cancer.""",69\r\n30,"""BREAST CANCER""","""IBC""","""IBC is a subtype of Breast Cancer that requires specific treatment.""",63\r\n52,"""IBC""","""PCR""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) patients who achieve pCR (Pathological Complete Response) have better survival outcomes than those who do not. pCR is a measure of the effectiveness of treatment for IBC, indicating that the treatment has successfully eliminated all cancer cells from the breast tissue.",62\r\n62,"""IBC""","""PACLITAXEL""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) is a type of breast cancer that can be treated with Paclitaxel, a chemotherapy medication. According to the descriptions, Paclitaxel is used as part of a neoadjuvant regimen to treat IBC patients, and it is also used to treat IBC patients directly. Additionally, Paclitaxel is used to treat IBC, a type of breast cancer. Overall, Paclitaxel is a treatment option for IBC patients, and its use is likely part of a comprehensive treatment plan that may include other medications and therapies.",62\r\n75,"""IBC""","""NERATINIB""","""Neratinib is used in adjuvant therapy for high-risk recurrent disease like IBC.""",62\r\n40,"""SYSTEMIC TREATMENT""","""IBC""","""IBC is treated with systemic treatment, including chemotherapy and targeted therapy.""",62\r\n53,"""IBC""","""OS""","""IBC patients have poor overall survival rates, with a 5-year OS rate of less than 5%.""",61\r\n89,"""IBC""","""PD-L1""","""IBC is associated with PD-L1, an immune checkpoint molecule found in tumor cells and TILs.""",61\r\n91,"""IBC""","""INSTITUTE""","""Institute demonstrates IBC preclinical data supporting a combination of targeted therapy and an immune checkpoint inhibitor.""",61\r\n85,"""IBC""","""PEMBROLIZUMAB""","""Pembrolizumab is used in the treatment of IBC, a type of breast cancer characterized by rapid onset and aggressive growth.""",60\r\n74,"""IBC""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of a neoadjuvant treatment for IBC patients, which is a high-risk disease.""",59\r\n67,"""IBC""","""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""High-dose chemotherapy with autologous hematopoietic stem cell transplantation is a treatment option for IBC.""",58\r\n73,"""IBC""","""NEOSPHERE TRIAL""","""The NeoSphere trial included 29 IBC patients.""",58\r\n76,"""IBC""","""PANITUMUMAB""","""Panitumumab is used in certain circumstances for IBC cases, targeting EGFR expression.""",58\r\n77,"""IBC""","""EGFR""","""EGFR expression is associated with worse prognosis in IBC cases.""",58\r\n78,"""IBC""","""HER2+ IBC""","""HER2+ IBC is a subtype of IBC.""",58\r\n88,"""IBC""","""ARIAS-PULIDO ET AL.""","""Arias-Pulido et al. studied PD-L1 positivity in IBC samples.""",57\r\n87,"""IBC""","""BERCKELAER ET AL.""","""Berckelaer et al. studied PD-L1 expression in TILs in the context of IBC.""",57\r\n71,"""IBC""","""LABC""","""LABC includes IBC, a type of breast cancer with high-risk characteristics.""",57\r\n90,"""IBC""","""TILS""","Here is a comprehensive summary of the data:\n\nThe entities ""IBC"" and ""TILs"" are related to each other. TILs (Tumor-Infiltrating Lymphocytes) are found in the tumor microenvironment of IBC (Invasive Breast Cancer). Additionally, TILs are more frequently found in IBC compared to non-IBC.",57\r\n3,"""VICENTE VALERO""","""IBC""","""Vicente Valero is a member of the IBC working group.""",57\r\n43,"""IMMUNOTHERAPY""","""IBC""","Here is a comprehensive summary of the data:\n\nIMMUNOTHERAPY is a potential treatment option for Inflammatory Breast Cancer (IBC).",57\r\n63,"""IBC""","""FAC""","""FAC is used to treat IBC patients.""",56\r\n93,"""IBC""","""I-SPY2""","""IBC is the disease being treated in the I-SPY2 clinical trial.""",56\r\n58,"""IBC""","""RADIATION ONCOLOGIST""","""Radiation oncologists are part of a multidisciplinary team that treats IBC patients.""",56\r\n61,"""IBC""","""CRISTOFANILLI ET AL.""","""Cristofanilli et al. conducted a study on IBC patients.""",56\r\n68,"""IBC""","""INTERNATIONAL EXPERT CONSENSUS""","""International Expert Consensus provides guidance on the treatment of IBC.""",56\r\n70,"""IBC""","""STANDARD OF CARE""","""IBC is treated according to the Standard of Care, which involves the use of various therapies, including chemotherapy and transplantation.""",56\r\n79,"""IBC""","""TARGETED THERAPY""","""Targeted Therapy is a treatment option for IBC.""",56\r\n81,"""IBC""","""TAXANE-BASED CHEMOTHERAPY""","""Taxane-based Chemotherapy is used in the treatment of IBC.""",56\r\n92,"""IBC""","""KEYNOTE-522""","""IBC is the disease being treated in the KEYNOTE-522 clinical trial.""",56\r\n64,"""IBC""","""ANTHRACYCLINE""","""Anthracycline is used to treat IBC patients.""",55\r\n80,"""IBC""","""ANTHRACYCLINE-BASED CHEMOTHERAPY""","""Anthracycline-based Chemotherapy is used in the treatment of IBC.""",55\r\n95,"""IBC""","""ANTI-EGFR AGENT""","""Anti-EGFR agents are a potential treatment for IBC.""",55\r\n96,"""IBC""","""ANTIPD-L1 ANTIBODY""","""Anti-PD-L1 antibodies are a potential treatment for IBC.""",55\r\n98,"""IBC""","""BC""","""BC is related to IBC as a medical organization or institution may be involved in the study and treatment of IBC.""",55\r\n86,"""IBC""","""BERTUCCI ET AL.""","""Bertucci et al. reported PD-L1 overexpression in IBC tumors.""",55\r\n82,"""IBC""","""CARBOPLATIN""","""Carboplatin is used in the treatment of IBC.""",55\r\n60,"""IBC""","""CHEMOTHERAPY""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) is a type of breast cancer that can be treated with chemotherapy. According to the descriptions, chemotherapy is a potential treatment option for IBC, and it has been reported to be effective in treating the disease. Specifically, chemotherapy has been used to treat IBC with a reported objective response rate of 74% and a median overall survival (OS) of 37 months.",55\r\n57,"""IBC""","""DIAGNOSTIC RADIOLOGIST""","""Diagnostic radiologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n66,"""IBC""","""DITSCH ET AL.""","""Ditsch et al. conducted a study on chemotherapy dose intensity in IBC patients.""",55\r\n65,"""IBC""","""FAC REGIMEN""","""FAC regimen is used to treat IBC, a type of breast cancer.""",55\r\n54,"""IBC""","""MEDICAL ONCOLOGIST""","""Medical oncologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n55,"""IBC""","""SURGEON""","""Surgeons are part of a multidisciplinary team that treats IBC patients.""",55\r\n56,"""IBC""","""PATHOLOGIST""","""Pathologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n59,"""IBC""","""MD ANDERSON""","""MD Anderson conducted a retrospective study on IBC patients, providing insights into the treatment of IBC.""",55\r\n69,"""IBC""","""NON-IBC""","""IBC and non-IBC are compared in terms of OS rate and outcomes.""",55\r\n83,"""IBC""","""TALIMOGENE LAHERPAREPVEC""","""Talimogene laherparepvec is a treatment for IBC patients, specifically for TNBC patients.""",55\r\n84,"""IBC""","""MULTIDISCIPLINARY TEAM""","""The Multidisciplinary team evaluates and treats patients with IBC, a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body.""",55\r\n94,"""IBC""","""IMMUNE CHECKPOINT INHIBITOR""","""Immune checkpoint inhibitors are a potential treatment for IBC.""",55\r\n97,"""IBC""","""LAABC""","""LAABC is different from IBC.""",55\r\n99,"""IBC""","""LA BC""","""IBC is distinct from LA BC as a unique entity with different characteristics and treatment approaches.""",55\r\n46,"""TUMOR EMBOLI""","""IBC""","""IBC is characterized by the presence of tumor emboli in dermal lymphatics, which may be present or absent in biopsy specimens.""",55\r\n47,"""LYMPHEDEMA""","""IBC""","""IBC is characterized by lymphedema caused by tumor emboli within dermal lymphatics.""",55\r\n143,"""PACLITAXEL""","""TRASTUZUMAB""","""Trastuzumab is combined with paclitaxel in a treatment for breast cancer.""",23\r\n142,"""PACLITAXEL""","""LAPATINIB""","Here is a comprehensive summary of the data:\n\nPACLITAXEL and LAPATINIB are two medications used in cancer treatment. Specifically, they are combined in a treatment for breast cancer, where LAPATINIB is paired with PACLITAXEL to provide a comprehensive treatment approach. Additionally, both medications have different effects on the pCR (pathological complete response) rate, indicating that they have distinct mechanisms of action in cancer treatment.",20\r\n140,"""PACLITAXEL""","""NAC""","""Paclitaxel is part of the NAC regimen.""",19\r\n164,"""NAC""","""PD-L1""","""NAC is associated with PD-L1 expression in breast cancer.""",18\r\n144,"""PACLITAXEL""","""BEVACIZUMAB""","""Paclitaxel is used in certain circumstances with bevacizumab for metastatic breast cancer.""",16\r\n129,"""OS""","""PD-L1""","""PD-L1 expression in tumor cells is associated with worse overall survival in breast cancer patients.""",14\r\n141,"""PACLITAXEL""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",13\r\n134,"""HER2""","""PD-L1""","""HER2 is associated with PD-L1 expression in breast cancer.""",13\r\n27,"""BREAST CANCER""","""IMMUNOTHERAPY""","""Immunotherapy is a potential future direction for systemic therapy in Breast Cancer treatment, leveraging the body\'s immune system to fight cancer.""",12\r\n297,"""PD-L1""","""ARIAS-PULIDO ET AL.""","""Arias-Pulido et al. reported on PD-L1 positivity in IBC samples.""",10\r\n296,"""PD-L1""","""BERCKELAER ET AL.""","""Berckelaer et al. reported on PD-L1 expression in TILs.""",10\r\n145,"""PACLITAXEL""","""AC REGIME""","""AC regime and paclitaxel are used together in a chemotherapy regimen for breast cancer treatment.""",10\r\n139,"""PACLITAXEL""","""ESTROGEN RECEPTOR""","""Estrogen receptor is relevant to paclitaxel\'s effectiveness in treating breast cancer.""",9\r\n295,"""PD-L1""","""ER""","""ER is associated with PD-L1 expression in breast cancer.""",9\r\n298,"""ARIAS-PULIDO ET AL.""","""TILS""","""Arias-Pulido et al. reported PD-L1 positivity in TILs and its association with better DFS.""",6\r\n299,"""BERCKELAER ET AL.""","""TILS""","""Berckelaer et al. reported PD-L1 expression in TILs.""",6\r\n165,"""INTERNATIONAL EXPERT CONSENSUS""","""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""International Expert Consensus recommends High-dose chemotherapy with autologous hematopoietic stem cell transplantation as a treatment option for IBC.""",6\r\n167,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH""","""Center for International Blood and Marrow Transplant Research conducts research on High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IBC treatment.""",5\r\n166,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""INTERNATIONAL BLOOD AND MARROW TRANSPLANT REGISTRY""","""International Blood and Marrow Transplant Registry tracks data on High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IBC treatment.""",5\r\n302,"""KEYNOTE-522""","""I-SPY2""","""KEYNOTE-522 and I-SPY2 are clinical trials that combine chemotherapy and an immune checkpoint inhibitor.""",4\r\n42,"""IMMUNOTHERAPY""","""ONGOING IBC CLINICAL TRIALS""","""Immunotherapy is being investigated in Ongoing IBC Clinical Trials as a potential new treatment for IBC.""",4\r\n146,"""FAC""","""G-CSF""","""FAC and G-CSF are technologies used together in clinical trials.""",3\r\n136,"""RADIATION ONCOLOGIST""","""TEAM""","""Radiation oncologist is a member of the team working to improve the survival of IBC.""",3\r\n189,"""STANDARD OF CARE""","""RANDOMIZED TRIALS""","""Randomized Trials are used to determine the Standard of Care for IBC treatment.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:25,32 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 3/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:28,951 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:28,956 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n437,"""CRISTOFANILLI M""","Here is a comprehensive summary of the data:\n\nCristofanilli M is a researcher who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on inflammatory breast cancer management in the National Comprehensive Cancer Network. Additionally, they were involved in the GeparQuinto study, which further highlights their expertise in this area.\n\nCristofanilli M is also an author of several research papers and studies on inflammatory breast cancer. These publications include a study on breast cancer treatment, as well as studies on inflammatory breast cancer management, neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer, paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer, and the prognostic significance of HER-2 status in women with inflammatory breast cancer.\n\nOverall, Cristofanilli M is a prominent researcher in the field of inflammatory breast cancer, with a focus on management, treatment, and prognosis.",18\r\n172,"""LAPATINIB""","Here is a comprehensive summary of the data:\n\nLapatinib is a small-molecule tyrosine kinase inhibitor that blocks intracellular HER2 and EGFR signaling pathways. It is a targeted therapy used to treat cancer, and is also used in combination with other therapies, such as Pazopanib, trastuzumab, and NAC, to treat various types of cancer, including breast cancer. Specifically, it is a treatment option for inflammatory breast cancer (IBC) when used in combination with NAC and trastuzumab. Additionally, lapatinib is an antibody-drug conjugate used in breast cancer treatment. Overall, lapatinib is a medication used in cancer treatment, specifically targeting HER2 and EGFR signaling pathways to inhibit the growth and spread of cancer cells.",12\r\n228,"""PAZOPANIB""","Here is a comprehensive summary of the data:\n\nPazopanib is a small-molecule multi-tyrosine kinase inhibitor used to treat cancer. Specifically, it is a targeted therapy used in combination with other treatments for breast cancer, and also used in combination therapy to treat a disease.\n\nNote: I resolved the contradictions by combining the information from all the descriptions to provide a single, coherent summary.",7\r\n435,"""MATRO JM""","Here is a comprehensive summary of the data:\n\nMatro JM is a person who has conducted a study on inflammatory breast cancer management in the National Comprehensive Cancer Network.",5\r\n844,"""JOHNSTON SR""","Here is a comprehensive summary of the data:\n\nJohnston SR is a researcher who has made significant contributions to the field of breast cancer research. Specifically, he has been involved in studies focused on HER2-positive advanced breast cancer, demonstrating his expertise in this area. Additionally, he has also authored a research paper on inflammatory breast cancer, showcasing his breadth of knowledge and expertise in the field.",3\r\n528,"""GONZALEZ-ANGULO AM""","""Gonzalez-Angulo AM is an author of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",1\r\n529,"""KAU SW""","Here is a comprehensive summary of the data:\n\nKau SW is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Kau SW is an author of two studies that have shed light on the prognosis and treatment of inflammatory breast cancer. In one study, Kau SW investigated the impact of paclitaxel on the prognosis of estrogen receptor negative inflammatory breast cancer, demonstrating its potential to improve patient outcomes. In another study, Kau SW examined the prognostic significance of HER-2 status in women with inflammatory breast cancer, providing valuable insights into the role of this biomarker in predicting patient outcomes.",1\r\n530,"""FRYE DK""","""Frye DK is an author of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",1\r\n536,"""SMITH T""","""Smith T is an author of a study on breast cancer treatment.""",1\r\n537,"""WASAFF B""","""Wasaff B is an author of a study on breast cancer treatment.""",1\r\n538,"""IBRAHIM N""","""Ibrahim N is an author of a study on breast cancer treatment.""",1\r\n850,"""MANIKHAS A""","Here is a comprehensive summary of the data:\n\nManikhas A is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Manikhas A has been involved in studies focused on HER2-positive advanced breast cancer, demonstrating expertise in this area. Additionally, Manikhas A has also authored a research paper on inflammatory breast cancer, further expanding their scope of research and expertise.",1\r\n856,"""GOMEZ HL""","""Gomez HL is a researcher involved in studies on HER2-positive advanced breast cancer.""",1\r\n851,"""GLADKOV O""","Here is a comprehensive summary of the data:\n\nGladkov O is a researcher who has been involved in studies on HER2-positive advanced breast cancer and inflammatory breast cancer. Specifically, Gladkov O is an author of a research paper on inflammatory breast cancer, and has also contributed to studies on HER2-positive advanced breast cancer.\n\nNote: I did not find any contradictions in the provided descriptions, so the summary is a straightforward concatenation of the information.",1\r\n852,"""SHAO Z""","Here is a comprehensive summary of the data:\n\nShao Z is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Shao Z has been involved in studies on HER2-positive advanced breast cancer, demonstrating their expertise in this area. Additionally, Shao Z has also authored a research paper on inflammatory breast cancer, further highlighting their breadth of knowledge and research experience in the field of breast cancer.",1\r\n244,"""AFATINIB""","Here is a comprehensive summary of the data:\n\nAfatinib is a drug used in the treatment of HER2-positive inflammatory breast cancer. Specifically, it is an irreversible ErbB family blocker with preclinical activity in trastuzumab-resistant cell lines.",3\r\n247,"""SURVIVAL""","Here is a comprehensive summary of the data:\n\nThe entity ""SURVIVAL"" refers to the length of time a patient lives after being diagnosed with breast cancer. Specifically, it refers to the length of time a patient with breast cancer lives after diagnosis.\n\nNote: The two descriptions provided are identical, with only minor wording variations. I have combined them into a single summary to provide a clear and concise overview of the entity ""SURVIVAL"".",3\r\n229,"""VEG20007""","""VEG20007 is a randomized phase 2 study evaluating first-line lapatinib plus pazopanib therapy or lapatinib monotherapy.""",1\r\n236,"""LAPATINIB MONOTHERAPY""","""Lapatinib monotherapy is a treatment approach that uses a single medication to treat a disease.""",2\r\n438,"""HUGHES ME""","Here is a comprehensive summary of the data:\n\nHughes ME is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the National Comprehensive Cancer Network (NCCN) and authored a study on the same subject.",1\r\n436,"""LI T""","Here is a comprehensive summary of the data:\n\nLi T is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, Li T conducted a study on the topic within the National Comprehensive Cancer Network (NCCN), demonstrating expertise in the area. Additionally, Li T is an author of a study on inflammatory breast cancer management, further solidifying their reputation as a knowledgeable and experienced researcher in this field.",1\r\n439,"""OTTESEN RA""","Here is a comprehensive summary of the data:\n\nOttesen RA is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the national comprehensive cancer network, demonstrating their expertise and involvement in the field. Additionally, Ottesen RA is also an author of a study on inflammatory breast cancer management, further solidifying their reputation as a knowledgeable and authoritative figure in this area of research.",1\r\n440,"""WEEKS JC""","Here is a comprehensive summary of the data:\n\nWeeks JC is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the National Comprehensive Cancer Network (NCCN) and authored a study on the same subject.",1\r\n243,"""DISEASE""",No Description,1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n239,"""GEPARQUINTO""","""CRISTOFANILLI M""","""Cristofanilli M is a researcher involved in the GeparQuinto study.""",39\r\n227,"""LAPATINIB""","""CRISTOFANILLI M""","""Cristofanilli M is an author of a research paper on a randomized phase II study of lapatinib plus pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.""",30\r\n196,"""TRASTUZUMAB""","""LAPATINIB""","""Trastuzumab and lapatinib are combined in a dual antibody treatment for breast cancer.""",27\r\n277,"""PAZOPANIB""","""CRISTOFANILLI M""","""Cristofanilli M is an author of a research paper on a randomized phase II study of lapatinib plus pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.""",25\r\n353,"""MATRO JM""","""CRISTOFANILLI M""","""Matro JM and Cristofanilli M are co-authors of a study on inflammatory breast cancer management.""",23\r\n163,"""NAC""","""LAPATINIB""","""NAC with lapatinib has a low pCR rate in HER2+ patients.""",23\r\n326,"""HORTOBAGYI GN""","""CRISTOFANILLI M""","""Cristofanilli M and Hortobagyi GN are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",22\r\n358,"""CRISTOFANILLI M""","""BUZDAR AU""","""Cristofanilli M and Buzdar AU are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",21\r\n365,"""CRISTOFANILLI M""","""JOHNSTON SR""","""Cristofanilli M and Johnston SR are co-authors of a study on HER2-positive advanced breast cancer.""",21\r\n361,"""CRISTOFANILLI M""","""SNEIGE N""","""Cristofanilli M and Sneige N are co-authors of a study on breast cancer treatment.""",20\r\n120,"""PCR""","""LAPATINIB""","""lapatinib has a lower pCR rate than expected in HER2+ patients.""",20\r\n142,"""PACLITAXEL""","""LAPATINIB""","Here is a comprehensive summary of the data:\n\nPACLITAXEL and LAPATINIB are two medications used in cancer treatment. Specifically, they are combined in a treatment for breast cancer, where LAPATINIB is paired with PACLITAXEL to provide a comprehensive treatment approach. Additionally, both medications have different effects on the pCR (pathological complete response) rate, indicating that they have distinct mechanisms of action in cancer treatment.",20\r\n357,"""CRISTOFANILLI M""","""GONZALEZ-ANGULO AM""","""Cristofanilli M and Gonzalez-Angulo AM are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n359,"""CRISTOFANILLI M""","""KAU SW""","""Cristofanilli M and Kau SW are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n360,"""CRISTOFANILLI M""","""FRYE DK""","""Cristofanilli M and Frye DK are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n362,"""CRISTOFANILLI M""","""SMITH T""","""Cristofanilli M and Smith T are co-authors of a study on breast cancer treatment.""",19\r\n363,"""CRISTOFANILLI M""","""WASAFF B""","""Cristofanilli M and Wasaff B are co-authors of a study on breast cancer treatment.""",19\r\n364,"""CRISTOFANILLI M""","""IBRAHIM N""","""Cristofanilli M and Ibrahim N are co-authors of a study on breast cancer treatment.""",19\r\n366,"""CRISTOFANILLI M""","""MANIKHAS A""","""Cristofanilli M and Manikhas A are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n367,"""CRISTOFANILLI M""","""GOMEZ HL""","""Cristofanilli M and Gomez HL are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n368,"""CRISTOFANILLI M""","""GLADKOV O""","""Cristofanilli M and Gladkov O are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n369,"""CRISTOFANILLI M""","""SHAO Z""","""Cristofanilli M and Shao Z are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n222,"""LAPATINIB""","""PAZOPANIB""","""pazopanib is used in combination with lapatinib in a clinical trial (VEG20007) for the treatment of cancer.""",19\r\n125,"""OS""","""LAPATINIB""","""lapatinib does not differ in 3-year OS rate compared to trastuzumab.""",19\r\n132,"""HER2""","""LAPATINIB""","""Lapatinib blocks intracellular HER2, which is a target for cancer treatment.""",18\r\n224,"""LAPATINIB""","""AFATINIB""","""Lapatinib and Afatinib are both targeted therapies used to treat breast cancer, with Afatinib showing preclinical activity in trastuzumab-resistant cell lines.""",15\r\n226,"""LAPATINIB""","""JOHNSTON SR""","""Johnston SR is an author of a research paper on the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.""",15\r\n225,"""LAPATINIB""","""SURVIVAL""","""Lapatinib is associated with a higher rate of serious adverse events, which can impact patient survival.""",15\r\n223,"""LAPATINIB""","""VEG20007""","""VEG20007 is a study evaluating the effectiveness of lapatinib monotherapy or lapatinib plus pazopanib therapy for the treatment of cancer.""",13\r\n272,"""PAZOPANIB""","""COMBINATION THERAPY""","""Pazopanib is used in combination therapy to treat the disease.""",13\r\n274,"""PAZOPANIB""","""AFATINIB""","""Pazopanib and Afatinib are both targeted therapies used to treat breast cancer, with Pazopanib showing a higher rate of serious adverse events than Afatinib.""",10\r\n276,"""PAZOPANIB""","""JOHNSTON SR""","""Johnston SR is an author of a research paper on the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.""",10\r\n275,"""PAZOPANIB""","""SURVIVAL""","""Pazopanib is associated with a higher rate of serious adverse events, which can impact patient survival.""",10\r\n273,"""PAZOPANIB""","""LAPATINIB MONOTHERAPY""","""Pazopanib is used in lapatinib monotherapy to treat the disease.""",9\r\n283,"""AFATINIB""","""SURVIVAL""","""Afatinib is associated with a shorter survival time, which can impact patient outcomes.""",6\r\n354,"""MATRO JM""","""HUGHES ME""","""Matro JM and Hughes ME are co-authors of a study on inflammatory breast cancer management.""",6\r\n352,"""MATRO JM""","""LI T""","""Matro JM and Li T are co-authors of a study on inflammatory breast cancer management.""",6\r\n355,"""MATRO JM""","""OTTESEN RA""","""Matro JM and Ottesen RA are co-authors of a study on inflammatory breast cancer management.""",6\r\n356,"""MATRO JM""","""WEEKS JC""","""Matro JM and Weeks JC are co-authors of a study on inflammatory breast cancer management.""",6\r\n281,"""LAPATINIB MONOTHERAPY""","""DISEASE""","""Lapatinib monotherapy is used to treat the disease.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:28,957 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 4/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:28,962 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:28,965 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n475,"""BUZDAR AU""","Here is a comprehensive summary of the data:\n\nBuzdar AU is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Buzdar AU has authored research papers and studies on combined-modality treatment of inflammatory breast carcinoma, inflammatory breast cancer, breast cancer, and paclitaxel\'s impact on improving the prognosis in estrogen receptor negative inflammatory breast cancer. These publications demonstrate Buzdar AU\'s expertise and dedication to advancing our understanding of breast cancer, particularly in the context of inflammatory breast carcinoma and the role of paclitaxel in treatment outcomes.",3\r\n474,"""UENO NT""","Here is a comprehensive summary of the data:\n\nUeno NT is a researcher who has authored several studies and research papers on breast cancer. Specifically, they have published papers on combined-modality treatment of inflammatory breast carcinoma, gene expression profiles of inflammatory breast cancer, and inflammatory breast cancer itself. Additionally, they have conducted a study on early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.",10\r\n559,"""BERTUCCI F""","Here is a comprehensive summary of the data:\n\nBertucci F is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Bertucci F has authored research papers and studies on inflammatory breast cancer, a type of breast cancer characterized by rapid growth and spread of cancer cells. The studies conducted by Bertucci F have focused on various aspects of inflammatory breast cancer, including the expression of PDL1, a protein that plays a crucial role in the immune response to cancer. Additionally, Bertucci F has explored the effectiveness of high-dose chemotherapy and haematopoietic stem cell transplantation as a treatment option for inflammatory breast cancer, examining the relationship between pathologic response and outcome. Furthermore, Bertucci F has authored multiple studies on breast cancer treatment, demonstrating a broad range of expertise in the field. Overall, Bertucci F\'s work has shed light on the complexities of inflammatory breast cancer and has contributed to the development of more effective treatment strategies for this aggressive form of breast cancer.",7\r\n565,"""FINETTI P""","Here is a comprehensive summary of the data:\n\nFinetti P is a researcher who has made significant contributions to the field of inflammatory breast cancer. Specifically, Finetti P is an author of two research papers: one on the gene expression profiles of inflammatory breast cancer and another on the expression of PDL1 in inflammatory breast cancer. These studies demonstrate Finetti P\'s expertise in the area of inflammatory breast cancer and highlight their role as a leading researcher in the field.",5\r\n567,"""LUCCI A""","Here is a comprehensive summary of the data:\n\nLUCCI A is a researcher who has made significant contributions to the field of breast cancer research. Specifically, LUCCI A is an author of two research papers. The first paper focuses on the gene expression profiles of inflammatory breast cancer, providing valuable insights into the molecular mechanisms underlying this aggressive form of breast cancer. The second paper investigates the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients. This research highlights the importance of exploring alternative treatment options for this patient population.",5\r\n568,"""ROBERTSON FM""","""Robertson FM is an author of a research paper on gene expression profiles of inflammatory breast cancer.""",5\r\n566,"""VERMEULEN P""","""Vermeulen P is an author of a research paper on gene expression profiles of inflammatory breast cancer.""",5\r\n476,"""SINGLETARY SE""","Here is a comprehensive summary of the data:\n\nSingletary SE is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Singletary SE has authored research papers on combined-modality treatment of inflammatory breast carcinoma, as well as studies on inflammatory breast cancer and breast cancer in general.",2\r\n477,"""AMES""","""Ames is an author of a study on breast cancer.""",1\r\n494,"""CANCER CHEMOTHER PHARMACOL""","Here is a comprehensive summary of the data:\n\nCancer Chemother Pharmacol is a journal that publishes research papers on breast cancer. The publication features research on breast cancer, providing a platform for scholars and experts to share their findings and contribute to the advancement of knowledge in this field.",6\r\n560,"""ESPINOSA FERNANDEZ""","""Espinosa Fernandez is an author of a research paper on inflammatory breast cancer.""",1\r\n482,"""AMES FC""","Here is a comprehensive summary of the data:\n\nAmes FC is an author of research papers on inflammatory breast cancer. Specifically, Ames FC has written papers on combined-modality treatment of inflammatory breast carcinoma and inflammatory breast cancer.",1\r\n495,"""FRYE D""","""Frye D is an author of a research paper on inflammatory breast cancer.""",1\r\n483,"""MCNEESE MD""","Here is a comprehensive summary of the data:\n\nMcNeese MD is a researcher who has authored research papers on inflammatory breast carcinoma. Specifically, McNeese MD has written papers on the combined-modality treatment of inflammatory breast carcinoma, as well as inflammatory breast cancer in general.",1\r\n491,"""KOH EH""","Here is a comprehensive summary of the data:\n\nKoh EH is an author of research papers related to inflammatory breast cancer. Specifically, Koh EH has written papers on combined-modality treatment of inflammatory breast carcinoma and inflammatory breast cancer.",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n358,"""CRISTOFANILLI M""","""BUZDAR AU""","""Cristofanilli M and Buzdar AU are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",21\r\n419,"""UENO NT""","""J CLIN ONCOL""","""Ueno NT is an author of a research paper published in J Clin Oncol.""",20\r\n420,"""UENO NT""","""BERTUCCI F""","""Bertucci F and Ueno NT are co-authors of a research paper on inflammatory breast cancer.""",17\r\n421,"""UENO NT""","""FINETTI P""","""Ueno NT and Finetti P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n423,"""UENO NT""","""LUCCI A""","""Ueno NT and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n424,"""UENO NT""","""ROBERTSON FM""","""Ueno NT and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n422,"""UENO NT""","""VERMEULEN P""","""Ueno NT and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n425,"""UENO NT""","""MATSUDA N""","""Matsuda N and Ueno NT are co-authors of a study on early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.""",15\r\n487,"""BERTUCCI F""","""GONCALVES A""","Here is a comprehensive summary of the data:\n\nGoncalves A and Bertucci F are co-authors of multiple studies related to breast cancer. Specifically, they have collaborated on research focused on inflammatory breast cancer and breast cancer treatment.",14\r\n416,"""UENO NT""","""BUZDAR AU""","""Ueno NT and Buzdar AU are co-authors of a study on breast cancer.""",13\r\n483,"""BERTUCCI F""","""FINETTI P""","""Bertucci F and Finetti P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n484,"""BERTUCCI F""","""VERMEULEN P""","""Bertucci F and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n485,"""BERTUCCI F""","""LUCCI A""","""Bertucci F and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n486,"""BERTUCCI F""","""ROBERTSON FM""","""Bertucci F and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n417,"""UENO NT""","""SINGLETARY SE""","""Ueno NT and Singletary SE are co-authors of a study on breast cancer.""",12\r\n418,"""UENO NT""","""AMES""","""Ueno NT and Ames are co-authors of a study on breast cancer.""",11\r\n493,"""FINETTI P""","""VERMEULEN P""","""Finetti P and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n494,"""FINETTI P""","""LUCCI A""","""Finetti P and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n495,"""FINETTI P""","""ROBERTSON FM""","""Finetti P and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n498,"""LUCCI A""","""ROBERTSON FM""","""Lucci A and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n496,"""VERMEULEN P""","""LUCCI A""","""Vermeulen P and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n497,"""VERMEULEN P""","""ROBERTSON FM""","""Vermeulen P and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n426,"""BUZDAR AU""","""CANCER CHEMOTHER PHARMACOL""","""Buzdar AU is an author of a research paper published in Cancer Chemother Pharmacol.""",9\r\n482,"""BERTUCCI F""","""ESPINOSA FERNANDEZ""","""Bertucci F and Espinosa Fernandez are co-authors of a research paper on inflammatory breast cancer.""",8\r\n427,"""SINGLETARY SE""","""CANCER CHEMOTHER PHARMACOL""","""Singletary SE is an author of a research paper published in Cancer Chemother Pharmacol.""",8\r\n434,"""AMES FC""","""CANCER CHEMOTHER PHARMACOL""","""Ames FC is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n438,"""CANCER CHEMOTHER PHARMACOL""","""FRYE D""","""Frye D is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n435,"""MCNEESE MD""","""CANCER CHEMOTHER PHARMACOL""","""McNeese MD is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n437,"""KOH EH""","""CANCER CHEMOTHER PHARMACOL""","""Koh EH is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:28,965 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 4/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:29,183 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:29,186 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n459,"""CLIN BREAST CANCER""","Based on the provided data, here is a comprehensive summary of the entity ""CLIN BREAST CANCER"":\n\nCLIN BREAST CANCER is a medical journal that publishes research on breast cancer, specifically focusing on the management of inflammatory breast cancer. The journal has published studies on various aspects of breast cancer, including a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. This treatment regimen involves pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, along with trastuzumab as preoperative treatment.",7\r\n669,"""CANCELLO G""","Here is a comprehensive summary of the data:\n\nCancello G is a researcher who has been involved in studies on inflammatory breast cancer. Specifically, Cancello G is an author of a study on a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. The treatment regimen consisted of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, plus trastuzumab, as preoperative treatment.",2\r\n670,"""DELLAPASQUA S""","Here is a comprehensive summary of the data:\n\nDellapasqua S is a researcher who has been involved in studies on inflammatory breast cancer. Specifically, Dellapasqua S is an author of a study on a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. The treatment regimen consisted of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, plus trastuzumab, as preoperative treatment.",2\r\n815,"""BAGNARDI V""","""Bagnardi V is a researcher involved in studies on inflammatory breast cancer.""",1\r\n813,"""PALAZZO A""","""Palazzo A is a researcher involved in studies on inflammatory breast cancer.""",1\r\n814,"""MUNZONE E""","""Munzone E is a researcher involved in studies on inflammatory breast cancer.""",1\r\n816,"""MAZZA M""","""Mazza M is a researcher involved in studies on inflammatory breast cancer.""",1\r\n667,"""TORRISI R""","""Torrisi R is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",5\r\n671,"""BALDUZZI A""","""Balduzzi A is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n668,"""CARDILLO A""","""Cardillo A is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n672,"""GHISINI R""","""Ghisini R is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n398,"""CLIN BREAST CANCER""","""PIERGA JY""","""Pierga JY published a study in Clin Breast Cancer on inflammatory breast cancer.""",20\r\n397,"""CLIN BREAST CANCER""","""CANCELLO G""","""Cancello G published a study in Clin Breast Cancer on inflammatory breast cancer.""",9\r\n393,"""CLIN BREAST CANCER""","""DELLAPASQUA S""","""Dellapasqua S published a study in Clin Breast Cancer on inflammatory breast cancer.""",9\r\n395,"""CLIN BREAST CANCER""","""BAGNARDI V""","""Bagnardi V published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n392,"""CLIN BREAST CANCER""","""PALAZZO A""","""Palazzo A published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n394,"""CLIN BREAST CANCER""","""MUNZONE E""","""Munzone E published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n396,"""CLIN BREAST CANCER""","""MAZZA M""","""Mazza M published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n573,"""TORRISI R""","""CANCELLO G""","""Torrisi R and Cancello G are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",7\r\n574,"""TORRISI R""","""DELLAPASQUA S""","""Torrisi R and Dellapasqua S are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",7\r\n575,"""TORRISI R""","""BALDUZZI A""","""Torrisi R and Balduzzi A are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n572,"""TORRISI R""","""CARDILLO A""","""Torrisi R and Cardillo A are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n576,"""TORRISI R""","""GHISINI R""","""Torrisi R and Ghisini R are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:29,187 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 4/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:30,475 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:30,478 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n48,"""IBC""","Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.",54\r\n85,"""PACLITAXEL""","Here is a comprehensive summary of the data provided:\n\n""PACLITAXEL"" is a chemotherapy agent used to treat breast cancer, specifically in the treatment of HER2-negative locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). It is a chemotherapy drug studied in various clinical trials and has been evaluated for its effectiveness in treating breast cancer. PACLITAXEL is used in combination with other medications, such as pembrolizumab, bevacizumab, trastuzumab, and lapatinib, to treat breast cancer. It is also used as a single agent in the treatment regimen for breast cancer. PACLITAXEL is a type of chemotherapy medication used in the treatment of breast cancer, and it is a treatment option for IBC patients.",8\r\n322,"""PD-L1""","Here is a comprehensive summary of the data:\n\nPD-L1 is a protein that plays a crucial role in immunotherapy, particularly in the context of inflammatory breast cancer (IBC). It is expressed on the surface of some cancer cells and is targeted by atezolizumab, a therapeutic agent. Additionally, PD-L1 is an immune checkpoint molecule found in tumor cells and TILs (tumor-infiltrating lymphocytes) of IBC. Furthermore, PD-L1 refers to a protein expressed on the surface of tumor cells that can inhibit the immune system\'s ability to recognize and attack cancer cells. Overall, PD-L1 is a key protein involved in the immune response to cancer, and its expression and function have significant implications for the development of effective cancer therapies.",7\r\n117,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","Here is a comprehensive summary of the data:\n\nHIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION is a treatment regimen for Inflammatory Breast Cancer (IBC).\n\nThis summary includes information from the provided description, which states that HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION is a treatment regimen for IBC.",4\r\n335,"""ARIAS-PULIDO ET AL.""","Here is a comprehensive summary of the data:\n\nArias-Pulido et al. is a research group that has made significant contributions to the field of cancer research. Specifically, they reported on the presence of PD-L1 positivity in tumor-infiltrating lymphocytes (TILs) and its association with better disease-free survival (DFS).",3\r\n336,"""BERCKELAER ET AL.""","Here is a comprehensive summary of the data:\n\nBerckelaer et al. is a research group that has reported on PD-L1 expression in TILs (Tumor-Infiltrating Lymphocytes).",3\r\n338,"""TILS""","Here is a comprehensive summary of the data:\n\nTILs (Tumor-Infiltrating Lymphocytes) are a type of immune cell that plays a crucial role in immunotherapy, particularly in the context of inflammatory breast cancer (IBC). They are more frequently found in IBC than in non-IBC, indicating a specific association with this type of cancer. TILs are associated with PD-L1 expression, which is linked to better disease-free survival (DFS). As immune cells found in the tumor microenvironment, TILs are an important component of the immune response against cancer.",3\r\n17,"""IMMUNOTHERAPY""","Here is a comprehensive summary of the data:\n\nImmunotherapy is a type of cancer treatment that uses the body\'s immune system to fight cancer. It is a type of systemic treatment that targets cancer cells and helps the body\'s immune system recognize and attack them. Specifically, immunotherapy is a treatment option for breast cancer, including inflammatory breast cancer (IBC). This type of treatment harnesses the body\'s natural defenses to combat cancer, making it a promising approach for cancer patients.",3\r\n86,"""FAC""","Here is a comprehensive summary of the data:\n\nFAC is a chemotherapy regimen used to treat breast cancer, as well as a technology used in clinical trials.",2\r\n343,"""I-SPY2""","Here is a comprehensive summary of the data:\n\n""I-SPY2"" is a clinical trial that combines chemotherapy and an immune checkpoint inhibitor for the treatment of Inflammatory Breast Cancer (IBC).",2\r\n75,"""RADIATION ONCOLOGIST""","Here is a comprehensive summary of the data:\n\nA radiation oncologist is a medical professional who specializes in the treatment of cancer using radiation therapy. They are a type of doctor who focuses on the use of radiation therapy to combat cancer.\n\nNote: I combined the two descriptions to create a single, coherent summary that includes all the relevant information.",2\r\n116,"""INTERNATIONAL EXPERT CONSENSUS""","Here is a comprehensive summary of the data:\n\nThe ""INTERNATIONAL EXPERT CONSENSUS"" refers to a collective agreement on the treatment of Inflammatory Breast Cancer (IBC).",2\r\n143,"""STANDARD OF CARE""","""Standard of Care refers to the accepted and widely used treatment approach for IBC.""",2\r\n342,"""KEYNOTE-522""","Here is a comprehensive summary of the data:\n\nKEYNOTE-522 is a clinical trial that combines chemotherapy and an immune checkpoint inhibitor for the treatment of Inflammatory Breast Cancer (IBC).",2\r\n87,"""ANTHRACYCLINE""","Here is a comprehensive summary of the data:\n\nAnthracycline is a chemotherapy agent used to treat breast cancer. It is a type of chemotherapy specifically designed to combat breast cancer.\n\nNote: I resolved the contradictions by combining the two descriptions into a single, coherent summary.",1\r\n252,"""ANTHRACYCLINE-BASED CHEMOTHERAPY""","""Anthracycline-based Chemotherapy is a type of chemotherapy used in the treatment of IBC.""",1\r\n347,"""ANTI-EGFR AGENT""","""Anti-EGFR agents are a type of targeted therapy that targets the EGFR protein, which is overexpressed in IBC.""",1\r\n348,"""ANTIPD-L1 ANTIBODY""","""Anti-PD-L1 antibodies are a type of immune checkpoint inhibitor that helps the immune system fight cancer, including IBC.""",1\r\n353,"""BC""",No Description,1\r\n334,"""BERTUCCI ET AL.""","""Bertucci et al. is a research group that reported PD-L1 overexpression in breast cancer tumors.""",1\r\n215,"""CARBOPLATIN""","Here is a comprehensive summary of the data:\n\nCarboplatin is a chemotherapy agent used in the treatment of various types of cancer, including breast cancer and inflammatory breast cancer (IBC). It is a chemotherapy drug that is often used in combination with other medications to treat cancer. Specifically, Carboplatin is used in the treatment of breast cancer, and it is also used to treat IBC. Additionally, it is classified as a type of cancer treatment and a type of chemotherapy used in the treatment of IBC. Overall, Carboplatin is a medication used in cancer treatment, specifically in the treatment of breast cancer and IBC.",1\r\n80,"""CHEMOTHERAPY""","Here is a comprehensive summary of the data:\n\nChemotherapy is a type of systemic treatment that uses chemicals to kill cancer cells, including those associated with breast cancer, including inflammatory breast cancer (IBC). It is a treatment option for breast cancer, including IBC, and is evaluated in clinical trials for its effectiveness in treating the disease. Specifically, chemotherapy is combined with T-DM1 in the TCHP regimen, a treatment approach that has shown promise in the fight against breast cancer. Overall, chemotherapy is a widely used and effective treatment for breast cancer, including IBC, that has been shown to be effective in clinical trials and is often used in combination with other treatments.",1\r\n74,"""DIAGNOSTIC RADIOLOGIST""","""Diagnostic radiologist is a type of doctor who specializes in the interpretation of imaging tests.""",1\r\n89,"""DITSCH ET AL.""","""Ditsch et al. are researchers who conducted a study on chemotherapy dose intensity in IBC patients.""",1\r\n88,"""FAC REGIMEN""","""FAC regimen is a chemotherapy treatment protocol.""",1\r\n71,"""MEDICAL ONCOLOGIST""","""Medical oncologist is a type of doctor who specializes in cancer treatment.""",1\r\n72,"""SURGEON""","""Surgeon is a type of doctor who specializes in surgical procedures.""",1\r\n73,"""PATHOLOGIST""","""Pathologist is a type of doctor who specializes in the diagnosis of diseases through the examination of tissues and cells.""",1\r\n84,"""MD ANDERSON""",No Description,1\r\n106,"""NON-IBC""","Here is a comprehensive summary of the data:\n\nNon-IBC (Non-Inflammatory Breast Cancer) refers to a type of breast cancer that is not Inflammatory Breast Cancer (IBC). Notably, Non-IBC has a similar pathological complete response (pCR) rate to ER-negative IBC, indicating that it shares some similarities with IBC in terms of treatment outcomes.",1\r\n285,"""TALIMOGENE LAHERPAREPVEC""","Here is a comprehensive summary of the data:\n\nTalimogene laherparepvec is a treatment regimen. Specifically, it is a treatment regimen for local recurrence IBC (inflammatory breast cancer) or inoperable non-IBC (non-inflammatory breast cancer).",1\r\n319,"""MULTIDISCIPLINARY TEAM""","Here is a comprehensive summary of the data:\n\nThe MULTIDISCIPLINARY TEAM is a group of healthcare professionals who work together to provide comprehensive care for patients with breast cancer. This team of experts evaluates and treats patients with breast cancer, offering a collaborative approach to patient care.",1\r\n346,"""IMMUNE CHECKPOINT INHIBITOR""","""Immune checkpoint inhibitors are a type of treatment that helps the immune system fight cancer, including IBC.""",1\r\n351,"""LAABC""","""LAABC is a type of breast cancer that is different from IBC.""",1\r\n352,"""LA BC""","""LA BC is an abbreviation for Localized Adenocarcinoma Breast Cancer, a type of breast cancer.""",1\r\n38,"""TUMOR EMBOLI""","Here is a comprehensive summary of the data:\n\nTumor emboli refer to the presence of tumor cells in the lymphatic vessels, which may be present or absent in biopsy specimens.",1\r\n41,"""LYMPHEDEMA""","""Lymphedema is a condition characterized by swelling caused by tumor emboli within dermal lymphatics.""",1\r\n90,"""ESTROGEN RECEPTOR""",No Description,1\r\n121,"""CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH""","""Center for International Blood and Marrow Transplant Research is an organization that conducts research on blood and marrow transplants.""",1\r\n120,"""INTERNATIONAL BLOOD AND MARROW TRANSPLANT REGISTRY""","""International Blood and Marrow Transplant Registry is an organization that tracks and reports on blood and marrow transplant data.""",1\r\n18,"""ONGOING IBC CLINICAL TRIALS""","""Ongoing IBC Clinical Trials refer to current research studies investigating new treatments for IBC.""",1\r\n96,"""G-CSF""","Here is a comprehensive summary of the data:\n\nG-CSF is a medication used to support the treatment regimen, specifically in clinical trials for the treatment of HER2-negative (HER2-) Locally Advanced Breast Cancer (LABC) or Inflammatory Breast Cancer (IBC). It is a growth factor used to support the dose-dense chemotherapy regimen, as well as to support the growth of white blood cells during chemotherapy. Additionally, G-CSF is a technology used in clinical trials, highlighting its role in the development and evaluation of new treatments. Overall, G-CSF plays a crucial role in supporting patients undergoing chemotherapy, particularly those with HER2- LABC or IBC, and is an important component of clinical trials aimed at improving treatment outcomes.",1\r\n78,"""TEAM""","""Team is a group of medical professionals working together to improve the survival of IBC.""",1\r\n144,"""RANDOMIZED TRIALS""","""Randomized Trials are studies that compare the effectiveness of different treatment approaches for IBC.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n72,"""IBC""","""TRASTUZUMAB""","""Trastuzumab is used in the treatment of IBC, a type of breast cancer.""",69\r\n30,"""BREAST CANCER""","""IBC""","""IBC is a subtype of Breast Cancer that requires specific treatment.""",63\r\n52,"""IBC""","""PCR""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) patients who achieve pCR (Pathological Complete Response) have better survival outcomes than those who do not. pCR is a measure of the effectiveness of treatment for IBC, indicating that the treatment has successfully eliminated all cancer cells from the breast tissue.",62\r\n62,"""IBC""","""PACLITAXEL""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) is a type of breast cancer that can be treated with Paclitaxel, a chemotherapy medication. According to the descriptions, Paclitaxel is used as part of a neoadjuvant regimen to treat IBC patients, and it is also used to treat IBC patients directly. Additionally, Paclitaxel is used to treat IBC, a type of breast cancer. Overall, Paclitaxel is a treatment option for IBC patients, and its use is likely part of a comprehensive treatment plan that may include other medications and therapies.",62\r\n75,"""IBC""","""NERATINIB""","""Neratinib is used in adjuvant therapy for high-risk recurrent disease like IBC.""",62\r\n40,"""SYSTEMIC TREATMENT""","""IBC""","""IBC is treated with systemic treatment, including chemotherapy and targeted therapy.""",62\r\n53,"""IBC""","""OS""","""IBC patients have poor overall survival rates, with a 5-year OS rate of less than 5%.""",61\r\n89,"""IBC""","""PD-L1""","""IBC is associated with PD-L1, an immune checkpoint molecule found in tumor cells and TILs.""",61\r\n91,"""IBC""","""INSTITUTE""","""Institute demonstrates IBC preclinical data supporting a combination of targeted therapy and an immune checkpoint inhibitor.""",61\r\n85,"""IBC""","""PEMBROLIZUMAB""","""Pembrolizumab is used in the treatment of IBC, a type of breast cancer characterized by rapid onset and aggressive growth.""",60\r\n74,"""IBC""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of a neoadjuvant treatment for IBC patients, which is a high-risk disease.""",59\r\n67,"""IBC""","""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""High-dose chemotherapy with autologous hematopoietic stem cell transplantation is a treatment option for IBC.""",58\r\n73,"""IBC""","""NEOSPHERE TRIAL""","""The NeoSphere trial included 29 IBC patients.""",58\r\n76,"""IBC""","""PANITUMUMAB""","""Panitumumab is used in certain circumstances for IBC cases, targeting EGFR expression.""",58\r\n77,"""IBC""","""EGFR""","""EGFR expression is associated with worse prognosis in IBC cases.""",58\r\n78,"""IBC""","""HER2+ IBC""","""HER2+ IBC is a subtype of IBC.""",58\r\n88,"""IBC""","""ARIAS-PULIDO ET AL.""","""Arias-Pulido et al. studied PD-L1 positivity in IBC samples.""",57\r\n87,"""IBC""","""BERCKELAER ET AL.""","""Berckelaer et al. studied PD-L1 expression in TILs in the context of IBC.""",57\r\n71,"""IBC""","""LABC""","""LABC includes IBC, a type of breast cancer with high-risk characteristics.""",57\r\n90,"""IBC""","""TILS""","Here is a comprehensive summary of the data:\n\nThe entities ""IBC"" and ""TILs"" are related to each other. TILs (Tumor-Infiltrating Lymphocytes) are found in the tumor microenvironment of IBC (Invasive Breast Cancer). Additionally, TILs are more frequently found in IBC compared to non-IBC.",57\r\n3,"""VICENTE VALERO""","""IBC""","""Vicente Valero is a member of the IBC working group.""",57\r\n43,"""IMMUNOTHERAPY""","""IBC""","Here is a comprehensive summary of the data:\n\nIMMUNOTHERAPY is a potential treatment option for Inflammatory Breast Cancer (IBC).",57\r\n63,"""IBC""","""FAC""","""FAC is used to treat IBC patients.""",56\r\n93,"""IBC""","""I-SPY2""","""IBC is the disease being treated in the I-SPY2 clinical trial.""",56\r\n58,"""IBC""","""RADIATION ONCOLOGIST""","""Radiation oncologists are part of a multidisciplinary team that treats IBC patients.""",56\r\n61,"""IBC""","""CRISTOFANILLI ET AL.""","""Cristofanilli et al. conducted a study on IBC patients.""",56\r\n68,"""IBC""","""INTERNATIONAL EXPERT CONSENSUS""","""International Expert Consensus provides guidance on the treatment of IBC.""",56\r\n70,"""IBC""","""STANDARD OF CARE""","""IBC is treated according to the Standard of Care, which involves the use of various therapies, including chemotherapy and transplantation.""",56\r\n79,"""IBC""","""TARGETED THERAPY""","""Targeted Therapy is a treatment option for IBC.""",56\r\n81,"""IBC""","""TAXANE-BASED CHEMOTHERAPY""","""Taxane-based Chemotherapy is used in the treatment of IBC.""",56\r\n92,"""IBC""","""KEYNOTE-522""","""IBC is the disease being treated in the KEYNOTE-522 clinical trial.""",56\r\n64,"""IBC""","""ANTHRACYCLINE""","""Anthracycline is used to treat IBC patients.""",55\r\n80,"""IBC""","""ANTHRACYCLINE-BASED CHEMOTHERAPY""","""Anthracycline-based Chemotherapy is used in the treatment of IBC.""",55\r\n95,"""IBC""","""ANTI-EGFR AGENT""","""Anti-EGFR agents are a potential treatment for IBC.""",55\r\n96,"""IBC""","""ANTIPD-L1 ANTIBODY""","""Anti-PD-L1 antibodies are a potential treatment for IBC.""",55\r\n98,"""IBC""","""BC""","""BC is related to IBC as a medical organization or institution may be involved in the study and treatment of IBC.""",55\r\n86,"""IBC""","""BERTUCCI ET AL.""","""Bertucci et al. reported PD-L1 overexpression in IBC tumors.""",55\r\n82,"""IBC""","""CARBOPLATIN""","""Carboplatin is used in the treatment of IBC.""",55\r\n60,"""IBC""","""CHEMOTHERAPY""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) is a type of breast cancer that can be treated with chemotherapy. According to the descriptions, chemotherapy is a potential treatment option for IBC, and it has been reported to be effective in treating the disease. Specifically, chemotherapy has been used to treat IBC with a reported objective response rate of 74% and a median overall survival (OS) of 37 months.",55\r\n57,"""IBC""","""DIAGNOSTIC RADIOLOGIST""","""Diagnostic radiologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n66,"""IBC""","""DITSCH ET AL.""","""Ditsch et al. conducted a study on chemotherapy dose intensity in IBC patients.""",55\r\n65,"""IBC""","""FAC REGIMEN""","""FAC regimen is used to treat IBC, a type of breast cancer.""",55\r\n54,"""IBC""","""MEDICAL ONCOLOGIST""","""Medical oncologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n55,"""IBC""","""SURGEON""","""Surgeons are part of a multidisciplinary team that treats IBC patients.""",55\r\n56,"""IBC""","""PATHOLOGIST""","""Pathologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n59,"""IBC""","""MD ANDERSON""","""MD Anderson conducted a retrospective study on IBC patients, providing insights into the treatment of IBC.""",55\r\n69,"""IBC""","""NON-IBC""","""IBC and non-IBC are compared in terms of OS rate and outcomes.""",55\r\n83,"""IBC""","""TALIMOGENE LAHERPAREPVEC""","""Talimogene laherparepvec is a treatment for IBC patients, specifically for TNBC patients.""",55\r\n84,"""IBC""","""MULTIDISCIPLINARY TEAM""","""The Multidisciplinary team evaluates and treats patients with IBC, a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body.""",55\r\n94,"""IBC""","""IMMUNE CHECKPOINT INHIBITOR""","""Immune checkpoint inhibitors are a potential treatment for IBC.""",55\r\n97,"""IBC""","""LAABC""","""LAABC is different from IBC.""",55\r\n99,"""IBC""","""LA BC""","""IBC is distinct from LA BC as a unique entity with different characteristics and treatment approaches.""",55\r\n46,"""TUMOR EMBOLI""","""IBC""","""IBC is characterized by the presence of tumor emboli in dermal lymphatics, which may be present or absent in biopsy specimens.""",55\r\n47,"""LYMPHEDEMA""","""IBC""","""IBC is characterized by lymphedema caused by tumor emboli within dermal lymphatics.""",55\r\n143,"""PACLITAXEL""","""TRASTUZUMAB""","""Trastuzumab is combined with paclitaxel in a treatment for breast cancer.""",23\r\n142,"""PACLITAXEL""","""LAPATINIB""","Here is a comprehensive summary of the data:\n\nPACLITAXEL and LAPATINIB are two medications used in cancer treatment. Specifically, they are combined in a treatment for breast cancer, where LAPATINIB is paired with PACLITAXEL to provide a comprehensive treatment approach. Additionally, both medications have different effects on the pCR (pathological complete response) rate, indicating that they have distinct mechanisms of action in cancer treatment.",20\r\n140,"""PACLITAXEL""","""NAC""","""Paclitaxel is part of the NAC regimen.""",19\r\n164,"""NAC""","""PD-L1""","""NAC is associated with PD-L1 expression in breast cancer.""",18\r\n144,"""PACLITAXEL""","""BEVACIZUMAB""","""Paclitaxel is used in certain circumstances with bevacizumab for metastatic breast cancer.""",16\r\n129,"""OS""","""PD-L1""","""PD-L1 expression in tumor cells is associated with worse overall survival in breast cancer patients.""",14\r\n141,"""PACLITAXEL""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",13\r\n134,"""HER2""","""PD-L1""","""HER2 is associated with PD-L1 expression in breast cancer.""",13\r\n27,"""BREAST CANCER""","""IMMUNOTHERAPY""","""Immunotherapy is a potential future direction for systemic therapy in Breast Cancer treatment, leveraging the body\'s immune system to fight cancer.""",12\r\n297,"""PD-L1""","""ARIAS-PULIDO ET AL.""","""Arias-Pulido et al. reported on PD-L1 positivity in IBC samples.""",10\r\n296,"""PD-L1""","""BERCKELAER ET AL.""","""Berckelaer et al. reported on PD-L1 expression in TILs.""",10\r\n145,"""PACLITAXEL""","""AC REGIME""","""AC regime and paclitaxel are used together in a chemotherapy regimen for breast cancer treatment.""",10\r\n139,"""PACLITAXEL""","""ESTROGEN RECEPTOR""","""Estrogen receptor is relevant to paclitaxel\'s effectiveness in treating breast cancer.""",9\r\n295,"""PD-L1""","""ER""","""ER is associated with PD-L1 expression in breast cancer.""",9\r\n298,"""ARIAS-PULIDO ET AL.""","""TILS""","""Arias-Pulido et al. reported PD-L1 positivity in TILs and its association with better DFS.""",6\r\n299,"""BERCKELAER ET AL.""","""TILS""","""Berckelaer et al. reported PD-L1 expression in TILs.""",6\r\n165,"""INTERNATIONAL EXPERT CONSENSUS""","""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""International Expert Consensus recommends High-dose chemotherapy with autologous hematopoietic stem cell transplantation as a treatment option for IBC.""",6\r\n167,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH""","""Center for International Blood and Marrow Transplant Research conducts research on High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IBC treatment.""",5\r\n166,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""INTERNATIONAL BLOOD AND MARROW TRANSPLANT REGISTRY""","""International Blood and Marrow Transplant Registry tracks data on High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IBC treatment.""",5\r\n302,"""KEYNOTE-522""","""I-SPY2""","""KEYNOTE-522 and I-SPY2 are clinical trials that combine chemotherapy and an immune checkpoint inhibitor.""",4\r\n42,"""IMMUNOTHERAPY""","""ONGOING IBC CLINICAL TRIALS""","""Immunotherapy is being investigated in Ongoing IBC Clinical Trials as a potential new treatment for IBC.""",4\r\n146,"""FAC""","""G-CSF""","""FAC and G-CSF are technologies used together in clinical trials.""",3\r\n136,"""RADIATION ONCOLOGIST""","""TEAM""","""Radiation oncologist is a member of the team working to improve the survival of IBC.""",3\r\n189,"""STANDARD OF CARE""","""RANDOMIZED TRIALS""","""Randomized Trials are used to determine the Standard of Care for IBC treatment.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:30,480 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 4/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:32,771 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:32,775 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n145,"""TRASTUZUMAB""","Here is a comprehensive summary of the data provided:\n\nTrastuzumab is a humanized anti-HER2 monoclonal antibody that is part of the anti-HER2 backbone for HER2+ IBC. It is a medication used in the treatment of HER2+ IBC, HER2-positive breast cancer, and breast cancer in general. Trastuzumab is a targeted therapy that targets HER2 receptors, blocking the HER2 protein to treat HER2-positive breast cancer. It is often used in combination with other medications, such as pertuzumab, docetaxel, and epirubicin, to treat breast cancer. Trastuzumab is also used in clinical trials and has been approved for HER2+ disease, including IBC. It is a type of monoclonal antibody that targets HER2 and is a treatment option for IBC, used in combination with lapatinib and paclitaxel. Additionally, trastuzumab is a chemotherapy drug used in the NeoSphere clinical trial and is a type of cancer treatment. Overall, trastuzumab is a medication used to treat HER2+ breast cancer by blocking the HER2 protein and is a targeted therapy approved for HER2+ disease, including IBC.",15\r\n200,"""NERATINIB""","Here is a comprehensive summary of the data:\n\nNeratinib is a medication used in various treatment settings for breast cancer. Specifically, it is used in adjuvant therapy for high-risk recurrent disease, including inflammatory breast cancer (IBC). Additionally, neratinib is used to treat HER2-positive breast cancer, particularly in high-risk situations. It is also offered as a treatment option for patients with HER2-positive breast cancer. Neratinib is a chemotherapy drug and a tyrosine kinase inhibitor, which is used in clinical trials. Overall, neratinib is a medication used in cancer treatment, with a focus on breast cancer, particularly HER2-positive disease.\n\nNote: I resolved the contradictions by combining the information from the different descriptions to provide a comprehensive summary. I also rephrased some of the sentences to ensure clarity and coherence.",8\r\n171,"""OVERMOYER ET AL.""","Here is a comprehensive summary of the data:\n\nOvermoyer et al. are researchers who have reported on the efficacy of a specific treatment regimen. According to their findings, neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab has shown promising results.",5\r\n62,"""HER2+ IBC""","Here is a comprehensive summary of the data:\n\nHER2+ IBC (Human Epidermal Growth Factor Receptor 2-positive Invasive Breast Cancer) is a subtype of Invasive Breast Cancer (IBC) that has been found to have the longest median Overall Survival (OS) after brain metastasis and is related to the anti-HER2 therapy era. This subtype is typically treated with pertuzumab plus trastuzumab as a standard neoadjuvant treatment. HER2+ IBC is a type of breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein and is treated with dual anti-HER2 antibodies and anthracycline-containing regimens.\n\nNote: I resolved the contradictions by combining the information from each description to provide a comprehensive summary. I also used third-person language and included the entity names for clarity.",4\r\n165,"""NEOSPHERE TRIAL""","Here is a comprehensive summary of the data:\n\nThe ""NEOSPHERE TRIAL"" is a clinical trial that investigated the use of pertuzumab plus trastuzumab in combination with an anthracycline-containing regimen in patients with HER2-positive breast cancer. Specifically, it is a phase 2 randomized neoadjuvant trial that tested the combination of pertuzumab with trastuzumab in breast cancer patients.",4\r\n114,"""NAC""","Here is a comprehensive summary of the data:\n\nNAC refers to neoadjuvant chemotherapy, a type of chemotherapy regimen used in the treatment of breast cancer. Specifically, NAC is a treatment protocol that is evaluated in clinical trials for the treatment of HER2-positive locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). It is a treatment option for IBC, used in combination with lapatinib, and has shown survival benefits for patients with LABC, including IBC, when combined with trastuzumab. NAC is a type of neoadjuvant chemotherapy that is associated with PD-L1 expression and is used in the TRYPHAENA study.",11\r\n340,"""PATIENT""","""Patient is the individual receiving treatment.""",10\r\n153,"""PERTUZUMAB""","Here is a comprehensive summary of the data provided:\n\nPertuzumab is a humanized anti-HER2 monoclonal antibody that binds the HER2 receptor at a different epitope from trastuzumab. It is a medication used in cancer treatment, specifically in the treatment of HER2-positive breast cancer, including inflammatory breast cancer (IBC). Pertuzumab is also used to treat HER2+ breast cancer, especially in combination with trastuzumab, by blocking the HER2 protein. As a targeted therapy, it targets HER2 receptors and induces antibody-dependent cell-mediated cytotoxicity. Pertuzumab is a type of monoclonal antibody that binds to the HER2 receptor and is used in breast cancer treatment. It is often used in combination with other treatments, such as T-DM1, as part of a treatment regimen for HER2+ breast cancer. Additionally, pertuzumab has been used in clinical trials, including the NeoSphere clinical trial, and is a chemotherapy drug.",10\r\n665,"""LANCET ONCOL""","Here is a comprehensive summary of the data:\n\n""Lancet Oncol"" is a medical research journal that has published numerous studies on various topics related to breast cancer. Specifically, the journal has published studies on adjuvant bevacizumab-containing therapy in triple-negative breast cancer, as well as neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer. Additionally, the journal has published research on Nab-paclitaxel and bevacizumab treatment in new models of inflammatory breast cancer, and has identified pathological response and circulating tumor cell count as indicators of excellent prognosis in treated HER2+ inflammatory breast cancer patients. Furthermore, the journal has published the results of the GeparQuinto study, which focused on inflammatory breast cancer. The journal has also published a study on lapatinib versus trastuzumab in combination with neoadjuvant chemotherapy. Overall, ""Lancet Oncol"" is a reputable and influential publication in the field of oncology, providing valuable insights and research findings to healthcare professionals and researchers.",3\r\n70,"""HER2""","Here is a comprehensive summary of the data:\n\nHER2 is a human epidermal growth factor receptor 2, a biomarker for breast cancer. It is a protein receptor that is often overexpressed in breast cancer, with an estimated prevalence of 25-35% in inflammatory breast cancer (IBC). HER2 is a target for breast cancer treatment, and its overexpression is associated with poor prognosis. The protein receptor is targeted by various therapies, including trastuzumab, lapatinib, pertuzumab, and T-DM1, among others. HER2 is also a predictive marker for the efficacy of trastuzumab addition in breast cancer treatment. Additionally, HER2 is a receptor that can dimerize with other ligands HER receptors and is associated with PD-L1 expression in breast cancer. HER2 status refers to the human epidermal growth factor receptor 2 status, which is an important factor in determining the effectiveness of breast cancer treatment. Overall, HER2 is a critical protein receptor in breast cancer, and its expression and targeting are crucial in the development of effective treatment strategies.",6\r\n189,"""T-DM1""","Here is a comprehensive summary of the data:\n\n""T-DM1"" is a medication used in the treatment of breast cancer. Specifically, it is a treatment for HER2+ Inflammatory Breast Cancer (IBC) cases without a pathologic complete response (pCR). Additionally, T-DM1 is a type of antibody-drug conjugate used to treat HER2+ breast cancer.",3\r\n151,"""ANTHRACYCLINE-CONTAINING REGIMEN""","Here is a comprehensive summary of the data:\n\nThe ""ANTHRACYCLINE-CONTAINING REGIMEN"" is a treatment protocol for breast cancer, specifically a type of chemotherapy regimen used to treat breast cancer. Furthermore, it is also used to treat HER2+ Inflammatory Breast Cancer (IBC). This regimen is a type of chemotherapy that is effective in treating HER2+ IBC.",1\r\n174,"""ATINIB""",No Description,1\r\n146,"""NOAH STUDY""","Here is a comprehensive summary of the data:\n\nThe NOAH study is a randomized phase 3 clinical trial that investigated the efficacy of trastuzumab addition in breast cancer treatment.",1\r\n107,"""BREAST MRI""","Here is a comprehensive summary of the data:\n\nBreast MRI is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n289,"""CAPECITABINE""","Here is a comprehensive summary of the data:\n\nCapecitabine is a chemotherapy drug used in the treatment of breast cancer. It is also a medication used in cancer treatment.",2\r\n97,"""CYCLOPHOSPHAMIDE""","Here is a comprehensive summary of the data:\n\nCyclophosphamide is a chemotherapy medication used in the treatment of breast cancer. It is a key component of a treatment regimen and is often used in combination with other medications, such as docetaxel, epirubicin, and trastuzumab, to effectively treat breast cancer. As a chemotherapy drug, cyclophosphamide is designed to target and destroy cancer cells, helping to slow or stop the growth of tumors.",1\r\n98,"""DOXORUBICIN""","Here is a comprehensive summary of the data:\n\nDoxorubicin is a chemotherapy medication used in the treatment of breast cancer and as part of a treatment regimen. It is a chemotherapy drug used to treat various types of cancer, including breast cancer.\n\nNote: I resolved the contradictions by combining the descriptions to provide a clear and concise summary. I also removed the quotation marks from the output to make it easier to read.",1\r\n337,"""ER""","Here is a comprehensive summary of the data:\n\nThe entity ""ER"" refers to estrogen receptor, which is a receptor associated with PD-L1 expression in breast cancer.",2\r\n148,"""FLUOROURACIL""","""Fluorouracil is a chemotherapy medication.""",1\r\n108,"""MAMMOGRAPHY""","Here is a comprehensive summary of the data:\n\nMammography is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n147,"""METHOTREXATE""","""Methotrexate is a chemotherapy medication.""",1\r\n680,"""N ENGL J MED""","Here is a comprehensive summary of the data:\n\n""N ENGL J MED"" is a medical journal that publishes research on various medical topics, including breast cancer. Specifically, it has published several studies on breast cancer, providing valuable insights and findings in the field. As a medical journal, it is dedicated to sharing knowledge and advancing the understanding of various medical conditions, including breast cancer. Additionally, it has published a study on pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, providing important information for healthcare professionals and researchers.",2\r\n109,"""SONOGRAPHY""","Here is a comprehensive summary of the data:\n\nSonography is a medical imaging technique used to assess the effectiveness of treatment in Inflammatory Breast Cancer (IBC) and to evaluate the response to neoadjuvant chemotherapy.",1\r\n685,"""VIALE G""","Here is a comprehensive summary of the data:\n\nVIALE G is a researcher who has been involved in a study on pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer. As an author, VIALE G has contributed to a medical study and a research paper, showcasing their expertise and involvement in the field of breast cancer research.",2\r\n773,"""TRASTUZUMAB EMTANSINE""","Here is a comprehensive summary of the data:\n\nTrastuzumab Emtansine is a medication that is used as a treatment for residual invasive HER2-positive breast cancer.",2\r\n256,"""ADJUVANT THERAPY""","Here is a comprehensive summary of the data:\n\nAdjuvant therapy refers to a treatment given after primary treatment to reduce the risk of recurrence. Specifically, in the context of Inflammatory Breast Cancer (IBC), adjuvant therapy is a type of treatment administered after surgery. This treatment is designed to target any remaining cancer cells that may have been left behind after initial surgery, with the goal of preventing the recurrence of the disease.",1\r\n341,"""AROMATASE INHIBITOR""","""Aromatase inhibitor is a medication used in cancer treatment.""",1\r\n303,"""BISPHOSPHONATE""","Here is a comprehensive summary of the data:\n\nBisphosphonate is a medication that has multiple uses in various medical contexts. In cancer treatment, it is used to help manage the disease. Specifically, it is used to increase bone density and improve survival rates in breast cancer patients. Additionally, bisphosphonate is used to treat osteoporosis by increasing bone density, which can help prevent fractures and other bone-related complications. Overall, bisphosphonate is a medication with a range of applications in both cancer treatment and osteoporosis management.",1\r\n775,"""KRISTINE""","""KRISTINE is a clinical trial.""",1\r\n292,"""TAMOXIFEN""","Here is a comprehensive summary of the data:\n\nTamoxifen is a medication that has been extensively studied in various papers and is used in the treatment of breast cancer. Specifically, it is a type of hormone therapy used in the treatment of breast cancer, and has been associated with improved survival outcomes when used for extended adjuvant endocrine therapy. Additionally, Tamoxifen is also used in cancer treatment more broadly.",1\r\n202,"""EXTENET""","Here is a comprehensive summary of the data:\n\nExteNET is a clinical trial that focused on HER2-positive breast cancer patients. Specifically, the trial studied the use of neratinib in breast cancer patients, providing valuable insights into its effectiveness in this patient population.",2\r\n198,"""KATERINE TRIAL""","Here is a comprehensive summary of the data:\n\nThe ""KATERINE TRIAL"" is a clinical trial that evaluates the effectiveness of adjuvant therapy in patients with HER2+ breast cancer, specifically in cases of inflammatory breast cancer (IBC) without a pathologic complete response (pCR). The trial investigates the use of adjuvant T-DM1, a type of targeted therapy, in these patients. The trial\'s findings recommend the use of adjuvant T-DM1 in HER2+ IBC cases without a pCR.\n\nNote: I resolved the contradictions by combining the information from the three descriptions, ensuring that the summary is coherent and accurate.",2\r\n288,"""CREATE-X""","""CREATE-X is a randomized phase 3 study on adjuvant capecitabine for breast cancer patients.""",2\r\n781,"""HARVEY VJ""","""Harvey VJ is an author of a medical study.""",1\r\n201,"""HER4""","""HER4 is a protein that is targeted by neratinib.""",1\r\n69,"""HR""","Here is a comprehensive summary of the data:\n\nHR, which stands for hormone receptor, is a protein receptor that plays a crucial role in breast cancer treatment. It is often overexpressed in breast cancer, making it a target for treatment. HR refers to the hormone receptor status, which is an important factor in determining the effectiveness of breast cancer treatment. In summary, HR is a protein receptor that is a target for breast cancer treatment due to its overexpression in the disease, and its status is an important consideration in treatment planning.",1\r\n778,"""CHAN A""","""Chan A is an author of a medical study.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n72,"""IBC""","""TRASTUZUMAB""","""Trastuzumab is used in the treatment of IBC, a type of breast cancer.""",69\r\n75,"""IBC""","""NERATINIB""","""Neratinib is used in adjuvant therapy for high-risk recurrent disease like IBC.""",62\r\n74,"""IBC""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of a neoadjuvant treatment for IBC patients, which is a high-risk disease.""",59\r\n78,"""IBC""","""HER2+ IBC""","""HER2+ IBC is a subtype of IBC.""",58\r\n73,"""IBC""","""NEOSPHERE TRIAL""","""The NeoSphere trial included 29 IBC patients.""",58\r\n196,"""TRASTUZUMAB""","""LAPATINIB""","""Trastuzumab and lapatinib are combined in a dual antibody treatment for breast cancer.""",27\r\n160,"""NAC""","""TRASTUZUMAB""","Based on the provided data, here is a comprehensive summary:\n\nNAC (Neoadjuvant Anthracycline-based Chemotherapy) is a treatment regimen that is combined with trastuzumab to treat certain types of breast cancer. Specifically, NAC is used in combination with trastuzumab to treat both Inflammatory Breast Cancer (IBC) and Locally Advanced Breast Cancer (LABC), which includes IBC. This treatment combination has been shown to provide survival benefits for patients with LABC, including those with IBC.\n\nNote: I resolved the potential contradiction by combining the two descriptions, ensuring that the summary accurately reflects the information provided.",26\r\n199,"""TRASTUZUMAB""","""PATIENT""","""Trastuzumab is used as a treatment option for patients.""",25\r\n192,"""TRASTUZUMAB""","""PERTUZUMAB""","Here is a comprehensive summary of the data:\n\nTrastuzumab and Pertuzumab are two medications that are used together to treat breast cancer, specifically HER2+ breast cancer. They are often used in combination therapy to combat this type of cancer. Both medications have similar mechanisms of binding to HER2 epitopes, making them suitable for combination therapy. Specifically, they are used together to treat breast cancer, with the combination of the two medications providing a more effective treatment option than either medication alone.\n\nNote: I resolved the contradictions by combining the information from all three descriptions to provide a clear and concise summary.",25\r\n246,"""GEPARQUINTO""","""LANCET ONCOL""","""GeparQuinto is published in Lancet Oncol.""",24\r\n163,"""NAC""","""LAPATINIB""","""NAC with lapatinib has a low pCR rate in HER2+ patients.""",23\r\n198,"""TRASTUZUMAB""","""BEVACIZUMAB""","""Bevacizumab is used in combination with Trastuzumab in the studies.""",23\r\n143,"""PACLITAXEL""","""TRASTUZUMAB""","""Trastuzumab is combined with paclitaxel in a treatment for breast cancer.""",23\r\n131,"""HER2""","""TRASTUZUMAB""","""Trastuzumab is targeted towards HER2+ disease, including IBC.""",21\r\n194,"""TRASTUZUMAB""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",20\r\n204,"""PERTUZUMAB""","""PATIENT""","""Pertuzumab is used as a treatment option for patients.""",20\r\n115,"""HER2+ IBC""","""TRASTUZUMAB""","""Trastuzumab is used as a standard neoadjuvant treatment for HER2+ IBC patients.""",19\r\n140,"""PACLITAXEL""","""NAC""","""Paclitaxel is part of the NAC regimen.""",19\r\n193,"""TRASTUZUMAB""","""NEOSPHERE TRIAL""","""Trastuzumab was used in the NeoSphere trial as part of combination therapy with pertuzumab and docetaxel.""",19\r\n132,"""HER2""","""LAPATINIB""","""Lapatinib blocks intracellular HER2, which is a target for cancer treatment.""",18\r\n164,"""NAC""","""PD-L1""","""NAC is associated with PD-L1 expression in breast cancer.""",18\r\n256,"""NERATINIB""","""PATIENT""","""Neratinib is offered as a treatment option for patients.""",18\r\n197,"""TRASTUZUMAB""","""T-DM1""","""T-DM1 is compared to trastuzumab in terms of response and toxicity in the neoadjuvant setting.""",18\r\n191,"""TRASTUZUMAB""","""ANTHRACYCLINE-CONTAINING REGIMEN""","""Trastuzumab is used in combination with an anthracycline-containing regimen for breast cancer treatment.""",16\r\n195,"""TRASTUZUMAB""","""ATINIB""","""atinib and trastuzumab are both medications used in cancer treatment, with different effects on pCR rate.""",16\r\n135,"""HER2""","""PATIENT""","""Patient\'s HER2 status is used to determine treatment options.""",16\r\n527,"""PIERGA JY""","""LANCET ONCOL""","""Pierga JY published a study in Lancet Oncol on inflammatory breast cancer.""",16\r\n190,"""TRASTUZUMAB""","""NOAH STUDY""","Here is a comprehensive summary of the data:\n\nThe NOAH study evaluated the efficacy of trastuzumab, specifically in the context of neoadjuvant treatment, in combination with chemotherapy, compared to chemotherapy alone. Additionally, the study investigated the effectiveness of adding trastuzumab to breast cancer treatment.\n\nNote: I resolved the potential contradiction by combining the two descriptions, focusing on the specific context of neoadjuvant treatment and the addition of trastuzumab to breast cancer treatment.",16\r\n202,"""PERTUZUMAB""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",15\r\n212,"""TRYPHAENA""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the results of the TRYPHAENA study, which investigated the efficacy of a neoadjuvant treatment for IBC patients.""",15\r\n133,"""HER2""","""NERATINIB""","""Neratinib targets HER2, a protein involved in breast cancer.""",14\r\n114,"""HER2+ IBC""","""PERTUZUMAB""","""Pertuzumab is used as a standard neoadjuvant treatment for HER2+ IBC patients.""",14\r\n201,"""PERTUZUMAB""","""NEOSPHERE TRIAL""","""Pertuzumab was used in the NeoSphere trial as part of combination therapy with trastuzumab and docetaxel.""",14\r\n134,"""HER2""","""PD-L1""","""HER2 is associated with PD-L1 expression in breast cancer.""",13\r\n28,"""BREAST CANCER""","""NEOSPHERE TRIAL""","""The NeoSphere trial tested the combination of pertuzumab with trastuzumab in breast cancer patients.""",13\r\n141,"""PACLITAXEL""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",13\r\n203,"""PERTUZUMAB""","""T-DM1""","Here is a comprehensive summary of the data:\n\nPertuzumab and T-DM1 are two entities related to the treatment of breast cancer. According to the descriptions, T-DM1 is an alternative to pertuzumab in the treatment of breast cancer, suggesting that it can be used as a substitute or complementary therapy. Additionally, T-DM1 is often combined with pertuzumab in a treatment for breast cancer, indicating that the two entities are frequently used together. Furthermore, T-DM1 is used in combination with pertuzumab in the neoadjuvant setting, which is a treatment approach that involves administering medications before surgery to shrink tumors and make them more manageable. Notably, this combination therapy is associated with a favorable toxicity profile, meaning that it is well-tolerated by patients.\n\nOverall, the descriptions suggest that pertuzumab and T-DM1 are both used in the treatment of breast cancer, often in combination with each other, and that this combination therapy has a favorable safety profile.",13\r\n152,"""BREAST MRI""","""NAC""","""Breast MRI is used to assess the effectiveness of NAC in IBC.""",12\r\n291,"""CAPECITABINE""","""PATIENT""","""Capecitabine is used as a treatment option for patients.""",12\r\n149,"""CYCLOPHOSPHAMIDE""","""NAC""","""Cyclophosphamide is part of the NAC regimen.""",12\r\n150,"""DOXORUBICIN""","""NAC""","""Doxorubicin is part of the NAC regimen.""",12\r\n300,"""ER""","""PATIENT""","""Patient\'s ER status is used to determine treatment options.""",12\r\n162,"""NAC""","""FLUOROURACIL""","""Fluorouracil is part of the NAC regimen.""",12\r\n153,"""MAMMOGRAPHY""","""NAC""","""Mammography is used to assess the effectiveness of NAC in IBC.""",12\r\n161,"""NAC""","""METHOTREXATE""","""Methotrexate is part of the NAC regimen.""",12\r\n208,"""PERTUZUMAB""","""N ENGL J MED""","""N Engl J Med published a paper on Pertuzumab.""",12\r\n154,"""SONOGRAPHY""","""NAC""","""Sonography is used to assess the effectiveness of NAC in IBC.""",12\r\n157,"""EGFR""","""NERATINIB""","""Neratinib targets EGFR, a protein involved in breast cancer.""",12\r\n205,"""PERTUZUMAB""","""VIALE G""","""Viale G is involved in the development of Pertuzumab.""",12\r\n206,"""PERTUZUMAB""","""TRASTUZUMAB EMTANSINE""","""Trastuzumab Emtansine is related to Pertuzumab.""",12\r\n285,"""ADJUVANT THERAPY""","""PATIENT""","""Adjuvant therapy is given to patients after primary treatment.""",11\r\n301,"""PATIENT""","""AROMATASE INHIBITOR""","""Aromatase inhibitor is used as a treatment option for patients.""",11\r\n293,"""BISPHOSPHONATE""","""PATIENT""","""Bisphosphonate is used as a treatment option for patients.""",11\r\n108,"""INSTITUTE""","""HER2+ IBC""","""The institute has reported on the results of HER2+ IBC, including its longest median OS after brain metastasis and relation to the anti-HER2 therapy era.""",11\r\n207,"""PERTUZUMAB""","""KRISTINE""","""KRISTINE is a clinical trial involving Pertuzumab.""",11\r\n292,"""TAMOXIFEN""","""PATIENT""","""Tamoxifen is used as a treatment option for patients.""",11\r\n254,"""NERATINIB""","""EXTENET""","""Neratinib was studied in the ExteNET clinical trial.""",10\r\n253,"""KATERINE TRIAL""","""NERATINIB""","""The KATERINE trial recommended adjuvant T-DM1, which includes Neratinib, in HER2+ IBC cases without a pCR.""",10\r\n128,"""OS""","""CREATE-X""","""CREATE-X shows that adjuvant capecitabine can improve overall survival in breast cancer patients.""",9\r\n295,"""PD-L1""","""ER""","""ER is associated with PD-L1 expression in breast cancer.""",9\r\n257,"""NERATINIB""","""HARVEY VJ""","""Harvey VJ is involved in the development of Neratinib.""",9\r\n255,"""NERATINIB""","""HER4""","""Neratinib targets HER4, a protein involved in breast cancer.""",9\r\n130,"""HR""","""HER2""","""HER2 and HR are protein receptors that are targets for breast cancer treatment.""",7\r\n258,"""EXTENET""","""LANCET ONCOL""","""ExteNET is published in Lancet Oncol.""",5\r\n252,"""T-DM1""","""KATERINE TRIAL""","""The KATERINE trial evaluated the use of T-DM1 as adjuvant therapy in patients with HER2+ breast cancer.""",5\r\n290,"""CREATE-X""","""CAPECITABINE""","""CREATE-X is a study on the effectiveness of adjuvant capecitabine in breast cancer patients.""",4\r\n583,"""N ENGL J MED""","""TRASTUZUMAB EMTANSINE""","""Trastuzumab Emtansine is published in N Engl J Med.""",4\r\n584,"""VIALE G""","""CHAN A""","""Viale G and Chan A are co-authors of a medical study.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:32,776 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 5/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:32,776 graphrag.index.graph.extractors.community_reports.community_reports_extractor ERROR error generating community report
Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\graph\extractors\community_reports\community_reports_extractor.py", line 58, in __call__
    await self._llm(
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\json_parsing_llm.py", line 34, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_token_replacing_llm.py", line 37, in __call__
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_history_tracking_llm.py", line 33, in __call__
    output = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\caching_llm.py", line 104, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 177, in __call__
    result, start = await execute_with_retry()
                    ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 159, in execute_with_retry
    async for attempt in retryer:
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\_asyncio.py", line 71, in __anext__
    do = self.iter(retry_state=self._retry_state)
         ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 325, in iter
    raise retry_exc.reraise()
          ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 158, in reraise
    raise self.last_attempt.result()
          ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 449, in result
    return self.__get_result()
           ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 401, in __get_result
    raise self._exception
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 165, in execute_with_retry
    return await do_attempt(), start
           ^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 151, in do_attempt
    await sleep_for(sleep_time)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 147, in do_attempt
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 48, in __call__
    return await self._invoke_json(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 82, in _invoke_json
    result = await generate()
             ^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 74, in generate
    await self._native_json(input, **{**kwargs, "name": call_name})
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 96, in _native_json
    result = await self._invoke(
             ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 53, in _invoke
    output = await self._execute_llm(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 55, in _execute_llm
    completion = await self.client.chat.completions.create(
                 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\resources\chat\completions.py", line 1289, in create
    return await self._post(
           ^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1826, in post
    return await self.request(cast_to, opts, stream=stream, stream_cls=stream_cls)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1519, in request
    return await self._request(
           ^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1620, in _request
    raise self._make_status_error_from_response(err.response) from None
openai.RateLimitError: Error code: 429 - {'error': {'message': 'Rate limit reached for model `llama3-8b-8192` in organization `org_01j1m7ha6hevrb19g7knxdmps3` on tokens per minute (TPM): Limit 30000, Used 33226, Requested 8766. Please try again in 23.985s. Visit https://console.groq.com/docs/rate-limits for more information.', 'type': 'tokens', 'code': 'rate_limit_exceeded'}}
13:02:32,791 graphrag.index.reporting.file_workflow_callbacks INFO Community Report Extraction Error details=None
13:02:32,791 graphrag.index.verbs.graph.report.strategies.graph_intelligence.run_graph_intelligence WARNING No report found for community: 14
13:02:33,229 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:33,234 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n418,"""VIENS P""","Here is a comprehensive summary of the data:\n\nVIENS P is a renowned researcher who has made significant contributions to the field of breast cancer treatment. Specifically, VIENS P was an author of several studies on breast cancer treatment, including a consensus statement for standardized diagnosis and treatment of inflammatory breast cancer. Additionally, VIENS P conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer, examining pathologic response and outcome. VIENS P\'s work has shed light on the diagnosis and treatment of inflammatory breast cancer, a rare and aggressive form of breast cancer.",7\r\n416,"""DAWOOD S""","Here is a comprehensive summary of the data:\n\nDawood S is a person who has made significant contributions to the field of inflammatory breast cancer. Specifically, Dawood S is an author of multiple studies on the topic, including a study on the standardized diagnosis and treatment of inflammatory breast cancer, as well as a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer. These studies demonstrate Dawood S\'s expertise and research focus on inflammatory breast cancer, and highlight their role as a leading authority in the field.",4\r\n598,"""PALANGIE T""","Here is a comprehensive summary of the data:\n\nPalangie T is an author of multiple studies related to inflammatory breast cancer. Specifically, Palangie T has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as a broader study on inflammatory breast cancer.",4\r\n603,"""BEUZEBOC P""","Here is a comprehensive summary of the data:\n\nBeuzeboc P is an author who has contributed to multiple studies in the field of breast cancer. Specifically, they have authored a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer. Additionally, they have also authored a study on inflammatory breast cancer, highlighting their expertise and research focus in this area.",2\r\n602,"""DELOZIER T""","Here is a comprehensive summary of the data:\n\nDelozier T is an author of multiple studies related to inflammatory breast cancer. Specifically, Delozier T has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as a broader study on inflammatory breast cancer.",2\r\n505,"""PENAULT-LLORCA F""","Here is a comprehensive summary of the data:\n\nPenault-Llorca F is a researcher who has made significant contributions to the field of early breast cancer diagnosis, treatment, and follow-up. Specifically, she has been involved in the development of ESMO Clinical Practice Guidelines for these areas. Additionally, she has authored a study on the use of high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer, examining the pathologic response and outcome of this treatment approach.",2\r\n601,"""ROCHE H""","Here is a comprehensive summary of the data:\n\nRoche H is a researcher who has authored studies on inflammatory breast cancer. Specifically, Roche H has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as on inflammatory breast cancer in general.",2\r\n502,"""CARDOSO F""","""Cardoso F is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",5\r\n503,"""KYRIAKIDES S""","""Kyriakides S is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n504,"""OHNO S""","""Ohno S is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n506,"""POORTMANS P""","""Poortmans P is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n507,"""RUBIO IT""","""Rubio IT is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n634,"""BROGLIO K""","""Broglio K is an author of a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer.""",1\r\n417,"""MERAJVER SD""","Here is a comprehensive summary of the data:\n\nMerajver SD is a notable figure in the field of inflammatory breast cancer research. As a contributor to the consensus statement for standardized diagnosis and treatment of inflammatory breast cancer, Merajver SD played a crucial role in shaping the understanding and management of this disease. Additionally, Merajver SD is also an author of a study on inflammatory breast cancer, further solidifying their expertise and contributions to the field.",1\r\n419,"""VERMEULEN PB""","Here is a comprehensive summary of the data:\n\nVermeulen PB is a person who has made significant contributions to the field of inflammatory breast cancer. Specifically, they were a key contributor to the development of a consensus statement for standardized diagnosis and treatment of inflammatory breast cancer. Additionally, Vermeulen PB is also an author of a study on inflammatory breast cancer, further demonstrating their expertise and research in this area.",1\r\n609,"""DIERAS V""","""Dieras V is an author of a study on inflammatory breast cancer.""",1\r\n610,"""DORVAL T""","""Dorval T is an author of a study on inflammatory breast cancer.""",1\r\n599,"""JANVIER M""","Here is a comprehensive summary of the data:\n\nJanvier M is an author of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\n\nNote: Since there is only one description provided, the summary is straightforward and concise.",2\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n342,"""VIENS P""","""GONCALVES A""","""Goncalves A and Viens P are co-authors of several studies on breast cancer treatment.""",14\r\n334,"""DAWOOD S""","""VIENS P""","""Dawood S and Viens P are co-authors of a study on inflammatory breast cancer.""",11\r\n338,"""VIENS P""","""PALANGIE T""","Here is a comprehensive summary of the data:\n\nPalangie T and Viens P are co-authors of two studies related to inflammatory breast cancer. The first study focuses on inflammatory breast cancer, while the second study explores first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\n\nNote: The descriptions are identical, except for the order of the authors\' names. This suggests that the two entities, Palangie T and Viens P, are co-authors of the same studies, and the descriptions are simply rephrased to reflect the different order of the authors\' names.",11\r\n341,"""VIENS P""","""BEUZEBOC P""","""Viens P and Beuzeboc P are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.""",9\r\n340,"""VIENS P""","""DELOZIER T""","""Viens P and Delozier T are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.""",9\r\n337,"""VIENS P""","""PENAULT-LLORCA F""","""Viens P and Penault-Llorca F are co-authors of a study on high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome.""",9\r\n339,"""VIENS P""","""ROCHE H""","""Viens P and Roche H are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.""",9\r\n447,"""CARDOSO F""","""PENAULT-LLORCA F""","""Cardoso F and Penault-Llorca F are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",7\r\n512,"""PALANGIE T""","""BEUZEBOC P""","""Palangie T and Beuzeboc P are co-authors of a study on inflammatory breast cancer.""",6\r\n445,"""CARDOSO F""","""KYRIAKIDES S""","""Cardoso F and Kyriakides S are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n446,"""CARDOSO F""","""OHNO S""","""Cardoso F and Ohno S are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n448,"""CARDOSO F""","""POORTMANS P""","""Cardoso F and Poortmans P are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n449,"""CARDOSO F""","""RUBIO IT""","""Cardoso F and Rubio IT are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n336,"""DAWOOD S""","""BROGLIO K""","""Dawood S and Broglio K are co-authors of a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer.""",5\r\n333,"""DAWOOD S""","""MERAJVER SD""","""Dawood S and Merajver SD are co-authors of a study on inflammatory breast cancer.""",5\r\n335,"""DAWOOD S""","""VERMEULEN PB""","""Dawood S and Vermeulen PB are co-authors of a study on inflammatory breast cancer.""",5\r\n513,"""PALANGIE T""","""DIERAS V""","""Palangie T and Dieras V are co-authors of a study on inflammatory breast cancer.""",5\r\n514,"""PALANGIE T""","""DORVAL T""","""Palangie T and Dorval T are co-authors of a study on inflammatory breast cancer.""",5\r\n516,"""JANVIER M""","""DELOZIER T""","""Janvier M and Delozier T are co-authors of a study on inflammatory breast cancer.""",4\r\n515,"""JANVIER M""","""ROCHE H""","""Janvier M and Roche H are co-authors of a study on inflammatory breast cancer.""",4\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:33,235 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 1/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:34,689 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:34,693 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n418,"""VIENS P""","Here is a comprehensive summary of the data:\n\nVIENS P is a renowned researcher who has made significant contributions to the field of breast cancer treatment. Specifically, VIENS P was an author of several studies on breast cancer treatment, including a consensus statement for standardized diagnosis and treatment of inflammatory breast cancer. Additionally, VIENS P conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer, examining pathologic response and outcome. VIENS P\'s work has shed light on the diagnosis and treatment of inflammatory breast cancer, a rare and aggressive form of breast cancer.",7\r\n416,"""DAWOOD S""","Here is a comprehensive summary of the data:\n\nDawood S is a person who has made significant contributions to the field of inflammatory breast cancer. Specifically, Dawood S is an author of multiple studies on the topic, including a study on the standardized diagnosis and treatment of inflammatory breast cancer, as well as a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer. These studies demonstrate Dawood S\'s expertise and research focus on inflammatory breast cancer, and highlight their role as a leading authority in the field.",4\r\n598,"""PALANGIE T""","Here is a comprehensive summary of the data:\n\nPalangie T is an author of multiple studies related to inflammatory breast cancer. Specifically, Palangie T has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as a broader study on inflammatory breast cancer.",4\r\n603,"""BEUZEBOC P""","Here is a comprehensive summary of the data:\n\nBeuzeboc P is an author who has contributed to multiple studies in the field of breast cancer. Specifically, they have authored a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer. Additionally, they have also authored a study on inflammatory breast cancer, highlighting their expertise and research focus in this area.",2\r\n602,"""DELOZIER T""","Here is a comprehensive summary of the data:\n\nDelozier T is an author of multiple studies related to inflammatory breast cancer. Specifically, Delozier T has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as a broader study on inflammatory breast cancer.",2\r\n505,"""PENAULT-LLORCA F""","Here is a comprehensive summary of the data:\n\nPenault-Llorca F is a researcher who has made significant contributions to the field of early breast cancer diagnosis, treatment, and follow-up. Specifically, she has been involved in the development of ESMO Clinical Practice Guidelines for these areas. Additionally, she has authored a study on the use of high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer, examining the pathologic response and outcome of this treatment approach.",2\r\n601,"""ROCHE H""","Here is a comprehensive summary of the data:\n\nRoche H is a researcher who has authored studies on inflammatory breast cancer. Specifically, Roche H has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as on inflammatory breast cancer in general.",2\r\n502,"""CARDOSO F""","""Cardoso F is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",5\r\n503,"""KYRIAKIDES S""","""Kyriakides S is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n504,"""OHNO S""","""Ohno S is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n506,"""POORTMANS P""","""Poortmans P is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n507,"""RUBIO IT""","""Rubio IT is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n634,"""BROGLIO K""","""Broglio K is an author of a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer.""",1\r\n417,"""MERAJVER SD""","Here is a comprehensive summary of the data:\n\nMerajver SD is a notable figure in the field of inflammatory breast cancer research. As a contributor to the consensus statement for standardized diagnosis and treatment of inflammatory breast cancer, Merajver SD played a crucial role in shaping the understanding and management of this disease. Additionally, Merajver SD is also an author of a study on inflammatory breast cancer, further solidifying their expertise and contributions to the field.",1\r\n419,"""VERMEULEN PB""","Here is a comprehensive summary of the data:\n\nVermeulen PB is a person who has made significant contributions to the field of inflammatory breast cancer. Specifically, they were a key contributor to the development of a consensus statement for standardized diagnosis and treatment of inflammatory breast cancer. Additionally, Vermeulen PB is also an author of a study on inflammatory breast cancer, further demonstrating their expertise and research in this area.",1\r\n609,"""DIERAS V""","""Dieras V is an author of a study on inflammatory breast cancer.""",1\r\n610,"""DORVAL T""","""Dorval T is an author of a study on inflammatory breast cancer.""",1\r\n599,"""JANVIER M""","Here is a comprehensive summary of the data:\n\nJanvier M is an author of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\n\nNote: Since there is only one description provided, the summary is straightforward and concise.",2\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n342,"""VIENS P""","""GONCALVES A""","""Goncalves A and Viens P are co-authors of several studies on breast cancer treatment.""",14\r\n334,"""DAWOOD S""","""VIENS P""","""Dawood S and Viens P are co-authors of a study on inflammatory breast cancer.""",11\r\n338,"""VIENS P""","""PALANGIE T""","Here is a comprehensive summary of the data:\n\nPalangie T and Viens P are co-authors of two studies related to inflammatory breast cancer. The first study focuses on inflammatory breast cancer, while the second study explores first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\n\nNote: The descriptions are identical, except for the order of the authors\' names. This suggests that the two entities, Palangie T and Viens P, are co-authors of the same studies, and the descriptions are simply rephrased to reflect the different order of the authors\' names.",11\r\n341,"""VIENS P""","""BEUZEBOC P""","""Viens P and Beuzeboc P are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.""",9\r\n340,"""VIENS P""","""DELOZIER T""","""Viens P and Delozier T are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.""",9\r\n337,"""VIENS P""","""PENAULT-LLORCA F""","""Viens P and Penault-Llorca F are co-authors of a study on high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome.""",9\r\n339,"""VIENS P""","""ROCHE H""","""Viens P and Roche H are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.""",9\r\n447,"""CARDOSO F""","""PENAULT-LLORCA F""","""Cardoso F and Penault-Llorca F are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",7\r\n512,"""PALANGIE T""","""BEUZEBOC P""","""Palangie T and Beuzeboc P are co-authors of a study on inflammatory breast cancer.""",6\r\n445,"""CARDOSO F""","""KYRIAKIDES S""","""Cardoso F and Kyriakides S are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n446,"""CARDOSO F""","""OHNO S""","""Cardoso F and Ohno S are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n448,"""CARDOSO F""","""POORTMANS P""","""Cardoso F and Poortmans P are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n449,"""CARDOSO F""","""RUBIO IT""","""Cardoso F and Rubio IT are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n336,"""DAWOOD S""","""BROGLIO K""","""Dawood S and Broglio K are co-authors of a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer.""",5\r\n333,"""DAWOOD S""","""MERAJVER SD""","""Dawood S and Merajver SD are co-authors of a study on inflammatory breast cancer.""",5\r\n335,"""DAWOOD S""","""VERMEULEN PB""","""Dawood S and Vermeulen PB are co-authors of a study on inflammatory breast cancer.""",5\r\n513,"""PALANGIE T""","""DIERAS V""","""Palangie T and Dieras V are co-authors of a study on inflammatory breast cancer.""",5\r\n514,"""PALANGIE T""","""DORVAL T""","""Palangie T and Dorval T are co-authors of a study on inflammatory breast cancer.""",5\r\n516,"""JANVIER M""","""DELOZIER T""","""Janvier M and Delozier T are co-authors of a study on inflammatory breast cancer.""",4\r\n515,"""JANVIER M""","""ROCHE H""","""Janvier M and Roche H are co-authors of a study on inflammatory breast cancer.""",4\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:34,693 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 2/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:37,438 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:37,440 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n437,"""CRISTOFANILLI M""","Here is a comprehensive summary of the data:\n\nCristofanilli M is a researcher who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on inflammatory breast cancer management in the National Comprehensive Cancer Network. Additionally, they were involved in the GeparQuinto study, which further highlights their expertise in this area.\n\nCristofanilli M is also an author of several research papers and studies on inflammatory breast cancer. These publications include a study on breast cancer treatment, as well as studies on inflammatory breast cancer management, neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer, paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer, and the prognostic significance of HER-2 status in women with inflammatory breast cancer.\n\nOverall, Cristofanilli M is a prominent researcher in the field of inflammatory breast cancer, with a focus on management, treatment, and prognosis.",18\r\n172,"""LAPATINIB""","Here is a comprehensive summary of the data:\n\nLapatinib is a small-molecule tyrosine kinase inhibitor that blocks intracellular HER2 and EGFR signaling pathways. It is a targeted therapy used to treat cancer, and is also used in combination with other therapies, such as Pazopanib, trastuzumab, and NAC, to treat various types of cancer, including breast cancer. Specifically, it is a treatment option for inflammatory breast cancer (IBC) when used in combination with NAC and trastuzumab. Additionally, lapatinib is an antibody-drug conjugate used in breast cancer treatment. Overall, lapatinib is a medication used in cancer treatment, specifically targeting HER2 and EGFR signaling pathways to inhibit the growth and spread of cancer cells.",12\r\n228,"""PAZOPANIB""","Here is a comprehensive summary of the data:\n\nPazopanib is a small-molecule multi-tyrosine kinase inhibitor used to treat cancer. Specifically, it is a targeted therapy used in combination with other treatments for breast cancer, and also used in combination therapy to treat a disease.\n\nNote: I resolved the contradictions by combining the information from all the descriptions to provide a single, coherent summary.",7\r\n435,"""MATRO JM""","Here is a comprehensive summary of the data:\n\nMatro JM is a person who has conducted a study on inflammatory breast cancer management in the National Comprehensive Cancer Network.",5\r\n844,"""JOHNSTON SR""","Here is a comprehensive summary of the data:\n\nJohnston SR is a researcher who has made significant contributions to the field of breast cancer research. Specifically, he has been involved in studies focused on HER2-positive advanced breast cancer, demonstrating his expertise in this area. Additionally, he has also authored a research paper on inflammatory breast cancer, showcasing his breadth of knowledge and expertise in the field.",3\r\n528,"""GONZALEZ-ANGULO AM""","""Gonzalez-Angulo AM is an author of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",1\r\n529,"""KAU SW""","Here is a comprehensive summary of the data:\n\nKau SW is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Kau SW is an author of two studies that have shed light on the prognosis and treatment of inflammatory breast cancer. In one study, Kau SW investigated the impact of paclitaxel on the prognosis of estrogen receptor negative inflammatory breast cancer, demonstrating its potential to improve patient outcomes. In another study, Kau SW examined the prognostic significance of HER-2 status in women with inflammatory breast cancer, providing valuable insights into the role of this biomarker in predicting patient outcomes.",1\r\n530,"""FRYE DK""","""Frye DK is an author of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",1\r\n536,"""SMITH T""","""Smith T is an author of a study on breast cancer treatment.""",1\r\n537,"""WASAFF B""","""Wasaff B is an author of a study on breast cancer treatment.""",1\r\n538,"""IBRAHIM N""","""Ibrahim N is an author of a study on breast cancer treatment.""",1\r\n850,"""MANIKHAS A""","Here is a comprehensive summary of the data:\n\nManikhas A is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Manikhas A has been involved in studies focused on HER2-positive advanced breast cancer, demonstrating expertise in this area. Additionally, Manikhas A has also authored a research paper on inflammatory breast cancer, further expanding their scope of research and expertise.",1\r\n856,"""GOMEZ HL""","""Gomez HL is a researcher involved in studies on HER2-positive advanced breast cancer.""",1\r\n851,"""GLADKOV O""","Here is a comprehensive summary of the data:\n\nGladkov O is a researcher who has been involved in studies on HER2-positive advanced breast cancer and inflammatory breast cancer. Specifically, Gladkov O is an author of a research paper on inflammatory breast cancer, and has also contributed to studies on HER2-positive advanced breast cancer.\n\nNote: I did not find any contradictions in the provided descriptions, so the summary is a straightforward concatenation of the information.",1\r\n852,"""SHAO Z""","Here is a comprehensive summary of the data:\n\nShao Z is a researcher who has made significant contributions to the field of breast cancer research. Specifically, Shao Z has been involved in studies on HER2-positive advanced breast cancer, demonstrating their expertise in this area. Additionally, Shao Z has also authored a research paper on inflammatory breast cancer, further highlighting their breadth of knowledge and research experience in the field of breast cancer.",1\r\n244,"""AFATINIB""","Here is a comprehensive summary of the data:\n\nAfatinib is a drug used in the treatment of HER2-positive inflammatory breast cancer. Specifically, it is an irreversible ErbB family blocker with preclinical activity in trastuzumab-resistant cell lines.",3\r\n247,"""SURVIVAL""","Here is a comprehensive summary of the data:\n\nThe entity ""SURVIVAL"" refers to the length of time a patient lives after being diagnosed with breast cancer. Specifically, it refers to the length of time a patient with breast cancer lives after diagnosis.\n\nNote: The two descriptions provided are identical, with only minor wording variations. I have combined them into a single summary to provide a clear and concise overview of the entity ""SURVIVAL"".",3\r\n229,"""VEG20007""","""VEG20007 is a randomized phase 2 study evaluating first-line lapatinib plus pazopanib therapy or lapatinib monotherapy.""",1\r\n236,"""LAPATINIB MONOTHERAPY""","""Lapatinib monotherapy is a treatment approach that uses a single medication to treat a disease.""",2\r\n438,"""HUGHES ME""","Here is a comprehensive summary of the data:\n\nHughes ME is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the National Comprehensive Cancer Network (NCCN) and authored a study on the same subject.",1\r\n436,"""LI T""","Here is a comprehensive summary of the data:\n\nLi T is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, Li T conducted a study on the topic within the National Comprehensive Cancer Network (NCCN), demonstrating expertise in the area. Additionally, Li T is an author of a study on inflammatory breast cancer management, further solidifying their reputation as a knowledgeable and experienced researcher in this field.",1\r\n439,"""OTTESEN RA""","Here is a comprehensive summary of the data:\n\nOttesen RA is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the national comprehensive cancer network, demonstrating their expertise and involvement in the field. Additionally, Ottesen RA is also an author of a study on inflammatory breast cancer management, further solidifying their reputation as a knowledgeable and authoritative figure in this area of research.",1\r\n440,"""WEEKS JC""","Here is a comprehensive summary of the data:\n\nWeeks JC is a person who has made significant contributions to the field of inflammatory breast cancer management. Specifically, they conducted a study on this topic within the National Comprehensive Cancer Network (NCCN) and authored a study on the same subject.",1\r\n243,"""DISEASE""",No Description,1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n239,"""GEPARQUINTO""","""CRISTOFANILLI M""","""Cristofanilli M is a researcher involved in the GeparQuinto study.""",39\r\n227,"""LAPATINIB""","""CRISTOFANILLI M""","""Cristofanilli M is an author of a research paper on a randomized phase II study of lapatinib plus pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.""",30\r\n196,"""TRASTUZUMAB""","""LAPATINIB""","""Trastuzumab and lapatinib are combined in a dual antibody treatment for breast cancer.""",27\r\n277,"""PAZOPANIB""","""CRISTOFANILLI M""","""Cristofanilli M is an author of a research paper on a randomized phase II study of lapatinib plus pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.""",25\r\n353,"""MATRO JM""","""CRISTOFANILLI M""","""Matro JM and Cristofanilli M are co-authors of a study on inflammatory breast cancer management.""",23\r\n163,"""NAC""","""LAPATINIB""","""NAC with lapatinib has a low pCR rate in HER2+ patients.""",23\r\n326,"""HORTOBAGYI GN""","""CRISTOFANILLI M""","""Cristofanilli M and Hortobagyi GN are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",22\r\n358,"""CRISTOFANILLI M""","""BUZDAR AU""","""Cristofanilli M and Buzdar AU are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",21\r\n365,"""CRISTOFANILLI M""","""JOHNSTON SR""","""Cristofanilli M and Johnston SR are co-authors of a study on HER2-positive advanced breast cancer.""",21\r\n361,"""CRISTOFANILLI M""","""SNEIGE N""","""Cristofanilli M and Sneige N are co-authors of a study on breast cancer treatment.""",20\r\n120,"""PCR""","""LAPATINIB""","""lapatinib has a lower pCR rate than expected in HER2+ patients.""",20\r\n142,"""PACLITAXEL""","""LAPATINIB""","Here is a comprehensive summary of the data:\n\nPACLITAXEL and LAPATINIB are two medications used in cancer treatment. Specifically, they are combined in a treatment for breast cancer, where LAPATINIB is paired with PACLITAXEL to provide a comprehensive treatment approach. Additionally, both medications have different effects on the pCR (pathological complete response) rate, indicating that they have distinct mechanisms of action in cancer treatment.",20\r\n357,"""CRISTOFANILLI M""","""GONZALEZ-ANGULO AM""","""Cristofanilli M and Gonzalez-Angulo AM are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n359,"""CRISTOFANILLI M""","""KAU SW""","""Cristofanilli M and Kau SW are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n360,"""CRISTOFANILLI M""","""FRYE DK""","""Cristofanilli M and Frye DK are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",19\r\n362,"""CRISTOFANILLI M""","""SMITH T""","""Cristofanilli M and Smith T are co-authors of a study on breast cancer treatment.""",19\r\n363,"""CRISTOFANILLI M""","""WASAFF B""","""Cristofanilli M and Wasaff B are co-authors of a study on breast cancer treatment.""",19\r\n364,"""CRISTOFANILLI M""","""IBRAHIM N""","""Cristofanilli M and Ibrahim N are co-authors of a study on breast cancer treatment.""",19\r\n366,"""CRISTOFANILLI M""","""MANIKHAS A""","""Cristofanilli M and Manikhas A are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n367,"""CRISTOFANILLI M""","""GOMEZ HL""","""Cristofanilli M and Gomez HL are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n368,"""CRISTOFANILLI M""","""GLADKOV O""","""Cristofanilli M and Gladkov O are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n369,"""CRISTOFANILLI M""","""SHAO Z""","""Cristofanilli M and Shao Z are co-authors of a study on HER2-positive advanced breast cancer.""",19\r\n222,"""LAPATINIB""","""PAZOPANIB""","""pazopanib is used in combination with lapatinib in a clinical trial (VEG20007) for the treatment of cancer.""",19\r\n125,"""OS""","""LAPATINIB""","""lapatinib does not differ in 3-year OS rate compared to trastuzumab.""",19\r\n132,"""HER2""","""LAPATINIB""","""Lapatinib blocks intracellular HER2, which is a target for cancer treatment.""",18\r\n224,"""LAPATINIB""","""AFATINIB""","""Lapatinib and Afatinib are both targeted therapies used to treat breast cancer, with Afatinib showing preclinical activity in trastuzumab-resistant cell lines.""",15\r\n226,"""LAPATINIB""","""JOHNSTON SR""","""Johnston SR is an author of a research paper on the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.""",15\r\n225,"""LAPATINIB""","""SURVIVAL""","""Lapatinib is associated with a higher rate of serious adverse events, which can impact patient survival.""",15\r\n223,"""LAPATINIB""","""VEG20007""","""VEG20007 is a study evaluating the effectiveness of lapatinib monotherapy or lapatinib plus pazopanib therapy for the treatment of cancer.""",13\r\n272,"""PAZOPANIB""","""COMBINATION THERAPY""","""Pazopanib is used in combination therapy to treat the disease.""",13\r\n274,"""PAZOPANIB""","""AFATINIB""","""Pazopanib and Afatinib are both targeted therapies used to treat breast cancer, with Pazopanib showing a higher rate of serious adverse events than Afatinib.""",10\r\n276,"""PAZOPANIB""","""JOHNSTON SR""","""Johnston SR is an author of a research paper on the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.""",10\r\n275,"""PAZOPANIB""","""SURVIVAL""","""Pazopanib is associated with a higher rate of serious adverse events, which can impact patient survival.""",10\r\n273,"""PAZOPANIB""","""LAPATINIB MONOTHERAPY""","""Pazopanib is used in lapatinib monotherapy to treat the disease.""",9\r\n283,"""AFATINIB""","""SURVIVAL""","""Afatinib is associated with a shorter survival time, which can impact patient outcomes.""",6\r\n354,"""MATRO JM""","""HUGHES ME""","""Matro JM and Hughes ME are co-authors of a study on inflammatory breast cancer management.""",6\r\n352,"""MATRO JM""","""LI T""","""Matro JM and Li T are co-authors of a study on inflammatory breast cancer management.""",6\r\n355,"""MATRO JM""","""OTTESEN RA""","""Matro JM and Ottesen RA are co-authors of a study on inflammatory breast cancer management.""",6\r\n356,"""MATRO JM""","""WEEKS JC""","""Matro JM and Weeks JC are co-authors of a study on inflammatory breast cancer management.""",6\r\n281,"""LAPATINIB MONOTHERAPY""","""DISEASE""","""Lapatinib monotherapy is used to treat the disease.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:37,440 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 5/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:37,441 graphrag.index.graph.extractors.community_reports.community_reports_extractor ERROR error generating community report
Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\graph\extractors\community_reports\community_reports_extractor.py", line 58, in __call__
    await self._llm(
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\json_parsing_llm.py", line 34, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_token_replacing_llm.py", line 37, in __call__
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_history_tracking_llm.py", line 33, in __call__
    output = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\caching_llm.py", line 104, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 177, in __call__
    result, start = await execute_with_retry()
                    ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 159, in execute_with_retry
    async for attempt in retryer:
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\_asyncio.py", line 71, in __anext__
    do = self.iter(retry_state=self._retry_state)
         ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 325, in iter
    raise retry_exc.reraise()
          ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 158, in reraise
    raise self.last_attempt.result()
          ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 449, in result
    return self.__get_result()
           ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 401, in __get_result
    raise self._exception
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 165, in execute_with_retry
    return await do_attempt(), start
           ^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 151, in do_attempt
    await sleep_for(sleep_time)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 147, in do_attempt
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 48, in __call__
    return await self._invoke_json(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 82, in _invoke_json
    result = await generate()
             ^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 74, in generate
    await self._native_json(input, **{**kwargs, "name": call_name})
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 96, in _native_json
    result = await self._invoke(
             ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 53, in _invoke
    output = await self._execute_llm(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 55, in _execute_llm
    completion = await self.client.chat.completions.create(
                 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\resources\chat\completions.py", line 1289, in create
    return await self._post(
           ^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1826, in post
    return await self.request(cast_to, opts, stream=stream, stream_cls=stream_cls)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1519, in request
    return await self._request(
           ^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1620, in _request
    raise self._make_status_error_from_response(err.response) from None
openai.RateLimitError: Error code: 429 - {'error': {'message': 'Rate limit reached for model `llama3-8b-8192` in organization `org_01j1m7ha6hevrb19g7knxdmps3` on tokens per minute (TPM): Limit 30000, Used 30836, Requested 6021. Please try again in 13.715s. Visit https://console.groq.com/docs/rate-limits for more information.', 'type': 'tokens', 'code': 'rate_limit_exceeded'}}
13:02:37,446 graphrag.index.reporting.file_workflow_callbacks INFO Community Report Extraction Error details=None
13:02:37,446 graphrag.index.verbs.graph.report.strategies.graph_intelligence.run_graph_intelligence WARNING No report found for community: 2
13:02:37,482 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:37,483 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n475,"""BUZDAR AU""","Here is a comprehensive summary of the data:\n\nBuzdar AU is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Buzdar AU has authored research papers and studies on combined-modality treatment of inflammatory breast carcinoma, inflammatory breast cancer, breast cancer, and paclitaxel\'s impact on improving the prognosis in estrogen receptor negative inflammatory breast cancer. These publications demonstrate Buzdar AU\'s expertise and dedication to advancing our understanding of breast cancer, particularly in the context of inflammatory breast carcinoma and the role of paclitaxel in treatment outcomes.",3\r\n474,"""UENO NT""","Here is a comprehensive summary of the data:\n\nUeno NT is a researcher who has authored several studies and research papers on breast cancer. Specifically, they have published papers on combined-modality treatment of inflammatory breast carcinoma, gene expression profiles of inflammatory breast cancer, and inflammatory breast cancer itself. Additionally, they have conducted a study on early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.",10\r\n559,"""BERTUCCI F""","Here is a comprehensive summary of the data:\n\nBertucci F is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Bertucci F has authored research papers and studies on inflammatory breast cancer, a type of breast cancer characterized by rapid growth and spread of cancer cells. The studies conducted by Bertucci F have focused on various aspects of inflammatory breast cancer, including the expression of PDL1, a protein that plays a crucial role in the immune response to cancer. Additionally, Bertucci F has explored the effectiveness of high-dose chemotherapy and haematopoietic stem cell transplantation as a treatment option for inflammatory breast cancer, examining the relationship between pathologic response and outcome. Furthermore, Bertucci F has authored multiple studies on breast cancer treatment, demonstrating a broad range of expertise in the field. Overall, Bertucci F\'s work has shed light on the complexities of inflammatory breast cancer and has contributed to the development of more effective treatment strategies for this aggressive form of breast cancer.",7\r\n565,"""FINETTI P""","Here is a comprehensive summary of the data:\n\nFinetti P is a researcher who has made significant contributions to the field of inflammatory breast cancer. Specifically, Finetti P is an author of two research papers: one on the gene expression profiles of inflammatory breast cancer and another on the expression of PDL1 in inflammatory breast cancer. These studies demonstrate Finetti P\'s expertise in the area of inflammatory breast cancer and highlight their role as a leading researcher in the field.",5\r\n567,"""LUCCI A""","Here is a comprehensive summary of the data:\n\nLUCCI A is a researcher who has made significant contributions to the field of breast cancer research. Specifically, LUCCI A is an author of two research papers. The first paper focuses on the gene expression profiles of inflammatory breast cancer, providing valuable insights into the molecular mechanisms underlying this aggressive form of breast cancer. The second paper investigates the limited efficacy and significant toxicities of lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive inflammatory breast cancer patients. This research highlights the importance of exploring alternative treatment options for this patient population.",5\r\n568,"""ROBERTSON FM""","""Robertson FM is an author of a research paper on gene expression profiles of inflammatory breast cancer.""",5\r\n566,"""VERMEULEN P""","""Vermeulen P is an author of a research paper on gene expression profiles of inflammatory breast cancer.""",5\r\n476,"""SINGLETARY SE""","Here is a comprehensive summary of the data:\n\nSingletary SE is a renowned author who has made significant contributions to the field of breast cancer research. Specifically, Singletary SE has authored research papers on combined-modality treatment of inflammatory breast carcinoma, as well as studies on inflammatory breast cancer and breast cancer in general.",2\r\n477,"""AMES""","""Ames is an author of a study on breast cancer.""",1\r\n494,"""CANCER CHEMOTHER PHARMACOL""","Here is a comprehensive summary of the data:\n\nCancer Chemother Pharmacol is a journal that publishes research papers on breast cancer. The publication features research on breast cancer, providing a platform for scholars and experts to share their findings and contribute to the advancement of knowledge in this field.",6\r\n560,"""ESPINOSA FERNANDEZ""","""Espinosa Fernandez is an author of a research paper on inflammatory breast cancer.""",1\r\n482,"""AMES FC""","Here is a comprehensive summary of the data:\n\nAmes FC is an author of research papers on inflammatory breast cancer. Specifically, Ames FC has written papers on combined-modality treatment of inflammatory breast carcinoma and inflammatory breast cancer.",1\r\n495,"""FRYE D""","""Frye D is an author of a research paper on inflammatory breast cancer.""",1\r\n483,"""MCNEESE MD""","Here is a comprehensive summary of the data:\n\nMcNeese MD is a researcher who has authored research papers on inflammatory breast carcinoma. Specifically, McNeese MD has written papers on the combined-modality treatment of inflammatory breast carcinoma, as well as inflammatory breast cancer in general.",1\r\n491,"""KOH EH""","Here is a comprehensive summary of the data:\n\nKoh EH is an author of research papers related to inflammatory breast cancer. Specifically, Koh EH has written papers on combined-modality treatment of inflammatory breast carcinoma and inflammatory breast cancer.",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n358,"""CRISTOFANILLI M""","""BUZDAR AU""","""Cristofanilli M and Buzdar AU are co-authors of a study on paclitaxel improving the prognosis in estrogen receptor negative inflammatory breast cancer.""",21\r\n419,"""UENO NT""","""J CLIN ONCOL""","""Ueno NT is an author of a research paper published in J Clin Oncol.""",20\r\n420,"""UENO NT""","""BERTUCCI F""","""Bertucci F and Ueno NT are co-authors of a research paper on inflammatory breast cancer.""",17\r\n421,"""UENO NT""","""FINETTI P""","""Ueno NT and Finetti P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n423,"""UENO NT""","""LUCCI A""","""Ueno NT and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n424,"""UENO NT""","""ROBERTSON FM""","""Ueno NT and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n422,"""UENO NT""","""VERMEULEN P""","""Ueno NT and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",15\r\n425,"""UENO NT""","""MATSUDA N""","""Matsuda N and Ueno NT are co-authors of a study on early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.""",15\r\n487,"""BERTUCCI F""","""GONCALVES A""","Here is a comprehensive summary of the data:\n\nGoncalves A and Bertucci F are co-authors of multiple studies related to breast cancer. Specifically, they have collaborated on research focused on inflammatory breast cancer and breast cancer treatment.",14\r\n416,"""UENO NT""","""BUZDAR AU""","""Ueno NT and Buzdar AU are co-authors of a study on breast cancer.""",13\r\n483,"""BERTUCCI F""","""FINETTI P""","""Bertucci F and Finetti P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n484,"""BERTUCCI F""","""VERMEULEN P""","""Bertucci F and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n485,"""BERTUCCI F""","""LUCCI A""","""Bertucci F and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n486,"""BERTUCCI F""","""ROBERTSON FM""","""Bertucci F and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",12\r\n417,"""UENO NT""","""SINGLETARY SE""","""Ueno NT and Singletary SE are co-authors of a study on breast cancer.""",12\r\n418,"""UENO NT""","""AMES""","""Ueno NT and Ames are co-authors of a study on breast cancer.""",11\r\n493,"""FINETTI P""","""VERMEULEN P""","""Finetti P and Vermeulen P are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n494,"""FINETTI P""","""LUCCI A""","""Finetti P and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n495,"""FINETTI P""","""ROBERTSON FM""","""Finetti P and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n498,"""LUCCI A""","""ROBERTSON FM""","""Lucci A and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n496,"""VERMEULEN P""","""LUCCI A""","""Vermeulen P and Lucci A are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n497,"""VERMEULEN P""","""ROBERTSON FM""","""Vermeulen P and Robertson FM are co-authors of a research paper on gene expression profiles of inflammatory breast cancer.""",10\r\n426,"""BUZDAR AU""","""CANCER CHEMOTHER PHARMACOL""","""Buzdar AU is an author of a research paper published in Cancer Chemother Pharmacol.""",9\r\n482,"""BERTUCCI F""","""ESPINOSA FERNANDEZ""","""Bertucci F and Espinosa Fernandez are co-authors of a research paper on inflammatory breast cancer.""",8\r\n427,"""SINGLETARY SE""","""CANCER CHEMOTHER PHARMACOL""","""Singletary SE is an author of a research paper published in Cancer Chemother Pharmacol.""",8\r\n434,"""AMES FC""","""CANCER CHEMOTHER PHARMACOL""","""Ames FC is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n438,"""CANCER CHEMOTHER PHARMACOL""","""FRYE D""","""Frye D is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n435,"""MCNEESE MD""","""CANCER CHEMOTHER PHARMACOL""","""McNeese MD is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n437,"""KOH EH""","""CANCER CHEMOTHER PHARMACOL""","""Koh EH is an author of a research paper published in Cancer Chemother Pharmacol.""",7\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:37,483 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 5/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:37,484 graphrag.index.graph.extractors.community_reports.community_reports_extractor ERROR error generating community report
Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\graph\extractors\community_reports\community_reports_extractor.py", line 58, in __call__
    await self._llm(
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\json_parsing_llm.py", line 34, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_token_replacing_llm.py", line 37, in __call__
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_history_tracking_llm.py", line 33, in __call__
    output = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\caching_llm.py", line 104, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 177, in __call__
    result, start = await execute_with_retry()
                    ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 159, in execute_with_retry
    async for attempt in retryer:
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\_asyncio.py", line 71, in __anext__
    do = self.iter(retry_state=self._retry_state)
         ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 325, in iter
    raise retry_exc.reraise()
          ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 158, in reraise
    raise self.last_attempt.result()
          ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 449, in result
    return self.__get_result()
           ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 401, in __get_result
    raise self._exception
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 165, in execute_with_retry
    return await do_attempt(), start
           ^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 151, in do_attempt
    await sleep_for(sleep_time)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 147, in do_attempt
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 48, in __call__
    return await self._invoke_json(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 82, in _invoke_json
    result = await generate()
             ^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 74, in generate
    await self._native_json(input, **{**kwargs, "name": call_name})
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 96, in _native_json
    result = await self._invoke(
             ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 53, in _invoke
    output = await self._execute_llm(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 55, in _execute_llm
    completion = await self.client.chat.completions.create(
                 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\resources\chat\completions.py", line 1289, in create
    return await self._post(
           ^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1826, in post
    return await self.request(cast_to, opts, stream=stream, stream_cls=stream_cls)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1519, in request
    return await self._request(
           ^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1620, in _request
    raise self._make_status_error_from_response(err.response) from None
openai.RateLimitError: Error code: 429 - {'error': {'message': 'Rate limit reached for model `llama3-8b-8192` in organization `org_01j1m7ha6hevrb19g7knxdmps3` on tokens per minute (TPM): Limit 30000, Used 30817, Requested 4820. Please try again in 11.274s. Visit https://console.groq.com/docs/rate-limits for more information.', 'type': 'tokens', 'code': 'rate_limit_exceeded'}}
13:02:37,488 graphrag.index.reporting.file_workflow_callbacks INFO Community Report Extraction Error details=None
13:02:37,488 graphrag.index.verbs.graph.report.strategies.graph_intelligence.run_graph_intelligence WARNING No report found for community: 6
13:02:37,996 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:37,999 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n418,"""VIENS P""","Here is a comprehensive summary of the data:\n\nVIENS P is a renowned researcher who has made significant contributions to the field of breast cancer treatment. Specifically, VIENS P was an author of several studies on breast cancer treatment, including a consensus statement for standardized diagnosis and treatment of inflammatory breast cancer. Additionally, VIENS P conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer, examining pathologic response and outcome. VIENS P\'s work has shed light on the diagnosis and treatment of inflammatory breast cancer, a rare and aggressive form of breast cancer.",7\r\n416,"""DAWOOD S""","Here is a comprehensive summary of the data:\n\nDawood S is a person who has made significant contributions to the field of inflammatory breast cancer. Specifically, Dawood S is an author of multiple studies on the topic, including a study on the standardized diagnosis and treatment of inflammatory breast cancer, as well as a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer. These studies demonstrate Dawood S\'s expertise and research focus on inflammatory breast cancer, and highlight their role as a leading authority in the field.",4\r\n598,"""PALANGIE T""","Here is a comprehensive summary of the data:\n\nPalangie T is an author of multiple studies related to inflammatory breast cancer. Specifically, Palangie T has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as a broader study on inflammatory breast cancer.",4\r\n603,"""BEUZEBOC P""","Here is a comprehensive summary of the data:\n\nBeuzeboc P is an author who has contributed to multiple studies in the field of breast cancer. Specifically, they have authored a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer. Additionally, they have also authored a study on inflammatory breast cancer, highlighting their expertise and research focus in this area.",2\r\n602,"""DELOZIER T""","Here is a comprehensive summary of the data:\n\nDelozier T is an author of multiple studies related to inflammatory breast cancer. Specifically, Delozier T has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as a broader study on inflammatory breast cancer.",2\r\n505,"""PENAULT-LLORCA F""","Here is a comprehensive summary of the data:\n\nPenault-Llorca F is a researcher who has made significant contributions to the field of early breast cancer diagnosis, treatment, and follow-up. Specifically, she has been involved in the development of ESMO Clinical Practice Guidelines for these areas. Additionally, she has authored a study on the use of high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer, examining the pathologic response and outcome of this treatment approach.",2\r\n601,"""ROCHE H""","Here is a comprehensive summary of the data:\n\nRoche H is a researcher who has authored studies on inflammatory breast cancer. Specifically, Roche H has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as on inflammatory breast cancer in general.",2\r\n502,"""CARDOSO F""","""Cardoso F is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",5\r\n503,"""KYRIAKIDES S""","""Kyriakides S is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n504,"""OHNO S""","""Ohno S is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n506,"""POORTMANS P""","""Poortmans P is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n507,"""RUBIO IT""","""Rubio IT is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n634,"""BROGLIO K""","""Broglio K is an author of a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer.""",1\r\n417,"""MERAJVER SD""","Here is a comprehensive summary of the data:\n\nMerajver SD is a notable figure in the field of inflammatory breast cancer research. As a contributor to the consensus statement for standardized diagnosis and treatment of inflammatory breast cancer, Merajver SD played a crucial role in shaping the understanding and management of this disease. Additionally, Merajver SD is also an author of a study on inflammatory breast cancer, further solidifying their expertise and contributions to the field.",1\r\n419,"""VERMEULEN PB""","Here is a comprehensive summary of the data:\n\nVermeulen PB is a person who has made significant contributions to the field of inflammatory breast cancer. Specifically, they were a key contributor to the development of a consensus statement for standardized diagnosis and treatment of inflammatory breast cancer. Additionally, Vermeulen PB is also an author of a study on inflammatory breast cancer, further demonstrating their expertise and research in this area.",1\r\n609,"""DIERAS V""","""Dieras V is an author of a study on inflammatory breast cancer.""",1\r\n610,"""DORVAL T""","""Dorval T is an author of a study on inflammatory breast cancer.""",1\r\n599,"""JANVIER M""","Here is a comprehensive summary of the data:\n\nJanvier M is an author of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\n\nNote: Since there is only one description provided, the summary is straightforward and concise.",2\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n342,"""VIENS P""","""GONCALVES A""","""Goncalves A and Viens P are co-authors of several studies on breast cancer treatment.""",14\r\n334,"""DAWOOD S""","""VIENS P""","""Dawood S and Viens P are co-authors of a study on inflammatory breast cancer.""",11\r\n338,"""VIENS P""","""PALANGIE T""","Here is a comprehensive summary of the data:\n\nPalangie T and Viens P are co-authors of two studies related to inflammatory breast cancer. The first study focuses on inflammatory breast cancer, while the second study explores first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\n\nNote: The descriptions are identical, except for the order of the authors\' names. This suggests that the two entities, Palangie T and Viens P, are co-authors of the same studies, and the descriptions are simply rephrased to reflect the different order of the authors\' names.",11\r\n341,"""VIENS P""","""BEUZEBOC P""","""Viens P and Beuzeboc P are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.""",9\r\n340,"""VIENS P""","""DELOZIER T""","""Viens P and Delozier T are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.""",9\r\n337,"""VIENS P""","""PENAULT-LLORCA F""","""Viens P and Penault-Llorca F are co-authors of a study on high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome.""",9\r\n339,"""VIENS P""","""ROCHE H""","""Viens P and Roche H are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.""",9\r\n447,"""CARDOSO F""","""PENAULT-LLORCA F""","""Cardoso F and Penault-Llorca F are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",7\r\n512,"""PALANGIE T""","""BEUZEBOC P""","""Palangie T and Beuzeboc P are co-authors of a study on inflammatory breast cancer.""",6\r\n445,"""CARDOSO F""","""KYRIAKIDES S""","""Cardoso F and Kyriakides S are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n446,"""CARDOSO F""","""OHNO S""","""Cardoso F and Ohno S are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n448,"""CARDOSO F""","""POORTMANS P""","""Cardoso F and Poortmans P are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n449,"""CARDOSO F""","""RUBIO IT""","""Cardoso F and Rubio IT are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n336,"""DAWOOD S""","""BROGLIO K""","""Dawood S and Broglio K are co-authors of a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer.""",5\r\n333,"""DAWOOD S""","""MERAJVER SD""","""Dawood S and Merajver SD are co-authors of a study on inflammatory breast cancer.""",5\r\n335,"""DAWOOD S""","""VERMEULEN PB""","""Dawood S and Vermeulen PB are co-authors of a study on inflammatory breast cancer.""",5\r\n513,"""PALANGIE T""","""DIERAS V""","""Palangie T and Dieras V are co-authors of a study on inflammatory breast cancer.""",5\r\n514,"""PALANGIE T""","""DORVAL T""","""Palangie T and Dorval T are co-authors of a study on inflammatory breast cancer.""",5\r\n516,"""JANVIER M""","""DELOZIER T""","""Janvier M and Delozier T are co-authors of a study on inflammatory breast cancer.""",4\r\n515,"""JANVIER M""","""ROCHE H""","""Janvier M and Roche H are co-authors of a study on inflammatory breast cancer.""",4\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:38,0 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 3/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:38,554 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:38,557 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n459,"""CLIN BREAST CANCER""","Based on the provided data, here is a comprehensive summary of the entity ""CLIN BREAST CANCER"":\n\nCLIN BREAST CANCER is a medical journal that publishes research on breast cancer, specifically focusing on the management of inflammatory breast cancer. The journal has published studies on various aspects of breast cancer, including a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. This treatment regimen involves pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, along with trastuzumab as preoperative treatment.",7\r\n669,"""CANCELLO G""","Here is a comprehensive summary of the data:\n\nCancello G is a researcher who has been involved in studies on inflammatory breast cancer. Specifically, Cancello G is an author of a study on a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. The treatment regimen consisted of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, plus trastuzumab, as preoperative treatment.",2\r\n670,"""DELLAPASQUA S""","Here is a comprehensive summary of the data:\n\nDellapasqua S is a researcher who has been involved in studies on inflammatory breast cancer. Specifically, Dellapasqua S is an author of a study on a phase II trial of a combination treatment for locally advanced and inflammatory breast cancer. The treatment regimen consisted of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil, plus trastuzumab, as preoperative treatment.",2\r\n815,"""BAGNARDI V""","""Bagnardi V is a researcher involved in studies on inflammatory breast cancer.""",1\r\n813,"""PALAZZO A""","""Palazzo A is a researcher involved in studies on inflammatory breast cancer.""",1\r\n814,"""MUNZONE E""","""Munzone E is a researcher involved in studies on inflammatory breast cancer.""",1\r\n816,"""MAZZA M""","""Mazza M is a researcher involved in studies on inflammatory breast cancer.""",1\r\n667,"""TORRISI R""","""Torrisi R is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",5\r\n671,"""BALDUZZI A""","""Balduzzi A is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n668,"""CARDILLO A""","""Cardillo A is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n672,"""GHISINI R""","""Ghisini R is an author of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n398,"""CLIN BREAST CANCER""","""PIERGA JY""","""Pierga JY published a study in Clin Breast Cancer on inflammatory breast cancer.""",20\r\n397,"""CLIN BREAST CANCER""","""CANCELLO G""","""Cancello G published a study in Clin Breast Cancer on inflammatory breast cancer.""",9\r\n393,"""CLIN BREAST CANCER""","""DELLAPASQUA S""","""Dellapasqua S published a study in Clin Breast Cancer on inflammatory breast cancer.""",9\r\n395,"""CLIN BREAST CANCER""","""BAGNARDI V""","""Bagnardi V published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n392,"""CLIN BREAST CANCER""","""PALAZZO A""","""Palazzo A published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n394,"""CLIN BREAST CANCER""","""MUNZONE E""","""Munzone E published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n396,"""CLIN BREAST CANCER""","""MAZZA M""","""Mazza M published a study in Clin Breast Cancer on inflammatory breast cancer.""",8\r\n573,"""TORRISI R""","""CANCELLO G""","""Torrisi R and Cancello G are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",7\r\n574,"""TORRISI R""","""DELLAPASQUA S""","""Torrisi R and Dellapasqua S are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",7\r\n575,"""TORRISI R""","""BALDUZZI A""","""Torrisi R and Balduzzi A are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n572,"""TORRISI R""","""CARDILLO A""","""Torrisi R and Cardillo A are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n576,"""TORRISI R""","""GHISINI R""","""Torrisi R and Ghisini R are authors of a study on phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.""",6\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:38,558 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 5/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:38,558 graphrag.index.graph.extractors.community_reports.community_reports_extractor ERROR error generating community report
Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\graph\extractors\community_reports\community_reports_extractor.py", line 58, in __call__
    await self._llm(
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\json_parsing_llm.py", line 34, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_token_replacing_llm.py", line 37, in __call__
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_history_tracking_llm.py", line 33, in __call__
    output = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\caching_llm.py", line 104, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 177, in __call__
    result, start = await execute_with_retry()
                    ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 159, in execute_with_retry
    async for attempt in retryer:
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\_asyncio.py", line 71, in __anext__
    do = self.iter(retry_state=self._retry_state)
         ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 325, in iter
    raise retry_exc.reraise()
          ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 158, in reraise
    raise self.last_attempt.result()
          ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 449, in result
    return self.__get_result()
           ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 401, in __get_result
    raise self._exception
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 165, in execute_with_retry
    return await do_attempt(), start
           ^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 151, in do_attempt
    await sleep_for(sleep_time)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 147, in do_attempt
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 48, in __call__
    return await self._invoke_json(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 82, in _invoke_json
    result = await generate()
             ^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 74, in generate
    await self._native_json(input, **{**kwargs, "name": call_name})
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 96, in _native_json
    result = await self._invoke(
             ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 53, in _invoke
    output = await self._execute_llm(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 55, in _execute_llm
    completion = await self.client.chat.completions.create(
                 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\resources\chat\completions.py", line 1289, in create
    return await self._post(
           ^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1826, in post
    return await self.request(cast_to, opts, stream=stream, stream_cls=stream_cls)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1519, in request
    return await self._request(
           ^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1620, in _request
    raise self._make_status_error_from_response(err.response) from None
openai.RateLimitError: Error code: 429 - {'error': {'message': 'Rate limit reached for model `llama3-8b-8192` in organization `org_01j1m7ha6hevrb19g7knxdmps3` on tokens per minute (TPM): Limit 30000, Used 30278, Requested 3594. Please try again in 7.744s. Visit https://console.groq.com/docs/rate-limits for more information.', 'type': 'tokens', 'code': 'rate_limit_exceeded'}}
13:02:38,566 graphrag.index.reporting.file_workflow_callbacks INFO Community Report Extraction Error details=None
13:02:38,566 graphrag.index.verbs.graph.report.strategies.graph_intelligence.run_graph_intelligence WARNING No report found for community: 5
13:02:39,346 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:39,351 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n48,"""IBC""","Here is a comprehensive summary of the data provided:\n\nIBC stands for Inflammatory Breast Cancer, a type of breast cancer characterized by rapid onset and aggressive growth. It is a high-risk disease and a type of breast cancer that carries a high risk for recurrence. IBC is a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body, and is classified as a high-risk disease. It is characterized by inflammation and has been studied in the context of immunotherapy.\n\nIBC is a type of breast cancer that is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes. It is treated with various systemic treatments, including trastuzumab and pertuzumab, and may be treated with trastuzumab and lapatinib. IBC is also included in the KRISTINE trial and the NeoSphere trial.\n\nIBC is a type of breast cancer that is locally advanced and metastatic, and has poor outcomes. It is a type of breast cancer that is characterized by the presence of cancer cells in the milk ducts or lobules, and is included in the working group focused on inflammatory breast cancer, of which Vicente Valero is a member.\n\nIn summary, IBC is a type of breast cancer that is characterized by inflammation, is high-risk and recurrent, and is treated with various systemic treatments. It is associated with PD-L1 expression and has been studied in the context of brain metastasis and survival outcomes.",54\r\n85,"""PACLITAXEL""","Here is a comprehensive summary of the data provided:\n\n""PACLITAXEL"" is a chemotherapy agent used to treat breast cancer, specifically in the treatment of HER2-negative locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). It is a chemotherapy drug studied in various clinical trials and has been evaluated for its effectiveness in treating breast cancer. PACLITAXEL is used in combination with other medications, such as pembrolizumab, bevacizumab, trastuzumab, and lapatinib, to treat breast cancer. It is also used as a single agent in the treatment regimen for breast cancer. PACLITAXEL is a type of chemotherapy medication used in the treatment of breast cancer, and it is a treatment option for IBC patients.",8\r\n322,"""PD-L1""","Here is a comprehensive summary of the data:\n\nPD-L1 is a protein that plays a crucial role in immunotherapy, particularly in the context of inflammatory breast cancer (IBC). It is expressed on the surface of some cancer cells and is targeted by atezolizumab, a therapeutic agent. Additionally, PD-L1 is an immune checkpoint molecule found in tumor cells and TILs (tumor-infiltrating lymphocytes) of IBC. Furthermore, PD-L1 refers to a protein expressed on the surface of tumor cells that can inhibit the immune system\'s ability to recognize and attack cancer cells. Overall, PD-L1 is a key protein involved in the immune response to cancer, and its expression and function have significant implications for the development of effective cancer therapies.",7\r\n117,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","Here is a comprehensive summary of the data:\n\nHIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION is a treatment regimen for Inflammatory Breast Cancer (IBC).\n\nThis summary includes information from the provided description, which states that HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION is a treatment regimen for IBC.",4\r\n335,"""ARIAS-PULIDO ET AL.""","Here is a comprehensive summary of the data:\n\nArias-Pulido et al. is a research group that has made significant contributions to the field of cancer research. Specifically, they reported on the presence of PD-L1 positivity in tumor-infiltrating lymphocytes (TILs) and its association with better disease-free survival (DFS).",3\r\n336,"""BERCKELAER ET AL.""","Here is a comprehensive summary of the data:\n\nBerckelaer et al. is a research group that has reported on PD-L1 expression in TILs (Tumor-Infiltrating Lymphocytes).",3\r\n338,"""TILS""","Here is a comprehensive summary of the data:\n\nTILs (Tumor-Infiltrating Lymphocytes) are a type of immune cell that plays a crucial role in immunotherapy, particularly in the context of inflammatory breast cancer (IBC). They are more frequently found in IBC than in non-IBC, indicating a specific association with this type of cancer. TILs are associated with PD-L1 expression, which is linked to better disease-free survival (DFS). As immune cells found in the tumor microenvironment, TILs are an important component of the immune response against cancer.",3\r\n17,"""IMMUNOTHERAPY""","Here is a comprehensive summary of the data:\n\nImmunotherapy is a type of cancer treatment that uses the body\'s immune system to fight cancer. It is a type of systemic treatment that targets cancer cells and helps the body\'s immune system recognize and attack them. Specifically, immunotherapy is a treatment option for breast cancer, including inflammatory breast cancer (IBC). This type of treatment harnesses the body\'s natural defenses to combat cancer, making it a promising approach for cancer patients.",3\r\n86,"""FAC""","Here is a comprehensive summary of the data:\n\nFAC is a chemotherapy regimen used to treat breast cancer, as well as a technology used in clinical trials.",2\r\n343,"""I-SPY2""","Here is a comprehensive summary of the data:\n\n""I-SPY2"" is a clinical trial that combines chemotherapy and an immune checkpoint inhibitor for the treatment of Inflammatory Breast Cancer (IBC).",2\r\n75,"""RADIATION ONCOLOGIST""","Here is a comprehensive summary of the data:\n\nA radiation oncologist is a medical professional who specializes in the treatment of cancer using radiation therapy. They are a type of doctor who focuses on the use of radiation therapy to combat cancer.\n\nNote: I combined the two descriptions to create a single, coherent summary that includes all the relevant information.",2\r\n116,"""INTERNATIONAL EXPERT CONSENSUS""","Here is a comprehensive summary of the data:\n\nThe ""INTERNATIONAL EXPERT CONSENSUS"" refers to a collective agreement on the treatment of Inflammatory Breast Cancer (IBC).",2\r\n143,"""STANDARD OF CARE""","""Standard of Care refers to the accepted and widely used treatment approach for IBC.""",2\r\n342,"""KEYNOTE-522""","Here is a comprehensive summary of the data:\n\nKEYNOTE-522 is a clinical trial that combines chemotherapy and an immune checkpoint inhibitor for the treatment of Inflammatory Breast Cancer (IBC).",2\r\n87,"""ANTHRACYCLINE""","Here is a comprehensive summary of the data:\n\nAnthracycline is a chemotherapy agent used to treat breast cancer. It is a type of chemotherapy specifically designed to combat breast cancer.\n\nNote: I resolved the contradictions by combining the two descriptions into a single, coherent summary.",1\r\n252,"""ANTHRACYCLINE-BASED CHEMOTHERAPY""","""Anthracycline-based Chemotherapy is a type of chemotherapy used in the treatment of IBC.""",1\r\n347,"""ANTI-EGFR AGENT""","""Anti-EGFR agents are a type of targeted therapy that targets the EGFR protein, which is overexpressed in IBC.""",1\r\n348,"""ANTIPD-L1 ANTIBODY""","""Anti-PD-L1 antibodies are a type of immune checkpoint inhibitor that helps the immune system fight cancer, including IBC.""",1\r\n353,"""BC""",No Description,1\r\n334,"""BERTUCCI ET AL.""","""Bertucci et al. is a research group that reported PD-L1 overexpression in breast cancer tumors.""",1\r\n215,"""CARBOPLATIN""","Here is a comprehensive summary of the data:\n\nCarboplatin is a chemotherapy agent used in the treatment of various types of cancer, including breast cancer and inflammatory breast cancer (IBC). It is a chemotherapy drug that is often used in combination with other medications to treat cancer. Specifically, Carboplatin is used in the treatment of breast cancer, and it is also used to treat IBC. Additionally, it is classified as a type of cancer treatment and a type of chemotherapy used in the treatment of IBC. Overall, Carboplatin is a medication used in cancer treatment, specifically in the treatment of breast cancer and IBC.",1\r\n80,"""CHEMOTHERAPY""","Here is a comprehensive summary of the data:\n\nChemotherapy is a type of systemic treatment that uses chemicals to kill cancer cells, including those associated with breast cancer, including inflammatory breast cancer (IBC). It is a treatment option for breast cancer, including IBC, and is evaluated in clinical trials for its effectiveness in treating the disease. Specifically, chemotherapy is combined with T-DM1 in the TCHP regimen, a treatment approach that has shown promise in the fight against breast cancer. Overall, chemotherapy is a widely used and effective treatment for breast cancer, including IBC, that has been shown to be effective in clinical trials and is often used in combination with other treatments.",1\r\n74,"""DIAGNOSTIC RADIOLOGIST""","""Diagnostic radiologist is a type of doctor who specializes in the interpretation of imaging tests.""",1\r\n89,"""DITSCH ET AL.""","""Ditsch et al. are researchers who conducted a study on chemotherapy dose intensity in IBC patients.""",1\r\n88,"""FAC REGIMEN""","""FAC regimen is a chemotherapy treatment protocol.""",1\r\n71,"""MEDICAL ONCOLOGIST""","""Medical oncologist is a type of doctor who specializes in cancer treatment.""",1\r\n72,"""SURGEON""","""Surgeon is a type of doctor who specializes in surgical procedures.""",1\r\n73,"""PATHOLOGIST""","""Pathologist is a type of doctor who specializes in the diagnosis of diseases through the examination of tissues and cells.""",1\r\n84,"""MD ANDERSON""",No Description,1\r\n106,"""NON-IBC""","Here is a comprehensive summary of the data:\n\nNon-IBC (Non-Inflammatory Breast Cancer) refers to a type of breast cancer that is not Inflammatory Breast Cancer (IBC). Notably, Non-IBC has a similar pathological complete response (pCR) rate to ER-negative IBC, indicating that it shares some similarities with IBC in terms of treatment outcomes.",1\r\n285,"""TALIMOGENE LAHERPAREPVEC""","Here is a comprehensive summary of the data:\n\nTalimogene laherparepvec is a treatment regimen. Specifically, it is a treatment regimen for local recurrence IBC (inflammatory breast cancer) or inoperable non-IBC (non-inflammatory breast cancer).",1\r\n319,"""MULTIDISCIPLINARY TEAM""","Here is a comprehensive summary of the data:\n\nThe MULTIDISCIPLINARY TEAM is a group of healthcare professionals who work together to provide comprehensive care for patients with breast cancer. This team of experts evaluates and treats patients with breast cancer, offering a collaborative approach to patient care.",1\r\n346,"""IMMUNE CHECKPOINT INHIBITOR""","""Immune checkpoint inhibitors are a type of treatment that helps the immune system fight cancer, including IBC.""",1\r\n351,"""LAABC""","""LAABC is a type of breast cancer that is different from IBC.""",1\r\n352,"""LA BC""","""LA BC is an abbreviation for Localized Adenocarcinoma Breast Cancer, a type of breast cancer.""",1\r\n38,"""TUMOR EMBOLI""","Here is a comprehensive summary of the data:\n\nTumor emboli refer to the presence of tumor cells in the lymphatic vessels, which may be present or absent in biopsy specimens.",1\r\n41,"""LYMPHEDEMA""","""Lymphedema is a condition characterized by swelling caused by tumor emboli within dermal lymphatics.""",1\r\n90,"""ESTROGEN RECEPTOR""",No Description,1\r\n121,"""CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH""","""Center for International Blood and Marrow Transplant Research is an organization that conducts research on blood and marrow transplants.""",1\r\n120,"""INTERNATIONAL BLOOD AND MARROW TRANSPLANT REGISTRY""","""International Blood and Marrow Transplant Registry is an organization that tracks and reports on blood and marrow transplant data.""",1\r\n18,"""ONGOING IBC CLINICAL TRIALS""","""Ongoing IBC Clinical Trials refer to current research studies investigating new treatments for IBC.""",1\r\n96,"""G-CSF""","Here is a comprehensive summary of the data:\n\nG-CSF is a medication used to support the treatment regimen, specifically in clinical trials for the treatment of HER2-negative (HER2-) Locally Advanced Breast Cancer (LABC) or Inflammatory Breast Cancer (IBC). It is a growth factor used to support the dose-dense chemotherapy regimen, as well as to support the growth of white blood cells during chemotherapy. Additionally, G-CSF is a technology used in clinical trials, highlighting its role in the development and evaluation of new treatments. Overall, G-CSF plays a crucial role in supporting patients undergoing chemotherapy, particularly those with HER2- LABC or IBC, and is an important component of clinical trials aimed at improving treatment outcomes.",1\r\n78,"""TEAM""","""Team is a group of medical professionals working together to improve the survival of IBC.""",1\r\n144,"""RANDOMIZED TRIALS""","""Randomized Trials are studies that compare the effectiveness of different treatment approaches for IBC.""",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n72,"""IBC""","""TRASTUZUMAB""","""Trastuzumab is used in the treatment of IBC, a type of breast cancer.""",69\r\n30,"""BREAST CANCER""","""IBC""","""IBC is a subtype of Breast Cancer that requires specific treatment.""",63\r\n52,"""IBC""","""PCR""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) patients who achieve pCR (Pathological Complete Response) have better survival outcomes than those who do not. pCR is a measure of the effectiveness of treatment for IBC, indicating that the treatment has successfully eliminated all cancer cells from the breast tissue.",62\r\n62,"""IBC""","""PACLITAXEL""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) is a type of breast cancer that can be treated with Paclitaxel, a chemotherapy medication. According to the descriptions, Paclitaxel is used as part of a neoadjuvant regimen to treat IBC patients, and it is also used to treat IBC patients directly. Additionally, Paclitaxel is used to treat IBC, a type of breast cancer. Overall, Paclitaxel is a treatment option for IBC patients, and its use is likely part of a comprehensive treatment plan that may include other medications and therapies.",62\r\n75,"""IBC""","""NERATINIB""","""Neratinib is used in adjuvant therapy for high-risk recurrent disease like IBC.""",62\r\n40,"""SYSTEMIC TREATMENT""","""IBC""","""IBC is treated with systemic treatment, including chemotherapy and targeted therapy.""",62\r\n53,"""IBC""","""OS""","""IBC patients have poor overall survival rates, with a 5-year OS rate of less than 5%.""",61\r\n89,"""IBC""","""PD-L1""","""IBC is associated with PD-L1, an immune checkpoint molecule found in tumor cells and TILs.""",61\r\n91,"""IBC""","""INSTITUTE""","""Institute demonstrates IBC preclinical data supporting a combination of targeted therapy and an immune checkpoint inhibitor.""",61\r\n85,"""IBC""","""PEMBROLIZUMAB""","""Pembrolizumab is used in the treatment of IBC, a type of breast cancer characterized by rapid onset and aggressive growth.""",60\r\n74,"""IBC""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of a neoadjuvant treatment for IBC patients, which is a high-risk disease.""",59\r\n67,"""IBC""","""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""High-dose chemotherapy with autologous hematopoietic stem cell transplantation is a treatment option for IBC.""",58\r\n73,"""IBC""","""NEOSPHERE TRIAL""","""The NeoSphere trial included 29 IBC patients.""",58\r\n76,"""IBC""","""PANITUMUMAB""","""Panitumumab is used in certain circumstances for IBC cases, targeting EGFR expression.""",58\r\n77,"""IBC""","""EGFR""","""EGFR expression is associated with worse prognosis in IBC cases.""",58\r\n78,"""IBC""","""HER2+ IBC""","""HER2+ IBC is a subtype of IBC.""",58\r\n88,"""IBC""","""ARIAS-PULIDO ET AL.""","""Arias-Pulido et al. studied PD-L1 positivity in IBC samples.""",57\r\n87,"""IBC""","""BERCKELAER ET AL.""","""Berckelaer et al. studied PD-L1 expression in TILs in the context of IBC.""",57\r\n71,"""IBC""","""LABC""","""LABC includes IBC, a type of breast cancer with high-risk characteristics.""",57\r\n90,"""IBC""","""TILS""","Here is a comprehensive summary of the data:\n\nThe entities ""IBC"" and ""TILs"" are related to each other. TILs (Tumor-Infiltrating Lymphocytes) are found in the tumor microenvironment of IBC (Invasive Breast Cancer). Additionally, TILs are more frequently found in IBC compared to non-IBC.",57\r\n3,"""VICENTE VALERO""","""IBC""","""Vicente Valero is a member of the IBC working group.""",57\r\n43,"""IMMUNOTHERAPY""","""IBC""","Here is a comprehensive summary of the data:\n\nIMMUNOTHERAPY is a potential treatment option for Inflammatory Breast Cancer (IBC).",57\r\n63,"""IBC""","""FAC""","""FAC is used to treat IBC patients.""",56\r\n93,"""IBC""","""I-SPY2""","""IBC is the disease being treated in the I-SPY2 clinical trial.""",56\r\n58,"""IBC""","""RADIATION ONCOLOGIST""","""Radiation oncologists are part of a multidisciplinary team that treats IBC patients.""",56\r\n61,"""IBC""","""CRISTOFANILLI ET AL.""","""Cristofanilli et al. conducted a study on IBC patients.""",56\r\n68,"""IBC""","""INTERNATIONAL EXPERT CONSENSUS""","""International Expert Consensus provides guidance on the treatment of IBC.""",56\r\n70,"""IBC""","""STANDARD OF CARE""","""IBC is treated according to the Standard of Care, which involves the use of various therapies, including chemotherapy and transplantation.""",56\r\n79,"""IBC""","""TARGETED THERAPY""","""Targeted Therapy is a treatment option for IBC.""",56\r\n81,"""IBC""","""TAXANE-BASED CHEMOTHERAPY""","""Taxane-based Chemotherapy is used in the treatment of IBC.""",56\r\n92,"""IBC""","""KEYNOTE-522""","""IBC is the disease being treated in the KEYNOTE-522 clinical trial.""",56\r\n64,"""IBC""","""ANTHRACYCLINE""","""Anthracycline is used to treat IBC patients.""",55\r\n80,"""IBC""","""ANTHRACYCLINE-BASED CHEMOTHERAPY""","""Anthracycline-based Chemotherapy is used in the treatment of IBC.""",55\r\n95,"""IBC""","""ANTI-EGFR AGENT""","""Anti-EGFR agents are a potential treatment for IBC.""",55\r\n96,"""IBC""","""ANTIPD-L1 ANTIBODY""","""Anti-PD-L1 antibodies are a potential treatment for IBC.""",55\r\n98,"""IBC""","""BC""","""BC is related to IBC as a medical organization or institution may be involved in the study and treatment of IBC.""",55\r\n86,"""IBC""","""BERTUCCI ET AL.""","""Bertucci et al. reported PD-L1 overexpression in IBC tumors.""",55\r\n82,"""IBC""","""CARBOPLATIN""","""Carboplatin is used in the treatment of IBC.""",55\r\n60,"""IBC""","""CHEMOTHERAPY""","Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) is a type of breast cancer that can be treated with chemotherapy. According to the descriptions, chemotherapy is a potential treatment option for IBC, and it has been reported to be effective in treating the disease. Specifically, chemotherapy has been used to treat IBC with a reported objective response rate of 74% and a median overall survival (OS) of 37 months.",55\r\n57,"""IBC""","""DIAGNOSTIC RADIOLOGIST""","""Diagnostic radiologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n66,"""IBC""","""DITSCH ET AL.""","""Ditsch et al. conducted a study on chemotherapy dose intensity in IBC patients.""",55\r\n65,"""IBC""","""FAC REGIMEN""","""FAC regimen is used to treat IBC, a type of breast cancer.""",55\r\n54,"""IBC""","""MEDICAL ONCOLOGIST""","""Medical oncologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n55,"""IBC""","""SURGEON""","""Surgeons are part of a multidisciplinary team that treats IBC patients.""",55\r\n56,"""IBC""","""PATHOLOGIST""","""Pathologists are part of a multidisciplinary team that treats IBC patients.""",55\r\n59,"""IBC""","""MD ANDERSON""","""MD Anderson conducted a retrospective study on IBC patients, providing insights into the treatment of IBC.""",55\r\n69,"""IBC""","""NON-IBC""","""IBC and non-IBC are compared in terms of OS rate and outcomes.""",55\r\n83,"""IBC""","""TALIMOGENE LAHERPAREPVEC""","""Talimogene laherparepvec is a treatment for IBC patients, specifically for TNBC patients.""",55\r\n84,"""IBC""","""MULTIDISCIPLINARY TEAM""","""The Multidisciplinary team evaluates and treats patients with IBC, a type of breast cancer that is invasive and has spread to the lymph nodes or other parts of the body.""",55\r\n94,"""IBC""","""IMMUNE CHECKPOINT INHIBITOR""","""Immune checkpoint inhibitors are a potential treatment for IBC.""",55\r\n97,"""IBC""","""LAABC""","""LAABC is different from IBC.""",55\r\n99,"""IBC""","""LA BC""","""IBC is distinct from LA BC as a unique entity with different characteristics and treatment approaches.""",55\r\n46,"""TUMOR EMBOLI""","""IBC""","""IBC is characterized by the presence of tumor emboli in dermal lymphatics, which may be present or absent in biopsy specimens.""",55\r\n47,"""LYMPHEDEMA""","""IBC""","""IBC is characterized by lymphedema caused by tumor emboli within dermal lymphatics.""",55\r\n143,"""PACLITAXEL""","""TRASTUZUMAB""","""Trastuzumab is combined with paclitaxel in a treatment for breast cancer.""",23\r\n142,"""PACLITAXEL""","""LAPATINIB""","Here is a comprehensive summary of the data:\n\nPACLITAXEL and LAPATINIB are two medications used in cancer treatment. Specifically, they are combined in a treatment for breast cancer, where LAPATINIB is paired with PACLITAXEL to provide a comprehensive treatment approach. Additionally, both medications have different effects on the pCR (pathological complete response) rate, indicating that they have distinct mechanisms of action in cancer treatment.",20\r\n140,"""PACLITAXEL""","""NAC""","""Paclitaxel is part of the NAC regimen.""",19\r\n164,"""NAC""","""PD-L1""","""NAC is associated with PD-L1 expression in breast cancer.""",18\r\n144,"""PACLITAXEL""","""BEVACIZUMAB""","""Paclitaxel is used in certain circumstances with bevacizumab for metastatic breast cancer.""",16\r\n129,"""OS""","""PD-L1""","""PD-L1 expression in tumor cells is associated with worse overall survival in breast cancer patients.""",14\r\n141,"""PACLITAXEL""","""OVERMOYER ET AL.""","""Overmoyer et al. reported the efficacy of neoadjuvant weekly paclitaxel combined with pertuzumab and trastuzumab.""",13\r\n134,"""HER2""","""PD-L1""","""HER2 is associated with PD-L1 expression in breast cancer.""",13\r\n27,"""BREAST CANCER""","""IMMUNOTHERAPY""","""Immunotherapy is a potential future direction for systemic therapy in Breast Cancer treatment, leveraging the body\'s immune system to fight cancer.""",12\r\n297,"""PD-L1""","""ARIAS-PULIDO ET AL.""","""Arias-Pulido et al. reported on PD-L1 positivity in IBC samples.""",10\r\n296,"""PD-L1""","""BERCKELAER ET AL.""","""Berckelaer et al. reported on PD-L1 expression in TILs.""",10\r\n145,"""PACLITAXEL""","""AC REGIME""","""AC regime and paclitaxel are used together in a chemotherapy regimen for breast cancer treatment.""",10\r\n139,"""PACLITAXEL""","""ESTROGEN RECEPTOR""","""Estrogen receptor is relevant to paclitaxel\'s effectiveness in treating breast cancer.""",9\r\n295,"""PD-L1""","""ER""","""ER is associated with PD-L1 expression in breast cancer.""",9\r\n298,"""ARIAS-PULIDO ET AL.""","""TILS""","""Arias-Pulido et al. reported PD-L1 positivity in TILs and its association with better DFS.""",6\r\n299,"""BERCKELAER ET AL.""","""TILS""","""Berckelaer et al. reported PD-L1 expression in TILs.""",6\r\n165,"""INTERNATIONAL EXPERT CONSENSUS""","""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""International Expert Consensus recommends High-dose chemotherapy with autologous hematopoietic stem cell transplantation as a treatment option for IBC.""",6\r\n167,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH""","""Center for International Blood and Marrow Transplant Research conducts research on High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IBC treatment.""",5\r\n166,"""HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION""","""INTERNATIONAL BLOOD AND MARROW TRANSPLANT REGISTRY""","""International Blood and Marrow Transplant Registry tracks data on High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation for IBC treatment.""",5\r\n302,"""KEYNOTE-522""","""I-SPY2""","""KEYNOTE-522 and I-SPY2 are clinical trials that combine chemotherapy and an immune checkpoint inhibitor.""",4\r\n42,"""IMMUNOTHERAPY""","""ONGOING IBC CLINICAL TRIALS""","""Immunotherapy is being investigated in Ongoing IBC Clinical Trials as a potential new treatment for IBC.""",4\r\n146,"""FAC""","""G-CSF""","""FAC and G-CSF are technologies used together in clinical trials.""",3\r\n136,"""RADIATION ONCOLOGIST""","""TEAM""","""Radiation oncologist is a member of the team working to improve the survival of IBC.""",3\r\n189,"""STANDARD OF CARE""","""RANDOMIZED TRIALS""","""Randomized Trials are used to determine the Standard of Care for IBC treatment.""",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:39,352 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 5/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:02:39,352 graphrag.index.graph.extractors.community_reports.community_reports_extractor ERROR error generating community report
Traceback (most recent call last):
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\index\graph\extractors\community_reports\community_reports_extractor.py", line 58, in __call__
    await self._llm(
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\json_parsing_llm.py", line 34, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_token_replacing_llm.py", line 37, in __call__
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_history_tracking_llm.py", line 33, in __call__
    output = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\caching_llm.py", line 104, in __call__
    result = await self._delegate(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 177, in __call__
    result, start = await execute_with_retry()
                    ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 159, in execute_with_retry
    async for attempt in retryer:
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\_asyncio.py", line 71, in __anext__
    do = self.iter(retry_state=self._retry_state)
         ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 325, in iter
    raise retry_exc.reraise()
          ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\tenacity\__init__.py", line 158, in reraise
    raise self.last_attempt.result()
          ^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 449, in result
    return self.__get_result()
           ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\concurrent\futures\_base.py", line 401, in __get_result
    raise self._exception
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 165, in execute_with_retry
    return await do_attempt(), start
           ^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 151, in do_attempt
    await sleep_for(sleep_time)
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\rate_limiting_llm.py", line 147, in do_attempt
    return await self._delegate(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 48, in __call__
    return await self._invoke_json(input, **kwargs)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 82, in _invoke_json
    result = await generate()
             ^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 74, in generate
    await self._native_json(input, **{**kwargs, "name": call_name})
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 96, in _native_json
    result = await self._invoke(
             ^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\base\base_llm.py", line 53, in _invoke
    output = await self._execute_llm(input, **kwargs)
             ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\graphrag\llm\openai\openai_chat_llm.py", line 55, in _execute_llm
    completion = await self.client.chat.completions.create(
                 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\resources\chat\completions.py", line 1289, in create
    return await self._post(
           ^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1826, in post
    return await self.request(cast_to, opts, stream=stream, stream_cls=stream_cls)
           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1519, in request
    return await self._request(
           ^^^^^^^^^^^^^^^^^^^^
  File "C:\Users\Pesankar\AppData\Local\Programs\Python\Python311\Lib\site-packages\openai\_base_client.py", line 1620, in _request
    raise self._make_status_error_from_response(err.response) from None
openai.RateLimitError: Error code: 429 - {'error': {'message': 'Rate limit reached for model `llama3-8b-8192` in organization `org_01j1m7ha6hevrb19g7knxdmps3` on tokens per minute (TPM): Limit 30000, Used 29882, Requested 8450. Please try again in 16.664s. Visit https://console.groq.com/docs/rate-limits for more information.', 'type': 'tokens', 'code': 'rate_limit_exceeded'}}
13:02:39,359 graphrag.index.reporting.file_workflow_callbacks INFO Community Report Extraction Error details=None
13:02:39,359 graphrag.index.verbs.graph.report.strategies.graph_intelligence.run_graph_intelligence WARNING No report found for community: 4
13:02:42,828 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
13:02:42,831 graphrag.index.reporting.file_workflow_callbacks INFO Error Invoking LLM details={'input': '\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community\'s key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    "title": "Verdant Oasis Plaza and Unity March",\n    "summary": "The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.",\n    "rating": 5.0,\n    "rating_explanation": "The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.",\n    "findings": [\n        {{\n            "summary": "Verdant Oasis Plaza as the central location",\n            "explanation": "Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza\'s association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]"\n        }},\n        {{\n            "summary": "Harmony Assembly\'s role in the community",\n            "explanation": "Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]"\n        }},\n        {{\n            "summary": "Unity March as a significant event",\n            "explanation": "The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community\'s dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]"\n        }},\n        {{\n            "summary": "Role of Tribune Spotlight",\n            "explanation": "Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n418,"""VIENS P""","Here is a comprehensive summary of the data:\n\nVIENS P is a renowned researcher who has made significant contributions to the field of breast cancer treatment. Specifically, VIENS P was an author of several studies on breast cancer treatment, including a consensus statement for standardized diagnosis and treatment of inflammatory breast cancer. Additionally, VIENS P conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer, examining pathologic response and outcome. VIENS P\'s work has shed light on the diagnosis and treatment of inflammatory breast cancer, a rare and aggressive form of breast cancer.",7\r\n416,"""DAWOOD S""","Here is a comprehensive summary of the data:\n\nDawood S is a person who has made significant contributions to the field of inflammatory breast cancer. Specifically, Dawood S is an author of multiple studies on the topic, including a study on the standardized diagnosis and treatment of inflammatory breast cancer, as well as a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer. These studies demonstrate Dawood S\'s expertise and research focus on inflammatory breast cancer, and highlight their role as a leading authority in the field.",4\r\n598,"""PALANGIE T""","Here is a comprehensive summary of the data:\n\nPalangie T is an author of multiple studies related to inflammatory breast cancer. Specifically, Palangie T has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as a broader study on inflammatory breast cancer.",4\r\n603,"""BEUZEBOC P""","Here is a comprehensive summary of the data:\n\nBeuzeboc P is an author who has contributed to multiple studies in the field of breast cancer. Specifically, they have authored a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer. Additionally, they have also authored a study on inflammatory breast cancer, highlighting their expertise and research focus in this area.",2\r\n602,"""DELOZIER T""","Here is a comprehensive summary of the data:\n\nDelozier T is an author of multiple studies related to inflammatory breast cancer. Specifically, Delozier T has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as a broader study on inflammatory breast cancer.",2\r\n505,"""PENAULT-LLORCA F""","Here is a comprehensive summary of the data:\n\nPenault-Llorca F is a researcher who has made significant contributions to the field of early breast cancer diagnosis, treatment, and follow-up. Specifically, she has been involved in the development of ESMO Clinical Practice Guidelines for these areas. Additionally, she has authored a study on the use of high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer, examining the pathologic response and outcome of this treatment approach.",2\r\n601,"""ROCHE H""","Here is a comprehensive summary of the data:\n\nRoche H is a researcher who has authored studies on inflammatory breast cancer. Specifically, Roche H has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as on inflammatory breast cancer in general.",2\r\n502,"""CARDOSO F""","""Cardoso F is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",5\r\n503,"""KYRIAKIDES S""","""Kyriakides S is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n504,"""OHNO S""","""Ohno S is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n506,"""POORTMANS P""","""Poortmans P is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n507,"""RUBIO IT""","""Rubio IT is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",1\r\n634,"""BROGLIO K""","""Broglio K is an author of a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer.""",1\r\n417,"""MERAJVER SD""","Here is a comprehensive summary of the data:\n\nMerajver SD is a notable figure in the field of inflammatory breast cancer research. As a contributor to the consensus statement for standardized diagnosis and treatment of inflammatory breast cancer, Merajver SD played a crucial role in shaping the understanding and management of this disease. Additionally, Merajver SD is also an author of a study on inflammatory breast cancer, further solidifying their expertise and contributions to the field.",1\r\n419,"""VERMEULEN PB""","Here is a comprehensive summary of the data:\n\nVermeulen PB is a person who has made significant contributions to the field of inflammatory breast cancer. Specifically, they were a key contributor to the development of a consensus statement for standardized diagnosis and treatment of inflammatory breast cancer. Additionally, Vermeulen PB is also an author of a study on inflammatory breast cancer, further demonstrating their expertise and research in this area.",1\r\n609,"""DIERAS V""","""Dieras V is an author of a study on inflammatory breast cancer.""",1\r\n610,"""DORVAL T""","""Dorval T is an author of a study on inflammatory breast cancer.""",1\r\n599,"""JANVIER M""","Here is a comprehensive summary of the data:\n\nJanvier M is an author of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\n\nNote: Since there is only one description provided, the summary is straightforward and concise.",2\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n342,"""VIENS P""","""GONCALVES A""","""Goncalves A and Viens P are co-authors of several studies on breast cancer treatment.""",14\r\n334,"""DAWOOD S""","""VIENS P""","""Dawood S and Viens P are co-authors of a study on inflammatory breast cancer.""",11\r\n338,"""VIENS P""","""PALANGIE T""","Here is a comprehensive summary of the data:\n\nPalangie T and Viens P are co-authors of two studies related to inflammatory breast cancer. The first study focuses on inflammatory breast cancer, while the second study explores first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\n\nNote: The descriptions are identical, except for the order of the authors\' names. This suggests that the two entities, Palangie T and Viens P, are co-authors of the same studies, and the descriptions are simply rephrased to reflect the different order of the authors\' names.",11\r\n341,"""VIENS P""","""BEUZEBOC P""","""Viens P and Beuzeboc P are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.""",9\r\n340,"""VIENS P""","""DELOZIER T""","""Viens P and Delozier T are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.""",9\r\n337,"""VIENS P""","""PENAULT-LLORCA F""","""Viens P and Penault-Llorca F are co-authors of a study on high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome.""",9\r\n339,"""VIENS P""","""ROCHE H""","""Viens P and Roche H are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.""",9\r\n447,"""CARDOSO F""","""PENAULT-LLORCA F""","""Cardoso F and Penault-Llorca F are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",7\r\n512,"""PALANGIE T""","""BEUZEBOC P""","""Palangie T and Beuzeboc P are co-authors of a study on inflammatory breast cancer.""",6\r\n445,"""CARDOSO F""","""KYRIAKIDES S""","""Cardoso F and Kyriakides S are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n446,"""CARDOSO F""","""OHNO S""","""Cardoso F and Ohno S are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n448,"""CARDOSO F""","""POORTMANS P""","""Cardoso F and Poortmans P are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n449,"""CARDOSO F""","""RUBIO IT""","""Cardoso F and Rubio IT are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.""",6\r\n336,"""DAWOOD S""","""BROGLIO K""","""Dawood S and Broglio K are co-authors of a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer.""",5\r\n333,"""DAWOOD S""","""MERAJVER SD""","""Dawood S and Merajver SD are co-authors of a study on inflammatory breast cancer.""",5\r\n335,"""DAWOOD S""","""VERMEULEN PB""","""Dawood S and Vermeulen PB are co-authors of a study on inflammatory breast cancer.""",5\r\n513,"""PALANGIE T""","""DIERAS V""","""Palangie T and Dieras V are co-authors of a study on inflammatory breast cancer.""",5\r\n514,"""PALANGIE T""","""DORVAL T""","""Palangie T and Dorval T are co-authors of a study on inflammatory breast cancer.""",5\r\n516,"""JANVIER M""","""DELOZIER T""","""Janvier M and Delozier T are co-authors of a study on inflammatory breast cancer.""",4\r\n515,"""JANVIER M""","""ROCHE H""","""Janvier M and Roche H are co-authors of a study on inflammatory breast cancer.""",4\r\n\n\nThe report should include the following sections:\n\n- TITLE: community\'s name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community\'s overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        "title": <report_title>,\n        "summary": <executive_summary>,\n        "rating": <impact_severity_rating>,\n        "rating_explanation": <rating_explanation>,\n        "findings": [\n            {{\n                "summary":<insight_1_summary>,\n                "explanation": <insight_1_explanation>\n            }},\n            {{\n                "summary":<insight_2_summary>,\n                "explanation": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)]."\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add "+more" to indicate that there are more.\n\nFor example:\n"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)]."\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:'}
13:02:42,832 graphrag.llm.base.rate_limiting_llm WARNING create_community_report failed to invoke LLM 4/5 attempts. Cause: rate limit exceeded, will retry. Recommended sleep for 0 seconds. Follow recommendation? True
13:03:02,496 httpx INFO HTTP Request: POST https://api.groq.com/openai/v1/chat/completions "HTTP/1.1 200 OK"
13:03:02,500 graphrag.llm.base.rate_limiting_llm INFO perf - llm.chat "create_community_report" with 4 retries took 10.688000000023749. input_tokens=4315, output_tokens=595
13:03:02,615 datashaper.workflow.workflow INFO executing verb window
13:03:02,622 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_final_community_reports.parquet
13:03:03,200 graphrag.index.run INFO Running workflow: create_final_text_units...
13:03:03,201 graphrag.index.run INFO dependencies for create_final_text_units: ['create_base_text_units', 'join_text_units_to_relationship_ids', 'join_text_units_to_entity_ids']
13:03:03,203 graphrag.index.run INFO read table from storage: create_base_text_units.parquet
13:03:03,216 graphrag.index.run INFO read table from storage: join_text_units_to_relationship_ids.parquet
13:03:03,352 graphrag.index.run INFO read table from storage: join_text_units_to_entity_ids.parquet
13:03:03,475 datashaper.workflow.workflow INFO executing verb select
13:03:03,549 datashaper.workflow.workflow INFO executing verb rename
13:03:03,617 datashaper.workflow.workflow INFO executing verb join
13:03:03,685 datashaper.workflow.workflow INFO executing verb join
13:03:03,752 datashaper.workflow.workflow INFO executing verb aggregate_override
13:03:03,793 datashaper.workflow.workflow INFO executing verb select
13:03:03,797 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_final_text_units.parquet
13:03:04,378 graphrag.index.run INFO Running workflow: create_base_documents...
13:03:04,393 graphrag.index.run INFO dependencies for create_base_documents: ['create_final_text_units']
13:03:04,421 graphrag.index.run INFO read table from storage: create_final_text_units.parquet
13:03:04,580 datashaper.workflow.workflow INFO executing verb unroll
13:03:04,659 datashaper.workflow.workflow INFO executing verb select
13:03:04,701 datashaper.workflow.workflow INFO executing verb rename
13:03:04,734 datashaper.workflow.workflow INFO executing verb join
13:03:04,777 datashaper.workflow.workflow INFO executing verb aggregate_override
13:03:04,878 datashaper.workflow.workflow INFO executing verb join
13:03:05,68 datashaper.workflow.workflow INFO executing verb rename
13:03:05,112 datashaper.workflow.workflow INFO executing verb convert
13:03:05,282 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_base_documents.parquet
13:03:05,826 graphrag.index.run INFO Running workflow: create_final_documents...
13:03:05,826 graphrag.index.run INFO dependencies for create_final_documents: ['create_base_documents']
13:03:05,827 graphrag.index.run INFO read table from storage: create_base_documents.parquet
13:03:05,932 datashaper.workflow.workflow INFO executing verb rename
13:03:05,937 graphrag.index.emit.parquet_table_emitter INFO emitting parquet table create_final_documents.parquet
